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HNSCC is the sixth most common cancer in the world and over the last decade its 
genetic landscape has been extensively investigated. However, due to the 
heterogenic nature of HNSCC tumours, which is complicated by HPV infection, 
the effectiveness of current therapies and the development of new therapies have 
been hindered.  
In this thesis, by using a combination of genome-wide methods, the cis-regulatory 
network was investigated in HNSCC cell lines and compared to non-tumourigenic 
primary oral cells. The analyses revealed a common core regulatory network shared 
by both the HNSCC and non-tumourigenic cells. The network included pathways, 
which have previously been found to promote HNSCC such as the EGFR, MAPK, 
TGF- and WNT pathways. A novel finding was the involvement of the Hippo 
pathway and its transcription factor effector, TEAD4. The network appears to be 
driven primarily by the p63-AP1-TEAD4 transcription factors and in conjunction 
with the mentioned pathways, appears to form the underlying network required for 
epithelial function but also holds the potential to become deregulated, leading to 
HNSCC. Disruption of Hippo-driven gene transcription can reduce HNSCC cell 
viability therefore pointing to potential therapeutic targets and mechanisms to 
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CHAPTER 1: INTRODUCTION 
1.1 Epithelial structure 
Epithelial tissue is one of the most varied tissues in the body and lines most of the 
body’s surfaces including skin, organs and blood vessels. The tissue’s primary 
function is to protect against dehydration and mechanical, chemical and microbial 
insults [1]. Two main varieties of epithelial structure exist- simple and stratified. 
Simple epithelium consists of a single layer of cells allowing for diffusion or 
filtering of small molecules [1]. Anatomical locations of simple epithelium include, 
the stomach lining, intestines, circulatory system and lungs, while stratified 
squamous epithelium can be found in the skin, oral mucosa and oesophagus [1].  
The stratified squamous epithelium is a tightly packed, multi-layered and 
differentiated tissue. The deepest layer of stratified epithelia is the basement 
membrane, which provides support, allows exchange of nutrients and separates the 
epithelium from the dermis- a fibrous connective tissue [1, 2] (Figure 1.1). 
Epithelia can be keratinised or non-keratinised; the main difference is at the surface 
of the structure, where keratinised epithelia possess a layer of dead cells (keratinised 
layer), while non-keratinised epithelia possess a superficial layer of squamous cells, 





Figure 1.1 The structure of stratified epithelium. 
The stratified epithelium is a multi-layered structure and its cells (keratinocytes) 
express keratin proteins, which form keratin filaments (intermediate filaments). The 
keratin proteins are characteristic for each type of epithelium (keratinised or non-
keratinised) and for the different layers. The dermis (a fibrous connective tissue) is 
required for mechanical support of the epithelium, but also provides nutrients and 
a blood supply. Between the dermis and epithelium is the basement membrane, 
whose primary function is to anchor the basal cells with cell adhesion molecules. 
(A) Keratinised epithelium is composed of five layers; the basal layer, the spinous 
layer, the granular layer and the keratinised layer. (B) The non-keratinised 
epithelium consists of the basal, intermediate and superficial layers. (Figure 
recreated and adapted with permission from Roberts S., 2015 [3]). 
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1.1.1 Oral epithelia 
Within the oral cavity, regions involved in mastication, such as gingiva and hard 
palate, are typically lined by keratinised epithelia [1]. Less rigid regions, such as 
the mucosal lining, required for speech and swallowing, tend to be covered by non-
keratinised epithelia [1].  
Keratinised stratified epithelia consist of the basal layer, spinous layer, granular 
layer and keratinised layer (Figure 1.1A). Layers of non-keratinised epithelia 
include the basal, intermediate and superficial layers [4] (Figure 1.1B). The basal 
layer, in order to replace dead cells, provides proliferative and differentiation 
capacity to the tissue [1, 2]. Upon differentiation, the basal cells migrate upwards 
and undergo changes to replace cells of the remaining layers [4].  
Epithelial cells produce proteins called keratin (also known as cytokeratins), 
therefore the cells are sometimes referred to as keratinocytes [5]. Keratins are a 
family of fibrous proteins encoded by 54 different genes, which form heterodimers 
and polymerise as intermediate filaments to form an essential part of the 
cytoskeletal network [5]. The functional importance of keratin has been 
demonstrated in a study in which keratin 6 null mice developed fragile oral mucosal 
epithelia and were not viable [6]. The basal cells of keratinised epithelia express 
keratins 5 and 14, while directly above in the spinous layer, keratins 1, 6, 10 and 16 
are expressed [4] (Figure 1.1A). The cells of the granular layer in keratinised 
epithelia are flatter and contain the most dense network of keratin filaments, which 
offers protection against mechanical and chemical insults [4, 7]. Cells of the 
keratinised layer possess fewer cell adhesion junctions and no organelles and 
therefore can be shed from the epithelium [4]. Shed cells are eventually replaced by 
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basal cells as they migrate upwards [4]. Basal cells of non-keratinised epithelia 
express keratin 7 and 19, while cells of the intermediate layer express keratins 4 
and 13 [4] (Figure 1.1B). 
The packed cell structure characteristic of epithelia is maintained by cell adhesion 
molecules (CAMs), which are located either between two cells for cell-cell 
adhesion or between the cell and extracellular matrix (ECM) (cell-matrix adhesion) 
[8] (Figure 1.2). There are five main types of CAMs: cadherins, the 
immunoglobulin superfamily, selectins, mucins and integrins [8] (Figure 1.2). 
CAMs can assemble with adapter proteins into junctions, of which there are four 
types: tight junctions, gap junctions, cell-cell and cell-matrix adhesion junctions [8] 
(Figure 1.2). Tight junctions connect cells and prevent diffusion or passing of 
molecules, while gap junctions allow the controlled exchange of small molecules 
between cells [8]. Cell-cell and cell-matrix junctions utilise distinct CAM proteins; 
cadherins, immunoglobulin superfamily, selectins and mucins, which are involved 
in cell-cell junctions, while integrins are involved in cell-matrix junctions [8] 
(Figure 1.2).  
Cell-cell adhesion proteins are found throughout epithelial tissue, except in the 
upper layer of keratinised epithelia [4, 8]. Specialised cell-cell junctions also exist, 
which consist of clusters of CAMs. For example, adherens junctions consist of 
cadherin proteins, which bind actin filaments of the cytoskeletal network [8] 
(Figure 1.2). Actin filaments are composed of F-actin monomers which polymerise 
to form the filaments [9]. 
Epithelial basal cells are anchored to the basement membrane by cell-matrix 
adhesion proteins [2, 8] (Figure 1.2). Integrin proteins are involved in cell-ECM 
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junctions which can form hemidesmosome junctions, which anchor the epithelium 
to the basement membrane via intermediate filaments [2, 8] (Figure 1.2). 
 
  
Figure 1.2. Cell adhesion.  
Epithelial cells possess a tightly packed structure held together by four main types of 
junctions: tight junctions (prevent the passing of small molecules between cells), gap 
junctions (allow controlled passing of small molecules between cells), cell-cell adhesion 
junctions (anchor adjacent cells or to the cell exterior via the cytoskeleton) (e.g. adherens 
junction, which bind actin filaments) and cell-matrix junctions (anchor the cell to the 
extracellular matrix (ECM) or basement membrane via intermediate filaments) (e.g. 
hemidesmosomes). The junctions consist of cell adhesion molecules (CAMs): cadherins, 
immunoglobulin superfamily, selectins, mucins (involved in cell-cell adhesion) and 




1.2 Molecular mechanisms in the development of epithelia 
1.2.1 The role of p63 in epithelial development 
Two of the most important features of stratified epithelia are its differentiated state 
and the maintenance of balance between cell proliferation and cell death. The p63 
protein is a transcription factor, encoded by the TP63 gene. p63 has been identified 
as being key in epithelial development and the first transcription factor to be 
expressed by basal cells in the developing epithelium [10, 11]. The importance of 
p63 function has been demonstrated in mice and humans. For example, p63-null 
mice have been shown to display incomplete or missing epithelial stratification and 
truncated limbs [12]. In humans, mutations of TP63 result in ectodermal dysplasia-
associated disorders, leading to cleft lip/palate and skin erosion [12].  
The function of p63 can be complicated by alternative splicing events in the TP63 
gene (Figure 1.3A). Due to the presence of alternative promoters, splicing of TP63 
can give rise to two main p63 protein isoforms; p53-like N-terminal transactivation 
domain (TAp63), while the other isoform lacks this domain (∆Np63) [12, 13] 
(Figure 1.3B and C). TAp63 is the first protein of the isoforms to be expressed and 
is thought to initiate K14 expression in the basal layer [13]. Epidermal-specific 
deletion of the ∆Np63 isoform in mice leads to skin erosions and impaired terminal 
keratinocyte differentiation [14, 15]. In addition, further alternative splicing events 
can give rise to three TAp63 isoforms and three ∆Np63 isoforms: ,  and  [12, 




Figure 1.3. Schematic of the TP63 gene, its splice sites and p63 isoforms. 
(A) The TP63 gene contains 14 exons and two promoters: promoter 1 allows transcription 
initiation of the TAp63 isoform, while promoter 2 allows for ∆Np63 transcription initiation. 
(B) The TAp63 protein consists of four main domains, the TA (transactivation) domain 
(yellow exons), DNA binding domain (red exons), oligomerisation domain (green exons) 
and the c-terminal domain (purple exons). (C) The N-terminal TA domain of ∆Np63 is 
truncated. (B and C) In both protein types, alternative splicing can produce three isoforms 
(α, β and γ). 
 
The role of p63 in epithelial proliferation has been reported in many studies [13, 
16, 17]. For example, the role of Np63 in proliferation of primary human 
keratinocytes was highlighted after observing hypoproliferation in Np63 
knockdown cells [17]. Another study reported that Np63 can maintain 
keratinocyte cell proliferation by inhibiting expression of the CDKN1A (cyclin 
dependent kinase inhibitor 1A) gene, which encodes the p21 protein [13]. The p21 
protein is a cyclin-dependent kinase inhibitor, which inhibits cyclin D/CDK (cyclin 
dependent kinase) complexes, required for M phase cell cycle progression [13, 16]. 
p63 can also inhibit p21 expression via inhibition of NOTCH (neurogenic locus 
notch homolog), an upstream regulator of p21 [13, 16]. NOTCH proteins are a 
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family of transmembrane receptors involved in the terminal differentiation of 
keratinocyte cells [18]. 
1.2.2 The role of the NOTCH signalling pathway in epithelial 
development 
The primary role of the NOTCH pathway is cell-cell signalling mediated by 
NOTCH receptors [19]. NOTCH receptors include NOTCH1-4 and their ligands 
include Jagged1/2 and Delta-like ligands1/3/4 [20]. A study by Dotto et al. supports 
this by demonstrating abnormal integrin expression in Notch1 deficient mice; 
expression was observed in the suprabasal layers of the epidermis [21]. Another 
study reported that Notch1 overexpression in mice leads to cell cycle arrest and 
differentiation by induction of p21 expression [22]. Therefore, it has been suggested 
that NOTCH1 may be a tumour suppressor gene. Further evidence of this is that 
Notch1 knockdown mice display an increase in oncogenic Wnt (wingless)/-
catenin signalling [23]. The role of NOTCH in tumour development will be 
discussed in more detail later.  
1.2.3 The role of the WNT signalling pathway in epithelial 
development 
WNT proteins are a family of 19 secreted glycoproteins, which function as part of 
the WNT pathway [24]. The WNT pathway can be divided into two pathways: 
canonical, which involves the -catenin protein (WNT/-catenin pathway), and 
non-canonical, which is -catenin-independent [24]. The -catenin protein is a 
transcription factor, which upon activation of the WNT pathway, translocates to the 
nucleus to induce transcription of WNT-target genes [24]. The WNT pathway has 
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a role in many cell processes including proliferation, survival, migration and 
differentiation [24]. During normal development of oral epithelia, the WNT/-
catenin pathway plays a prominent role in the development of oral organs including 
teeth, taste buds, lip and palate [25]. In the context of tumour development, aberrant 
WNT/-catenin activation can induce transcription of genes involved in cell cycle 
progression, such as CCND1, which encodes cyclin D1 [24]. 
1.2.4 The role of the EGFR signalling pathway in epithelial 
development 
EGFR (epidermal growth factor receptor) is part of the ERBB family of receptor 
tyrosine kinases, which includes ERBB-1 (EGFR/HER1), ERBB-2 (HER2), 
ERBB-3 (HER3) and ERBB-4 (HER4) [26]. EGFR is expressed by epithelial basal 
cells and expression is lost after maturation and differentiation of cells [27]. 
Activation of the EGFR signalling pathway results in cell cycle progression, 
proliferation and inhibition of apoptosis [26] (Figure 1.4). EGFR consists of three 
domains; an extracellular ligand-binding domain; an intracellular tyrosine kinase 
domain and a hydrophobic transmembrane domain [26, 28] (Figure 1.4). The 
hydrophobic domain allows for interaction between receptors, resulting in hetero- 
or homodimerization, while the intracellular domain is involved in phosphorylation 
of signalling proteins and EGFR itself (Figure 1.4B).  
EGFR ligands include the epidermal growth factor (EGF), transforming growth 
factor (TGF)-α, amphiregulin (AREG) and epiregulin (EREG) [26, 28]. Upon 
ligand binding, EGFR homo- or heterodimerisation with other members of its 
family occurs, resulting in autophosphorylation of the tyrosine kinase domains [26, 
28] (Figure 1.4B). This results in activation of two main protein axes: (i) mitogen-
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activated protein kinases (MAPK) (RAS, RAF (Raf-1 proto-oncogene, 
serine/threonine kinase), MEK and ERK (extracellular signal-regulated kinase)), 
which are involved in cell proliferation, and (ii) activation of PI3K 
(phosphotidylinositol-3 kinase)-AKT (protein kinase B)-mTOR (mechanistic target 
of rapamycin), which are involved in cell cycle progression (Figure 1.4B). 
 
 
Figure 1.4. EGFR signalling promotes cell survival and proliferation. 
(A) The EGF (epidermal growth factor) receptor consists of three domains: ligand binding 
domain (extracellular), a hydrophobic domain (transmembrane) and tyrosine kinase 
domain (intracellular). In the absence of EGFR-ligands the pathway is inactive. (B) Upon 
binding of EGFR ligands (EGF, AREG, TGF- and EREG), the receptor undergoes 
homodimerization or heterodimerisation with either member of ERBB2-4. The tyrosine 
kinase domain undergoes autophosphorylation, leading to dephosphorylation of RAS 
(resistance to audiogenic seizures) adaptor proteins, initiating a phosphorylation cascade of 
the remaining MAPK proteins: RAF once phosphorylated, phosphorylates MEK (MAP 
kinase-ERK kinase), which in turn phosphorylates ERK. This cascade promotes cell 
proliferation. A second cascade activated by EGFR involves PI3K, which phosphorylates 
AKT, which activates mTOR to promote cell cycle progression. 
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1.3 Head and neck squamous cell carcinoma (HNSCC) 
Deregulation in epithelial maintenance and development can result in a wide range 
of disorders, some of which are briefly mentioned in Section 1.2. One potential 
outcome of epithelial misregulation could be the development of head and neck 
squamous cell carcinoma (HNSCC).  
HNSCC is the sixth most common cancer in the world with a five-year survival rate 
of 40-50% [29, 30]. Anatomical regions of the head and neck where HNSCC 
develops include the oral cavity, pharynx (nasopharynx, oropharynx (which 
includes the base of the tongue and tonsils) and hypopharynx), larynx, paranasal 
sinuses, nasal cavity and the salivary glands [23] (Figure 1.5). The most common 
risk factors for HNSCC are exposure to tobacco and alcohol; over 75% of HNSCC 
cases can be attributed to these risk factors [31, 32]. There also exists a smaller 
group of HNSCC cases (5-30%) where the patient has no history of smoking [31]. 
The majority (~90%) of tobacco- and alcohol-associated tumours arise in the larynx 
and oral cavity (tongue and floor of the mouth) with a smaller proportion of cases 
developing in the oro- or hypopharynx [33, 34]. 
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Figure 1.5. Anatomical regions of the head and neck.  
Regions of the head and neck include the oral cavity, larynx, pharynx (nasopharynx, 
oropharynx and hypopharynx), paranasal sinuses, nasal cavity and salivary glands (Figure 
used with permission from the National Cancer Institute., 2012 [35]). 
 
In addition to alcohol and tobacco, infection by the human papillomavirus (HPV) 
is a major risk factor. For HNSCC tumours which arise due to HPV are called HPV-
positive(+) HNSCC tumours, while those which arise due to factors other than HPV 
are called HPV-negative(-). The majority of HPV(-) tumours are of non-
oropharyngeal origin (94%) [23, 36, 37]. HPV(+) tumours arise either in the 
oropharynx (45.8%), specifically in the tonsils and base of the tongue, in the oral 
cavity (24.2%) or larynx (22.1%) [38, 39]. Investigation of the incidence of HPV(+) 
HNSCC cases in a meta-analysis of 12,163 HNSCC patients, revealed that 41% of 
patients in Europe were HPV(+); 60% of patients are HPV(+) in USA [40]. While 
in many developed countries the incidence of HPV(-) tumours is decreasing due to 
a decline in smoking habits, the incidence of HPV(+) HNSCC cases are increasing 
[37].  
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1.3.1 HPV classification 
HPVs are small non-enveloped, double-stranded circular DNA viruses, which tend 
to infect squamous epithelial cells [20]. Over 210 types of HPVs have been 
identified thus far and can be categorised into five genera: alpha-, beta-, gamma-, 
mu- and nu-papillomaviruses [41, 42]. Infection by HPV can induce benign 
papillomas and persistent infection can lead to cell transformation and cancer [20, 
41]. HPVs can be further grouped into low-risk and high-risk depending on the 
virus’ ability to induce malignant cell transformation [20]. Overall, cases of HPV-
induced HNSCC result from infection by a high-risk -HPV. An example of a high-
risk type is HPV16, which infects mucosal epithelia and is most frequently detected 
in HNSCC as it is present in more than 90% of oropharyngeal cancers [43]. 
1.3.2 HPV genome 
The HPV genome can exist in two forms, either as an episome, where DNA 
replication is independent of the chromosomal DNA and is typically associated with 
non-malignancy, or HPV can be integrated into the host genome, giving rise to 
cancer [20]. The HPV genome encodes eight main proteins, which can be 
categorized into early (E) proteins and late (L) proteins. The early proteins include, 
E1, E2, E5, E6 and E7 and late proteins include, L1 and L2 [20] (Figure 1.6A and 
B). While E4 is named as an early protein, it is expressed later in the HPV life cycle, 
as discussed next. 
The E1 and E2 proteins are expressed in the basal and spinous layers (or 
intermediate layer) [3] (Figure 1.6C). The early protein, E1 is an ATP (adenosine 
triphosphate)-dependent helicase, which along with E2 initiates viral replication 
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[20]. E2 is involved in segregation of the viral DNA plasmid during cell division 
and also functions as a transcription factor to regulate E6 and E7 expression [20, 
44].  
The E4 protein is expressed during the later stages of the HPV life cycle, in the 
spinous and granular layers [41]. E4 has been reported to be involved in viral DNA 
amplification by support of the G2 cell cycle phase [41].  
E5 is expressed in low levels and is difficult to detect [45]. However, E5 transcript 
levels have been measured in HPV(+) HNSCC tumours and has been found to be 
variable [46]. E5 is an anti-apoptotic protein but also affects cell-matrix adhesion 
and epithelial differentiation, possibly through upregulation of the PI3K/AKT [47]. 
Interestingly, E5 expression has been found to correlate with EGFR expression 
[46].  
The E6 and E7 proteins are expressed in the basal and spinous layers [3] (Figure 
1.6C). High expression levels of E6 and E7 are key for cell transformation in 
HNSCC, as discussed later. E6 and E7 expression is maintained at very low levels 
until integration of its genome into the host genome [41]. Alternative mechanisms 
of increased E6/E7 expression have been reported. For example, knockdown of 
ERBB3 in oral SCC cell lines has been seen to decrease E6/E7 protein levels [48]. 
A second mechanism of increased E6/E7 expression has been described in primary 
human foreskin keratinocytes (HFKs) and cervical cancer cell lines, where the SP1 
transcription factor induces HPV16 E6/E7 expression [49, 50]. In HFKs it has 
further been demonstrated that E6/E7 can induce human telomerase reverse 
transcriptase (hTERT) expression, which can lead to genomic instability and cell 
transformation [50]. 
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The late proteins are expressed in the granular and keratinised (or superficial) 
epithelial layers [3, 20] (Figure 1.6C). These proteins are structural capsid proteins; 
L1, the late major protein, is synthesised in the cytoplasm and then transported to 
the nucleus, where it has a role in the packaging of viral particles [20]. The L2 minor 
capsid protein binds the viral DNA in the nucleus, in order to recruit L1 for new 
viral particles to be assembled [20]. 
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Figure 1.6. HPV16 genome and life cycle.  
(A) The size of the HPV16 genome is ~7,900bp. The genome contains six early genes: E1 
(1,950bp), E2 (1,098bp), E4 (288bp), E5 (252bp), E6 (477bp) and E7 (297bp) and two late 
genes: L1 (1,596bp) and L2 (1,422bp). (B) HPV can infect epithelia via small abrasions or 
cuts, where the viral particles infect the basal cells, as they hold the potential to proliferate 
and migrate upwards through the layers, eventually aiding viral release. The infected basal 
cells will be forced to proliferate and remain undifferentiated until viral amplification is 
completed. The E1, E2 and E4 proteins are expressed predominantly in the spinous layer 
of the epithelium, while the E6 and E7 proteins are expressed primarily in the basal layer 
[51]. The L1 and L2 proteins are expressed in the granular layer [51]. (Figure A recreated 
and adapted with permission from Rampias et al., 2014 [20]. Figure B recreated and 
adapted with permission from Roberts, 2015 [3]). 
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1.3.3 HPV life cycle 
The route of HPV infection is not well described in HNSCC, nor are the 
mechanisms of HPV transformation, however these processes are better understood 
in cervical cells. Cervical cancer is also a mucosal SCC and nearly all cases (99.7%) 
are associated with HPV infection [52]. Therefore, cervical SCC can be a useful 
model to compare with and gain insights into the mechanism of HPV-driven 
carcinogenesis in HNSCC [52-54]. HPV enters cervical epithelial tissue via small 
abrasions or lesions in the mucosa [42] (Figure 1.6B). Epithelial basal cells possess 
the highest proliferative potential; therefore, the virus preferentially infects these 
cells [4, 42]. Viral DNA enters the nucleus of the undifferentiated basal cell, where 
E1 and E2 gene transcription and protein synthesis occurs [42]. E1 and E2 proteins 
can then initiate replication of the viral episome to ~50-100 copies per cell [42]. 
The E6 and E7 viral oncoproteins are also expressed, which can hijack regulators 
of the host DNA replication machinery, namely p53 and pRB (retinoblastoma 
protein), respectively. The combined action of both E6 and E7 forces the host cell 
to remain in the cell cycle, uncoupling the proliferation and differentiation 
processes [42]. Although terminal differentiation of the infected cells is delayed by 
E6 and E7 expression, eventual differentiation in the upper layers of the epithelium 
results in expression of late genes, including E4, which promotes viral genome 
amplification [42, 55]. In addition, expression of the L1 and L2 capsid proteins 
facilitate assembly of infectious virions, which are sloughed off with dead cells on 





1.4 The molecular basis of HPV-induced HNSCC 
In normal non-proliferating cells, both pRB and p53 act as tumour suppressor 
proteins (Figure 1.7). pRB is bound to the E2F (E2 factor) transcription factor, 
inhibiting E2F-induced gene transcription [29]. Upon mitogen signalling, cyclin 
D1/CDK-4 or -6 hyperphosphorylate pRB, releasing E2F and initiating 
transcription of E2F target genes, which are involved in the progression of the cell 
cycle into S phase [29]. E2F target genes encode for proteins such as DNA 
polymerase α, PCNA (proliferating cell nuclear antigen) and cyclins A and E [56] 
(Figure 1.7). Upon receiving senescence and differentiation signals, the p16INK4A 
protein (encoded by CDKN2A (cyclin dependent kinase inhibitor 2A) inhibits 
cyclin D1/CDK4- or -6, blocking G1/S progression [29] (Figure 1.7). For 
progression of G2 phase into M phase, the p53 protein plays a central role in the 
regulation of genes involved in growth arrest, DNA repair and apoptosis [18]. p53 
is part of a protein family, which also includes p63 and p73 [12]. One of the roles 
of p53 is to induce cell cycle arrest or apoptosis upon recognition of DNA damage, 
and this is mediated by the p21 protein [29] (Figure 1.7). p21 inhibits cyclin 
E/CDK2 complexes, which normally hyperphosphorylate pRB, inhibiting G1/S 
progression [29]. p21 also inhibits cyclin A/CDK1, which is required for S phase 




Figure 1.7. Cell cycle regulation.  
Progression of the cell cycle depends on two checkpoints (red bars); G1/S and G2/M. The 
checkpoints are regulated by pRB and p53, respectively. G1/S regulation: upon mitogen 
signalling, cyclin D1/CDK-4 or -6 complexes hyperphosphorylate pRB, releasing the E2F 
transcription factor to induce gene transcription of genes involved in S phase progression. 
The p16INK4A protein (encoded by CDKN2A) is involved in inhibition of CDK-4, -6/cyclin 
D1 complexes, preventing hyperphosphorylation of pRB and stabilising E2F. In HPV(+) 
HNSCC, the E7 viral oncoprotein binds pRB, which releases E2F allowing transcription 
induction. In HPV(-) HNSCC, CDKN2A is often mutated, resulting in loss of p16INK4A, 
leading to release of E2F. G2/M regulation: Upon detection of DNA damage, p53 induces 
the p21 protein, which inhibits cyclin A/CDK1 and cyclin E/CDK2 from 
hyperphosphorylating pRB, thereby blocking E2F-mediated transcription. p21 also inhibits 
cyclin B/CDK 1 complex, which is required for progression to M phase. In HPV(+) 
HNSCC, the E6 viral oncoprotein binds p53, targeting it for ubiquitin-mediated 
degradation. In HPV(-) HNSCC, the TP53 gene which encodes for p53, is often mutated, 




Upon HPV infection, actions of the viral oncoproteins E6 and E7 can deregulate 
the cell cycle by inhibiting p53 and pRB, respectively [42]. In malignant cells the 
E6 and E7 proteins of high-risk HPVs are considered to be the strongest protein 
effectors of cancer development due to their ability to transform keratinocytes [42]. 
E6 acts to limit the pro-apoptotic function of p53 by forming a complex with a host 
protein called, E6-AP (E6 associated protein) and p53 [20, 57, 58]. The complex 
functions as a p53-specific ubiquitin ligase to induce p53 degradation, leading to 
aberrant cell cycle progression [20] (Figure 1.7). Another way in which E6 may 
contribute to cell transformation is by binding to the hDlg (human disks large 
homolog 1) protein, which is a PDZ domain-containing protein [59]. The hDlg 
protein is a homologue of the drosophila dlg protein [59]. Mutations of the dlg gene 
have demonstrated a loss in cell polarity in epithelial cells and neoplastic 
proliferation [59, 60]. Furthermore, the hDlg protein is thought to have a role in 
cell-cell adhesion and E6 binding may contribute to this [61].  
In addition to E6, the E7 oncoprotein can promote cell cycle progression in several 
ways. E7 can disrupt the tumour suppressor protein, pRB, leading to disruption of 
the interaction of pRB with E2F and inducing aberrant transcription of E2F target 
genes [56, 62] (Figure 1.7). E7 can also target pRB for degradation by hijacking 
the cullin 2 E3 ubiquitin ligase complex [20]. Another way E7 can promote cell 
cycle progression is by inhibiting cyclin-dependent kinase inhibitors, such as p21 
and as a result, aberrantly activating cyclin-CDK complexes leading to cell cycle 
progression [63]. In addition, E7 can disrupt histone modifications such as 
acetylation and methylation by interacting with histone acetyltransferases, 
deacetylases, methyltransferases and demethylases [20]. The function of histone 
modifications is discussed in detail later.  
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Integration of the HPV genome can also contribute to malignancy, as the E2 and 
E5 genomic sequences, which have a role in repressing E6 and E7 expression, are 
often lost from the episome [20, 41, 64]. A study conducted by The Cancer Genome 
Atlas of 36 HPV(+) tumours revealed HPV integration in most tumours and 
association with genomic amplifications of the host genome [36]. However, such 
integration events were not recurrent and so a single driver could not be identified. 
Other studies have reported loss of function of tumour suppressor genes as a result 
of HPV integration, such as the RAD51 (RAD51 recombinase) gene, which encodes 
an enzyme involved in DNA repair [65]. In addition, amplification of oncogenes 
such as NR4A2 (nuclear receptor subfamily 4 group A member 2) have also been 
reported [65]. 
1.5 Genetic alterations in HNSCC 
In recent years, genome-wide and high-throughput DNA sequencing of tumours has 
become more common. These methods allow large cohorts of tumour samples to 
be investigated for genetic alterations such as gene mutations, amplifications or 
deletions, gene expression changes and changes in protein function. In HNSCC, the 
majority of genetic alterations occur in tumour suppressor genes and genes involved 
in cell survival, proliferation and metastasis. 
The largest study of genetic alterations in HNSCC was conducted by The Cancer 
Genome Atlas (TCGA) consortium in 2015, which consisted of 279 tumours [36]. 
The study investigated the HPV status, copy number alterations, somatic mutations 
and gene expression changes in HNSCC tumours. The cohort consisted of tumours 
derived from the oral cavity (172/279, 62%), oropharynx (33/279, 12%) and larynx 
(72/279, 26%). The HPV status of the tumours was determined by RNA-sequencing 
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to investigate expression levels of the viral oncogenes, E6 and E7 [36]. The majority 
of the tumours were HPV(-) (243/279, 87%) and agreeing with previously 
published data nearly all of the HPV(-) tumours were of non-oropharyngeal origin 
[23, 36, 37].  
The TCGA study was followed up three years later with the Pan-Atlas study, in 
which the cohort was expanded to 522 HNSCC tumours [66]. In the Pan-Atlas 
study, 33 different cancer types were studied, including five types of SCCs 
(HNSCC, lung, oesophageal, cervical and bladder) [66]. The aim of this study was 
to compare features of SCC with other cancers. Genes found to be significantly 
altered in SCC included stem cell markers (SOX2 (SRY-box 2)), mitogenic growth 
and cell cycle related genes (PDGFRA (platelet derived growth factor receptor 
alpha), IGF1R (insulin like growth factor 1 receptor), CDK6, RAC1 (AKT 
serine/threonine kinase 1), MAPK1, EPHA2 (EPH receptor A2), and CREBBP 
(CREB binding protein), PI3K signalling genes (AKT1/3), NF-kB signalling genes 
(REL (REL proto-oncogene) and TRAF3 (tumour necrosis factor receptor 
associated factor 3), genes related to squamous differentiation (FAT (FAT atypical 
adherin)-1/2, ROBO (roundabout)-1, ZNF (zinc finger protein)-750, JUB (Ajuba 
LIM protein), NOTCH1, and TP63) and immune system related genes (PD-L1 
(programmed cell death ligand 1) and B2M (β2 microglobulin)) [66].  
Seven genome-wide studies including the two TCGA studies are summarised in 
Table 1.1, showing the most commonly altered genes in HNSCC. Four studies 
reported genetic alterations while discriminating by HPV status, generating two 
datasets for HPV(+) and HPV(-) tumours [36, 67-69]. Three studies reported 
alterations in HNSCC tumours without discriminating for HPV and will be referred 
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to as HNSCC tumours [66, 70, 71]. Genetic alterations and gene expression changes 




Table 1.1. Summary of genetic alterations reported by seven genome-wide studies of 
HNSCC tumours. 
 
The table consists of seven studies in which genetic alterations in HPV(-), HPV(+) and 
HNSCC tumours are characterised. Genetic alterations include mutations (M), deletions 
(D) and amplifications (A). Genes in red indicate transcription factor genes. Data 







1.5.1 Mutations of the TP53 gene 
The tumour suppressor gene TP53 was the most commonly mutated gene in the 
TCGA cohort of HPV(-) tumours, agreeing with the remaining six studies where 
between 66% and 81% of HPV(-) or HNSCC tumours displayed TP53 loss-of-
function mutations [36, 66-71] (Table 1.1). The TP53 gene encodes for the p53 
tumour suppressor protein, the function of which is described previously in Section 
1.4. Mutations of the TP53 gene were rarely reported in HPV(+) HNSCC tumours; 
the TCGA reported 1/36 HPV(+) tumours harbouring a TP53 mutation [36]. The 
importance of the TP53 gene has been highlighted by the association between TP53 
mutations and reduced patient survival [36] (Table 1.1).  
1.5.2 Amplification of chromosome 3q (TP63, SOX2 and PIK3CA) 
The TP63 gene is located on chromosome 3q and is amplified in 19-26% of HPV(-
) tumours and 16-28% of HPV(+) tumours [36, 66-70, 72] (Table 1.1). 
Chromosome 3q also contains the PIK3CA (phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha) and SOX2 genes [58, 67, 73]. As a result of focal 
amplifications, all three genes are amplified in HNSCC; TP63 and PIK3CA 
amplifications are observed in both HPV(+) and HPV(-) tumour types, while SOX2 
amplifications are observed in HPV(+) tumours [58, 67, 73] (Table 1.1).  
The PIK3CA gene encodes a kinase catalytic subunit of PI3K called p110, which 
is part of the PI3K/AKT/mTOR pathway. Upon ligand activation of EGFR, 
phosphorylation of p110 occurs, which in turn phosphorylates the serine-





progression of various cancers [74] (Figure 1.4). The pathway then triggers 
downstream events associated with tumour cell survival and transformation [74]. 
For example, the interleukin-6 (IL-6) protein is a mediator of the PI3K/AKT/mTOR 
pathway and is often overexpressed in cancers, including HNSCC, and is associated 
with reduced overall survival of HNSCC patients [75].  
In HPV(+) HNSCC cells, it has been reported that HPV can bind to heparan-
sulfonated proteoglycans to enter keratinocyte cells [76]. It is thought that this 
stimulates the PI3K/AKT/mTOR pathway via activation of 64 integrins [76]. In 
addition, it has been reported that the viral oncoproteins E6 and E7 can promote 
viral survival by activation of AKT and mTOR [77, 78]. Furthermore, the ability of 
E7 to inactivate pRB has been reported to upregulate AKT protein expression and 
E7 can promote sustained PI3K/AKT signalling by inhibiting their 
dephosphorylation [77, 78].  
SOX2 is a transcription factor commonly involved in embryonic development and 
it has been shown to be important in the development and maintenance of squamous 
epithelia [79]. The SOX2 gene has been reported as being oncogenic in many SCCs, 
including oesophageal carcinomas [79]. Interestingly, both SOX2 and p63 
transcription factors have been shown to co-localise at intragenic regions, indicating 
co-regulation between the two transcription factors [79].  
1.5.3 Mutations of the NOTCH gene family 
Inactivating mutations in NOTCH (neurogenic locus notch homolog)-1-3 are 





genes, NOTCH1 exhibits mutations most frequently in HPV(-) HNSCC tumours 
(Table 1.1) [36, 66-71]. NOTCH1 signalling is involved in terminal differentiation 
of primary keratinocyte cells [80]. In addition to NOTCH1 mutations, EGFR can 
also block NOTCH1-mediated keratinocyte differentiation [80]. In addition, p63 is 
also able to block NOTCH1 signalling in cells of the basal layer, inhibiting p21 and 
allowing cell cycle progression [13, 16, 18].  
1.5.4 Mutations of the CDKN2A gene 
The second most frequently altered gene in HPV(-) HNSCC tumours is the tumour 
suppressor gene CDKN2A, which displays alterations including mutations and 
deletions rendering the gene inactive [36, 66-71] (Table 1.1). Between 17% and 
97% of HPV(-) tumours display CDKN2A alterations and no HPV(+) tumours have 
been reported to display any such alterations (Table 1.1) [36, 66-71]. As discussed 
earlier, the CDKN2A gene encodes for the p16INK4A protein, which is involved in 
senescence and differentiation signalling (Figure 1.7). Due to the pRB protein 
being a negative regulator of p16 and pRB being inactive in HPV(+) tumours, the 
p16 protein is often used as a marker for HPV [36, 67-69, 81, 82]. In addition, it 
has been shown in cervical carcinoma cell lines that E7 expression can induce 
expression of the histone demethylase protein, KDM6B which in turn can induce 
p16INK4A expression [83]. 
1.5.5 Amplification of chromosome 11q13 (CCND1, FADD, CTTN) 
Amplification of the 11q13 chromosome containing the CCND1, FADD (fas 





HNSCC tumours and the majority of amplifications are observed in HPV(-) 
tumours [36, 67-69, 84, 85] (Table 1.1). CCND1, which encodes cyclin D1, has 
been reported to be an oncogene in many cancers including HNSCC, breast, 
bladder, liver and lung cancers [86]. The FADD (fas associated via death domain) 
gene is an adaptor molecule involved in apoptosis by interaction with cell surface 
death receptors, inducing caspase recruitment to initiate apoptosis [86]. FADD 
expression is linked to HNSCC metastasis and decrease in patient survival [86]. 
Amplification of CTTN, which encodes cortactin (an actin binding protein), has 
been observed in several cancers, including HNSCC and has a role in tumour cell 
migration and invasion [86].  
1.5.6 Amplification of chromosome 11q22 (BIRC2 and YAP1) 
The TCGA have reported chromosome 11q22 as being frequently amplified in 
HNSCC, which has also been observed in lung, cervical and oesophageal SCC [36, 
66] (Table 1.1). This chromosome location contains the BIRC2 (baculoviral IAP 
repeat-containing protein 2) and YAP1 (yes-associated protein 1) genes [36]. The 
BIRC2 gene encodes for a member of the cellular inhibitor of apoptosis family of 
proteins (c-IAP1), which inhibits caspase activity including CASP8 (cysteine-
dependent aspartate-directed proteases) [23]. The CASP8 gene, which encodes for 
the pro-apoptotic enzyme caspase 8, is also mutated in HNSCC more frequently in 
HPV(-) tumours than in HPV(+) [36, 68, 69] (Table 1.1).  
The YAP1 gene encodes the YAP protein. YAP1 is often observed as being 
overexpressed in many cancers, including prostate, ovary and colon [87]. YAP is 





growth and cell-cell contact signalling [88]. In HNSCC, YAP has been reported to 
be upregulated compared with surrounding benign tissues, furthermore, YAP 
expression has been observed more strongly at HNSCC tumour margins [87].  
1.5.7 Amplification of the EGFR gene 
Recurrent focal amplifications of the EGFR gene were observed primarily in HPV(-
) tumours (3-40%), which has also been confirmed by other studies [36, 67, 89, 90] 
(Table 1.1). In HNSCC, EGFR amplification is commonly observed with PIK3CA, 
AKT1, RPS6KB1 (ribosomal protein S6 kinase B1) and MYC (MYC proto-
oncogene, bHLH transcription factor) gene amplifications [70]. Amplification of 
genes of other tyrosine kinase receptors- Erb tyrosine kinases (ERBB2, ERBB3, 
ERBB4) have also been observed [36]. Despite EGFR amplification occurring in 3-
40% of the HNSCC tumour cohorts investigated, EGFR protein overexpression is 
observed in up to 90% of HNSCC tumours [70, 91] (Table 1.1). Therefore, EGFR 
expression may be increased by an alternative, mutation-independent mechanism.  
1.5.8 Mutations of the AJUBA and FAT1 genes 
AJUBA (ajuba LIM protein) is altered exclusively in of HPV(-) tumours, while 
FAT-1 is altered in 14-57% of HPV(-) tumours and in 3% of HPV(+) tumours [36, 
66, 68-71]. Both AJUBA, which is a tumour suppressor protein, and FAT1 are 
involved in the WNT and Hippo pathways [29]. AJUBA is a LIM domain-
containing protein, which forms part of a larger family of LIM proteins [29]. In 
primary keratinocyte cells, through interaction with the WNT/-catenin pathway, 





reported to associate with LATS (large tumour suppressor kinase)-1/2 of the Hippo 
pathway [29]. LATS proteins are kinases, which are negative regulators of the 
Hippo pathway, as they mediate inhibition of the downstream family of 
transcription factor effectors, TEAD (TEA domain transcription factor)-1-4 [88, 
92]. The FAT1 protein is part of the family of cadherin proteins, also involved in 
cell adhesion [29]. In addition, FAT1 has been linked to the WNT/-catenin 
pathway, as FAT1 can bind to -catenin to inhibit -catenin-mediated gene 
transcription [29]. Recently, it has been reported that loss of FAT1 results in YAP 
activation in HNSCC [93].  
Therefore, analysis of genetic alterations in the datasets outlined in Table 1.1 reveal 
that alterations are observed both in HPV(-) and HPV(+) HNSCC tumours. While 
the signature of gene alterations differ in HPV(+) tumours compared to HPV(-), 
these alterations can affect the same pathways in both tumour types (Figure 1.8). 
In addition to the complicated molecular landscape, there are clinical differences 
between patients suffering from HPV(-) and HPV(+) HNSCC. For example, 
patients with HPV(+) HNSCC tumours tend to be younger than those diagnosed 
with HPV(-) (median age: 53.5 and 57 years old, respectively). Furthermore, 
prognosis is often poorer for patients suffering from HPV(-) tumours compared to 
those with HPV(+) tumours [94]. Therefore, the treatment of HNSCC remains 








Figure 1.8. Genetic and pathway alterations in HPV(-) and HPV(+) HNSCC tumours. 
The pathways deregulated in HPV(+) and HPV(-) HNSCC tumours can be common. In 
HPV(+) tumours, the viral oncoproteins E6 and E7 can hijack the p53 and pRB proteins, 
respectively, leading to deregulation of the cell cycle. In HPV(-) tumours, inactivating 
mutations and/or deletions in TP53 and CDKN2A genes can lead to deregulation of the p53 
and pRB proteins. EGFR amplifications can lead to deregulation of the EGFR/PI3K/AKT 
pathway. Loss of FAT1 and AJUBA genes through inactivating mutations and deletions can 
lead to deregulation of the WNT/-catenin pathway. In both HPV(+) and HPV(-) tumours, 
E2F1 amplifications can deregulate p53 and pRB. PIK3CA amplifications and loss of 
NOTCH1-3 genes can lead to deregulation of the WNT/-catenin, EGFR/PI3K/AKT and 
NOTCH pathways. 
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1.5.9 Detection of HPV 
To determine the HPV status of HNSCC tumours, one of the most commonly used 
methods is immunohistochemical staining for p16INK4A. Levels of p16INK4A can 
increase as a result of HPV infection, as the inactivated pRB protein is a negative 
regulator of p16INK4A [63, 95]. In addition, as mentioned earlier, E7 expression can 
induce KDM6B expression, leading to increased high p16INK4A expression [83]. 
PCR (polymerase chain reaction) or immunohistochemistry can also be used to 
detect HPV DNA and determine HPV status [23]. However, the disadvantage of 
DNA-based methods is that the presence of viral DNA may not mean cell 
transformation and cancer, as persistent HPV infection is required for this [96]. In 
fact, nearly all HPV infections (~90%) are cleared in 6-24 months [96, 97]. In 
addition, the presence of HPV DNA does not mean the virus is driving the tumour, 
other factors may induce lead to tumour formation. Therefore, detection of HPV 
DNA can be useful in determining the HPV status of the tumours but is not very 
predictive of HNSCC development. A more predictive marker of HPV 
transformation is the detection of RNA of the viral oncoproteins E6/E7, as the 
presence of RNA indicates a transcriptionally active viral genome [36, 97]. 
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1.6 HNSCC therapies 
HNSCC tumours are currently treated with a combination of therapies including 
surgery, radiation and adjuvant chemotherapy [23]. Early stage tumours are 
typically treated with surgery and radiation, while more advanced tumours are 
treated with a combination of all three therapies [23, 98]. Most recent progress in 
the development of HNSCC therapies include targeted immunotherapies to combat 
the immunosuppressive nature of HNSCC [99]. However, despite these advances, 
the five-year HNSCC survival rate reported in 2015 was 25-40% for HPV(-) and 
70-80% for HPV(+) tumours and these numbers have not changed in the past three 
decades [100, 101]. 
As discussed earlier, recurrent focal amplifications of EGFR are observed in 
HNSCC, with up to 90% of tumours displaying EGFR protein overexpression [36, 
102, 103]. The importance of EGFR overexpression in HNSCC is highlighted by 
its association with reduced overall survival [36]. Therefore, inhibition of EGFR 
was introduced as one of the therapies for HNSCC patients [104]. 
1.6.1 Monoclonal antibodies and tyrosine kinase inhibitors as 
therapies 
In 2006, a monoclonal antibody called cetuximab, which inhibits the EGFR was 
approved by the Food and Drug Administration (FDA) as a therapy for HNSCC 
[104]. Cetuximab targets the EGFR extracellular domain and blocks EGFR by 
competition with ligands for the ligand-binding domain (Figure 1.9). Furthermore, 
in HNSCC cells it has been reported that inhibition by a monoclonal antibody can 
result in internalisation of the receptor, preventing ligand binding [26]. This can 
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lead to inhibition of cell growth and induction of apoptosis [28]. A second 
mechanism of action of cetuximab is antibody-dependent cell-mediated 
cytotoxicity (ADCC) [105]. ADCC is an EGFR-independent mechanism, which 
involves the Fc region of the antibody interacting with Fc receptors on immune 
effector cells [105, 106]. This triggers an immune response rendering tumour cells 
more susceptible to cytotoxicity [105, 106]. 
A second class of EGFR inhibitors are tyrosine kinase inhibitors, which inhibit the 
intracellular tyrosine kinase domain (Figure 1.9). An example of this is an 
experimental drug called, AG1478 (tyrphostin). AG1478 and mAB 806 (an 
experimental EGFR epitope-binding drug), have been used together to successfully 
inhibit growth of a xenograft composed of an oral SCC cell line [107]. It was 
demonstrated that AG1478 can induce a conformational change of EGFR, allowing 
mAb 806 to bind with greater affinity [107]. 
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Figure 1.9. EGFR as a therapeutic target.  
EGFR contains two main targetable domains, (i) the extracellular domain, which harbours 
the ligand-binding domain, and (ii) the intracellular domain, which upon ligand binding 
and receptor activation, is involved in receptor dimerization. Extracellular domain: all 
therapies of the extracellular domain are monoclonal antibodies. Cetuximab, 
panitumumab, are antibodies which block ligand-binding. Sym004 and MM-151 consist 
of a mixture of antibodies, which bind to non-overlapping EGFR epitopes in order to 
increase efficacy of the therapy. mAb 806 is EGFR epitope-binding. mAb 528 inhibits the 
ligand-binding domain. MEHD7945A binds both EGFR and ERBB3 to prevent 
heterodimerisation. Intracellular domain: all therapies of the intracellular domain are 
tyrosine kinase inhibitors. Gefitinib, erlotinib and PD153035 are reversible tyrosine 
kinase inhibitors, which compete for the kinase domain with ATP to inhibit receptor 
activation by phosphorylation. Lapatinib inhibits both EGFR and ERBB2 receptors. 
Afatinib binds irreversibly to the kinase domain. AG1478 is an EGFR-specific molecule, 
which competes reversibly for the kinase domain and induces a conformational change. 
Therapies approved for cancer treatment by the FDA are in bold within the figure. (Figure 
adapted with permission from Tebbutt and Pedersen., 2013 [108]). 
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1.6.2 Cetuximab resistance and alternative therapies 
Despite EGFR overexpression being identified in 90% of HNSCC tumours, only 
10-20% of patients respond to the cetuximab treatment [109, 110]. Moreover, it has 
been demonstrated that cetuximab resistance cannot be predicted by EGFR copy 
number [110, 111]. This indicates that the EGFR pathway does not function 
independently and therefore, elucidating co-regulators may offer alternative or 
complementary therapies to cetuximab. 
Mechanisms of cetuximab resistance have been investigated by many groups. For 
example, it has been demonstrated that ERBB2 gene overexpression has been 
associated with resistance to cetuximab [112, 113]. Furthermore, the use of 
lapatinib, an EGFR and ERBB2 tyrosine kinase inhibitor, in conjunction with 
chemoradiation has been shown to increase overall survival by 11% [114, 115]. 
Another mechanism of cetuximab resistance involves epithelial to mesenchymal 
transition (EMT). During EMT, phenotypic changes that appear to facilitate 
metastasis include loss of cell junction proteins and has been associated with 
gefitinib resistance [116]. In addition, upregulation of EMT markers such as 
vimentin have been observed in cetuximab resistant cell lines [117]. Another 
mechanism of cetuximab resistance is overexpression of proteins involved in the 
suppression of immune effector cells. For example, the cytokine TGF-, which has 
been shown to be overexpressed in HNSCC cells can also suppress immune effector 
molecules, thereby supressing the function of cetuximab [105, 118]. Therefore, 
alternative therapies to target the EGFR pathway could involve targeting the 
immune system.  
   
37  
In 2016, the first HNSCC treatment since cetuximab, Pembrolizumab (an anti-
programmed cell death-1 (PD-1) antibody) was FDA-approved [101]. PD-1 is an 
immunoreceptor, which upon ligand activation can induce cell survival in HNSCC 
[101]. Pembrolizumab has shown promise in an ongoing trial, as decreases in 
HPV(-) and HPV(+) tumour lesion size have been observed in 57% and 62% of 192 
patients, respectively [119]. Moreover, recently, the TCGA have highlighted 
upregulation in RNA levels for PDL (programmed cell death ligand)-1 [66]. 
Despite the development of a new therapy and extensive investigation of the genetic 
landscape, between the development and clinical use of cetuximab and 
pembrolizumab there was a ten-year gap. Therefore, many aspects of HNSCC 
biology require enhanced investigation. One approach could be to define the cis-
regulatory network by interrogation of epigenetic gene regulation such as 
transcription factor binding and chromatin changes in HNSCC. 
1.7 Chromatin structure 
The human genome consists of 3.2×109 nucleotides and the structure of chromatin 
allows this considerably large structure to be packaged into a relatively smaller 
nucleus [120] (Figure 1.10). This is achieved by DNA being wrapped around 
proteins called histones to form a nucleosome complex. A nucleosome consists of 
147bp of DNA wrapped around a histone octamer [121] (Figure 1.10). The octamer 
consists of four types of histone proteins, H2A, H2B, H3 and H4, which assemble 
into two histone H2A-H2B dimers and one H3-H4 tetramer [121]. In between each 
nucleosome is a stretch of DNA called ‘spacer DNA’, which is bound to the H1 
linker histone [121] (Figure 1.10). Nucleosomes can be further assembled into a 
higher order chromatin structure, where the chromatin coils into a ‘30nm fibre’ and 
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is further packaged to form a chromatid and eventually a chromosome [122]. Apart 
from the packaging of DNA, a second feature of chromatin structure is its influence 
on gene transcription by either occluding or exposing DNA sequences to proteins 




Figure 1.10. Chromatin structure.  
Chromatin consists of DNA and its associated proteins. Nucleosomes are 147bp of DNA 
wrapped around eight histone proteins to form an octamer. An octamer consists of two 
H2A-H2B dimers and one H3-H4 tetramer. The nucleosomes are linked by the H1 linker 
histone (spacer histone), which binds to the loops of DNA in between nucleosomes. 
Nucleosomes can further coil into a ’30nm fibre’, which is further packaged to form a 
chromatid and eventually a chromosome (Figure adapted with permission from Figuiredo 
et al., 2009 [123]). 
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1.8 Cis-regulation 
Only ~1.5% of the human genome is involved in encoding an estimated 20,000 
genes [124-126]. Therefore, nearly 99% of the genome is involved in functions 
other than protein coding. It is now known that a part of the non-protein-coding 
DNA sequences form distinct regions called regulatory elements, such as 
promoters, enhancers, silencers and insulators [126] (Figure 1.11). These elements 
have a role in cis-regulation of gene expression, which is spatially and temporally 
coordinated by TF proteins, co-activator proteins, chromatin remodelling 
complexes and associated epigenetic modifications (DNA methylation and post-
translational histone modifications) [127].  
1.8.1 Insulator and silencer elements 
One type of regulatory element are insulators, which are found at gene boundaries 
and function to block the neighbouring gene from becoming active [128]. Insulator 
elements are bound by TF repressor proteins such as, CTCF (CCCTC- binding 
factor) [129] (Figure 1.11). Recently, a role for insulator elements has been 
demonstrated in topologically associating domains (TADs) [130-132]. TADs are 
discrete chromatin domains of several megabases and serve distinct biological 
functions. For example, developmental genes involved in cell identity may be 
contained within a TAD and to prevent interaction of the genes with those in other 
regions, insulator elements maintain the boundary between different TADs [130-
132].  
A second type of element are silencer elements, which as the name suggests, 
function to silence gene transcription and can be found as a part of promoter or 
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enhancer elements [128] (Figure 1.11). Similarly to insulator elements, silencer 
elements function by facilitating the binding of TF repressors [128]. Repressors 
may recruit co-factor proteins (co-repressors) to interfere with transcription 
activating proteins [128].  
It is important to mention that other non-coding DNA elements exist apart from the 
ones mentioned above. For example, repeat elements, which make up nearly 50% 
of the genome, have a role in genomic maintenance and make up non-coding RNA 
such as microRNAs, which can repress RNA by blocking their translation or 
targeting the RNA for degradation [126, 133, 134]. In addition to these elements, 
promoter and enhancer elements are required for gene function, as discussed later. 
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Figure 1.11. Gene structure.  
Gene regulation is mediated in part by four regulatory elements: promoters, enhancers, 
insulators and silencers. Promoters are typically found in proximity to a TSS (transcription 
start site) of a gene and can consist of three units; the core, proximal and distal promoters. 
The core promoter contains the TSS and TATA box; the assembly sites for transcription 
initiation factors, such as RNA polymerase II. The proximal and distal promoters are sites 
of TF binding, which facilitate binding of transcription initiation machinery. Enhancer 
elements can facilitate gene transcription by binding to promoters via TFs. Spatially, 
enhancer elements can be proximal or distal to the promoter element and can be up- or 
downstream of the promoter. Insulator elements, which often overlap with gene 
boundaries, restrict transcription by blocking neighbouring genes from being activated. 
Insulators are bound by TF repressors such as CTCF, which has many functions, among 
which is aiding insulator function. Silencer elements are also sites of repressor TFs and 
block transcription. The N-termini of histones (also known as histone tails) are sites of post-
translational modifications (PTMs). PTMs include acetylation and methylation of lysine 
amino acid residues; H3K4me1, -me2 and -me3 are marks of active enhancers; H3K27me3 
is a poised enhancer mark; and H3K4me3 is also a mark for active promoter elements. 
Histone protein variants H3.3 and H2A.Z, along with histone marks of active enhancers, 
are often found flanking TF binding sites. (Figure adapted with permission from Ong and 
Corces., 2011[135]). 
   
42  
1.8.2 Transcription factor binding to regulatory elements 
Approximately 5-7% of the genome encodes between 1,700 and 1,900 TFs [136, 
137]. Regulatory elements harbour TF motifs (short DNA sequences between 6-
12bp), which allow TF recognition and interaction with regulatory elements [137]. 
TFs have been reported to display at least 1,000-fold more affinity for TF motifs 
compared to other sequences [137]. The motifs can be computationally predicted 
and classified into families by sequence homology to previously characterised TF 
DNA-binding domains [137].  
Upon binding to the DNA, TFs can either activate or repress transcription [137]. 
For example, in laryngeal SCC cell lines, it has been shown that Np63 can directly 
bind to the YAP1 promoter to inhibit its expression [138, 139]. Furthermore, TF 
binding can be dependent on other TFs. For example, TF binding investigated in 
mouse embryonic stem cells revealed regions where Nanog (nanog homeobox), 
Oct4 (POU5F1- POU class 5 homeobox 1) or Sox2 TFs cluster and preferentially 
bind together [140]. Depletion of Nanog or Oct4 led to a decrease in the number of 
TF interactions at these regions [140].  
1.8.3 Promoter-enhancer interactions 
In order for gene transcription to occur, the promoter element (core promoter) is 
located near to the gene transcription start site (TSS) and serves as a hub for the 
assembly of transcription machinery, such as the RNA polymerase II enzyme 
(RNAP II) and the pre-initiation complex (PIC) [127] (Figure 1.11). This process 
is facilitated by TFs, as they can directly recruit transcription machinery. For 
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example, the TBP (TATA-binding protein) TF can directly recruit RNAP II to the 
promoter [137]. 
Enhancer elements are required for the activation of promoters to initiate gene 
transcription. Enhancer elements are sequences typically between 200-500bp and 
are largely found in intergenic and intronic regions [141]. Rarely, some enhancer 
elements can overlap with exons of neighbouring genes or with the exons of genes 
they regulate [142-144]. Enhancers can activate transcription by interacting with 
one or more promoters, but enhancers can often be several kilobases away from 
their promoter [145]. One of the most striking examples of this is an enhancer for 
the POU3F4 (POU class 3 homeobox 4) gene, which is located 900kb upstream of 
its target [146]. A mechanism as to how promoter and enhancer interactions may 
occur is DNA looping, which will be discussed in the next section. 
In order for enhancer elements to carry out their function, TF binding is required. 
TFs can exhibit specificity to enhancer elements, as demonstrated in a study by 
Visel et al., which revealed that, of 41 TF motifs identified in enhancer elements, 
at least 90% were unique to its enhancer and were not found at promoter elements 
[147]. This has been confirmed by another group who investigated TF binding in 
mice, and found 7/14 TFs (e.g. Oct4, Sox2 and Nanog) bound preferentially to 
enhancers, while the remainder (e.g. c-Myc), bound promoter elements [148].  
Upon TF binding to enhancers, recruitment of other proteins (co-activators) can be 
required to induce transcription [149]. Co-activators do not harbour specific motifs 
enabling them to bind regulatory elements, but can recognize different chromatin 
states (i.e. accessibility) and alter chromatin state through histone modifying 
enzymatic activity, i.e. histone acetyltransferases (HATs), histone 
   
44  
methyltransferases (HMTs) or ATP-dependent chromatin remodelling complexes, 
as will be discussed later [150]. 
Therefore, in order for enhancers to facilitate transcription, two main criteria must 
be fulfilled; firstly, chromatin decondensation must occur to allow TFs access to 
enhancers; and secondly, the chromatin structure must be altered, a process known 
as DNA or chromatin looping, to allow proximity and interaction between 
enhancers and promoters [145]. There are several mechanisms which can influence 
chromatin structure, which include DNA looping, chromatin remodelling 
complexes, histone modifications and DNA methylation, as discussed next. 
1.8.4 DNA looping 
It is not yet fully understood how enhancers and promoter elements gain proximity. 
One model is DNA looping, a mechanism first proposed by Rippe et al., 1995 and 
since then many models have been put forward as to how DNA looping may occur 
[151, 152]. The most commonly reported model involves architectural proteins: 
CTCF (CCCTC-binding factor), cohesin and the mediator (MED) complex [152, 
153] (Figure 1.12). The model suggests that sections of the chromatin at both 
enhancers and promoters are surrounded by a ring-like cohesin complex, along with 
MED complexes and CTCF [152] (Figure 1.12B). It is thought that CTCF has a 
role in separating folding chromatin domains, while also maintaining the position 
of cohesin [154]. TF binding has also been shown to influence chromatin structure, 
as recruitment of factors such as Nanog and Oct4 have been observed during DNA 
looping [140]. 
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Figure 1.12. DNA looping.  
(A) In a transcriptionally inactive state, enhancers can be located several hundred kilobases 
away from their target promoter. (B) Upon binding of TFs to enhancers and promoters, 
both elements are brought into proximity with each other. It is thought that promoter-
enhancer proximity occurs by DNA (chromatin) looping, which involves the architectural 
proteins: cohesin, mediator (MED) protein and CTCF. Both enhancers and promoters are 
surrounded by a ring-like cohesin complex, along with MED complexes and CTCF. CTCF 
may function to separate the folding chromatin domains, while also maintaining the 
position of cohesin. TF recruitment also occurs during DNA looping and may aid the 
process. 
 
1.8.5 Chromatin remodelling complexes 
One of the mechanisms by which chromatin decondensation can be induced is with 
the aid of chromatin remodelling complexes (CRCs). CRCs can use ATP energy to 
reposition nucleosomes, hence exposing TF motifs for TF binding [155]. Four 
families of ATP-dependent CRCs exist, the SWI/SNF family (switching 
defective/sucrose non-fermenting), ISWI family (imitation switch), the NuRD 
family (Mi-2/nucleosome remodelling and histone deacetylation) and the INO80 
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family (inositol requiring 80) [155]. Interestingly, ACTL6A (actin like 6A), a 
subunit of the SWI/SNF CRCs, is overexpressed in laryngeal SCC cells and has 
been associated with increased cell proliferation [155].  
1.8.6 Histone modifications 
In addition to the distinct functions carried out by regulatory elements which are 
mediated by TFs, histone modifications are also required to aid spatially and 
temporally coordinated gene regulation.  
The N-terminal histone tails can undergo post-translational modifications (PTMs), 
including addition of acetyl, methyl, phosphate or ubiquitin groups, amongst others 
[121]. These modifications are added or removed by enzymes specific to the PTM; 
acetyl groups are transferred by histone acetyltransferases (HATs) and removed by 
histone deacetylases (HDACs), while methyl groups can be transferred by histone 
methyltransferases (HMTs) and removed by histone demethylases (HMT) [150]. 
The addition of PTMs occur on specific amino acid residues, for example, 
acetylation occurs on lysine residues, while methylation occurs on arginine, lysine 
and histidine residues [121]. It is important to note that this is not an exhaustive list 
of PTMs and the same PTM can be added on to an amino acid residue multiple 
times [156]. The common nomenclature for denoting a histone modification is, for 
example, H3K27Ac, which is acetylation of lysine 27 of histone H3. Methylation 
is denoted with ‘me’ and the number of modifications can be denoted by mono-, di- 
or tri- (me1, me2 and me3, respectively). 
PTMs have distinct effects on chromatin structure and therefore on DNA 
accessibility. For example, the addition of an acetyl group can neutralise the 
histone’s positive charge, relaxing the chromatin, leading to select DNA sequences 
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being made accessible to TFs [157]. An example of a histone modification leading 
to an open (active) chromatin state is H3K27ac [121]. On the other hand, 
methylation of histone tails can make DNA inaccessible, for example H3K9me is 
typically associated with closed, inactive chromatin [121]. 
Altered histone modifications resulting from expression changes of their respective 
enzymes have been associated with many cancers, including oral SCC. For 
example, HDAC6 overexpression has been observed in oral SCC cell lines and is 
associated with tumour aggressiveness [155]. In a further example, increased 
HDAC-8 and -9 levels have been associated with increased cell proliferation in oral 
SCC cells [155].  
1.8.7 DNA methylation 
DNA can also undergo modifications by addition of methyl groups onto the fifth 
carbon of the cytosine residue in CpG dinucleotides [158, 159]. Methylation of 
DNA is largely associated with gene silencing and inaccessible chromatin. For 
example, methylation has a role in X chromosome inactivation and genetic 
imprinting [159]. A family of DNA methyltransferase (DNMT) enzymes carry out 
methylation of CpGs and can be removed either by a family of TET (ten-eleven 
translocation) enzymes or by a passive process of DNA demethylation, which is 
dependent on replication [159]. Approximately, 15% of CpG dinucleotides are 
found in CpG islands (CGIs), which are dense regions of CpGs defined as 
containing a GC content of more than 50% [159]. CGIs overlap with ~70% of all 
gene promoter elements in the human genome [159]. 
Alterations in the pattern of DNA methylation is commonly observed in cancer 
cells, in the form of, for example, hypermethylation and is frequently found to affect 
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tumour suppressor genes such as TP53 [160]. Recently, the PanCancer Atlas study, 
which used TCGA data derived from lung, HNSCC, oesophageal, cervical and 
bladder tumours to investigate alterations common to SCC, reported 
hypomethylation of CpGs near the Np63 TSS, which may be a reason for its 
overexpression in HNSCC [66].  
1.9 Cell-specificity and identification of regulatory 
elements 
As highlighted thus far, cis-regulation is a complicated and dynamic process, reliant 
on coordination between several regulatory elements, DNA/histone modifications 
and TF proteins. This coordination can be further refined by cell type specificity of 
enhancers. For example, within the mammalian genome, some 400,000 to 1.4 
million putative enhancers have been identified and each cell type can contain 
between 10,000 and 150,000 enhancers [161, 162]. Therefore, due to their complex 
nature, both abundance and lack of distinguishing features, genome-wide 
identification of enhancers has proven difficult. Several criteria are used to identify 
enhancer elements, which involve interrogation of the local chromatin structure 
through histone modifications, TF binding, nucleosome occupancy and sensitivity 
to DNase I digestion [147]. 
In 2004, the challenge of characterising enhancers was undertaken by the ENCODE 
(ENCyclopaedia Of DNA Elements) consortium [163]. The pilot ENCODE project 
involved using genome-wide methods to sequence and annotate ~1% of the human 
genome, including regulatory elements [163]. With the advance in genome-wide 
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methods, this study was followed up in 2012 to encompass sequencing data from 
147 cell types [164].  
One of the features of enhancers highlighted by ENCODE were histone 
modifications [164]. Histone modifications on enhancer elements can indicate three 
different enhancer states, active, silent and poised. For example, the histone 
modifications H3K27ac and H3K4me1 are marks of active enhancers, while 
H3K27me3 is a mark of silenced enhancers [164-167]. Poised enhancers are largely 
associated with developmental genes, which are poised for expression upon 
differentiation [168]. Poised enhancers therefore possess both repressive marks and 
active marks [167, 169]. To identify putative enhancers, an approach used in many 
studies is genome-wide chromatin immunoprecipitation, followed by sequencing 
(ChIP-seq) for enhancer histone marks (H3K4me1 and H3K27ac) [129, 162, 164, 
170]. To verify the DNA sequences as enhancers, reporter assays can be conducted 
where the reporter construct contains the putative enhancer sequence next to a 
promoter element upstream from a reporter gene [129, 162, 164, 170]. 
A second feature of enhancers and method of identification is the presence of two 
histone variants H3.3 and H2A.Z. Nucleosomes consisting of these histone variants 
are unstable and coupled with active histone marks (H3K27ac and H3K4me1), the 
nucleosomes offer easier access to occluded TF binding sites [129, 168, 171]. 
Therefore, the presence of H3.3 and H2A.Z often mark active enhancers [172].  
Another characteristic of enhancers was described by Heintzman et al., where p300, 
a HAT enzyme, was discovered as a marker for enhancers, demonstrating their cell 
type-specific pattern. In addition, p300 was shown to overlap with DNase I-
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hypersensitive sites (DHSs), which are indicative of regulatory elements, as will be 
discussed later [129, 167].  
1.10 Enhancer clusters and stretch enhancers 
In addition to typical enhancer elements described above, several studies have 
reported that enhancers can also be found clustered in 2D space [173-177]. These 
enhancer types were termed ‘super-enhancers’ and were first introduced by Whyte 
et al. in 2013 [173, 175]. However, this term implies an enhanced role of these 
elements in transcriptional regulation, but this is yet to be proven. Therefore, in this 
thesis, super-enhancers will be called ‘enhancer clusters’ (ECs). 
ECs have been implicated as features of the chromatin, which can reflect cell 
identity. They were first described in mouse embryonic stem cells and were found 
to be bound by master TFs, Oct4, Sox2 and Nanog, which have an essential role in 
development [173, 175]. The criteria for defining an EC was the following: (i) a 
site bound by all three master TFs, (ii) concatenation of neighbouring enhancers 
within a 12.5 kb region, and (iii) the concatenated 12.5kb regions were ranked based 
on Med1 enrichment levels, normalised to the background (Figure 1.13). A ranked 
score of more than one was defined as an EC and the remaining enhancers were 
classed as ‘normal’ [173] (Figure 1.13). The criteria set out by Whyte et al. for EC 
identification has not been adhered to by all groups. For example, instead of using 
the master TFs as markers of enhancers, alternative enhancer marks have been used 
such as, H3K27ac [174, 175]. In addition, in the final step, instead of Med1 
enrichment, H3K27ac levels or MyoD (myoblast determination protein D) levels (a 
master TF involved in mouse development) have been used to assess for enhancer 
enrichment [173, 175]. 
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Other features of ECs, which separate them from ‘normal’ enhancers, include EC 
median length, which was reported to be 8,667bp compared to 703bp, respectively. 
In addition, ECs are more enriched for enhancer features such as DNase I 
sensitivity, RNA polymerase II, p300, H3K4me1, H3K4me2 and H3K27ac marks 
[175]. 
Interestingly, ECs have been associated with known oncogenes, for example, EGFR 
in glioblastoma and pancreatic cancer, ERBB2 in liver, breast, prostate and 
colorectal cancers and NOTCH1 in T-cell leukaemia, lung, prostate and colorectal 
cancers [175]. Furthermore, an EGFR EC was identified in a cervical cancer cell 
line where it was reported to be activated by E6 expression [178]. Activation of the 
EGFR EC was shown to be induced by E6-mediated degradation of KDM5C (lysine 
demethylase 5C), a demethylase enzyme. This leads to deregulation of H3K4me1 
and H3K4me3 histone marks at the EGFR EC [178]. An EC has also been identified 
for the KLF (Krüppel-like factor)-5 gene in HNSCC tumours, where focal 
amplifications of the KLF5 EC have been linked to KLF5 protein overexpression 
[179]. The same study found that the KLF5 gene can activate transcription of genes 
associated with SCC cell identity such as KRT (keratin)-5, KRT6A, KRT13, TP63 
and WNT10A.  
Another type of enhancer has been described by Parker et al. called ‘stretch-
enhancers’, named due to their main feature of spanning more than 3kb. Unlike 
ECs, stretch-enhancers are not concatenated regions [141]. Stretch-enhancers have 
been associated with pancreatic islet function and linked to type 2 diabetes [177]. 
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Figure 1.13. Identification of enhancer clusters (ECs). 
ChIP-seq was conducted for cell type-specific master TF regulators and for MED1 
(Mediator 1). Regions of 12.5kb, which were co-bound by the TFs and exhibited MED1 
enrichment (normalised to background MED1 occupancy) were concatenated. 
Concatenated and individual enhancers were ranked by MED1 enrichment; MED1 ranking 
was geometrically scaled from 0-1. The point was determined for where a line with a slope 
of 1 was tangent to the curve. Regions beyond this point were considered to be ECs, while 
regions below were considered to be ‘normal’ enhancers. 
 
1.11 Genome-wide methods to identify accessible 
chromatin 
In addition to the abundance of features, regulatory elements are also characterised 
by accessible chromatin structure. These regions are found at nucleosome-depleted 
or structurally unstable chromatin regions during chromatin decondensation. Such 
regions overlap with regulatory elements to facilitate gene transcription [180-182]. 
Accessible chromatin and therefore DNA become sensitive to nuclease enzymes 
and can be exploited to identify regulatory elements [183, 184]. 
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Enzymes such as DNase I endonucleases and Tn5 transposases have been used, 
followed by genome-wide next-generation sequencing, giving rise to techniques 
such as, DNase I hypersensitivity assay (DNase I-seq) and Assay for Transposase 
Accessible Chromatin-sequencing (ATAC-seq), respectively. An alternative 
method to identify open chromatin regions is the FAIRE (formaldehyde-assisted 
isolation of regulatory element) assay, as discussed later. 
1.11.1 DNase I hypersensitivity assay (DNase I)-sequencing 
The DNase I assay involves the isolation of nuclei, followed by limited chromatin 
digestion with the DNase I enzyme, which preferentially digests open regions of 
the chromatin or regions with unstable nucleosomes, giving rise to DNase I 
hypersensitive sites (DHSs) [185].  
The assay was further advanced with the development of next-generation 
sequencing to identify DHSs genome-wide, giving rise to DNase I-sequencing 
(DNase I-seq). The field of next-generation sequencing has been rapidly advancing, 
and many platforms are available (reviewed in Barba et al., 2014). One of the more 
commonly used platforms is the Illumina HiSeq 2500 sequencer, which has the 
capacity to sequence the whole human genome in 24 hours [186]. However, to 
produce meaningful data (i.e. data of high enough resolution to minimise 
background noise) biological and technical factors must be considered, such as 
DNA complexity (particularly GC content) and depth of coverage [187]. A deeper 
depth of coverage increases signal of the data and reduces background, however 
this has to be compromised with cost as higher coverage is more expensive [186].  
DNase I-sequencing (DNase I-seq) has revealed that the genomic distribution of 
DHSs largely overlaps with intronic and intergenic regions and therefore with 
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enhancers [142-144]. Another characteristic of DHSs is their reflection of the cell 
type-specific nature of enhancers. For example, DNase I-seq was performed in 19 
cell lines and intergenic DHSs were the most cell type-specific, while DHSs 
overlapping with TSSs were the least cell specific [188]. Another study reported 
cell type-specific DHSs to be distal to TSSs, indicating overlap with distal 
regulatory elements [189].  
While the assay is a valuable tool to isolate regulatory networks, a drawback is that 
it requires between 25-50 million cells per DNase I preparation [190]. Furthermore, 
the required depth of coverage is 20-50 million reads [191]. A second method to 
identify open chromatin regions is FAIRE-seq. 
1.11.2  FAIRE (Formaldehyde-Assisted Isolation of Regulatory 
Elements)-sequencing 
In the FAIRE assay, to preserve DNA-protein interactions, the chromatin is 
crosslinked with formaldehyde, followed by shearing by sonication and phenol-
chloroform separation of the nucleosome-free and nucleosome-bound DNA [192, 
193]. Subsequently, qPCR (quantitative polymerase chain reaction) or next-
generation sequencing (FAIRE-seq) can be used to identify the DNA sequences. 
Similarly to the DNase I-seq assay, FAIRE-seq requires cells in the millions (1-50 
million) [194]. The advantage of FAIRE-seq is that nuclei isolation is not required 
as in DNase I-seq [191]. Instead, chromatin crosslinking by formaldehyde is 
required, which preserves DNA-protein contacts [191]. Many groups have utilized 
the assay, including the ENCODE Consortium [164]. However, optimization of the 
fixation step is required and the signal:noise ratio in FAIRE is much lower 
compared to DNase I-seq [189]. 
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Comparisons of FAIRE-seq and DNase I-seq assays have revealed that there is a 
discrepancy in the regions identified by both methods. For example, it was found 
that 30-40% of the top 100,000 peaks (regions) from a total of 870,000 across seven 
cell lines overlapped, while 80% of the top 10,000 peaks overlapped [189]. This 
suggests the most stable peaks are more frequently identified by both assays. To 
investigate this further, ChIP-seq was conducted for CTCF and MYC TFs to 
identify accessible regions and then compared with peaks identified in DNase I-seq 
and FAIRE-seq [189]. It was found that over 96% of ChIP peaks overlapped in both 
assays. A similar result was found when p63 ChIP-seq was conducted; it was found 
that 80% of peaks overlapped with all three assays [189]. Therefore, the vast 
majority of open regions are identified by both assays, but DNase I-seq 
demonstrates a better signal:noise ratio. 
1.11.3 ATAC (Assay for Transposase-Accessible Chromatin)-
sequencing 
More recently, the ATAC-seq assay has been developed allowing sequencing of 
open regions of just one cell or using a population of between 500 and 50,000 cells, 
as oppose to the millions of cells needed for DNase I-seq and FAIRE-seq [195]. 
Therefore, ATAC-seq can be advantageous for the identification of open regions in 
primary cells and non-malignant cell lines where cells have a limited lifespan or 
proliferation can be slow. Furthermore, the ATAC-seq protocol can be completed 
in three hours compared to two overnight incubations for both DNase I-seq and 
FAIRE-seq [190, 194]. Briefly, the ATAC-seq protocol involves cell lysis, 
followed by the transposition reaction. The transposition reaction uses the Tn5 
transposase enzyme, which probes and digests open chromatin regions, while 
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inserting adapters required for next-generation sequencing and this is followed by 
PCR amplification of the DNA and eventual sequencing [181]. 
The correlation of open regions yielded from ATAC-seq were compared with those 
from DNase I-seq. Both assays were conducted in a lymphoblastoid cell line and it 
was found that the specificity and sensitivity was comparable, despite the difference 
in starting cell number [195]. Furthermore, intensities of peaks displayed high 
correlation between DNase I-seq and ATAC-seq [195].  
Until recently, the major disadvantage of this method was that, due to 
contamination with mitochondrial DNA, the assay required 60-100 million reads 
(compared to 20-50 million reads for DNase I- and FAIRE-seq) [195]. While 
mitochondrial DNA can be computationally filtered out, during sequencing it will 
deplete the number of reads from the nuclear DNA [195]. However, the assay was 
improved on by the addition of two detergents (Tween-20 and digitonin) during cell 
lysis, followed by an extra wash step after lysis and the addition of phosphate 
buffered saline (PBS) to the transposition reaction [196]. Upon sequencing it was 
discovered that these changes yielded a three-fold higher percentage of nuclear 
mapped reads [196].  
1.11.4 Chromatin immunoprecipitation (ChIP)-sequencing 
The spatial and temporal nature of TF binding can be studied with the aid of 
chromatin immunoprecipitation (ChIP). Very briefly, this technique involves 
preserving protein-DNA interactions by performing formaldehyde crosslinking 
[197]. The DNA is then sheared by sonication yielding fragmented DNA. Next, an 
antibody, specific to the protein of interest, is used to isolate the DNA sequence to 
which the protein is bound [197].  
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ChIP conducted with crosslinked chromatin is also known as X-ChIP, while N 
(native)-ChIP is conducted on non-crosslinked chromatin and is most commonly 
used to map histone modifications [198, 199]. N-ChIP offers the advantage of 
preserving the antibody epitope, which in the presence of formaldehyde may be 
disrupted or destroyed [199]. On the other hand, an advantage of X-ChIP is that 
histone organisation remains intact, while in N-ChIP histone rearrangement and 
protein-TF complex disruption may occur during the procedure [199].  
In order to interrogate the DNA sequences yielded from ChIP, the assay can be 
followed by hybridisation to an array harbouring DNA probes (ChIP-ChIP) or 
qPCR, which involves using specific primer sites (ChIP-qPCR) [200]. However, 
both these techniques require prior knowledge of where the protein may bind. An 
alternative is ChIP-seq, which involves following ChIP with next-generation 
sequencing and allows genome-wide analysis [200].  
1.12 Aims 
Great advances have been made in the investigation of the HNSCC genetic 
landscape. More recently, The Cancer Genome Atlas consortium HNSCC cohort, 
has greatly contributed to this, as highlighted in the introduction. The findings of 
these studies have indicated a role for the cis-regulatory network in HNSCC 
development, however this is yet to be put into context. Therefore, the aims of this 
thesis are the following: 
(i)   To identify elements of the cis-regulatory network in HNSCC cell lines by 
genome-wide localisation of open chromatin regions, key TFs and signalling 
pathways. 
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(ii) To investigate and compare the cis-regulatory network in HPV(+) and 
HPV(-) HNSCC cell lines. 
(iii) To compare the cis-regulatory network between HNSCC and non-
tumourigenic oral keratinocyte cells.  
(iv) To pharmacologically manipulate the identified signalling pathways to 
elucidate new therapeutic targets for HNSCC. 
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CHAPTER 2: METHODS AND MATERIALS 
2.1 Cell culture 
2.1.1 General cell culture and origin 
Four head and neck squamous cell carcinoma (HNSCC) cell lines were used. Two 
were negative for the human papillomavirus (HPV) and two were positive for 
HPV16. The presence or absence of HPV will be denoted by (+) or (-), respectively. 
The HPV(-) cell lines were, VU40T(-) and SCC040(-), and the two HPV(+) cell 
lines were VU147(+) and UDSCC2(+) (Table 2.1). The SCC040(-) cells were 
purchased from the German Culture Collection, DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen) (#ACC660) by Dr. S. Roberts (Supervisor, 
University of Birmingham). The VU40T(-) and VU147(+) cell lines were gifted to 
Dr. S. Roberts from Prof. H. Joenje (VU University Medical Centre, Netherlands). 
The UDSCC2(+) cells were obtained from Dr. J.S. Gutkind (National Institute of 
Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), 
Bethesda).  
All HNSCC cell lines were cultured in Dulbecco′s Modified Eagle′s Medium 
(DMEM) (Sigma-Aldrich, UK), supplemented with 2% L-glutamine (Gibco, UK), 
10% (v/v) foetal bovine serum (FBS) (Sigma-Aldrich, UK), 1% (v/v) 
penicillin/streptomycin (Gibco, UK), 1% (v/v) MEM (minimum essential medium) 
non-essential amino acids (Gibco, UK) and 1% (v/v) sodium pyruvate (Gibco, UK).  
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Table 2.1. Cell lines and primary cell.  









28 M N/A -/- - 










VU40T(-) Tongue 65 F T3N0 -/- (-) 




58 M T4N2 +/+ HPV16 
UDSCC2(+) Hypopharynx 58 M T1N2 Unknown HPV16 
The table outlines cell line information including, anatomical origin, age and sex of cell 
donor, stage of cancer (if applicable; not applicable is denoted by ‘N/A’), smoking and 
alcohol habits of donor and HPV status of cells (if applicable). OKF6 [201-203], VU40T(-
) [204], SCC040(-) [205, 206], VU147(+) [207], UDSCC2(+) [208]. 
 
A hTERT (human telomerase reverse transcriptase) immortalised human oral 
keratinocyte cell line, OKF6 (obtained from Prof. Paul Cooper, University of 
Birmingham) was used (Table 2.1). OKF6 cells were cultured in keratinocyte-
serum free medium (SFM) (Gibco, UK) and supplemented with 5ng/ml epidermal 
growth factor (EGF) 1-53 (Gibco, UK), 50µg/ml bovine pituitary extract (BPE) 
(Gibco, UK), 0.4mM calcium chloride (Sigma-Aldrich, UK), 1% (v/v) 
penicillin/streptomycin (Gibco, UK). 
Two primary cell types were also used, human oral keratinocyte (HOK) and human 
oral tonsil keratinocyte (OTK) cells (Table 2.1). The cells were cultured in Oral 
Keratinocyte Medium (OKM), supplemented with 1% (v/v) penicillin/streptomycin 
and 1% (v/v) oral keratinocyte growth supplement (OKGS). The HOK cells and all 
reagents used to culture them were purchased from Caltag Medsystems, UK (HOK 
   
61  
cells’ catalogue number: 2610). The OTK cells were a gift from Dr. S. Roberts 
(ethical approval number: REC 06/Q1702/45. 
The OTK cells were cultured in 90mm dishes using Complete E media (CEM) 
which consisted of DMEM (Gibco, UK), supplemented with 32% (v/v) Ham’s F12, 
(Gibco, UK), 0.1% (v/v) hydrocortisone (Sigma-Aldrich, UK), 10% (v/v) Hyclone 
FCS (Thermo Fisher Scientific, UK), 0.5% (v/v) EGF (epidermal growth factor) 
(BD Biosciences, UK), 2% (v/v) L-glutamine (Gibco, UK), 0.1% (v/v) cholera 
toxin A (MP Biomedicals, USA), 0.2% (v/v) insulin (Sigma-Aldrich, UK), 0.2% 
(v/v) transferrin (Sigma-Aldrich, UK), 4nM tri-iodo–lL-thyronine (Sigma-Aldrich, 
UK) and 36µM adenine (Sigma-Aldrich, UK). Irradiated NIH J2-3T3 cells were 
used as a feeder layer for the maintenance of OTK cells (Table 2.1). The J2-3T3 
cells were cultured in DMEM, supplemented with 2% (v/v) L-glutamine and 10% 
(v/v) adult calf serum (Gibco, UK).  
All cell lines were maintained in 5% CO2 at 37ºC and were confirmed negative for 
mycoplasma throughout the study, as described in Section 2.1.4.  
2.1.2 Cell harvesting and subculturing 
The HNSCC cells were cultured to approximately 70% confluency before being 
subcultured. To subculture, the cells were washed with PBS (Sigma-Aldrich, UK) 
and trypsinised using 0.25% trypsin-EDTA (ethylene diaminetetraacetic acid) 
(Thermo Fisher Scientific, UK). The cells were incubated at 37ºC until 
approximately 80% of cells had detached. The trypsin was neutralised with an equal 
volume of serum-containing medium. To subculture, the VU40T(-) and SCC040(-
) cells were reseeded at approximately 30-40% cell density, and the UDSCC2(+) 
and VU147(+) cells were reseeded at approximately 40-50% cell density. 
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The OKF6 cells were cultured to 80% confluency before being subcultured as 
described above, with the added step of pelleting the cells at 300 xg for 5mins after 
neutralising the trypsin. The cells were resuspended in medium and reseeded at a 
confluency of 60-70%. To subculture, the cells were reseeded at approximately 
60% cell density. 
The HOK cells were cultured to 80% confluency before subculturing. To 
subculture, the cells were washed with PBS and trypsinised with 2ml of 0.25% 
trypsin-EDTA in 8ml of PBS. The cells were incubated for 1-5mins at 37ºC until 
they appeared round and were transferred to a centrifuge tube containing 5ml of 
FBS. The flask was transferred back into the incubator for 1-2mins to detach any 
remaining cells. The trypsin in the flask was neutralised with 10% FBS in PBS and 
the cells were transferred to the centrifuge tube. To wash off any remaining cells, 
5ml of 10% FBS in PBS was used and transferred to the centrifuge tube. The cells 
were centrifuged for 5mins at 300 xg, the supernatant was discarded and the cells 
resuspended in an appropriate volume of medium. To subculture cells, the cells 
were counted (Section 2.1.3) and seeded into poly-L-lysine (PLL) coated flasks at 
a density of 5,000 cells/cm2. The PLL was used at a density of 2μg/cm2. 
To subculture OTK cells, the feeder layer (-irradiated J2-3T3 cells) was first 
removed by adding 0.5mM of EDTA in PBS and incubating the cells until detached. 
The dish was washed with the solution to dislodge any remaining J2-3T3 cells and 
the suspension was discarded. The dish was further washed twice with 5ml of PBS 
to remove all cells of the feeder layer and was viewed under a light microscope to 
ensure all J2-3T3 cells had been removed. Next, the OTK cells were removed by 
adding 2ml of the TrypLE trypsin solution (Gibco, UK). The dish was incubated at 
37ºC until approximately 90% of OTK cells had detached. The trypsin was 
   
63  
neutralised with CEM and the dish was washed with a further 10ml of CEM. The 
suspension was transferred to a centrifuge tube and centrifuged for 538 xg for 5mins 
and the supernatant was discarded. The cells were resuspended in CEM, counted 
and seeded at a density of 2x105 per dish onto 2x106 cells of irradiated J2-3T3 cells, 
which had been seeded at least 24hrs earlier. The cells were irradiated with 30 Grays 
of caesium-137 and were stored in CEM at 4ºC for up to 5 days. 
J2-3T3 cells were grown to 80% confluency before being subcultured. To 
subculture, the cells were washed twice with 5ml of PBS and were incubated with 
TrypLE for 1-5mins until the cells became non-adherent. The trypsin was 
neutralised with media and cells were washed off with the solution. The cells were 
centrifuged for 300 xg for 5mins and the supernatant was discarded. The cells were 
resuspended in appropriate media, counted and seeded at a density of 1x104/ml.  
2.1.3 Cell counting  
To plate the required number of cells, or to calculate the proportion of viable cells 
by trypan blue staining, cells were harvested and counted using a haemocytometer. 
Ten microlitres of the cell suspension was loaded into the haemocytometer. To 
assess cell viability, trypan blue solution (Sigma-Aldrich, UK) was used and 
prepared by diluting 1:1 with PBS; the cells were diluted 1:10 in the solution. The 
cell membrane of non-viable cells can breakdown, allowing penetration of trypan 
blue. Therefore, non-viable cells appear blue, while viable cells appear clear. To 
determine viability, the ratio of clear cells to blue cells was calculated. 
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2.1.4 Mycoplasma testing 
Cells were tested for mycoplasma infection every six months. Mycoplasma are a 
bacteria which can infect cells in culture. Infection can disrupt cell function in many 
ways including altering DNA, RNA and protein levels [209]. 
The MycoAlert mycoplasma detection kit was used as per manufacturer’s 
instructions (Lonza, USA). The kit utilises mycoplasma specific enzymes, which 
catalyse the conversion of ADP (adenosine diphosphate) to ATP (adenosine 
triphosphate). Therefore, in the presence of mycoplasma, ATP will be produced. 
The levels of ATP were measured before and after cell lysis. Samples with a ratio 
of less than 0.9 (after lysis:before lysis) were considered as non-contaminated. 
The MycoAlert reagent and substrates were supplied as lyophilised pellets and were 
dissolved in 600μl of MycoAlert assay buffer. The reagent and substrate were 
stored at 4ºC. For use, the solutions were equilibrated to room temperature (RT) for 
15mins prior to using. Cells were cultured for at least 48hrs in antibiotic-free 
medium before taking a 200μl aliquot. The medium was centrifuged at 200 xg for 
5mins, 100μl of supernatant medium was transferred to a new centrifuge tube and 
fresh medium was transferred to a second tube as a negative control. Next, an equal 
volume of MycoAlert reagent was added to each sample. The solution was 
incubated in the dark at RT for 5mins. Luminescence was measured to obtain a 
reading of ATP before conversion. Next, 100μl of MycoAlert Substrate was added 
and the samples were incubated for 10mins in the dark. The luminescence was 
measured after lysing mycoplasma and a ratio of the reading before and after was 
calculated.  
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2.1.5 HPV detection 
To assess the HPV status of the HNSCC cell lines, PCR (polymerase chain reaction) 
was conducted to amplify the HPV16 oncogene E6. RNA was isolated from three 
biological replicates of each HNSCC cell line and from the non-tumourigenic 
OKF6 cell line, followed by cDNA synthesis (Section 2.13.1-2.13.2). PCR was 
conducted, as outlined in Tables 2.2 and 2.3. The OKF6 cell line served as a 
negative control. The HPV16 E6 genomic sequence (NC_001526) was obtained 
from the GenBank database to design the PCR primers (forward 5’ 
AGGACCCACAGGAGCGACCC 3’, reverse 5’ 
ACGTCGCAGTAACTGTTGCTTGCA 3’). PCR was conducted using a 
TProfessional Standard PCR Thermocycler (Biometra, Germany). 
The PCR product was run on a 2% agarose gel, as described in Section 2.3. The 
expected size of the PCR product was 112bp and the observed product was just 
above the 100bp marker, indicating amplification of the E6 transcript (Figure 2.1). 
The presence of the E6 transcript was verified in the three biological replicates of 
the HPV(+) cell lines, UDSCC2(+) and VU147(+). An E6 amplicon was not 
detected in the HPV(-) cell lines (VU40T(-) and SCC040(-)) or in OKF6 cells. 
Therefore, it was concluded that only UDSCC2(+) and VU147(+) cells contain E6 
transcripts and are HPV16 positive, confirming previously published findings [207, 
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Table 2.2. PCR reaction setup.  
PCR reagent Final concentration 
GoTaq (Promega, UK) 1x 
cDNA 1 µl of 1:4 diluted in nuclease-free water 
Forward primer 62nM 
Reverse primer 62nM 
Water up to 12µl 
Table 2.3. PCR parameters 
Cycle Step Temperature (ºC) Time (Secs) Number of cycles 
Initial denaturation 95 300  
Denaturation 95 10 
x30 
Annealing 60 10 





Figure 2.1. PCR of HPV16 E6 gene.  
PCR was conducted using primers designed to the HPV16 oncogene, E6 (112bp). Three 
biological replicates were assessed for each cell line. The non-tumourigenic OKF6 cell line, 
VU40T(-) and SCC040(-) were negative for the E6 amplicon. The HPV(+) cell lines, 
UDSCC2(+) and VU147(+) were positive for E6 transcripts. (HN12 is a cell line which 
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2.2 General methods 
2.3 Agarose gel electrophoresis 
To separate DNA fragments by size, agarose gel electrophoresis was used. The 
agarose gel was made by mixing agarose powder (Sigma-Aldrich, UK) in 0.75x 
TBE (Tris/Borate/EDTA) and boiling the solution until clear. The percentage of 
agarose gel depended on fragment size; fragments larger than 500bp or smaller than 
500bp were separated out on 1% and 2% agarose gels, respectively. To visualise 
the DNA, 1x ethidium bromide, a DNA intercalator, was used to stain the DNA 
(Sigma-Aldrich, UK). Ethidium bromide is visible under ultraviolet light and so the 
presence of DNA can be detected. 
The gel was poured into a casting tray with a comb to form wells and left until it 
had polymerised. The comb was removed, and the PCR product was loaded into the 
well. A marker for DNA size was also loaded; 1μg of a 100bp or 1kb ladder 
(Fermentas, UK). The gel was run at 80V for either ~1hr for a 1% gel or ~2hrs for 
a 2% gel. The gel was visualised using the Gel Doc™ XR system (Bio-Rad, UK). 
2.4 Quantification of nucleic acids 
The quality and purity of nucleic acids were assessed using the UV-based 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, UK). The output 
was nucleic acid concentration in ng/µl. The purity and quality of the nucleic acids 
was determined by the ratio of the absorbance wavelengths: 260/280 and 260/230. 
The ratio of 260/280 of ~1.8 for DNA and ~2.0 for RNA and the ratio of 260/230 
of ~2.0 for DNA and RNA indicated ‘pure’ nucleic acid preparations [210] 
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2.5 QPCR 
QPCR (quantitative polymerase chain reaction) was used for relative quantification 
of gene expression levels and to assess DHSs (DNase I hypersensitive sites) and 
ChIP (chromatin immunoprecipitation) enrichment. QPCR was conducted using 
the LightCycler 480 II instrument (Roche, UK). The qPCR reaction composition 
and conditions are shown in Tables 2.4 and 2.5, respectively. Primers were 
designed using the ‘in silico PCR’ tool in UCSC (University of California Santa 
Cruz) and the Primer3 software [211, 212]. Primers were designed to produce a 
product between 90-150bp. A standard curve of three standards were prepared and 
run for each primer set. To prepare the standard curve, a 10x serial dilution was 
prepared. The first standard was prepared by taking an equal volume of each 
experimental sample.  
QPCR results were calculated and shown as relative to a housekeeping gene for 
gene expression assays (Section 2.13.3), as percentage of input for chromatin 
immunoprecipitation-sequencing (ChIP-seq) samples (Section 2.8.4) and relative 
to a DHS-negative region for DNase I-seq samples (Section 2.7.7). In experiments 
involving time course or different drug treatments, results were calculated and 
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Table 2.4: qPCR reagents.  
qPCR reagent Final concentration 




Forward primer 62nM 
Reverse primer 62nM 
Water up to 12µl 
N= x10 or x50; all DNA samples were diluted x10, except library DNA which was diluted 
x50. This is due to the library preparation method involving a PCR step, which increases 
DNA concentration. 
 
Table 2.5: qPCR parameters.  
Cycle step Temperature (C) Time (Secs) Number of cycles 




x45 60 10 
72 10 
Melting curve 
95 5  
65 60  
Cooling 40 30  
 
2.6 Statistical analysis 
The Roche LightCycler 480 software was used for analysis of qPCR data. The 
output after conducting qPCR was the Cp (cross point) value, which is the number 
of cycles taken for the DNA to cross fluorescence threshold. All qPCR reactions 
were conducted in technical duplicates, except quantification of sequencing 
libraries using the Kapa quantification kit, which were conducted in triplicates 
(Section 2.7.3). Any technical replicates differing by more than 0.5 cycle were 
repeated. The software utilises the standard curve to calculate mean concentration 
of samples. 
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Every experimental condition for each gene in gene expression studies (Section 
2.13), cell viability assays (Section 2.16), western blots (Section 2.14) and 
apoptosis/cell cycle analyses by FACS (fluorescence-activated cell sorting) 
(Section 2.17) was tested using at least three biological replicates, thus error bars 
represent standard error of the mean (SEM). Statistical significance between two 
conditions was determined by performing an unpaired t-test. A statistically 
significant p-value was considered as <0.05. Bars shown for qPCR reactions for 
genome-wide quality control checks display the range between technical duplicates. 
2.7 DNase I-seq 
2.7.1 Overview 
The DNase I-seq method was used to identify and map regulatory elements in the 
VU40T(-), SCC040(-), VU147(+) and UDSCC2(+) HNSCC cell lines. The assay 
utilises the DNase I enzyme, which digests accessible regions of the chromatin 
more quickly than closed regions, therefore by digesting for a short amount of time, 
accessible regions are released (DNase I hypersensitive sites (DHSs)) (Figure 2.2). 









Figure 2.2. DNase I-seq flowchart.  
 
Nuclei were isolated by treatment with a 
detergent (NP-40), at a concentration 
optimised for each cell line. The DNase 
I enzyme was used to preferentially 
digest open/unstable regions of the 
chromatin. Digestion was conducted for 
3mins at 37ºC. A range of DNase I 
amounts between 30-50U were used, as 
the amount of DNase I can be cell type-
specific. DNase I digestion releases 
small fragments of less than 300bp in 
size. DNA fragments were size-selected 
using a sucrose gradient fractionation 
method and 20 fractions were collected, 
which were visualised by gel 
electrophoresis. Due to limitations of the 
Illumina next-generation sequencing 
platform, DNA fragments between 100-
200bp were desirable and were 
collected. The agarose gel revealed that 
fragments of this size separated into 
fractions 4-8. To verify collection of 
DNA, qPCR was conducted of genes 
known to be expressed in HNSCC and 
compared with a negative control region 
(No DHS). A DNA library was 
constructed, which was required to 
modify the DNA and facilitate 
compatibility with the sequencing 




2.7.2 Nuclei isolation 
Cell nuclei must first be isolated and intact nuclei with preserved chromatin 
structure are treated with DNase I. All buffers in this method were freshly prepared 
and filtered using the Corning 500ml vacuum filter/storage bottle system (Corning, 
UK). Before DNase I digestion, nuclei were isolated to allow DNase I access to the 
chromatin (Figure 2.2). Cells were washed twice with pre-warmed (37ºC) PBS and 
harvested (Section 2.1.2). The cells were centrifuged at 387 xg at 4ºC for 5mins and 
washed twice with cold PBS supplemented with 1x complete EDTA-free protease 
inhibitor (PI) (Roche, UK). The supernatant was discarded and the suspension was 
resuspended in Buffer A (15mM Tris-HCl (pH 8.0), 100nM NaCl2, 60mM KCl2 
1mM EDTA (pH 8.0), 0.5mM EGTA (egtazic acid) (pH 8.0), 100nM spermidine 
(Sigma-Aldrich, UK), 1x PI). The ratio of live:dead cells was calculated, as 
described in Section 2.1.3. Samples containing at least 90% live cells were carried 
forward. The concentration of cells was adjusted to 2x106/ml in Buffer A. Next, an 
equal volume of Buffer A with the required concentration of NP-40 (Sigma-
Aldrich, UK) was added and the cells were incubated for 10mins on ice. The 
concentration of NP-40 was adjusted for each cell line to give 95-100% nuclei. Four 
concentrations of NP-40 were used: 0.01-0.04% at increments of 0.01%. The 
optimal NP-40 concentration was determined by counting trypan stained nuclei 
(Section 2.1.3). After NP-40 treatment, the nuclei were centrifuged at 387 xg for 
5mins at 4°C and the supernatant was discarded. The pellet was washed twice with 
PBS/1x PI solution and resuspended in 1ml of Buffer A. The nuclei were counted 
and adjusted to 2x107/ml in Buffer A and centrifuged, as above.  
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2.7.3 DNase I digestion 
The nuclei pellet was incubated at 37ºC for 1min. DNase I digestion buffer (150mM 
NaCl2, 60mM CaCl2, optimal DNase I amount (Roche, UK)) was prepared by 
adding 1ml of DNase I digestion buffer and 9ml of Buffer A and warming to 37ºC 
for 10mins. The chromatin was digested by adding 1ml of DNase I digestion buffer 
per 1x107 of cells for 3mins at 37ºC (Figure 2.2). The optimal amount of DNase I 
was established for each cell line by using three different amounts; 30, 40 or 50 
units. This step was required as under-digestion of the sample with DNase I can 
lead to incomplete isolation of DHSs, while over-digestion can lead to the inclusion 
of non-specific and inaccessible sites. A negative DNase I control was also used to 
test for DNA degradation. The digestion was terminated by adding an equal volume 
of stop buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl, 0.1% (v/v) SDS solution, 
1mM EDTA (pH 8.0), 100nM spermidine (Roche, UK), RNase (500µg/ml) (Roche, 
UK)). The reaction was incubated overnight at 55ºC. After the incubation, 
proteinase K (50ug/ml) (Roche, UK) was added and the sample was incubated at 
55ºC for a further 5-7hrs. DNase I digestion was verified by gel electrophoresis on 
a 2% agarose gel (Section 2.3) (Figure 2.2).  
2.7.4 Phenol/chloroform extraction 
The DNA was purified by adding an equal volume of phenol:chloroform:isoamyl 
alcohol 25:24:1 (saturated with 10mM Tris (pH 8.0), 1mM EDTA) (Sigma-Aldrich, 
UK). The sample was mixed by inverting the tube until the solution appeared white 
and centrifuged at 2,755 xg at RT for 10mins. The aqueous phase containing the 
DNA was removed without disturbing the water/phenol interface and transferred to 
a fresh tube. 
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2.7.5 DHS fractionation 
To conduct sucrose gradient DNA fractionation, a 9% (v/v) sucrose aqueous 
solution (Sigma-Aldrich, UK) was prepared and filtered (Figure 2.2). Ten 
millilitres of the sucrose solution was added to a thin wall polypropylene centrifuge 
tube (Beckman Coulter, UK) and 2ml of the purified DNA was layered on the top. 
The sample was centrifuged using the Beckman Coulter Ultracentrifuge, SW40 Ti 
rotor at 25,000 rpm, RT for 24hrs. Nineteen fractions were collected using a syringe 
carefully positioned at the top of the solution. A volume of 500µl was taken for 
each fraction and were visualised by agarose electrophoresis to ensure the correct 
sized fractions were collected (Figure 2.2). 
2.7.6 DNA precipitation 
Of the 19 fractions collected, those containing the 100-200bp DNA fragments were 
precipitated by adding 10µg/ml glycogen (Invitrogen), 10% (v/v) 3M sodium 
acetate (pH 7.0) (Sigma- Aldrich, UK) and 70% (v/v) isopropanol (Sigma-Aldrich, 
UK). The sample was incubated at -20ºC overnight to precipitate the DNA, 
centrifuged at 17,000 xg for 30mins and the supernatant was discarded. The pellet 
was washed with 70% ethanol, centrifuged, and was air-dried and resuspended in 
25µl of nuclease-free water. The DNA was taken forward for quality control qPCR 
(next Section) and library preparation (Section 2.9). 
2.7.7 DNase I hypersensitivity assay quality control qPCR  
To confirm enrichment of DHSs, qPCR was conducted, as described in Section 2.5 
(Figure 2.2). QPCR primers were designed based on three positive control regions, 
one at the keratin 6A (KRT6A) promoter, which was selected as it is known to be 
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important in epithelial development and is constitutively expressed in epithelial 
cells [4, 6, 213, 214] (Table 2.6). In addition, the region was used as a positive 
control in preliminary DNase I experiments with the UDSCC2(+) (Wiench, 
unpublished). Based on the initial experiment, two positive control primers were 
designed at two DHS peaks near the IL-6 gene (Table 2.6). The IL-6 gene has been 
reported as being overexpressed in HNSCC [75]. In addition, a negative control 
region was selected near to the KRT6A gene, which lacks any DHSs based on 
ENCODE (ENCyclopaedia Of DNA Elements) data of 125 cell lines [164, 215]. 
To determine DHS enrichment by qPCR, a ratio was calculated from the 
amplification signals of the positive control regions against the negative control 
region. The required ratio was at least five (positive signal:negative signal), as 
described in Results, Section 3.6. 
DNase I preparations that pass the quality control were taken for library preparation 
and sequenced as described in Section 2.9. 
Table 2.6. DNase I quality control qPCR primer sequences. 
Primer 
name 

















2.8 Chromatin immunoprecipitation (ChIP) 
To investigate and identify genome-wide binding of transcription factors (TFs) the 
chromatin immunoprecipitation (ChIP)-seq method was used. This assay allows the 
identification of protein-DNA interactions by crosslinking and isolating protein-
bound DNA fragments. The crosslinked complexes can then be de-crosslinked, the 
DNA can be sequenced and mapped to the human genome.  
2.8.1 Chromatin collection 
All buffers in this method were freshly prepared and filtered using the Corning 
500ml vacuum filter/storage bottle system (Corning, UK). The ChIP assay was 
conducted as previously described [216]. The VU40T(-) and VU147(+) cells were 
cultured on 150mm dishes until 70% confluent. The medium was discarded, and 
cells were fixed using 10ml of pre-warmed (37ºC) and 1% (v/v) formaldehyde in 
PBS and incubated for 10mins at 37ºC (Figure 2.3). The crosslinking reaction was 
inhibited by addition of 1ml of 2.5M glycine and then incubation for 5mins at RT, 
while rocking. The fixative was discarded and the cells were washed twice with ice-
cold PBS. The cells were then scraped into a centrifuge tube and centrifuged for 
4mins at 780 xg at 4ºC. The supernatant was discarded and the cell pellet was 
resuspended in 500l SDS lysis buffer (1% (v/v) SDS, 10mM EDTA, 50mM Tris-
HCL (pH 8.0), 1x PI) (Figure 2.3). The cells were incubated on ice for 30mins and 
in order to shear the DNA by sonication the cell suspension was transferred to 
sonication tubes (Active Motif, UK).
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Cells were crosslinked using formaldehyde to preserve the DNA-protein 
complexes. The cells were lysed using an SDS buffer to isolate the chromatin. 
Chromatin was sheared by sonication in order to yield DNA fragments of ~200bp. 
Magnetic dynabeads were crosslinked to the antibody in preparation for the 
chromatin-bound protein of interest to bind the antibody-bound beads. Chromatin 
was also pre-cleared with the Dynabeads, to reduce background. The protein and 
DNA were de-crosslinked to isolate DNA fragments and qPCR or next-generation 




Sonication was conducted using the EpiShear sonicator (Active Motif, UK) and the 
parameters used were 85% amplitude for 14 cycles (30secs of sonication and 30secs 
of cooling per cycle) (Figure 2.3). After sonication, the sample was transferred to 
a centrifuge tube and centrifuged for 10mins at 13,000 xg, at 4ºC. A 5µl aliquot of 
the sonicated chromatin was taken to assemble a reaction for DNA quantification 
by Nanodrop Spectrophotometry (Section 2.4). The reaction for DNA 
quantification was de-crosslinked by adding 5µl of sample, 0.2M NaCl, 4mg/ml 
proteinase K (Roche, UK), 92% (v/v) SDS lysis buffer to a volume of 200µl and 
incubated at 65°C for 1hr. A second aliquot of sonicated chromatin was taken to 
visualise DNA fragment size by agarose gel electrophoresis (Section 2.3). The 
chromatin for DNA visualisation was de-crosslinked by adding 10µl of sample to 
0.2M NaCl, 4mg/ml proteinase K (Roche, UK) and 21% (v/v) SDS lysis buffer to 
a volume of 20µl. The reaction was incubated for 1hr at 45ºC, followed by 4hrs at 
65°C. The remaining sample was diluted five times in ChIP dilution buffer (0.01% 
(v/v) SDS, 1.1% (v/v) Triton-X 100, 1.2mM EDTA, 16.7mM Tris-HCl (pH 8.1), 
167mM NaCl). Chromatin aliquots of 100µg were made and stored at -80ºC. 
2.8.3 Chromatin immunoprecipitation (ChIP) 
ChIPs were performed using antibodies for p63, JUND, FOSL1 (FOS like 1, AP-1 
transcription factor subunit) (FRA-1) and TEAD (TEA domain transcription 
factor)-4 TFs (Table 2.7). The assay involved crosslinking magnetic Dynabeads 
with an antibody to form bead-antibody complexes (Figure 2.3). Next, chromatin 
was added to the bead-antibody complexes, so that the antibody binds the chromatin 
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proteins. The complex was eluted and de-crosslinked, releasing the DNA fragment 
to which the protein was bound.  
To crosslink the antibody to beads, 60µl of the magnetic beads, Dynabeads™ M-
280 Sheep IgG anti-rabbit or anti-mouse (Thermo Fisher Scientific, UK) were 
added to centrifuge tubes. The beads were washed twice with 1ml of PBS for 5mins 
at 4ºC while rotating. To separate the beads from solution, a DynaMag™-2 Magnet 
magnetic rack was used. The tubes were placed on the rack for 1min until the 
solution appeared clear and the supernatant was removed. The tubes were removed 
from the rack and the corresponding species of antibody was added to the washed 
beads and pipetted several times to ensure the beads go into solution. A ‘no 
antibody’ control, containing PBS in place of antibody was also prepared. The 
beads and antibody with 1x PI were crosslinked for 6hrs. The beads were washed 
twice with low salt immune complex buffer (0.1% (v/v) SDS, 1% (v/v) Triton x-
100, 2mM EDTA, 20mM Tris-HCl (pH 8.1), 150mM NaCl) for 5mins at 4ºC while 
rotating.  







TEAD4 10 Mouse Abcam (ab58310) 
P63 5 Mouse Abcam (ab735) 
JUND (329) 1 Rabbit Santa Cruz (sc-74) 






Simultaneously, to reduce non-specific binding, chromatin was pre-cleared. To pre-
clear, fresh beads were washed as described before. Next, 100µg of chromatin per 
ChIP was added to the washed beads and the suspension was incubated for 2hrs at 
4ºC while rotating. The pre-cleared chromatin was separated from the beads as 
before. An aliquot of 10% of the chromatin sample volume was taken to serve as a 
background control for genomic deletions, insertions or amplifications (input 
DNA). The input DNA was processed at the elution step. The remaining pre-cleared 
chromatin was added to the antibody-bound beads and incubated overnight at 4ºC 
while rotating to ensure that the chromatin proteins bind to the antibody (Figure 
2.3). The chromatin-bound beads were washed sequentially with 1ml of the 
following buffers for 15mins each: low salt immune complex buffer, high salt 
immune complex buffer (0.1% (v/v) SDS, 1% (v/v) Triton X-100, 2mM EDTA, 
20mM Tris-HCl (pH 8.1), 500mM NaCl), LiCl immune complex buffer (0.25M 
LiCl, 1% (v/v) NP-40, 1% (v/v) deoxycholate, 1mM EDTA, 10mM Tris-HCl (pH 
8.1)) and 1x Tris-EDTA (TE) buffer (pH 8.0)). 
The DNA from the ChIP samples and input were eluted and de-crosslinked from 
protein complexes by adding 400μl of elution buffer (10mM Tris-HCl (pH 8.0), 
300mM NaCl, 55mM EDTA, 0.5% (v/v) SDS) and 50μg/1ml proteinase K (Figure 
2.3). The beads were incubated 6-16hrs at 65°C, while shaking. The supernatant 
was removed and transferred to a centrifuge tube. An equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added and thoroughly mixed by 
pipetting. A Phase Lock Light Gel (5PRIME, UK) was used to extract the aqueous 
phase of the solution. To do this, the Phase Lock tube was centrifuged at 12,000 xg 
for 30secs at RT to collect the gel at the bottom of the tube and the sample was 
transferred to the tube. To separate the aqueous phase from the organic phase, the 
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tube was centrifuged at 12,000 xg for 5mins at RT. The upper aqueous phase was 
transferred into a centrifuge tube. The DNA was precipitated as described in Section 
2.7.6.  
2.8.4 ChIP quality control qPCR 
To determine ChIP enrichment, qPCR was conducted as described in Section 2.5. 
To identify potential binding sites for p63, TEAD4, JUND and FOSL1 TFs, the 
Cistrome Data Browser was used [217]. ChIP data for HNSCC cell lines used in 
this project were not available in the database, therefore data from similar cell types 
were used. Previously published data report overlap between DHSs and TF binding, 
therefore each TF site was verified as a DHS using our DNase I-seq data [188, 191, 
218] (Table 2.8). The selected binding sites are shown in Results, Chapter five, 
Section 5.6 and Appendix: Figures 3-7. 
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Table 2.8. ChIP qPCR primers.  
 
DNA sequences were downloaded using the UCSC browser. Primers were designed using 
Primer3 and were checked using the in-silico PCR design tool in UCSC. Primers were 
designed to produce a product between 90-150bp. 
 
2.9 DNase I-seq and ChIP-seq library preparation 
2.9.1 Library preparation overview 
The DNA isolated during ChIP and DHS preparations must be made compatible for 
the Illumina next-generation sequencing platform. Therefore, the DNA was 
converted into sequencing libraries (Figure 2.4). The synthesis of libraries involved 
three main reactions; the first was ‘end-repair’ in which the ends of fragmented 
DNA is repaired to produce blunt ends. DNA fragmentation can be caused by 
Primer name Forward (5’ to 3’) Genomic location 
p63 and TEAD4 ChIPs 
p63 site 1 (Fw) ACCAGAAGCAATTATATGTGCGT 
chr1:3,628,730-3,628,843 
p63 site 1 (Rv) GCTGCAATTTCGCCCTAAGT 
p63 site 2 (Fw) TCTAAGGAGCAGTGGTAAGCC 
chr15:42125252+42125365 
p63 site 2 (Rv) CACTCCCACCCAAAGCATTC 
TEAD4 site 1 (Fw) ATCTCAGAATCCCAGTGCCC 
chr12:47665103+47665245 
TEAD4 site 1 (Rv) ACTTCAGACAGAGACGAGGC 
TEAD4 site 2 (Fw) ATACACCGCCACACTCACAG 
chr12:52541325+52541450 
TEAD4 site 2 (Rv) GAATGTCTCACAGCACCACC 
JUND and FOSL1 ChIPs 
PC (Fw) GCCTGGGATGACTAAGAGCT 
chr11:66659803+66659903 
PC Rv) GGACTGTTGCTTTGCCCTTT 
LMNA (Fw) CTGCCTCTGTACAATGCCAC 
chr1:156093605+156093694 
LMNA (Rv) CGCAACTCCAGTAGAAGTGC 
ANXA2 (Fw) CCCTACTGACTTGTTGCAGC 
chr15:60685428+60685524 
ANXA2 (Rv) TTCTTCCTGCCGGTCTCTTT 
S100A10 (Fw) GCTTCAAGGTCTGCTGTGAG 
chr1:151961138+151961253 
S100A10 (Rv) CACTGCCATCTGAAACCCAT 
 83 
 
DNase I digestion or shearing by sonication. The end-repair reaction required two 
enzymes, T4 polynucleotide kinase and T4 DNA polymerase. The first enzyme 
added phosphate groups to the 5’ ends of damaged DNA fragments, while the 
second enzyme incorporated dNTPs (nucleoside triphosphates) and created blunt 
ends by removing any overhangs on the 5’ and 3’ ends of the DNA. 
The second step was dA-tailing, which required the Klenow Large fragment in the 
presence of dAMPs (deoxyadenosine monophosphates) to produce dA-tails to the 
3’ end of DNA. This reaction prevented the formation of concatemers during the 
ligation step and facilitated adapter ligation (Figure 2.4). 
The third step is a ligation step to ligate adapters to either end of the DNA 
fragments. The adapters are short sequences of nucleotides and serve two main 
purposes; they allow the DNA fragments to bind to the sequencing platform and 
they contain an index sequence unique to each sample. This allowed the samples to 
be pooled and sequenced, while still being identified during data analysis. The 





Figure 2.4. Library preparation workflow.  
The NEB Next workflow: The DNA end-repair step, repairs the ends of fragmented 
DNA to produce blunt ends. The 5’ and 3’ overhangs are removed and 5’ phosphate group 
added. The AMPureXP bead clean-up steps were required to remove salts and nucleotides 
which may interfere with downstream steps. The dA-tailing step was required to prevent 
the formation of concatemers during the ligation step and facilitated adapter ligation. The 
adapter ligation step was required to allow identification of each sample during 
sequencing analysis, as samples are pooled for sequencing and the adapter contains a 
unique index of 6 nucleotides. This step also involves digestion by the Uracil-Specific 
Excision Reagent (USER™) Enzyme. The USER enzyme cuts the adapter at a uracil 
nucleotide, creating a gap of one nucleotide, changing the conformation of the adapter so 
it is able to bind to the Illumina flowcell. PCR enrichment was required to increase library 
concentration. Size selection was conducted using the AMPure beads, where the ratio of 
beads:DNA could be adjusted to select for the desired DNA fragment size. Kapa Hyper 
prep workflow: This workflow combines the DNA end-repair and dA-tailing steps. The 
size-selection step is combined with a clean-up step. This is followed by PCR enrichment 
and the final clean-up step. 
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2.9.2 DNase I-seq library preparation 
DNase I libraries were constructed using NEBNext ChIP-Seq Library Prep Master 
Mix Set and the Multiplex Oligos (Index Primers Set 1) (NEB, UK). All clean-up 
steps were conducted using Agencourt AMPure XP beads (Beckman Coulter, UK). 
Each use of the AMPure beads involved the following steps: the beads were 
vortexed to resuspend, added to the sample and pipetted several times to mix. The 
beads were incubated with the sample for 5mins at RT. A magnetic rack was used 
to separate the beads from solution. The supernatant was discarded, and the beads 
were washed twice for 30secs with 80% fresh ethanol and dried for 5mins before 
resuspension. 
Library preparation was conducted by first performing the end repair reaction. The 
reaction was assembled by adding 10ng of DNA, 5μl of 10x NEBNext End Repair 
Reaction Buffer and 1μl of NEBNext End Repair Enzyme Mix (204 units/ml of T4 
polynucleotide kinase and 61 units/ml of T4 DNA polymerase) (Figure 2.4). The 
reaction volume was made up to 50μl with nuclease-free water and incubated at 
20ºC for 30mins. To clean-up the DNA, 1.8x volumes of AMPure XP beads were 
added to the reaction and cleaned up, as described before. The beads were 
resuspended in 50μl of 0.1x TE buffer. The beads and DNA were separated as 
before and 44μl of DNA was taken forward.  
The dA-tailing step was conducted by adding 44μl of DNA, 5μl of 10x NEBNext 
dA-Tailing Reaction Buffer and 1μl of the Klenow Fragment (3’ to 5’ exonuclease) 
(Figure 2.4). The reaction was incubated at 37°C for 30mins and the DNA was 
cleaned-up as before. The DNA was eluted in 25μl 0.1x TE buffer.  
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To conduct adapter ligation, one of the twelve NEBNext adapters were ligated by 
combining 19μl of the DNA, 6μl of 5x Quick Ligation Reaction buffer, 1μl of 
1.5μM NEBNext Adaptor and 4μl of 5x Quick T4 DNA Ligase (Figure 2.4). The 
reaction was incubated for 15mins at RT. One microlitre of the adapter Uracil-
Specific Excision Reagent (USER™) Enzyme Mix (1 unit/μl) was added to the 
reaction and incubated for a further 15mins at 37ºC (Figure 2.4). The DNA was 
cleaned up as before and eluted in 105μl of 0.1x TE buffer.  
The DNA was size-selected using the appropriate volume of beads to obtain the 
optimum beads:DNA ratio (Figure 2.4). The desired size for sequencing was 270bp 
(total library size), therefore 0.9x volumes of beads were used. The beads and DNA 
were incubated for 5mins at RT. A further 0.2x volumes of beads were added to 
clean-up the DNA as before. The DNA was eluted in 20μl of 0.1x TE buffer. 
The library was amplified by PCR. The reaction was assembled by taking 20μl of 
adaptor-ligated DNA, 25μl of NEBNext High-Fidelity 2x PCR Master Mix, 2.5μM 
Universal PCR Primer, 2.5μM Index N Primer (‘N’ denotes the index number). The 
PCR amplification was conducted as shown in Table 2.9. A final clean-up step was 
conducted as described before and qPCR was conducted to verify DHS enrichment 
in libraries as described in Sections 2.5 and 2.7.7. 
Table 2.9. PCR parameter for NEB Next library preparation. 
Cycle step Temperature (C) Time (secs) Number of cycles 
Initial denaturation 98 45  
Denaturation 98 15 
x15 Annealing 60 30 
Extension 72 30 
Final extension 72 300  
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2.9.3 ChIP-seq library preparation 
ChIP libraries were prepared using the Kapa Hyper Prep kit (Roche, UK). The 
workflow for this kit offers the advantage of being less time consuming, as fewer 
clean-up steps are required and some of the steps are combined (Figure 2.4). As 
described for DNase I library preparation, all clean-up steps were conducted using 
Agencourt AMPure XP beads (Beckman Coulter, UK). One change to the clean-up 
step was that the beads were incubated with the sample for 10mins at RT, instead 
of 5mins. 
For each ChIP sample, 10ng of sample was made up to 50μl. The End Repair and 
A-Tailing buffer mix and enzyme mixes were pre-mixed (7μl and 3μl, respectively) 
and were added to the sample. The reaction was incubated at RT for 30mins and 
then at 65ºC for 30mins.  
Adapter ligation was conducted at a ratio of 200:1 adapter:DNA and incubated for 
15mins at RT. The DNA was cleaned-up by adding 0.8x volumes of AMPure beads. 
The supernatant was removed, and the beads were washed as before, with the added 
step of a 2mins incubation in 25μl elution buffer (10mM Tris-HCl). The supernatant 
was transferred to a fresh tube. 
PCR was carried out by adding 25μl of the 2x Kapa HiFi HotStart ReadyMix and 
5μl of 10x Kapa Library Amplification Primer Mix to the DNA and amplified as 
shown in Table 2.10. The sample was cleaned up by adding one volume of beads 
and the remaining clean-up steps were conducted as above.  
To size-select DNA fragments of 150-350bp, 0.6x volumes of beads to DNA were 
added and incubated for 10mins. The beads were washed as above and eluted in 
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27μl of elution buffer. Aliquots of the sample were taken for quality control checks: 
1.5μl of sample was taken for BioAnalyzer analysis (Section 2.11.2), 1μl was taken 
for Kapa quantification (Section 2.11.3) and the remainder was taken forward for 
Illumina next-generation sequencing (Section 2.12). 
Table 2.10. PCR parameters for Kapa Hyper library preparation. 
Cycle step Temperature (C) Time (secs) Number of cycles 
Initial denaturation 98 45  
Denaturation 98 15 
x10 Annealing 60 30 
Extension 72 30 
Final extension 72 60  
 
2.10 ATAC (Assay for Transposase-Accessible 
Chromatin)-sequencing 
2.10.1 Overview 
The Assay for Transposase Accessible Chromatin (ATAC)-seq is a method to map 
accessible chromatin and regulatory elements. The ATAC-seq method utilises a 
transposase enzyme called, Tn5, which probes and inserts sequencing adapters at 
accessible regions of the chromatin, combining the digestion and library preparation 
into one step [181]. The transposed DNA fragments were amplified by PCR. QPCR 
was conducted on the amplified transposed DNA to ensure sequencing libraries are 
minimally amplified, while still obtaining sufficient material to sequence. Library 
over-amplification may introduce GC bias. QPCR revealed how many more PCR 




2.10.2 Nuclei isolation 
A total of 50,000 cells were harvested from the OTK cells and were pelleted at 500 
xg for 5mins, 4ºC. The supernatant was discarded and the cell pellet was washed 
once with cold PBS by centrifuging at 500 xg for 10mins at 4ºC. The cell pellet was 
resuspended in 50μl of cold lysis buffer (10mM Tris-HCl (pH 7.4), 10mM NaCl, 
3mM MgCl2, 0.1% (v/v) IGEPAL CA-630). The lysate was centrifuged at 500 xg 
for 10mins at 4ºC and the supernatant was discarded. 
2.10.3 Transposition reaction and purification 
The Nextera DNA Library Preparation Kit (Illumina, UK) was used to carry out the 
transposition reaction. The reaction was assembled by adding 25μl TD (2x reaction 
buffer), 2.5μl TDE1 (Nextera Tn5 Transposase) and 22.5μl nuclease-free water to 
a tube. The lysed cells were resuspended in the transposition reaction mix and 
incubated at 37ºC for 30mins. 
The transposed DNA was then purified using the MinElute PCR Purification kit 
(Qiagen, UK) as per manufacturer’s instructions. All centrifugation steps were 
conducted at 17,900 xg for 1min at RT. First, to allow DNA to bind the spin column 
membrane, 5 volumes of Buffer PB were added to the reaction volume and 
transferred to the column. The column was centrifuged and the flow-through was 
discarded. Next, the column was washed with 750μl of Buffer PE. The column was 
centrifuged and the flow-through was discarded. The column was centrifuged again 
to remove any residual Buffer PE. The transposed DNA was eluted by adding 10μl 
of elution buffer and collected by centrifugation. 
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2.10.4 PCR amplification 
The transposed DNA was amplified by PCR, followed by qPCR to determine the 
amount of DNA in the sample and establish the number of additional cycles 
required for the second PCR. In the first PCR, the number of amplification cycles 
were restricted to 5 cycles to limit GC bias and maintain DNA complexity (Tables 
2.11 and 2.12). The qPCR reaction was assembled alongside a DNA negative 
control. The qPCR setup is outlined in Tables 2.13 and 2.14. To calculate the 
number of additional cycles required, the qPCR fluorescence signal was plotted 
against cycle number. The cycle number which corresponded to 25% of the 
maximum fluorescence intensity was the number of additional cycles needed.  
Table 2.11. PCR reaction setup for ATAC libraries 
Reagent Volume (μl) 
Transposed DNA 10 
Nuclease-free water 10 
25μM Custom Nextera PCR Primer 1 2.5 
25μM Custom Nextera PCR Primer 2 (with barcode) 2.5 
NEBNext High-Fidelity 2x PCR Master Mix 25 
 
 
Table 2.12. PCR parameters for ATAC libraries.  
Cycle Step Temperature (ºC) Time (secs) Number of cycles 
Extension 72 300 1 
Initial denaturation 98 30 1 
Denaturation 98 10 
x5 + N 
Annealing 63 30 
Final extension 72 60  









Table 2.13. qPCR reaction for ATAC libraries. 
Reagent Volume (μl) 
PCR amplified DNA or water 5 
Nuclease-free water 4.41 
25μM Custom Nextera PCR Primer 1 0.25 
25μM Custom Nextera PCR Primer 2 0.25 
100x SYBR Green I 0.09 
NEBNext High-Fidelity 2x PCR Master Mix 5μl 
 
 
Table 2.14. qPCR parameters for ATAC libraries. 
Cycle Step Temperature (ºC) Time (secs) Number of cycles 
Initial denaturation 98 30 1 
Denaturation 98 10 
x20 
Annealing 63 30 
Final extension 72 60  
 
2.11 Quality control of sequencing libraries 
2.11.1 Quality control qPCR 
To verify enrichment of DNA in the DNase I hypersensitivity and ChIP assays 
sequencing libraries, qPCR was conducted using the parameters described in 
Tables 2.4 and 2.5. Primers used for DNase I and ChIP qPCRs are described in 
Sections 2.7.7 and 2.8.4, respectively. 
2.11.2 Bioanalyzer 
The Agilent 2100 Bioanalyzer instrument (Agilent Technologies, UK) was used to 
determine the amount of DNA in the libraries, as well as determine the library size. 
Libraries were diluted 50x and the DNA fragment size was verified by using the 
Agilent High Sensitivity DNA Assay protocol, as per the manufacturer’s 
instructions (Agilent Technologies, UK). In order to be able to visualise the DNA, 
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a gel-dye mix was first prepared. The High Sensitivity dye concentrate (dye) and 
High Sensitivity DNA gel matrix reagent (gel) were equilibrated at RT for 30mins. 
Next, 15μl of the dye was added to the gel and were mixed by vortexing. A 
‘cleaning microfluidic chip’ was loaded with 350μl of nuclease-free water and 
placed into the BioAnalyzer machine for 10secs to clean the electrodes. The 
cleaning Chip was removed, and the electrodes were left to dry until the samples 
were ready to be run. The samples were run using the microfluidic Agilent High 
Sensitivity DNA Chip (Chip). The Chip was prepared by loading 9μl of the gel-dye 
mix into the appropriate well, marked ‘G’. The Chip was then loaded into the 
Priming Station, which applies pressure to remove any bubbles. The plunger of the 
Priming Station was pushed down for 60secs and then released. The remaining 
wells marked ‘G’ were loaded with 9μl of the gel-dye mix. Next, 5μl of the High 
Sensitivity DNA marker (marker) was loaded into the ‘ladder’ well, followed by 
1μl of the High Sensitivity DNA ladder. Subsequently, 1μl of the sample was loaded 
into each of the sample wells or 1μl of marker into any ‘unused’ wells. 
The Chip was then placed into an IKA MS2 Vortex Mixer (IKA Works) and 
vortexed for30 secs at 2,000 rpm before being loaded into the BioAnalyzer. 
Analysis was conducted using the 2100 Expert Software where an 
electropherogram was produced by plotting the fluorescence signal of the sample 
against the size in bp. The fluorescence signal is relative to the DNA ladder and so 
the amount of DNA can be determined.  
2.11.3 Kapa Quantification 
Libraries were quantified using the Kapa SYBR FAST LightCycler 480 qPCR kit, 
as per manufacturer’s instructions. First, 1ml of 10x Illumina Primer Premix was 
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added to the 5ml 2x Kapa FAST qPCR Master Mix and was vortexed to mix. A 
serial dilution of each library was conducted, 1:1000, 1:2000 and 1:4000 to account 
for library concentrations which may be out of range of the six known standard 
concentrations. The libraries were diluted in library dilution buffer (10mM Tris-
HCl (pH 8.0), 0.05% (v/v) Tween-20). A master mix was assembled of 12μl of 
Kapa SYBR FAST qPCR Master Mix and 4μl of water per sample. The master mix 
was added to the wells of a 96-well plate, followed by 4μl of diluted DNA or DNA 
standards 1-6. Samples were loaded in triplicates. The parameters for qPCR are 
shown in Table 2.15. For the analysis, the concentration in pM was calculated from 
the average of the three technical replicate library samples. The average pM was 
multiplied by the average bp size of DNA standards (452bp), divided by the average 
fragment size of the library in bp as indicated the BioAnalyzer (Section 2.11.2). 
The undiluted library concentration was then calculated by multiplying with the 
corresponding dilution factor.  
Table 2.15. qPCR parameters for Kapa quantification of libraries. 
Cycle Step Temperature (ºC) Time (Secs) Number of cycles 
Initial denaturation 95 300  
Denaturation 95 30 
x35 
Annealing/Extension 60 45 
 
2.12 Illumina sequencing and bioinformatics analysis 
2.12.1 Illumina sequencing 
Libraries were indexed according to the number of samples to be sequenced on each 
sequencing lane. Eight indexed libraries were pooled per lane and sequenced on the 
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HiSeq 2500 platform, using the V3 SBS chemistry (1x50 cycles) (Illumina, UK). A 
10nM pool (20μl) of indexed of libraries was assembled. 
2.12.2 Genome alignment 
After library sequencing, a FASTQ file was obtained containing sequences of reads. 
Each read is assigned a quality score between 1 and 40. Using the HOMER 
(Hypergeometric Optimization of Motif EnRichment) software low quality reads, 
i.e. any read with a score of less than 30 that points to ambiguous nucleotide 
callings, were removed. Next, the Bowtie2 tool was used to align the reads to the 
hg19 version of the human genome [219]. The output was a BAM file, which 
contains the alignment data for the reads. The HOMER software was used to 
remove any duplicated and ENCODE blacklisted reads [220]. Blacklisted reads 
were first identified by the ENCODE consortium and are defined as reads which, 
when aligned to the genome, can be anomalous or display a high or low signal 
regardless of cell type and experimental technique from which they were derived 
[164]. Non-uniquely mapped reads were filtered out and peaks were called using 
the ‘factor mode’ in HOMER based on a 350bp fragment size [220, 221]. The 
BEDTools suite was used to calculate coverage maps, whose output includes reads 
mapped to chromosome number and the coverage depth (the number of reads for 
each nucleotide) [221]. When the coverage maps were created, a Bigwig file was 
also generated. This file was uploaded to the UCSC Genome Browser to allow for 
visualization of the cumulated reads [212]. Any analyses using HOMER and 
subsequent analyses were conducted by Dr Sam Clokie (West Midlands Regional 
Genetics Laboratory, Birmingham Women’s Hospital). 
 95 
 
2.12.3 Transcription factor motif and pathway enrichment 
analyses 
Potential TF binding sites within DHSs or ChIP peaks were identified through motif 
analysis using the ‘findMotifsGenome’ script within HOMER. Motifs were 
identified by first, controlling for background by taking at least 50,000 randomly 
selected background sequences from the DHS sequences (target sequences). 
Enriched motifs were identified by calculating the frequency of target sequences 
versus background sequences. The GC content of the target DHSs were also 
considered in order to avoid GC bias, which due to the presence of CpG islands 
(regions of dense C and G bases), can be introduced during the PCR step of library 
preparation [159, 222]. TF motifs were identified based on sequence similarity from 
a database of known TF motifs, derived from published ChIP-seq data. 
Pathway enrichment analysis of genes of interest was conducted using the 
‘AnnotatePeaks’ script within HOMER. This analysis assigns each DHS, enhancer 
cluster (EC), ATAC or ChIP peak to the closest transcription start site (TSS) of a 
gene to create a list of potentially regulated genes. The list of genes was run through 
a combination of two pathway overrepresentation databases: Kyoto Encyclopaedia 
of Genes and Genomes (KEGG) [223] and WikiPathways (WP) [224]. This 
analysis was also conducted using genes obtained from RNA-seq analyses. 
2.12.4 Enhancer cluster identification 
The ‘superenhancer’ script within HOMER was used to identify enhancer clusters 
(ECs) using ‘called’ DHS peaks. EC identification was based on the method first 
described by Whyte et al. [173]. DHS peaks within a distance of 12.5kb were 
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identified and concatenated. The EC signal was determined by a normalisation step, 
which involved normalisation of all reads minus normalised input reads. The 
putative enhancer signal was then sorted by score and normalised to the highest 
score, as well as to the number of putative enhancers. Any regions with a score 
above one were determined as an EC. However, it must be noted that in order to 
truly label these regions as enhancers, ChIP-seq assays for known enhancer marks 
and functional reporter assays must be conducted. Therefore, this method was used 
as a means of reinforcing data revealed by DNase I-seq, ChIP-seq and RNA-seq, 
rather than a method to identify novel regulators. 
2.13 Gene expression analysis 
2.13.1 RNA extraction 
Cells were cultured in 6-well plates (Corning, UK) until 70% confluent and RNA 
was extracted using the RNeasy Mini kit (Qiagen, UK) as per manufacturer’s 
instructions. The cells were washed twice in cold PBS. To lyse the cells and 
denature any RNases, 500μl of Buffer RLT containing 0.01% (v/v) β-
mercaptoethanol was added. Next, 100% ethanol was added 1:1 to the sample, 
which was loaded onto the RNeasy Mini spin column and was centrifuged 13,000 
xg for 30secs at RT, the flow-through was discarded. The RNA bound to the column 
membrane was washed twice with Buffer RPE and eluted with 20μl of nuclease-




2.13.2 cDNA synthesis 
CDNA synthesis was conducted using the iScript cDNA synthesis kit (Bio-Rad, 
UK). The reaction was set up by adding 4μl of 5x iScript reaction mix, 1μl of iScript 
reverse transcriptase to 1μg RNA and made up to 20μl with nuclease-free water. 
The reaction consisted of three steps, primer annealing, DNA polymerisation and 
enzyme deactivation. The reaction was incubated at 25ºC for 5mins (annealing), 
42ºC for 30mins (polymerisation) and 85ºC for 5mins (enzyme deactivation).  
2.13.3 qPCR 
The cDNA samples were diluted 1:4 in nuclease-free water and qPCR was 
performed as described in Section 2.5. Primer sequences are shown in Table 2.16. 
The transcript amplification signal was normalised to the signal for the 
housekeeping genes GAPDH and β-ACTIN. Three biological replicates of RNA 
were used for cDNA synthesis and qPCR was conducted in technical duplicates. 
 98 
 
Table 2.16. Gene expression primers 
Gene Forward (5’-3’) Reverse (5’-3’) 
ATF3 TTGCCATCCAGAACAAGCAC CCTCGGCTTTTGTGATGGAC 
BACH1 AACAGTGTCGTCAGAGTGGT AGACGCTGCCAAAACTTCAG 
β-ACTIN AAAGACCTGTACGCCAACAC GTCATACTCCTGCTTGCTGAT 







GAPDH CCTGGCCAAGGTCATCCAT AGGGGCCATCCACAGTCTT 
JUN CAACATGCTCAGGGAACAGG CCCGACGGTCTCTCTTCAAA 
JUNB TGCACAAGATGAACCACGTG GCTGAGGTTGGTGTAAACGG 
JUND AAATTCTCCGCCCCTTTCCT AAAACAGAAAACCGGGCGAA 
TP63 GTTTCGACGTGTCCTTCCAG TCTGGATGGGGCATGTCTTT 
TEAD1 TGCAAGGTTTGAGAATGGCC ATGTTGTGCTCCGTCTTCAC 
TEAD2 CATGACCCTCACCTGTTCCT CCAGGACGCTGTTCATCATG 
TEAD3 CTTCCTTGCCCCTTTGTGTC AAACCCAGAGACCTACGCTC 
TEAD4 AAGGATCTCTTCGAACGGGG TGTTCTCGGGGCTCTCATAC 
RNA sequences were downloaded from the UCSC browser. Primers were designed 
using Primer3 and were checked using the in-silico PCR design tool in UCSC. 
Where possible, primers were designed over an intron-exon junction to prevent 





RNA was extracted, as described in Section 2.13.1. Three biological replicates were 
extracted and pooled in equal amounts. The libraries were prepared and sequenced 
by the Environmental Omics Facility, University of Birmingham. The sample pools 
were quantified using the Qubit Fluorometer (Thermo Fisher Scientific, UK). To 
assess RNA integrity, the RNA integrity number (RIN) was determined by the 
Agilent TapeStation instrument. All samples displayed a RIN of >9, indicating 
intact RNA [225]. Libraries for RNA-seq were made using the TruSeq Stranded 
mRNA Library Prep kit (Illumina, UK). The libraries were sequenced using the 
HiSeq 2500 instrument. 
2.13.5 RNA-seq analysis 
Within the Galaxy platform, the FASTQC file and the ‘Trim sequences’ tool were 
used assess and remove any reads with a Phred quality score of <30, as well as 
removing adapter sequences. The ‘Hisat2’ tool was used to align reads to the hg19 
genome [226, 227]. The ‘Stringtie’ tool was used to assemble and quantify 
transcripts and each gene was assigned a FPKM value (fragments per kilobase exon 
per million mapped reads) [228]. The FPKM was normalised by the number of 
reads mapped and the gene length. The cut-off point for the FPKM value was set at 
1 and genes with FPKM values above 1 were taken for pathway enrichment analysis 
using the Consensus Pathway database [229-231].  
Principal components analyses were conducted using the ‘PCAexplorer’ script in 
the R software (Dr Sam Clokie, West Midlands Regional Genetics Laboratory, 
Birmingham Women’s Hospital). 
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2.14 Western blot analysis 
2.14.1 Protein lysate collection 
Cells were cultured in 100mm cell culture dishes until 70% confluent. The dishes 
were placed on ice and washed twice with ice-cold PBS. To lyse the cells, 500μl of 
RIPA lysis buffer (150mM NaCl, 1% (v/v) NP-40, 0.5% (v/v) sodium 
deoxycholate, 0.1% (v/v) SDS, 50mM Tris (pH 8.0)) was added to each dish and 
left on ice for 2mins. The lysate was scraped and transferred to a 1.5ml tube. The 
lysate was incubated for 45mins at 4ºC while rotating. The insoluble protein and 
cell debris were collected by centrifuging at 13,000 xg for 10mins and the RIPA 
soluble proteins was transferred to a tube.  
2.14.2 Bradford protein assay 
The Bradford assay was used to measure protein concentration. First, a standard 
curve was prepared using eight known bovine serum albumin (BSA) protein 
concentrations. To measure protein concentration, 200μl of 5x Bradford reagent 
(Bio-Rad, UK), 5μl sample or RIPA buffer (blank) and 795μl water were combined 
and added to a cuvette and measured on a nanophotometer (Geneflow).  
2.14.3 Protein loading 
To denature the protein, 1x Laemmli buffer (40% (v/v) glycerol, 0.4% (v/v) β-
mercaptoethanol, 0.04% (w/v) bromophenol blue, 0.1M Tris-HCl (pH 6.8), 4% 
(v/v) SDS) was added to adjust protein concentration to 0.5µg/µl. The sample was 
heated to 95ºC for 10mins and centrifuged briefly to pool any liquid. Five 
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microlitres of Pageruler Prestained Protein ladder (Thermo Fisher Scientific) was 
loaded into each gel, followed by 10µg of each sample. 
2.14.4 SDS-PAGE gel electrophoresis 
Gels for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
were prepared using the Mini Protean 3 Bio-Rad apparatus (Bio-Rad, UK). A 10% 
resolving gel (10% (v/v) 37.5:1 acylamide:bisacrylamide (Protogel, UK), 375mM 
Tris-HCl (pH 8.8), 0.1% (w/v) SDS (sodium dodecyl sulphate) (Sigma-Aldrich, 
UK), 0.1% (v/v) N,N,N’,N’-tetramethylethylenediamine (TEMED) (Sigma-
Aldrich, UK) and 0.1% (w/v) ammonium persulphate (APS) (Sigma-Aldrich, UK)) 
was made. The gel was covered with a layer of 100% isopropanol to achieve a 
uniform gel edge. Once the resolving gel had polymerised, the isopropanol was 
removed, and the remaining was soaked up with filter paper. 
A stacking gel (4.5% (v/v) 37.5:1 acylamide:bisacrylamide (Protogel, UK), 375mM 
Tris-HCl (pH 6.8), 0.1% (w/v) SDS, 0.1% (w/v) TEMED and 0.1% (w/v) APS 
(ammonium persulphate)) was poured on top of the resolving gel. A comb was 
placed in the stacking gel and the gel was left to polymerise. The gels were 
transferred into MiniProtean 3 tanks (Bio-Rad, UK), containing 1x running buffer 
(25mM Tris-HCl (pH 7.5), 2mM glycine (Thermo Fisher Scientific) and 10% (w/v) 
SDS). The protein samples were separated by electrophoresis at 100V for 1hr. 
2.14.5 Electrophoretic protein transfer 
Two pieces of sponge, two pieces of Whatman
 
chromatography paper (Sigma-
Aldrich, UK) and one piece of Amersham Hybond P 0.45µm PVDF 
(polyvinylidene difluoride) membrane (GE Healthcare Life Sciences, UK) were cut 
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to gel size. The sponge and Whatman paper were soaked in transfer buffer (100mM 
Tris-HCl (pH 7.2), 200mM glycine (Sigma-Aldrich, UK), 0.05% (w/v) SDS, 20% 
(v/v) methanol). The membrane was soaked in 100% methanol, rinsed with distilled 
water and transferred to transfer buffer. To transfer, one sponge, Whatman paper, 
gel, membrane, Whatman paper and sponge were assembled in a Bio-Rad transfer 
cassette (Bio-Rad, UK). The ‘sandwich’ was flattened to ensure that any air bubbles 
were forced out. The cassette was put into a transfer tank (Bio-Rad, UK) and filled 
with transfer buffer. An ice pack was used to ensure the transfer buffer remained 
cool and the protein was transferred for 1hr at 200 V. 
2.14.6 Protein visualisation 
All washes were conducted in PBST (1x PBS with 0.1% (v/v) Tween-20) three 
times for 5mins. Non-specific binding was eliminated by incubating the membrane 
in 20% (w/v) non-fat milk (Marvel, Premier Foods) in PBST at RT for 1hr. When 
a membrane was probed with more than one antibody, whose proteins had different 
molecular weights, the membrane was cut with a scalpel before the blocking step. 
After blocking, the membrane was washed and incubated with a primary antibody 
in 5% (w/v) BSA or 5% (w/v) milk in PBST, either overnight at 4ºC or 1hr at RT 
(Table 2.17). To assess for equal loading of protein, the membrane was also probed 
with the housekeeping protein lamin A/C (Table 2.17). The membrane was washed 
and incubated with horse radish peroxidase (HRP)-conjugated secondary IgG 
antibody (NEB, UK) for 1hr at RT. If the molecular weight of a protein overlapped 
with that of lamin A/C, then the membrane was stripped. To strip, the membrane 
was incubated with stripping buffer (1.5% (w/v) glycine, 0.1% (w/v) SDS, 0.01% 
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(v/v) Tween-20 (pH 2.2)) for 15mins at RT and the buffer was replaced halfway 
through the incubation. 
To detect the protein signal, the EZ-ECL (enhanced chemiluminescence) detection 
kit for HRP (Biological Industries, UK) was used. The detection reagents were 
mixed (1:1) and 1ml was applied to each membrane for 1min. Excess ECL reagent 
was removed by soaking up with a paper towel. The membrane was wrapped in 
plastic film and fixed into place in an autoradiography cassette. In a dark room, a 
Hyperfilm X-ray film (Amersham Biosciences, UK) was placed into the cassette 
for 1min and the exposure time was adjusted accordingly. The film was developed 
using a PROTEC ECOMAX automatic film processor (PROTEC GmbH & Co.). 
Table 2.17. Antibodies for Western blotting. 




Lamin A/C Rabbit 
1: 10,000 in 
5% BSA 




1: 1,000 in 
5% milk 
1hr at RT 
Abcam 
(ab52894) 
JUND (329) Rabbit 
1:200 in 5% 
milk 






1:200 in 5% 
milk 







1: 5,000 in 
5% milk 




2.15 Preparation of drugs for cell culture 
Verteporfin (VP) (Sigma-Aldrich, UK) was dissolved in 1ml of 100% DMSO 
(dimethyl sulfoxide) (Sigma-Aldrich, UK) as a stock concentration of 2mg/ml. The 
stock VP was aliquoted in 10μl aliquots, stored at -20ºC and freeze-thawed once 
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before discarding. VP is light-sensitive and therefore was protected from light by 
wrapping in foil. Tyrphostin (AG1478) (Sigma-Aldrich, UK) was dissolved in 1ml 
of 100% ethanol to give a stock concentration of 1mg/ml. The stock AG1478 was 
stored at -20ºC in 20μl aliquots. Cetuximab was unavailable for purchase and 
therefore was requested from Merck, Germany. The drug was given as a ready-
made stock solution of 5mg/ml. The complete composition of the drug buffer was 
not revealed. However, it was known that the buffer contained 0.01% Tween-80 
(Personal communication with Dr. C. Stroh, Merck, Germany). The drug was stored 
in aliquots at 4ºC. 
2.16 Cell viability assay 
To assess changes in cell viability after drug treatment, the CellTiter-Blue assay 
(Promega, UK) was used. This kit is based on a reduction reaction of the blue non-
fluorescent reagent, resazurin, to the pink fluorescent reagent resorufin by 
dehydrogenase enzymes. The reaction only takes place in the presence of 
dehydrogenase, which is produced by metabolically active cells.  
VU40T(-) and VU147(+) cells were seeded at a density of 0.3x103cells/well and 
2.4x103/well, respectively in 96-well plates in a volume of 80μl. Six technical 
replicates were plated for each of the ten conditions. Two control conditions were 
used: (i) cells treated with vehicle and (ii) media in the absence of cells to control 
for background absorbance (Table 2.18). The remaining conditions were treatments 
of eight different concentrations of verteporfin (VP) (Sigma-Aldrich, UK), 
Cetuximab (Merck, UK) or tyrphostin (AG1478) (Sigma-Aldrich, UK). The drugs 
and vehicles were made up in microcentrifuge tubes before 20μl of each was added 
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to the appropriate wells. The drugs were added to the cells 8hrs after seeding and 
the cells were treated for 96hrs. The media and drugs were replaced after 48hrs.  
Following 96hrs of cell culture, 20μl of the CellTiter-Blue reagent (Promega, UK) 
was added to each well. The cells were cultured for approximately another 4hrs 
until the colour changed from blue to pink. The plate was read on a Synergy HT 
microplate reader (BioTek, UK). The absorbance for resazurin and resorufin were 
read at 600nm and 507nm, respectively. To determine changes in cell viability, 
firstly, the difference in absorbance was calculated by subtracting the absorbance 
of resorufin from the absorbance of resazurin. Secondly, to adjust for background, 
the absorbance signal for media only was subtracted. The final value was 
normalized to cells treated with vehicle only. At least three biological replicates 
were obtained for each condition. Statistical analysis was conducted as described in 
Section 2.6. The SigmaPlot software (Systat Software Inc, USA) was used to 
generate four-parameter logistic dose-response curves. 
Table 2.18. Cell viability assay template.  
 -Cells +Cells 















Ethanol 400 200 100 50 25 12.5 6.25 3.125 
The ‘media only’ condition served as a control for background absorbance. The 
media, vehicle and cells condition served as a control for cell viability changes 
induced by the vehicle. VU40T(-) and VU147(+) cells were seeded 8hrs before drug 
treatment to allow the cells to adhere. Each treatment was for 96hrs and the drug 
and controls were replaced after 48hrs. Six technical replicates of each condition 





2.17 Fluorescence-Activated Cell Sorting (FACS) 
Propidium iodide staining followed by fluorescence-activated cell sorting (FACS) 
was used to investigate changes in the cell cycle after drug treatment. Propidium 
iodide is a dye, which intercalates into DNA stoichiometrically. Once intercalated, 
the subsequent fluorescence levels of propidium iodide can be measured and are 
directly proportional to the amount of DNA [232]. Annexin V staining was used as 
a marker of apoptosis. The annexin V protein has high affinity for the 
phosphatidylserine receptor, which is exposed upon the induction of apoptosis 
[233]. 
2.17.1 Propidium iodide-staining 
To prepare cells for propidium iodide staining and cell cycle analysis, the cells were 
harvested and counted as described in Sections 2.1.2 and 2.1.3, respectively. After 
counting, 1x106 cells were fixed by adding 1ml of 70% cold ethanol. The ethanol 
was added drop-wise while vortexing to minimise cell clumping. The cells were 
incubated at 4ºC overnight and washed twice with cold PBS and centrifuged for 
5mins at 850 xg, 4ºC. The supernatant was discarded and 50µl of RNase (100µg/ml) 
and 200µl of propidium iodide (50 µg/ml) (Sigma-Aldrich, UK) were added to the 
cells and transferred to a 5ml polypropylene round bottom tube (BD Falcon, UK).  
2.17.2 Annexin V-DNA double staining 
To prepare the cells for annexin V-DNA double staining, the cells were harvested, 
counted as before and were prepared using the eBioscience Annexin V Apoptosis 
Detection FITC (fluorescein isothiocyanate) Kit, as per manufacturer’s instructions 
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(Thermo Fisher Scientific, UK). The cells were washed twice with cold PBS for 
5mins at 4ºC for 450 xg and resuspended at a concentration of 1x106 cells/ml in 1x 
Binding Buffer (10µM Hepes (pH 7.4), 140µM NaCl, 2.5mM CaCl2). To detect 
annexin V binding, 100μl of the cell solution was transferred to a centrifuge tube 
and 5µl of annexin V conjugated with the fluorophore FITC (annexin V-FITC) was 
added to the cells. The cells were incubated at RT in the dark for 10-15mins. Next, 
the cells were washed in 2ml of 1x Binding Buffer and centrifuged for 5mins at 450 
xg, RT. To stain for propidium iodide, the supernatant was discarded, and the cell 
pellet was resuspended in 200µl of Binding Buffer and 5µl of propidium iodide. 
The suspension was made up to 500µl with PBS. Two control conditions were 
included; cells were stained with only propidium iodide or only FITC to assess any 
bleed-through of signal. Post-acquisition analysis was conducted on the CyAn ADP 
flow cytometer (Beckman Coulter, UK). 
2.17.3 FACS analysis 
To gate out cell doublets and debris, two scatter plots were used, pulse width vs. 
forward scatter (FSC) and FSC vs. side scatter (SSC).  
To determine DNA content and cell cycle distribution of cells, a histogram of 
propidium iodide emission vs. cell count was plotted. The appropriate peaks were 
gated to measure propidium iodide emission in the G1, S and G2/M phases. To 
measure levels of apoptosis, a scatter plot for propidium iodide vs. FITC was plotted 
and divided into quadrants based on subpopulations of necrotic cells (high 
propidium iodide and low FITC emission), apoptotic cells (low or high propidium 
iodide and high FITC emission) and viable cells (low PI and low FITC emission). 
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CHAPTER 3: CHARACTERISING THE CIS-
REGULATORY NETWORK IN HNSCC 
3.1 Introduction 
Research efforts into understanding molecular changes underlying head and neck 
cancer (HNSCC) have been intensifying over the last few years. For example, The 
Cancer Genome Atlas (TCGA) consortium have highlighted somatic gene 
alterations in a panel of 279 HNSCC tumours, some of which reflect the clinical 
outcome of HNSCC patients [36]. For example, HNSCC patients harbouring 
mutations of the TP53 gene and amplification of chromosome 11q13 have a less 
favourable clinical outcome than those without [36]. Furthermore, EGFR 
(epidermal growth factor receptor) overexpression and reduced overall patient 
survival particularly in HNSCC has been reported [36, 234]. However, despite a 
flurry of genome-wide HNSCC studies being published over the last few years [36, 
66-71], the five-year survival rate of patients with HPV (human papillomavirus)-
negative (HPV(-)) tumours currently stands at 25-40% and 70-80% for HPV-
positive (HPV(+)) patients [101]. In addition, only a few new therapies are in 
clinical trials, and survival rate for patients who fail to respond to first-line therapy 
is less than one year [235]. The cis-regulatory network in HNSCC has not 





The first aim of this project was to identify and characterise regulatory elements in 
HNSCC cell lines. The second aim was to compare differences in regulatory regions 
in HPV(-) and HPV(+) HNSCC cells to highlight differences in cis-regulation 
underlying both tumour types.  
To investigate the above aims, the DNase I-hypersensitivity assay followed by next 
generation sequencing (DNase I-seq) was conducted in four HNSCC cell lines; two 
HPV(-): VU40T(-) and SCC040(-) and two HPV(+): VU147(+) and UDSCC2(+). 
Transcription factor (TF) motif analysis and pathway enrichment analysis were 
applied to identify key transcriptional regulators. The findings were also compared 
to the genome-wide gene expression data obtained through RNA-seq. 
3.3 DNase I hypersensitivity assay development: an 
overview 
To isolate regulatory elements, the DNase I hypersensitivity assay was conducted 
in each of the above cell lines, followed by next-generation sequencing (DNase I-
seq) (Figure 3.1). The assay is briefly described as follows and will be discussed 
in more detail later. Nuclei were isolated using a detergent (NP-40) to disrupt the 
cell membrane, while maintaining intact nuclei with preserved chromatin structure. 
The concentration of NP-40 was optimised for each cell line, as the concentration 
can be cell line-specific (Figure 3.1: OP1). DNase I digestion can also be cell-line 
specific and so the amount of DNase I enzyme was optimised (Figure 3.1: OP2). 
Since the enzyme digests open chromatin regions more readily than closed regions, 
by limiting the digestion time, only accessible regions were released, which are 
called DNase I hypersensitive sites (DHSs). DNase I over-digestion can result in 
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the collection of unspecific fragments, while under-digestion can lead to a poor 
yield of DHSs. Therefore, before conducting the experiment, the best experimental 
conditions were established for each HNSCC cell line by optimising the amount of 
DNase I and concentration of NP-40 used.  
Once the optimisation steps were established, the efficiency of DNase I digestion 
was determined by agarose gel electrophoresis for each experiment (Figure 3.1: 
QC1). The digested chromatin was fractionated by size using ultra-centrifugation 
and the resulting fractions were visualised by agarose gel to ensure the DNA had 
been fractionated (Figure 3.1: QC2). Fractions enriched for DNA fragments 
between 100bp and 200bp were collected for downstream library preparation. 
QPCR (quantitative polymerase chain reaction) was also conducted as a quality 
control step to verify DHS enrichment by using DHS-specific primer sets (Figure 
3.1: QC3). Library preparation was required to modify the DNA and make it 
compatible for the Illumina sequencing platform. Once libraries were prepared, 
they were amplified by PCR (polymerase chain reaction) and amplification was 
verified by qPCR (Figure 3.1: QC4). Library size was verified using a 
microfluidics gel-based system (Agilent Bioanalyzer system) (Figure 3.1: QC5) 
and libraries were quantified using a qPCR-based method (Kapa quantification) 
(Figure 3.1: QC6). Post sequencing genome alignment, peak calling and analyses 
is described from Section 3.9 onwards. The quality control (QC) measures were 






Figure 3.1. Overview of DNase I-seq assay optimisation (OP) and quality control (QC) 
steps.  
Isolation of nuclei was optimised for each cell line by using a range of NP-40 
concentrations (OP1). The concentration of DNase I was optimised for each cell line to 
avoid incomplete digestion or over-digestion of the chromatin (OP2) and visualised on an 
agarose gel (QC1). The fragments were separated by size using the sucrose gradient 
method and separation was visualised by agarose gel electrophoresis (QC2). Fragments 
between 100-200bp were collected (3) and enrichment was assessed by qPCR using 
primers specific for known open chromatin regions and comparing to signal obtained from 
a ‘no DHS’ negative region (QC3). Library preparation involved modifying the samples 
by adding adapters for Illumina HiSeq compatibility and indexed for identification during 
analysis (4). Successful library preparation was assessed by performing qPCR on the 
library sample (QC4). The total library size, which includes the insert and adapters, was 
measured using the Agilent Bioanalyzer system (QC5). The concentration of library was 
measured using a qPCR-based assay (Kapa quantification kit) (QC6). After sequencing, 
peaks were called using the HOMER software as described in Materials and Methods (6) 
and motif analysis (7), pathway enrichment analysis (8) and enhancer cluster analysis (9) 
was conducted using the ‘findMotifsGenome’, ‘AnnotatePeaks’ and ‘superenhancer’ 
scripts in HOMER. 
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3.4 NP-40 and DNase I optimisation 
To isolate the maximum number of nuclei without over-digesting the cells, the 
concentration of NP-40 was optimised in a small-scale test using 1x106 cells per 
preparation. The optimisation step for NP-40 provided an indication of the 
concentration to use for the actual experiment. Four concentrations from 0.01% to 
0.04% were tested at increments of 0.01%. The percentage of intact nuclei was 
assessed for each cell line by conducting trypan blue staining. In SCC040(-), 
VU40T(-) and VU147(+) cells the optimal NP-40 concentration used was 
established to be 0.02%, while in UDSCC2(+) cells it was 0.01%. The optimum 
NP-40 concentrations yielded between 51-60% nuclei.  
To optimise the amount of DNase I, a small-scale test was conducted and a range 
of DNase I concentrations was tested for each cell line: 30U, 40U or 50U of DNase 
I per 1x106 nuclei. To control for degraded chromatin, a sample was included where 
no DNase I enzyme was added. After digestion, the samples were run on a 2% 
agarose gel for visual inspection. The desirable level of DNase I digestion resulted 
in a limited release of smaller DNA fragments from the high molecular weight DNA 
band and was compared to the untreated negative control, as exemplified in Figure 
3.2. Based on this optimisation, 50U of DNase I was selected for follow up 




Figure 3.2. Agarose gel electrophoresis of DNase I digested DNA in SCC040(-) cells.  
Nuclei from SCC040(-) cells were isolated and treated with 30U, 40U or 50U of DNase I 
enzyme for 3 mins at 37oC. The samples were visualised on a 2% agarose gel. A ‘no DNase 
I’ negative control was used to assess for endogenous chromatin digestion. The absence of 
a DNA smear in the negative control indicates lack of endogenous chromatin digestion. 
 
3.5 DNase I digestion and fractionation 
After DNase I digestion, DNA was isolated from the chromatin and the fragments 
were separated by size using a sucrose gradient (Figure 3.1). A total of 19 fractions 
containing the separated DNA fragments were collected for visualization on an 
agarose gel (Figure 3.3). Fragments between 100-200bp were enriched for library 
preparation. It was observed that fractions 1-3 contained DNA fragment sizes less 
than 100bp, while fractions 4-8 contained fragments largely between 100-200bp 
(Figure 3.3). To verify this, fractions 4-8 were combined and visualized on the 
Agilent Bioanalyzer system, as exemplified in Figure 3.4. The peak containing 
fractions 4-8 displayed up to 300 fluorescence units. Bleed-through of DNA 
fragments above the desired size of 200bp was observed. However, the majority of 
the DNA were within the desired range and DNA fragments beyond this range were 
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filtered out during the size-selection step of library preparation, as described in 
Materials and Methods, Section 2.9. 
 
 
Figure 3.3. Agarose gel electrophoresis of fractionated DNase I fragments in 
SCC040(-) cells.  
Generated DNA fragments were separated by ultra-centrifugation on a sucrose gradient. A 
total of 19 fractions were collected and visualised on an agarose gel to check for successful 





Figure 3.4. Agilent Bioanalyzer electropherogram for fractions 4-8 from SCC040(-) 
cells. 
DNA fragments were fractionated by size and fractions 4-8 were collected. The lower 
marker peak is observed at 35bp and the upper marker peak at 10,380bp. The peak between 
35bp and 200bp represents the combined 4-8 fractions (indicated by the dashed lines). 
 
3.6 QPCR primer design  
DHS enrichment in fractions 4-8 was assessed by conducting qPCR amplification 
of three positive control regions; keratin 6A (KRT6A) DHS region (Figure 3.5) and 
two DHS sites near the interleukin-6 (IL-6) gene (IL-6 site 1 and site 2) (Figure 
3.6). The KRT6A gene was selected as it is known to be constitutively expressed in 
epithelial cells and was used as a positive control region in initial experiments for 
UDSCC2(+) (Unpublished, Wiench) [213, 214]. Upon sequencing and mapping the 
UDSCC2(+) DHS fragments, two DHS peaks close to the IL-6 gene were observed 
(Figure 3.6). The IL-6 gene is often overexpressed in HNSCC and the IL-6 protein 
is a regulator of the HNSCC-related pathway, PI3K (phosphotidylinositol-3 
kinase)/AKT (protein kinase B)/mTOR (mechanistic target of rapamycin) [75]. 
Therefore, it was hypothesised that amplification of IL-6 may reflect DHS 


























sets were designed to the two DHS peaks close to IL-6 (site 1 and site 2) (Figure 
3.6).  
In addition to the positive control primers, a negative control region was selected 
near the KRT6A gene, which lacks any DHSs based on ENCODE (ENCyclopaedia 
Of DNA Elements) data of 125 cell lines [164] (Figure 3.5). To determine DHS 
enrichment by qPCR, a ratio was calculated from the amplification signals of the 
positive control regions against the negative control region. Based on data obtained 
from sequenced samples, which displayed high background (not shown), a fold 






Figure 3.5. Primer locations for quality control of DNase I-digested samples at the KRT6A gene.  
This figure displays the KRT6A DHS from subsequent DNase I-seq experiments conducted in HNSCC cell lines. Bigwig and BED files for SCC040(-) (dark 
blue), VU40T(-) (light blue), VU147(+) (orange) and UDSCC2(+) (red) were uploaded to the UCSC (University of California Santa Cruz) browser and 
visualised as coverage tracks. Identified (called) peaks (the cumulative reads for each location) for each cell line are depicted below the coverage tracks (depicted 
by the black bars). Primers were designed at a KRT6A DHS peak close to the 5’ end (KRT6A DHS), which serves as a positive control signal for qPCR of 
epithelial cells. Primers were also designed, based on the ENCODE data, to a nearby region lacking DHS peaks (‘no DHS’) to assess for over-digestion and 




Figure 3.6. Primer locations for quality control of DNase I-digested samples near the IL-6 gene.  
The genomic features and DHS data are presented as in Figure 3.5. This figure displays the IL-6 DHS from subsequent DNase I-seq experiments conducted in 
HNSCC cell lines. Positive control primers for qPCR were designed at two sites close to the IL-6 gene (indicated by green bars, ‘site 1’, ‘site 2’).
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3.7 Assessment of DHS enrichment by qPCR  
All DNase I experiments yielded enough cells for two DNase I treatments. 
Therefore, for comparison, along with qPCR data from treatments with 50U of 
DNase I in all HNSCC cell lines, 30U DNase I in UDSCC2(+) cells and 40U DNase 
I in SCC040(-), VU40T(-) and VU147(+) cells are also shown (Figure 3.7).  
In SCC040(-), VU40T(-) and VU147(+) cells, DHS fold enrichment was assessed 
by comparing the amplification signals of IL-6 sites 1 and 2 of 40U and 50U DHS 
samples, to that of the ‘no DHS’ region (Figure 3.7). SCC040(-) DHSs amplified 
at IL-6 site 1, displayed fold enrichment of 6.8- and 9.5-fold, for 40U and 50U 
preparations, respectively, while amplification of the IL-6 site 2 revealed 8.3- and 
17-fold enrichment, respectively (Figure 3.7A). VU40T(-) DHSs amplified at IL-6 
site 1 displayed fold enrichment of 5.9-fold and 17.0-fold in 40U and 50U 
preparations, respectively, while amplification at the IL-6 site 2 displayed 8.3- and 
28.0-fold enrichment, respectively (Figure 3.7B). VU147(+) DHSs amplified at IL-
6 site 1 displayed fold enrichment of 13.1-fold and 48.6-fold in 40U and 50U 
preparations, respectively, while amplification of IL-6 site 2 displayed 15.5-fold 
and 74.8-fold enrichment, respectively (Figure 3.7C). UDSCC2(+) DHS 
enrichment was assessed using the KRT6A DHS region. The DHSs were isolated 
with either 30U or 50U of DNase I (Figure 3.7D). DHSs isolated with 30U of 
DNase I displayed fold enrichment of 28.8-fold, while 50U DHSs displayed 42.1-
fold enrichment. Therefore, in all experiments, DHSs derived from 50U DNase I 
treatment displayed enrichment over background above the 5-fold cut-off and so 





Figure 3.7. Size-selected DHS enrichment assessed by qPCR.  
Nuclei were treated with 30U, 40U or 50U of DNase I and qPCR was conducted of sites 1 
and 2 near the IL-6 gene in (A) SCC040(-), (B) VU40T(-), (C) VU147(+) and of the KRT6A 
DHS region in (D) UDSCC2(+) DHSs. The signal was normalised to a negative control 
‘no DHS’ region. The bars represent the range between technical duplicates. 
 
3.8 DHS library preparation and quality control 
After verification of DHS enrichment by qPCR, libraries were prepared, as 
described in Materials and Methods, Section 2.9. Library preparation involves an 
adapter ligation step, which modifies the DNA making it compatible with the 
sequencing platform. The adapter also contains a unique index sequence for each 
sample, allowing identification of the samples during analysis after pooling and 
sequencing. Once the DHS library was prepared, the DHS sequences (insert) were 
size-selected for ~270bp (~150bp DHS insert size + 120bp adapter size). PCR was 
conducted to amplify the library and amplification was determined by qPCR. The 
same primer sets were used as described in Figures 3.5 and 3.6 (KRT6A, IL-6 sites 
1 and 2 and the ‘no DHS’ region) (Figure 3.1: QC4).  
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Amplification of the SCC040(-) DHSs at the IL-6 sites 1 and 2 resulted in 134.8- 
and 434.8-fold enrichment, respectively (Figure 3.8A). In the VU40T(-) library 
amplification of IL-6 sites 1 and 2 displayed 281.3- and 824.6-fold enrichment, 
respectively (Figure 3.8B). Amplification of the VU147(+) library displayed fold 
enrichment of 547.7- and 626.2-fold at IL-6 sites 1 and 2, respectively (Figure 
3.8C). Amplification of the KRT6A region of the UDSCC2(+) library displayed a 
15.8-fold enrichment (Figure 3.8D). The low enrichment in the UDSCC2(+) library 
qPCR signal may be due to the size-selection step during library preparation, where 
DHSs out of the 100-200bp range are filtered out. Despite this, the signal after 
library preparation was above the 5-fold enrichment cut-off value.  
 
Figure 3.8. Assessment of DHS enrichment after library preparation by qPCR.  
DHS enrichment of libraries was determined by amplification of DHSs near the IL-6 gene 
(sites 1 and 2) in (A) SCC040(-), (B) VU40T(-), (C) VU147(+) or at the KRT6A gene in 
(D) UDSCC2(+). The qPCR signal obtained from DHSs was normalised using the ‘no 
DHS’ signal to calculate enrichment over background. The bars represent the range 
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After qPCR confirmation of library enrichment, library size was verified by using 
the Agilent Bioanalyzer system (Figure 3.1: QC5 and Figure 3.9). Verification of 
the library size was required, as the desirable total size for Illumina HiSeq 
sequencing is 250-300bp.  
The average library size for the SCC040(-) DHS library was 284bp (Figure 3.9). A 
smaller peak can be observed with an average size of ~80bp, which represents 
primer dimers. However, the amount of DNA within this peak relative to the library 
DNA was not sufficient to significantly deplete reads from the library. Therefore, 
the SCC040(-) library was carried forward to the next step. The average library 
sizes for the VU40T(-), VU147(+) and UDSCC2(+) libraries were 275bp, 271bp 
and 461bp, respectively. The average library size for UDSCC2(+) DHSs was higher 
than the desired size range. However, the amount of DNA within the desired range 
was sufficient for sequencing and so the library was carried forward to the next step, 
as were the remaining libraries.  
After verification of library size, the libraries were quantified using the qPCR-based 
Kapa quantification kit, as described in Materials and Methods, Section 2.11.3 
(Figure 3.1: QC6). After quantification, eight indexed libraries were pooled for 
sequencing; the amount of total library was 10nM and was verified by Kapa 
quantification. Quantification was required to achieve the correct cluster density on 
the sequencing platform. A cluster is formed when the DNA fragments undergo 
clonal amplification. Loading too much library could lead to over-clustering and 
poor accuracy in determining each read, while under-clustering could lead to too 




Figure 3.9. A screenshot of the electropherogram for the SCC040(-) library using the 
Agilent Bioanalyzer system.  
The DNA marker can be observed on the electropherogram as two peaks; a lower marker 
at 35bp and an upper marker at 10,380bp. To determine the average library size, gates were 
set surrounding the library peak. The average size of the fragments in the SCC040(-) library 
was 284bp (indicated by the peak labelled ‘SCC040 library’). A peak is visible at ~80bp, 
indicative of the presence of a small amount of primer dimers.  
 
3.9 Mapping of DHSs in HNSCC cell lines 
Between 20 and 40 million reads were uniquely mapped to the hg19 version of the 
human genome for each analysed cell line (‘reads aligned’ in Table 3.1). An 
example of the sequenced DHS data can be seen in Figure 3.10 at the ANXA1 
(annexin 1) gene. The ANXA1 protein is often deregulated in cancers including 
HNSCC and is implicated in the HNSCC-related pathway, PI3K/AKT/mTOR [236, 
237].  
Peaks were identified (called) as DHS peaks using the HOMER (Hypergeometric 
Optimization of Motif EnRichment) software [220]. The input sample for the 
corresponding cell lines was used to improve peak calling specificity and reduce 
background. The peaks were called using the ‘findpeaks’ command and the 
‘variable peak’ setting. The settings for peak width and minimum distance between 




























changes in DHS-rich regions considered to be transcriptionally active in HNSCC 
such as, the keratin genes, EGFR, TP63 and ANXA genes [4, 6, 10, 12, 36]. The 
peak width ‘size’ setting was set at 500 and the ‘minimum distance’ setting between 
peaks was 1000 (2x the peak size). The false discovery rate (FDR) was set at 0.01% 
for SCC040(-), VU40T(-) and VU147(+) cells and 0.05% for UDSCC2(+) cells. 
The ‘false discovery rate’ (FDR) setting allows control over false positive peak 
predictions. The FDR value negatively correlates with peak confidence and 
stringency, therefore, the lower the number the more stringently peaks will be 
called. In previously published data generated by the ENCODE consortium and 
others using DNase I-seq, the FDR was set between 0.1% to 1% [161, 220, 238]. 
Once the reads were mapped and the peaks were aligned to the genome for each of 
the four HNSCC cell lines (single cell line dataset), between 22,398 and 38,851 
peaks were identified in the cell lines (Table 3.1).  










SCC040(-) 29,539,814 29,222,932 99.0% 30,137 
VU147(+) 43,973,943 43,611,816 99.2% 38,815 
VU40T(-) 21,154,428 20,812,496 98.4% 30,851 
UDSCC2(+) 27,517,141 22,182,041 80.6% 22,398 
 
The distribution of DHSs across the genome was investigated to determine whether 
it agreed with previously published data. The called peaks were annotated by 
genomic feature using the HOMER ‘AnnotatePeaks’ function. The peaks were 
annotated into the following categories: intergenic, intronic, promoter, exon, 
transcription termination site (TTS) and untranslated regions (UTRs) (Figure 
3.11A-D). Agreeing with previously published data, the analysis revealed that the 
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majority of DHS peaks were located within intergenic and intronic regions; between 
28.3% and 39.2%, respectively [161, 188, 238, 239]. Furthermore, between 10.5% 
and 18.5% of DHSs in promoter regions and between 8.7% and 15.1% in exons 
were observed [142-144, 239]. 
Using the HOMER ‘mergepeaks’ function, a ‘merged-HNSCC’ dataset (73,414 
peaks) was generated in which peaks present in at least one cell line were 
considered. This enabled investigation of whether there was any overlap amongst 
DHSs within a heterogeneous HNSCC cell population of four cell lines with 




Figure 3.10. UCSC screenshot of DNase I-seq data at the ANXA1 gene.  
DHS reads were mapped to the hg19 genome and peaks were called using HOMER. 
Coverage tracks for each cell line are displayed; SCC040(-) (dark blue), VU40T(-) (light 
blue), VU147(+) (orange) and UDSCC2(+) (red). Called peaks for each cell line are 
depicted below the coverage tracks (depicted by the black bars, labelled ‘DHS’). The 
‘Merged’ peak calling track corresponds to the merged DHS dataset, which was produced 
by including DHS peaks present in at least one of the HNSCC cell lines. The ‘DNase 
Clusters’ track displays previously published data; mapped DHS reads in a panel of 125 
cell lines by the ENCODE consortium. The ‘layered H3K27Ac’ track displays previously 
published data; the active histone mark, H3K27Ac in ENCODE cell lines. The pink peaks 
in the H3K27Ac track represent the NHEK (normal human epidermal keratinocyte) cell 




Figure 3.11. Genomic distribution of DHS peaks.  
A total of (A) 30,137 DHS peaks were called in SCC040(-) cells, (B) 30,851 DHSs in 
VU40T(-) cells, (C) 38,815 DHSs in VU147(+) cells and (D) 22,398 DHS peaks in 
UDSCC2(+) cells. The locations of the DHSs were mapped using HOMER to the following 
genomic regions: intergenic regions, introns, promoters, exons, transcription termination 
site (TTS) and untranslated regions (UTR). 
 
In total, 6.7% of DHS peaks in the ‘merged-HNSCC’ dataset were shared amongst 
all four cell lines and 13.1% were found in any three cell lines (Figure 3.12A and 
B). Therefore, 24.4% were found in at least three of the investigated cell lines and 
are referred to as ‘common peaks’ (Figure 3.12B and C). As much as 62.5% of 
‘merged-HNSCC’ peaks were uniquely found in only one cell line. Next, the 
proportion of unique and common peaks for each cell line were investigated 
independently (Figure 3.12C). Between 26% and 55% were unique in any given 
cell line and between 35% and 46% were common with at least two other cell lines. 


























































The high proportion of unique peaks observed in the ‘merged-HNSCC’ dataset, 
indicates high heterogeneity between the cell lines. However, it was observed that 
unique peaks were smaller than common peaks, which may reflect the stability of 
the DHS [188]. Therefore, the top 10% of peaks (7,340 peaks selected based on the 
peak score from the annotation file) were investigated. In this data set, 32.5% of 
peaks were shared between all cell lines, 65.8% of peaks were common (at least 3 
out of 4) and only 19.2% were unique (Figure 3.13A and 3.13B). When each cell 
line was considered independently, there were more than 80% common peaks and 
5-13% unique peaks (Figure 3.13C) as compared to the ‘merged-HNSCC’ dataset 
(35-46% and 26-55%, respectively) (Figure 3.13C). This indicated that the most 





Figure 3.12. Cell line distribution of merged-HNSCC DHS peaks. 
(A) A total of 73,414 DHS peaks were merged by considering any peaks which were 
present in at least one HNSCC cell line (SCC040(-), VU40T(-), VU147(+) and 
UDSCC2(+). (B) The DHS peaks were assigned to one of four categories: Unique to one 
cell line or present in 2/4, 3/4 or 4/4 cell lines. (C) The percentage of unique or common 
(present in at least 3/4 cell lines) was calculated for each cell line; 26.4%, 41.7%, 34.6% 
and 54.7% of DHSs were unique to SCC040(-), VU40T(-), VU147(+) and UDSCC2(+) 
cells, respectively and 46.1%, 40.9%, 38.4% and 34.7% of DHSs were common in 







Figure 3.13. The cell line distribution of the top 10% of merged-HNSCC DHS peaks. 
(A) 7,340 DHS peaks with highest peak scores were selected from the ‘merged-HNSCC’ 
as top 10% of merged DHS peaks (B) The DHS peaks were assigned to one of four 
categories: Unique to one cell line, present in any 2/4, 3/4 or 4/4 cell lines. (C) The 
percentage of unique or common (present in at least three out of four cell lines) was 
calculated for each cell line; 5.0%, 5.8%, 6.3% and 12.8% of DHSs were unique to 
SCC040(-), VU40T(-), VU147(+) and UDSCC2(+) cells, respectively and 80.8%, 85.2%, 
80.0% and 84.0% of DHSs were common in SCC040(-), VU40T(-), VU147(+) and 




3.10 Transcription factor motif analysis of DHS peaks 
To determine which transcription factors (TFs) may be involved in HNSCC gene 
regulation, TF motif analysis was first performed for each HNSCC cell line using 
HOMER with the ‘known motif’ function. Motif analysis provides data on which 
sequences (motifs) the TFs preferentially bind to and predict motifs based on 
sequence similarity [220]. 
The number of TF motifs identified in DHSs of each cell line were: 177 TF motifs 
in VU40T(-), 177 in SCC040(-), 198 in VU147(+) and 180 in UDSCC2(+) cells. 
The analysis of the single cell line DHS dataset revealed a total of 217 different 
motifs across the four cell lines and over half (60.8%) of these were shared between 
all four. The top 20 motifs for each cell line are shown in Appendix Tables 1-4, 
which show high overlap between the lists. Due to similar TF motifs being 
identified between the cell lines, the top 20 TF motifs common between all four cell 
lines were taken for analysis (Table 3.2). This list included the AP-1 (activator 
protein-1) motif (ATF3, BACH (BTB domain and CNC homolog)-1, -2, FOSL-1, 
-2, JUN, MAFK (MAF bZIP transcription factor K), NRF2/NF-E2 (nuclear factor 
erythroid 2–related factor 2)). The AP-1 TF functions as a dimer comprised of 
members from three TF families, the JUN family (c-JUN, JUNB, JUND), the FOS 
family (c-FOS, FOSB, FOSL1 (FOS like 1, AP-1 transcription factor subunit) 
(FRA-1), FOSL2 (FRA-2)) and the ATF (activating transcription factor) family 
(ATF1-3) [240]. Motifs for members of all three AP-1 families were identified in 
all HNSCC cell lines and the merged TF table (Table 3.2 and Appendix Table 1-
4). Further motifs related to AP-1 were identified, including the BACH TF family, 
which were also observed in all HNSCC cell lines (Table 3.2 and Appendix Table 
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1-4). In addition, the NRF2/NF-E2 and MAFK motifs were also present in the 
merged TF table (Table 3.2). Other top 20 TF motifs included p53/p63 motifs, 
TEAD (TEA domain transcription factor), RUNX (runt-related transcription 
factor), KLF (Krüppel-like factor) family motifs, CTCF (CCCTC-binding factor) 
and BORIS (brother of regulator of imprinted sites, a paralogue TF of CTCF) TF 
motifs (Table 3.2).  
In addition to motifs common between the cell lines, cell line-specific TF motifs 
were also observed. In UDSCC2(+) DHSs, the LHX (LIM homeobox)-2, -3, ELK 
(ETS domain-containing protein)-4 and NF (nuclear factor)-1 TF motifs were 
observed. In VU40T(-) DHSs, the ERG (ETS-related gene) was observed 
(Appendix: Tables 2 and 4). 
The lists of the top 20 TF motifs, were compared by HPV status, which revealed 
the SP1 (specificity protein 1) motif to be enriched in only the HPV(+) cell lines, 
while the RUNX motif was observed only in the HPV(-) cell lines (Appendix: 





Table 3.2. Common top 20 statistically significant transcription factor motifs in four 
HNSCC cell lines. 
 
Motif analysis was conducted using the ‘findMotifsGenome’ script within HOMER. Six 
TF motif families were identified: AP-1 (TGAnTCA) (dark blue), p53/p63/p73 (red), 
TEAD (cyan), RUNX (green), BORIS/CTCF (light blue) and KLF (white). 
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Due to the high sequence similarity between motifs, there can be indistinguishable 
overlap with other motifs, therefore ‘de novo motif’ analysis was also conducted. 
A total of 21, 23, 22 and 24 motifs were predicted in VU40T(-), SCC040(-), VU147(+) 
and UDSCC2(+), respectively. This analysis involved matching a target sequence to 
a known motif, while ranking other motifs by similarity to generate a list of de novo 
motifs. The top 10 motifs are shown for each cell line in Figure 3.14. It was found 
that all motifs identified earlier through the ‘known motif’ analysis (AP-1, p53/p63, 
RUNX, TEAD, CTCF, KLF and NRF motifs) are included (Table 3.2). In addition, 
the de novo analysis identified the ETS (E twenty-six transcription factor), NFY 
(nuclear transcription factor Y), CRE (cAMP response element), GFY (general 
factor Y), YY1 (yin yang 1) and NF (nuclear factor)-1 motifs (Figure 3.14).  
The de novo motif analysis was also conducted to identify motifs which overlap 
with promoter DHSs and those which overlap with distal DHSs (>1kb from the 
promoter) (Figure 3.15). Analysis of the two subsets (promoter and distal) revealed 
three groups of motifs: unique to promoter (ETS, NFY, CRE, NRF (nuclear 
respiratory factor)-1, GFY, YY1) unique to distal (FOXx/SRY, NF1, TEAD, 
p53/p63, RUNX, CTCF), and present in both (AP-1 and SP1/KLF) (Table 3.3). 
While the SP1 and KLF motifs are separate TFs, they share a highly conserved 
DNA binding domain and are able to function in association with each other or 
separately [241]. The AP-1 motif is present in both elements, at distal DHSs AP-1 
displays higher significance and appears in 3-times more targets compared to in 





Table 3.3. Motifs identified in promoter, distal DHSs or both.  
Promoter only Distal only Both 
ETS FOXx/SRY AP-1 
NFY NF1 SP1/KLF 
CRE TEAD  
NRF1 p53/p63  
GFY RUNX  




Figure 3.14. De novo motif analysis of HNSCC cells. 
HOMER was used to predict de novo motifs using VU40T(-), SCC040(-), VU147(+) and 
UDSCC2(+) DHS peaks; a total of 21, 23, 22 and 24 motifs were identified, respectively. 
For each motif, the percentage of motifs in target sequences is displayed and the size of the 




Figure 3.15. De novo motifs identified in the merged-HNSCC DHS dataset in 
promoters or distal locations.  
De novo motif analysis was conducted in the merged-HNSCC DHS dataset using the 
‘findMotifsGenome’ script within HOMER. The analysis was conducted in DHSs which 
were in proximity to the promoter TSS (<1kb) and in DHSs distal to the TSS (>1kb). The 
motifs are ranked by percentage of target sequences (DHSs) that contained them. The size 




3.11 Pathway enrichment analysis of HNSCC DHSs. 
To investigate which molecular processes the HNSCC DHSs may be involved in, 
pathway enrichment analysis was conducted in HOMER using the ‘AnnotatePeaks’ 
script. This analysis assigns each DHS to the closest TSS of a gene to create a list 
of potentially regulated genes. The list of genes was run through a combination of 
two pathway databases: Kyoto Encyclopaedia of Genes and Genomes (KEGG) and 
WikiPathways (WP) [223, 224]. The KEGG database highlights molecular 
processes and the WP database identifies cell signalling pathways. Between 283 
and 608 signalling pathways were identified in the four HNSCC cell lines and 
between 10,709 and 13,705 genes were annotated in the pathways (Table 3.4). 
The top 20 pathways were investigated for each cell line (Tables 3.5-3.8). The total 
number of annotated genes for the 20 pathways yielded between 1,882 and 2,654 
genes (Table 3.4). The most commonly annotated genes encoding TFs identified in 
motif analysis were the AP-1 genes; between 45-55% of pathways were annotated 
with an AP-1-related gene (Tables 3.5-3.8). Other TFs highlighted in the merged 
TF motif analysis were less frequently annotated in the pathway enrichment 
analysis. For example, the BACH1 gene was annotated only in the integrated breast 
cancer pathway in VU147(+) and UDSCC2(+) DHSs (Tables 3.7 and 3.8). Of the 
KLF family, the KLF11 gene was annotated in the VU40T(-) EGFR (epidermal 
growth factor receptor) signalling pathway, while KLF2 was annotated in the Fox 
(Forkhead)-O signalling pathway (Table 3.6). The RUNX1 gene was annotated in 
the ‘pathways in cancer’ pathway in all four cell lines, while the RUNX2 gene was 
annotated in the androgen receptor signalling pathway in UDSCC2(+) cells (Table 
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3.8). Genes of the TEAD TF family were annotated in the Hippo signalling pathway 
in SCC040(-) and VU147(+) cells (Tables 3.5 and 3.7).  







annotated genes in 
top 20 pathways 
SCC040(-) 288 12,794 2,229 
VU40T(-) 283 13,705 2,580 
VU147(+) 286 13,639 2,654 






Table 3.5. The top 20 DHS pathways identified in SCC040(-) cells. 
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Table 3.6. The top 20 DHS pathways identified in VU40T(-) cells. 
V U 4 0 T ( - )  D H S :  P a t h w a y  o v e r r e p r e s e n t a t i o n
Te r m E n r i c h m e n t l o g P
#  o f  
g e n e s  i n  
t e r m
#  t a r g e t  
g e n e s  i n  
t e r m
%  o f  
t a r g e t s  i n  
t e r m
G e n e  s y m b o l s D a t a b a s e
Pa t h w ay s  i n  c a n c e r 2.76E-07 -15.10 327 267 81.7
BIRC2,CDK6, CCND1, CDKN1A, CDKN2A, 
EGF, EGFR, ERBB2, FOS, IL-6, JUN, MAPK-1, 
-3, -8, -10, PIK3CA, RB1, RUNX1, TGF-β2, -
β2, WNT-2, -2B, -3, -3A, -4, -5A,-6, -7A, -
7B, -9A, -10A, -11, -16
K E G G
E n d o c y t o s i s 3.43E-07 -14.88 203 172 84.7 EGF, EGFR, ERBB3, TGF-β2 K E G G
EG F R 1  S i g n a l l i n g  
Pa t h w ay
3.58E-07 -14.84 177 155 87.6
EGF, EGFR, FOS, JUN, JUND, KLF11, MAPK-
1,-3,-8,-14, PIK3CA
W P
Fo c a l  a d h e s i o n 2.13E-06 -13.06 207 173 83.6
EGF, EGFR, ERBB2, MAPK-1,-3,-8,-10, 
PIK3CA
K E G G
Fox O  s i g n a l l i n g  
p a t h w ay
4.92E-06 -12.22 132 114 86.4
CCND1, CDKN1A, MAPK-1,-9, -12, -14, 
PIK3CA, TGFB1
K E G G
P ro t e o g l yc a n s  i n  
c a n c e r
8.35E-06 -11.69 225 185 82.2
CCND1, CDKN1A, EGFR, ERBB-2, -3, MAPK-
1, -3, 11-14, PIK3CA, WNT-3, -3A, -4, -5A, -
6, -7B, -9A, -10A, -16
K E G G
A d h e re n s  j u n c t i o n 1.91E-05 -10.87 73 66 90.4 CTNND1, EGFR, ERBB2,, MAPK-1, -3, YES1 K E G G
TG F -β  Re c e p t o r  
S i g n a l l i n g  Pa t h w ay
2.41E-05 -10.63 151 130 86.1
CCND1, CDKN1A, FOS, FOSB, JUN,JUNB, 
JUND, MAPK14, TGF-β2, YAP1A
W P
E r b B  s i g n a l l i n g  
p a t h w ay
2.58E-05 -10.57 87 77 88.5
AKT3, AREG, CDKN1A, EGFR, ERBB2, EREG, 
JUN, MAPK-1, -3, -8, -10, MTOR, PIK3CA, 
RAF1
K E G G
A xo n  g u i d a n c e 3.95E-05 -10.14 127 108 85.0 CDK51, MAPK-1, -3 K E G G
D N A  d a m a g e  
re s p o n s e  ( o n l y  AT M  
d e p e n d e n t )
6.76E-05 -9.60 91 81 89.0
AKT-2, -3, CCND1, CDKN1A, DVL1, FOSL1, 
JUN, MAPK1, MAPK10, MAPK8, MAPK9, 
PTEN, RBB2, TP73, WNT-2, -2B, -3, -3A, -
5A, -6, -7A, -7B, -10A, -11, -16
W P
T  c e l l  re c e p t o r  
s i g n a l l i n g  p a t h w ay
1.17E-04 -9.06 104 89 85.6
AKT2, CD247, CDC42, CDK4, FOS, JUN, 
MAPK1, MAPK11, MAPK12, MAPK13, 
MAPK14, MAPK3, MAPK9, PIK3CA
K E G G
Wn t  S i g n a l l i n g  
Pa t h w ay
1.61E-04 -8.73 60 55 91.7
CCND1, FOSL1, JUN, MAPK-9, 10, WNT-2, -
2B, -3, -3A, -4, -5A, -5B, -6, -7A, -7B, -10A, 
-11, -16
W P
I n t e g ra te d  
Pa n c re a t i c  C a n c e r  
Pa t h w ay
1.97E-04 -8.53 194 161 83.0
CCND1, CDKN1A, CDKN2B, EGF, EGFR, 
ERBB2, JUN, JUNB, JUND, MAPK-1, -3, -4, -
8, -9, -14, PIK3CA
W P
H i p p o  s i g n a l l i n g  
p a t h w ay
2.03E-04 -8.50 153 126 82.4
AJUBA, AREG, BIRC2, CCND1, LATS2, 
MOB1A, MOB1B, NF2, TEAD1-4, TGF-β2, -
β2, TP73, WNT-2, 2B, -3, -3A, -4, -5A, -5B, -
6, -7A, -9A, -10A, YAP1, YWHAE
K E G G
S e n e s c e n c e  a n d  
A u t o p h a g y
2.04E-04 -8.50 106 92 86.8 CDKN1A, JUN, MAPK-1, -14, MTOR W P
Re g u l a t i o n  o f  a c t i n  
c y t o s ke l e t o n
2.06E-04 -8.49 214 172 80.4 EGF, EGFR, MAPK3 K E G G
P ro l a c t i n  S i g n a l l i n g  
Pa t h w ay
2.29E-04 -8.38 75 67 89.3
ERBB2, FOSB, JUN, MAPK-3, -6, -8, -9, -14, 
MTOR, PIK3CA
W P
C o r t i c o t ro p i n -
r e l e a s i n g  h o r m o n e
2.54E-04 -8.28 90 79 87.8
FOS, FOSB, FOSL1, FOSL2, JUNB, JUND, 
KRT1, MAPK-1,  -3,  -8,  -9,  -14
W P
C i rc a d i a n  r hy t h m 2.61E-04 -8.25 30 29 96.7 - K E G G
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Table 3.7. The top 20 DHS pathways identified in VU147(+) cells. 
 
 
V U 1 4 7 ( + )  D H S :  P a t h w a y  o v e r r e p r e s e n t a t i o n
Te r m E n r i c h m e n t l o g P
#  o f  
g e n e s  i n  
t e r m
#  t a r g e t  
g e n e s  i n  
t e r m
%  o f  
t a r g e t s  i n  
t e r m
G e n e  s y m b o l s D a t a b a s e
EG F R 1  S i g n a l l i n g  
Pa t h w ay
3.22E-12 -26.46 177 163 92.1
CTNND1, EGF, EGFR, FOS, JUN, 
JUND, MAPK-1, -8, -14, PIK3CA
W P
I n t e r fe ro n  t y p e  I 5.56E-08 -16.70 49 49 100.0 MAPK14, MTOR W P
E p s t e i n - B a r r  v i r u s  
i n fe c t i o n
1.51E-07 -15.70 200 169 84.5
CDKN1A, JUN, MAPK10, MAPK11, 
MAPK13, MAPK14, PIK3CA, RB1, 
YWHAE
K E G G
Pa t h w ay s  i n  c a n c e r 1.69E-07 -15.59 327 265 81.0
AKT3, BIRC2, CCND1, CDKN1A, 
CDKN2A, E2F1, EGF, EGFR, ERBB2, 
FOS, IL6, JUN, MAPK-8, -10, MTOR, 
PIK3CA, RB1, RUNX1, TGF-β1, -β3, 
WNT-2, -2B, -3, -3A, -4, -5B, -6, -7A, 
-7B, -9A, -10A, -11, -16
K E G G
R B  i n  C a n c e r 3.42E-07 -14.89 87 81 93.1 CCND1, CDKN1A, E2F1 W P
C e l l  c yc l e 3.95E-07 -14.74 124 109 87.9
CCND1, CDKN1A, CDKN2A, TGF-β1, 
-β2, -β3, YWHAE
K E G G
TG F -β Re c e p t o r  
S i g n a l l i n g  Pa t h w ay
4.50E-07 -14.61 151 133 88.1
ATF3, CCND1, CCND1, CDKN1A, 
FOS, FOSB, JUN, JUND, RUNX2, TGF-
β1, -β2, TP73, YAP1
W P
H i p p o  s i g n a l l i n g  
p a t h w ay
8.37E-07 -13.99 153 131 85.6
AJUBA, BIRC2, CCND1, CCND1, 
CTGF, LATS1, LATS2, MOB1A, 
TEAD1, TEAD4, TGF-β1, -β2, -β3, 
TP73, WNT-2B, -2B, -3, -3A, -4, -6, -
7A, -7B, -8B, -9A, 10A, 11, 16
K E G G
I n t e g ra t e d  B re a s t  
C a n c e r  Pa t h w ay
1.08E-06 -13.73 152 133 87.5
BACH1, CCND1, E2F1, EGFR, JUN, 
MAPK1, MTOR, NF1, RB1
W P
E n d o c y t o s i s 1.19E-06 -13.64 203 169 83.3 EGFR, ERBB-3, -4, TGF-β1 K E G G
H T LV- I  i n fe c t i o n 3.15E-06 -12.67 259 210 81.1
AKT-1, -3, ATF-1, -3, CCND1, 
CDKN1A, CDKN2A, E2F1, FOS, 
FOSL1, IL6, JUN, MAPK8, PIK3CA, 
RB1, TGF-β1, -β2, -β3, WNT-2, -2B, 
-3 -3A, -4, -5B, -6, 7B, -8B, -9A, -
10A, -11, -16
K E G G
V i ra l  c a rc i n o g e n e s i s 3.44E-06 -12.58 206 170 82.5
CCNA1, CCND1, CDKN1A, CDKN2A, 
MAPK1, PIK3CA, YWHAE
K E G G
Fox O  s i g n a l l i n g  
p a t h w ay
4.92E-06 -12.22 132 113 85.6
CCND1, CDKN1A, CDKN2B, EGF, 
EGFR, IL6, KLF2, MAPK-1, -10, -11, -
13, -14, PIK3CA, TGF-β1, -β2, -β3 
K E G G
I n s u l i n  S i g n a l l i n g 6.06E-06 -12.01 163 140 85.9
FOS, JUN, MAPK-1, -4, -6, -8 -10, -
11, 14, MTOR, PIK3CA
W P
N o n - a l c o h o l i c  fa t t y  
l i v e r  d i s e a s e  
( N A F L D )
8.56E-06 -11.67 147 124 84.4 IL6, MAPK-8, -10, PIK3CA, TGF-β1 K E G G
C h ro n i c  mye l o i d  
l e u ka e m i a
9.35E-06 -11.58 73 66 90.4
AKT1-3, CCND1, CDKN1A, CDKN2A, 
E2F1, MAPK1, PIK3CA, RB1, RUNX1, 
TGF-β1, -β2, -β3
K E G G
Re n a l  c e l l  c a rc i n o m a 1.58E-05 -11.05 66 60 90.9 JUN, MAPK1, TGF-β1, PIK3CA K E G G
D N A  d a m a g e  
re s p o n s e  ( o n l y  AT M  
d e p e n d e n t )
3.64E-05 -10.22 91 81 89.0
AKT-1, -3, CCND1, CDKN1A, 
CDKN2A, ERBB2, FOSL1, MAPK-1, -
8, -10, TP73, WNT-2, -2B, -3, -4, -
5B, -6, -7A, -7B, -10A, -11, -16
W P
I n t e g ra t e d  
Pa n c re a t i c  C a n c e r  
Pa t h w ay
3.84E-05 -10.17 194 162 83.5
AKT1, CCND1, CDKN1A, E2F1, EGF, 
EGFR, ERBB2, JUN, JUNB, JUND, 
MAPK-1, -4, -8, -14, PIK3CA, TGF-β1
W P
H u n t i n g t o n ' s  
d i s e a s e
3.91E-05 -10.15 177 145 81.9 - K E G G
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A high degree of overlap between the pathways of the four cell lines was observed, 
which resulted in 48 different pathways being identified and were assigned to 17 
broad functions: HNSCC-, cancer-related, cell adhesion, migration, proliferation, 
growth, signalling, senescence, CNS (central nervous system), immune function, 
cytoskeletal, development, DNA regulation, metabolism, protein/RNA processing, 
and viral (Figure 3.16). 
Based on cell line representation, the pathways could be grouped into six clusters. 
Half of the pathways were categorised into group (1), which contained pathways 
over-represented in all four cell lines (Figure 3.16). Many group (1) pathways were 
HNSCC-related (5/24) or cancer-related (7/24). For example, the EGFR pathway 
(HNSCC-related) and pathways in cancer (cancer-related) showed high statistical 
significance in all four cell lines, while other HNSCC-related pathways included 
the TGF (transforming growth factor)- signalling, p53 signalling and MAPK 
(mitogen activated protein kinase) pathways (Figure 3.16). Pathways related to cell 
adhesion/migration and the cytoskeletal network, such as adherens junction, focal 
adhesion and regulation of actin cytoskeleton were also over-represented in group 
(1) (Figure 3.16).  
Group (2) included a subset of six pathways which were under-represented in 
UDSCC2(+) cells. The pathways included Hippo signalling and proteoglycans in 
cancer, both of which are involved in cell adhesion, migration and proliferation 
processes (Figure 3.16).  
Group (3) included eight pathways which were under-represented in VU40T(-) 
DHSs (Figure 3.16). Half of these pathways were associated with RNA/protein 
processing. Furthermore, the viral carcinogenesis and Epstein Barr Virus (EBV) 
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pathways were observed in this group and were more over-represented in HPV(+) 
cell lines (Figure 3.16). 
Group (4) contained four pathways over-represented more in VU147(+) DHSs, one 
of which was the HTLV-1 (human T-lymphotropic infection) pathway (Figure 
3.16). Group (5) included the HNSCC-related WNT (wingless) signalling pathway 
and was over-represented in the VU40T(-) DHSs. Group (6) included three 
pathways which were the least represented in the HNSCC cell lines and included 
two pathways related to CNS and one related to metabolism (Figure 3.16). 
3.12 Enhancer cluster analysis of DHS peaks 
The HNSCC regulatory landscape was searched for enhancer clusters (EC) (also 
known as ‘super-enhancers’) [173, 175]. These regions contain a higher density of 
TF binding sites than normal enhancers and so it was hypothesised that ECs may 
highlight key genes and processes involved in HNSCC.  
EC (enhancer cluster) identification was based on the method first described by 
Whyte et al. and is described in Methods and Materials, Section 2.12.4. A total of 
459 ECs in SCC040(-) cells, 477 ECs in VU40T(-), 380 ECs in VU147(+) and 558 
ECs in UDSCC2(+) cells were identified. Examples of ECs are shown in Figures 
3.17 and 3.18 at the EGFR and TP63 genes, respectively. EGFR has frequently 
been reported as being overexpressed in HNSCC and is associated with reduced 
patient survival [36, 67, 89, 90]. The TP63 gene, which is normally involved in 
epithelial differentiation and proliferation is also deregulated in HNSCC and often 





Figure 3.16. Pathway enrichment analysis based on HNSCC DHSs.  
Analysis revealed 48 different pathways identified across the four HNSCC cell lines. The 
pathways were ranked by log p-value; green represents the least statistically significant 
pathways, red represents most significant and blank boxes indicate no enrichment. The 
pathways were grouped into six subsets based on cell representation: (1) over-represented 
in all (24/48; 50%), (2) under-represented in UDSCC2(+) (6/48; 13%), (3) under-
represented in VU40T(-) (8/48; 17%), (4) over-represented in VU147(+) (4/48; 8%), (5) 
over-represented in VU40T(-) (3/48; 6%) and (6) least represented in HNSCC (3/48; 6%). 
Pathways Function SCC040(-) VU40T(-) VU147(+) UDSCC2(+)
log p-value
EGFR1 Signaling Pathway HNSCC-related
(1)
Pathways in cancer Cancer-related
ErbB signaling pathway HNSCC-related
Adherens junction Cell adhesion
Endocytosis Cytoskeletal
TGF-beta Receptor Signaling Pathway HNSCC-related
FoxO signaling pathway Cell proliferation/death
Integrated Pancreatic Cancer Pathway Cancer-related
Integrated Breast Cancer Pathway Cancer-related
Small cell lung cancer Cancer-related
Renal cell carcinoma Cancer-related
Chronic myeloid leukemia Cancer-related
Insulin Signaling Metabolism
Cell cycle Cell proliferation
Focal adhesion Cell adhesion
Regulation of actin cytoskeleton Cell adhesion/migration
Alpha6-Beta4 Integrin Signaling Pathway Cell adhesion/migration
Leptin signaling pathway Metabolism
Signaling of Hepatocyte Growth Factor Receptor Cell proliferation
p38 MAPK Signaling Pathway HNSCC-related
Androgen receptor signaling pathway Cell proliferation
TSH signaling pathway Cell proliferation
p53 signaling pathway HNSCC-related
Prostate Cancer Cancer-related
DNA damage response (only ATM dependent) DNA-related
(2)
Proteoglycans in cancer Cell adhesion/migration/proliferation
Hippo signaling pathway Cell adhesion/migration/proliferation
AMPK signaling pathway Metabolism
Prolactin Signaling Pathway Metabolism
Senescence and Autophagy Cell proliferation
Viral carcinogenesis Viral
(3)
RB in Cancer HNSCC-related
Epstein-Barr virus infection Viral
Spliceosome RNA/protein processing
Ribosome RNA/protein processing
Protein processing in endoplasmic reticulum RNA/protein processing
TNF-alpha/NF-kB Signaling Pathway Immune-related
mRNA processing RNA/protein processing
Interferon type I Immune-related
(4)
HTLV-I infection Viral
Non-alcoholic fatty liver disease (NAFLD) Metabolism
Huntington's disease CNS
Axon guidance CNS
(5)T cell receptor signaling pathway Immune-related








Figure 3.17. UCSC screenshot of enhancer cluster data at the EGFR gene.  
HOMER was used to identify enhancer clusters (ECs) using ‘called’ DHS peaks. DHS 
peaks within a distance of 12.5kb were identified and concatenated. The enhancer cluster 
signal was normalised by taking EC reads minus normalised input reads. The signal was 
ranked by score and any regions with a score above one were determined an EC. A total of 
459, 477, 380 and 558 ECs were identified in SCC040(-), VU40T(-), VU147(+) and 
UDSCC2(+) cells, respectively. Coverage tracks for each cell line are displayed; SCC040(-
) (dark blue), VU40T(-) (light blue), VU147(+) (orange) and UDSCC2(+) (red). Called EC 
peaks for each cell line are depicted below the coverage tracks (depicted by the black bars, 
labelled ‘DHS’). The ‘DNase Clusters’ track contains mapped DHS reads in a panel of 125 
cell lines by the ENCODE consortium. The ‘layered H3K27Ac’ track displays the active 
histone mark, H3K27Ac in ENCODE cell lines. The pink peaks in the H3K27Ac track 
represent the NHEK (normal human epidermal keratinocyte) cell line, indicating that some 




























Figure 3.18. UCSC screenshot of enhancer cluster data at the TP63 gene.  
HOMER was used to identify ECs using ‘called’ DHS peaks. DHS peaks within a distance 
of 12.5kb were identified and concatenated. The enhancer cluster signal was normalised by 
taking EC reads minus normalised input reads. The signal was ranked by score any regions 
with a score above one were determined an EC. A total of 459, 477, 380 and 558 ECs were 
identified in SCC040(-), VU40T(-), VU147(+) and UDSCC2(+) cells, respectively. 
Coverage tracks for each cell line are displayed; SCC040(-) (dark blue), VU40T(-) (light 
blue), VU147(+) (orange) and UDSCC2(+) (red). Called EC peaks for each cell line are 
depicted below the coverage tracks (depicted by the black bars, labelled ‘DHS’). The 
‘DNase Clusters’ track contains mapped DHS reads in a panel of 125 cell lines by the 
ENCODE consortium. The ‘layered H3K27Ac’ track displays the active histone mark, 
H3K27Ac in ENCODE cell lines. The pink peaks in the H3K27Ac track represent the 
NHEK (normal human epidermal keratinocyte) cell line, indicating that some of these 
DHSs are epithelial specific. 
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The EC peaks identified in the HNSCC cell lines were assigned to the closest TSS 
to generate a list of genes associated with ECs. Genome-wide distribution of ECs 
was comparable in all four HNSCC cell lines and agreed with published data 
(Appendix: Figure 1) [44]. A total of 1,208 EC genes were identified across the 
four cell lines and the overlap of genes between the cell lines was investigated 
(Figure 3.19). A quarter of the genes were specific to UDSCC2(+) DHSs 
(360/1208), while 121 (10%) annotated EC genes were VU147(+)-specific, 212 
(18%) EC genes were VU40T(-)-specific and 177 (15%) EC genes were SCC040(-
)-specific (Figure 3.19A).  
The overlap of genes was investigated further by calculating the percentage of genes 
present in all cell lines, in 3 out of 4 cell lines, in 2 out of 4 cell lines or in one cell 
line (cell line-specific) (Figure 3.19B). It was found that the majority of genes were 
cell line-specific (72%), while 2.7% (33/1208) were found in all four cell lines, 
7.2% (87/1208) were found in 3 out of 4 cell lines and 18% (217/1208) were found 
in 2 out of 4 cell lines (Figure 3.19B). This pattern reflects the distribution of DHSs 
in the merged-HNSCC dataset (Figure 3.12) rather than the pattern in the top 10% 






Figure 3.19. Genes annotated to HNSCC EC peaks. 
EC peaks were assigned to the closest gene TSS using HOMER. (A) A total of 1,208 genes 
were annotated and the overlap between SCC040(-), VU40T(-), VU147(+) and 
UDSCC2(+) cells was investigated. (B) Percentage overlap of genes was investigated by 
calculating the percentage of genes which were cell line-specific, present in all cell lines, 
in 3 out of 4 cell lines or 2 out of 4 cell lines. 
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The 33 genes found in all four cell lines were investigated further by conducting 
pathway enrichment analysis by using DAVID (Database for Annotation, 
Visualization and Integrated Discovery) [242] (Figure 3.20). Despite the set being 
very small it clearly allowed for identification of the tissue as the ‘head and neck 
neoplasia’ using the Unigene database. Among the annotated genes in the ‘head and 
neck neoplasia’ pathway was the WWTR1 (WW domain containing transcription 
regulator 1) gene which encodes the TAZ (tafazzin) protein, a positive effector of 
the Hippo pathway and ANXA1, which as mentioned earlier is often deregulated in 
cancers including in HNSCC [236, 243]. The CGAP (Cancer Genome Anatomy 
Project) database also revealed the 33 genes to be related to oesophageal and 
pharyngeal tumour disease (Figure 3.20). Among the annotated genes in the 
oesophageal tumour disease pathway was the CLDN1 gene which encodes claudin, 




Figure 3.20. Pathway enrichment analysis of 33 genes common to all four HNSCC cell 
lines. 
The DAVID tool was used to conduct pathway enrichment analysis. Two databases were 















The overlap of TF genes was also investigated. A total of 23 TF genes were 
annotated in the HNSCC ECs, many of which were also identified by TF motif 
analysis, including TP63, AP-1 genes (FOS, FOSB, FOSL1), ETS2, SP1/KLF genes 
and RUNX1 (Table 3.9). In addition, LHX-2, LHX-3 and DLX6 (distal-less 
homeobox 6) genes appear to be UDSCC2(+)-specific, reflecting TF motif analysis 
(Tables 3.2 and 3.9).  








Pathway enrichment analysis was conducted using EC peaks for each HNSCC cell 
line; the top 20 most over-represented pathways were considered. A total of 1,179 
genes were allocated to the ECs across the four cell lines (Appendix: Tables 5-8). 
Pathway enrichment analysis was conducted as described for Figure 3.16. A total 
of 49 different pathways were identified, grouped based on log p-value and 
categorised into six clusters (Figure 3.21). 
Group (1) contained three pathways which were highly over-represented in all 
HNSCC cell lines: focal adhesion, 64 integrin signalling pathway and viral 
carcinogenesis (Figure 3.21). 
Group (2) consisted of 16 pathways which are also highly involved in most of the 
cell lines but are less significant in UDSCC2(+) cells. This subset of pathways 
appear to commonly control processes such as cell adhesion/migration, as over-
representation of the proteoglycans in cancer pathway, RAP1 (Rap1 GTPase) and 
Hippo signalling pathways are observed (Figure 3.21). RAP1 is a GTPase enzyme 
involved in the maintenance of cell-cell junctions [245].  
Group (3) consisted of seven common pathways which included two HNSCC-
related pathways, MAPK and TGF- signalling pathways (Figure 3.21). The 
HTLV-1 viral pathway, cell cycle and FAS (fas cell surface death receptor) 
pathways were also over-represented, more so in HPV(+) cell lines.  
Groups (4) and (5) contain 16 pathways which were over-represented in VU147(+) 
and in UDSCC2(+), respectively (Figure 3.21). Uniquely, these two subsets 
contained pathways associated with transcription and DNA regulation. In general, 
the differential regulation of UDSCC2(+) is more pronounced in EC analysis, with 
28 out of 46 pathways being either more (group 5) or less (group 2) enriched in 
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UDSCC2(+) than in other cell lines. Interestingly, in group six, the SCC040(-) cell 




Figure 3.21. Pathway enrichment analysis of enhancer clusters in four HNSCC cell 
lines.  
Analysis revealed 49 different pathways across the four HNSCC cell lines. The pathways 
were ranked by log p-value; green represents the least statistically significant pathways, 
red represents most significant and blank boxes indicate no enrichment. The pathways were 
grouped into six groups by cell representation: (1) over-represented in all (3/49; 6%), (2) 
under-represented in UDSCC2(+) (19/49; 39%), (3) over-represented in HNSCC (7/49; 
14%), (4) over-represented in VU147(+) (4/49; 8%), (5) over-represented in UDSCC2(+) 
(12/49; 24%), (6) over-represented in SCC040(-) or VU40T(-) (4/49; 8%). 
 
Pathway Function SCC040(-) VU40T(-) VU147(+) UDSCC2(+)
log -value
Focal adhesion Cell adhesion
(1)Alpha6-Beta4 Integrin Signaling Pathway Cell adhesion/migration
Viral carcinogenesis Viral
EGFR1 Signaling Pathway HNSCC-related
(2)
Rap1 signaling pathway Cell migration
Adherens junction Cell adhesion
Leukocyte transendothelial migration Immune function/cell migration
Proteoglycans in cancer Cell adhesion/migration/proliferation
Pathways in cancer Cancer-related
Regulation of actin cytoskeleton Cytoskeletal
Arrhythmogenic right ventricular cardiomyopathy (ARVC) Cell adhesion
Hippo signaling pathway Cell adhesion/migration/proliferation
Tight junction Cell adhesion
Epithelial cell signaling in Helicobacter pylori infection Bacterial
Androgen receptor signaling pathway Cell growth/proliferation
Bacterial invasion of epithelial cells Bacterial
Integrated Breast Cancer Pathway Cancer-related
Integrin-mediated cell adhesion Cell adhesion
Pancreatic cancer Cancer-related
Small cell lung cancer Cancer-related
Apoptosis Cell death
NF-kappa B signaling pathway Immune function
Endocytosis Cytoskeletal
(3)
MAPK signaling pathway HNSCC-related
IL-3 Signaling Pathway Immune function
FAS pathway and Stress induction of HSP regulation Cell death
Cell cycle Cell proliferation
HTLV-I infection Viral
TGF-beta signaling pathway HNSCC-related
Transcriptional misregulation in cancer Transcription regulation
(4)
Ras signaling pathway HNSCC-related
Signaling Pathways in Glioblastoma CNS
Integrated Pancreatic Cancer Pathway Cancer-related
Systemic lupus erythematosus Immune function
(5)
DNA replication DNA regulation
Alcoholism Metabolism
Mismatch repair DNA regulation
Nucleotide excision repair DNA regulation
DNA polymerase alpha / primase complex DNA regulation
RPA complex DNA regulation
Estrogen signaling pathway Cell growth/proliferation
IL-6 Signaling Pathway Immune function
Endometrial cancer Cancer-related
Signaling of Hepatocyte Growth Factor Receptor Cell growth/proliferation
Hypertrophy Model Protein processing
Wnt signaling pathway HNSCC-related
(6)
IL-1 Signaling Pathway Immune function
RANKL/RANK Signaling Pathway Immune function
Pathogenic Escherichia coli infection Bacterial
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In DHS and EC pathway enrichment analyses, 21 pathways were common to both 
datasets, including cell adhesion pathways (adherens junction, 64 integrin 
signalling pathway, focal adhesion, proteoglycans in cancer, regulation of actin 
cytoskeleton, Hippo), HNSCC-related (EGFR, MAPK, TGF- and WNT), cancer-
related pathways (integrated breast, pancreatic cancers, small cell lung cancer) and 
the viral carcinogenesis and HTLV-1 pathways (Figure 3.16 and 3.21).  
3.13 RNA-seq analysis of HNSCC cell lines 
Genome-wide gene expression was investigated by conducting RNA-seq analysis 
in the HNSCC cell lines. The Galaxy platform was used to analyse the data as 
described in Materials and Methods, Section 2.13.5. Within Galaxy, the Hisat2 tool 
was used to align reads to the hg19 genome [227]. Between 16 and 35 million reads 
were sequenced and between 92.6% and 97.5% of reads were aligned to the genome 
(Table 3.10).  
Table 3.10. Summary of RNA-seq alignment data. 
Cell line 
No. of reads 
sequenced 
% of reads aligned 
No. of genes >1 
FPKM 
SCC040(-) 16,556,164 92.6% 8,071 
VU40T(-) 34,941,803 97.5% 7,714 
VU147(+) 30,411,068 96.4% 8,185 
UDSCC2(+) 18,726,353 93.0% 8,807 
 
The Stringtie tool within Galaxy was used to assemble and quantify transcripts 
[228]. Each gene was assigned an FPKM value (fragments per kilobase exon per 
million mapped reads). The FPKM is normalised using the number of mapped reads 
and the gene length. The cut-off point for the FPKM value was set at 1 and genes 
with FPKM values above 1 were considered as being expressed and taken for 
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further analysis [229, 230]. The total number of genes with an FPKM value above 
1 were between 7,714 and 8,807 genes (Table 3.10). 
Clustering analysis was conducted to investigate variability between gene 
expression for SCC040(-), VU40T(-), VU147(+) and UDSCC2(+) genes (Figure 
3.22). The greatest variability was observed between UDSCC2(+) cells and the 
remaining three cell lines, while the least variability was observed between the 
VU40T(-) and VU147(+) genes. 
To investigate gene expression variability further, FPKM values were used to 
conduct principal components analysis (PCA) using the ‘PCAexplorer’ script 
within the R software (Figure 3.23). PCA analysis generates components which are 
ranked by score. Score 1 represents the largest component, as most genes fit into 
this component (PC1), while scores 2 (PC2) and 3 (PC3) represent the second and 
third largest components, respectively (Figure 3.23A). Over half of gene variability 
(54.3%) could be accounted for by PC1 (Figure 3.23B). The analysis revealed that 
this was due to differences in gene expression between UDSCC2(+) cells and 
SCC040(-), VU40T(-) and VU147(+) cells (Figure 3.23B). PC2 accounted for 
23.7% of variability and this was found to be due to VU147(+) expression 
differences compared to VU40T(-), SCC040(-) and UDSCC2(+) cells (Figure 
3.23B). PC3 accounted for 22.1% of variability and this was due to differences 
between SCC040(-) gene expression and the remaining three cell lines (Figure 
3.23C). Hierarchical clustering of FPKM values for the four HNSCC cell lines 
further demonstrated the UDSCC2(+) genes to vary the most between the cell lines 





Figure 3.22. Clustering analysis of gene expression data.  
RNA-seq data for SCC040(-), VU40T(-), VU147(+) and UDSCC2(+) cells yielded 8,071, 
7,714, 8,185 and 8,807 genes, respectively with an FPKM (fragments per kilobase exon 
per million mapped reads) value above the cut-off value of 1. Clustering analysis was 
performed using the ‘PCAexplorer’ script within the R software. The scale represents 






Figure 3.23. Principal components (PCA) and clustering analyses of gene expression 
data.  
(A) Three principal components (PCs) were identified upon clustering of variabilities in 
gene expression: PC1, PC2 and PC3. (B) PC1 accounted for 54.28% of variability and this 
was due to differences between UDSCC2(+) gene expression and VU40T(-), SCC040(-) 
and VU147(+) expression. (B and C) PC2 accounted for 23.66% of variability and this 
was due to differences between VU147(+) gene expression and VU40T(-), SCC040(-) and 
VU147(+) expression. (C) PC3 accounted for 22.06% variability, which was due to 
expression differences between SCC040(-) and the remaining three cell lines. (D) 
Clustering analysis of FPKM values revealed the greatest variability of UDSCC2(+) gene 
expression compared to the remaining three cell lines. Analysis was conducted using the 















































































To investigate which pathways the expressed genes in the HNSCC cell lines were 
associated with, pathway enrichment analysis was conducted using the 
ConsensusPath database [231]. The genes were sorted by FPKM values and the top 
2000 genes were run through the database; the data for the KEGG and WP databases 
were extracted. The top 20 pathways were identified and grouped as described in 
Figure 3.16. A total of 35 pathways were identified, within which four groups were 
identified (Figure 3.24).  
Group (1) consisted of 11 pathways, which were highly over-represented in two or 
more cell lines. Over half of the pathways in this group (6/11) were associated with 
RNA/protein processing. In addition, the cell cycle pathway was also over-
represented (Figure 3.24). 
Group (2) could be further split into two subsets: 2a and 2b. Subset 2a consisted of 
11 pathways which were largely over-represented in UDSCC2(+) cells (Figure 
3.24). Subset 2b mainly consisted of pathways associated with microRNAs 
(miRNA) (small single-stranded, non-coding RNAs) and were under-represented 
in VU147(+) (Figure 3.24). 
Group (3) consisted of pathways which were well represented in the VU40T(-), 
VU147(+) and UDSCC2(+) cell lines, while being significantly over-represented 
in SCC040(-) cells (Figure 3.24). This group contained pathways associated with 
cell adhesion, proliferation, migration, as well as the HNSCC-related pathway, 
TGF-. This group therefore, reflects well the DHS pathway enrichment analysis. 
Striking is the lack of HNSCC-related signalling pathways such as the EGFR, 
ERBB, p53, Hippo and MAPK signalling pathways (Figure 3.24). 
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Figure 3.24. Pathway enrichment analysis of genes expressed in HNSCC cells.  
Genes were sorted by FPKM and the top 2,000 genes were taken for pathway enrichment 
analysis by using the ConsensusPath database; a total of 35 pathways were over-
represented. The pathways were ranked by log p-value; green represents the least 
statistically significant pathways, red represents most significant and blank boxes indicate 
no enrichment. Pathways were grouped into four groups by representation: (1) over-
represented in all (11/35; 31%), (2) over-represented in UDSCC2(+) (11/35; 31%), (2a) 
under-represented in VU147(+) (6/35; 17%), (2b) over-represented in UDSCC2(+) (5/35; 
14%), (4) under-represented in all (5/35; 14%). 
Pathway Function SCC040(-) VU40T(-) VU147(+) UDSCC2(+)
log p-value
mRNA Processing Protein/RNA processing
(1)
Translation Factors Protein/RNA processing
Cytoplasmic Ribosomal Proteins Protein/RNA processing
Ribosome Protein/RNA processing
Cell cycle Cell proliferation
RNA transport Protein/RNA processing
Protein processing in endoplasmic reticulum Protein/RNA processing
Androgen receptor signaling pathway Cell growth/proliferation
Electron Transport Chain Metabolism
Retinoblastoma (RB) in Cancer HNSCC-related
Dilated cardiomyopathy Cell adhesion




miR-targeted genes in epithelium micro RNA
miR-targeted genes in muscle cell micro RNA
miR-targeted genes in lymphocytes micro RNA
miR-targeted genes in squamous cell micro RNA
Primary Focal Segmental Glomerulosclerosis FSGS Renal degeneration
Epstein-Barr virus infection Viral
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Cell adhesion
Pathogenic Escherichia coli infection Bacterial
Thyroid hormone signaling pathway Cell growth/proliferation
Tight junction Cell adhesion
(3)
Proteoglycans in cancer Cell adhesion
Regulation of actin cytoskeleton Cytoskeletal
Adherens junction Cell adhesion
TGF-beta Signaling Pathway HNSCC-related
Pathways in cancer Cancer-related
Estrogen signaling pathway Cell growth/proliferation
Focal adhesion Cell adhesion





Progesterone-mediated oocyte maturation Development
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3.14 Discussion 
Genome-wide analysis of the HNSCC (head and neck squamous cell carcinoma) 
regulatory network was conducted by using the DNase I-seq assay to generate 
DNase I hypersensitive sites (DHSs). As DHSs are representative of open 
chromatin regions, they were used to gain insight into cis-regulation of HNSCC by 
analysing a heterogeneous population of four HNSCC cell lines, derived from the 
tongue, floor of the mouth and hypopharynx.  
A large number (73,414) of potential regulatory elements were identified across the 
four cell lines with the majority of them being cell line-specific, therefore reflecting 
the heterogeneity of the cell lines used. However, these cell line-specific peaks were 
observed as being smaller than shared peaks. It has been suggested that small peaks 
may reflect the lack of stability of the DHS and it may be that cell line-specific 
DHSs may be present in a fraction of a given cell population [188]. Alternatively, 
it may be that cell-line specific peaks display dynamic chromatin accessibility, 
where DNA regulatory elements are transiently accessible for TF binding [180, 246, 
247].  
Despite the described heterogeneity, interrogation of the largest DHS peaks (top 
10%) revealed that nearly 70% were shared between all four cell lines indicating 
that similar active regions underlie the core regulatory network in these HNSCC 
cell lines. Alternatively, the shared, largest DHSs could reflect key regulation of 
basic cell metabolism including replication and translation. TF motif and pathway 
enrichment analyses also show a prominent overlap between the cell lines. 
Therefore, despite large differences in the localization of regulatory elements, the 
pattern of signalling pathway activation remains generally the same.  
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Pathway enrichment analysis of HNSCC DHSs revealed two large groups of 
pathways: over-represented in all HNSCC cell lines and under-represented 
specifically in UDSCC2(+) cells. The UDSCC2(+) cell line had the highest 
proportion of unique peaks, which was further reflected in a differential TF motif 
profile, as well as in pathway enrichment analysis. This observation was further 
confirmed and enhanced by EC (enhancer cluster) and RNA-seq analyses. 
Therefore, UDSCC2(+) cells being hypopharyngeal and originating from 
reticulated epithelium may explain its distinct regulatory and genetic profile 
compared to the other HNSCC cell lines, which are of oral origin. To support this, 
previously published data highlight molecular differences in HNSCC of the oral 
cavity compared to the hypopharynx. For example, methylation of the CDKN2A 
(cyclin dependent kinase inhibitor 2A) promoter, which encodes for the 
cyclin/CDK inhibitor, p16, was found to be significantly higher in oral tumours 
compared to those of the hypopharynx [248]. Furthermore, loss-of-heterozygosity 
of the TP53 gene was found to be significantly higher in hypopharyngeal tumours, 
compared to those derived from oral cancers [248]. 
TF motif analysis revealed that the HNSCC DHS peaks are dominated by the AP-
1 motif, but also the presence of p53 (p63 and p73), TEAD (TEA domain 
transcription factor) (1-4), RUNX (runt-related transcription factor) (1-3), KLF 
(Krüppel-like factor) (1-17) and ETS (E twenty-six transcription factor) family 
motifs were detected. The ETS TF family consists of 13 subfamilies, which 
includes the ETS, ERG (ETS related gene), ELK, ELF (E74-like factor), ETV (ETS 
variant), EHV (equine herpesvirus) and EHF (ETS homologous factor) TF families 
[249-251]. Members of these TF families have been previously characterised in 
SCC: (i) JUN and FOSL1, of the AP-1 family, have previously been linked to 
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invasion and metastasis of SCC cells, including in HNSCC [117, 252-255]. In 
addition, constitutive activation of JUND has been linked to the induction of pro-
inflammatory signals in HNSCC cells [240, 252, 255, 256]. (ii) The TP53 gene is 
one of the earliest genes to undergo mutations in HPV(-) HNSCC tumours, and its 
degradation can be induced by E6 in HPV(+) tumours leading to cell cycle 
deregulation [29, 36, 66-71]. (iii) The p63 protein is essential in the organisation of 
the epithelium and is known to be overexpressed in HNSCC [12, 13, 16, 257-259]. 
(iv) Expression of the KLF4 gene has been associated with poor prognosis in 
HNSCC patients and its overexpression in HNSCC cells has been shown to increase 
cell invasion and migration [260]. In addition, an EC has been identified, associated 
with the KLF5 gene in HNSCC tumours, moreover focal amplifications of this EC 
have been linked to KLF5 protein overexpression and associated with SCC [179]. 
(v) Both RUNX1 and RUNX2 were annotated in DHS pathway enrichment analysis 
of all HNSCC cell lines or UDSCC2(+) only, respectively. In oral SCC tumours in 
mice, Runx1 expression has been seen to be pro-tumourigenic [261]. RUNX2 has 
been reported to display abnormal methylation patterns in cancers, including 
HNSCC [262, 263]. RUNX3 TF overexpression has been shown to positively 
correlate with proliferation of HNSCC cell lines [264]. (vi) Evidence of gene 
alterations in the ETS1, ETV3 and ELF3 genes have been observed in HNSCC cell 
lines [265]. ETS-1/2 have been linked to activation of the RAS (resistance to 
audiogenic seizures)/MAPK pathway in epithelial cells (kidney and prostate cell 
lines) [266]. Therefore, TF motif analysis has revealed several TFs which are 
known to be involved in HNSCC development. 
Until recently, the TEAD TFs had not been implicated in HNSCC. It has now been 
reported that TEAD, its activator YAP (yes-associated protein), and an inactive 
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form of p53 have a role in the regulation of a circular RNA transcript of the PVT1 
(pvt1 oncogene) gene (a long non-coding RNA), which is often upregulated in 
cancers, including HNSCC tumours [267]. 
In addition to common regulation, cell line specificity was also observed- LHX 
(LIM homeobox)/DLX in UDSCC2(+) and GRHL2 (grainyhead-like protein 2) in 
SCC040(-). Of the LHX TF family, LHX-6 is a tumour suppressor gene, which 
undergoes hypermethylation in HNSCC tumours thereby silencing its expression 
[268]. This may be the case in UDSCC2(+) cells, as RNA-seq data generated from 
the UDSCC2(+) cells reveal no expression of LHX-6 expression (data not shown). 
On the other hand, GRHL2 has been reported to activate the MAPK pathway and 
contribute to HNSCC development in vivo and is expressed in our SCC040(-) cells 
(data not shown) [269]. 
Furthermore, the TF motif analysis highlighted two types of regulatory factors: 
acting at promoters and at the distal regulatory elements (located >1kb from the 
TSS). The promoter-specific de novo motifs highlighted in this work have been 
found by previous groups to be signatures of TSSs and include YY1 (yin yang 1), 
ETS, NRF (nuclear respiratory factor)-1, NFY, CRE (cAMP response element) and 
GFY (golgi associated olfactory signaling regulator) [270, 271]. Distal DHS-unique 
motifs identified here included TEAD, RUNX and p53/p63 families. Further to this, 
there is evidence that TEAD and RUNX can act as DNA binding partners for the 
downstream Hippo proteins, YAP/TAZ and p63 may be a downstream target of 
EGFR [272, 273]. Therefore, this may reflect associations of TEAD, RUNX and 
p63 at distal regulatory elements and involvement in the Hippo and EGFR pathways 
[88, 92]. The AP-1 motif, although present in both groups also showed much 
stronger association with distal enhancers. Occupancy of TEAD4, JUND, FOSL1 
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and FOSL2 has previously been investigated in A459 (lung epithelial cell line). It 
was observed that nearly 90% of ChIP (chromatin immunoprecipitation)-seq peaks 
overlapped active enhancer regions and 12% of peaks with active promoters, 
agreeing with our data [274].  
Pathway analysis of DHSs and ECs revealed many known HNSCC pathways 
(HNSCC-related). For example, EGFR, TGF (transforming growth factor)-, 
MAPK, pRB (retinoblastoma protein) and p53 were over-represented in all four cell 
lines. EGFR is well known in HNSCC to be overexpressed in 90% of HNSCC 
tumours and is a therapeutic target to control aberrant EGFR expression [70, 91]. 
The TGF- pathway is essential in epithelial homeostasis; disruption of the pathway 
in HNSCC mouse models by inhibition of Smad4 (mothers against decapentaplegic 
homolog 4), a key mediator of the pathway, can lead to the development of HNSCC 
tumours in mice [275]. The MAPK family are downstream effectors of the EGFR 
pathway and are involved in cell proliferation; MAPK gene levels have been 
reported to be significantly altered in SCC [66]. The p53 and pRB pathways are 
commonly disrupted in HNSCC either due to the action of the viral oncoproteins 
E6 and E7 in HPV (human papillomavirus)-(+) HNSCC tumours or, due to altering 
mutations in both HPV(+) and HPV(-) HNSCC tumours [20, 56-58]. 
Pathways associated with cancers other than HNSCC were also over-represented in 
DHS and EC pathway enrichment analysis (cancer-related pathways). For example, 
over-representation of the breast, pancreatic, renal, small cell lung, prostate cancers 
and chronic myeloid leukaemia were observed across the four cell lines. The 
presence of these pathways is perhaps expected, as many of the same genes are 
deregulated in different cancer types. For example, there is evidence that genes 
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belonging to the MAPK, WNT, AP-1 families and EGFR are associated with 
HNSCC but are also overexpressed in the cancers mentioned above [252, 276-278].  
Analysis of pathways associated with DHSs and highlighted by genes marked by 
ECs, revealed pathways involved in cell adhesion and migration to be over-
represented in the HNSCC cell lines. The reason for this may be that cell adhesion 
is strongly related to the identity of epithelial cells and underlies the structure of 
epithelium where cell-cell or cell-extracellular matrix contacts are of particular 
importance. However, in cancer, cell adhesion proteins become deregulated and 
such phenotypic changes aid cell invasion and metastasis [21, 116]. 
Pathway analysis of DHSs and ECs revealed an association with viral pathways. 
The HTLV-1 (human T-cell lymphotropic virus type 1) and EBV (Epstein Barr 
virus) pathways were over-represented more significantly in HPV(+) DHSs and 
ECs. The annotation of EBV and HTLV-1 could be explained by the fact that many 
of the same genes are disrupted in viral infections and therefore annotated. For 
example, upon EBV infection, the viral oncoprotein, latent membrane protein 1 
(LMP1) has been shown to indirectly inhibit p53-mediated apoptosis, thereby 
disrupting p53 and its target genes associated with apoptosis, proliferation and cell 
survival [279]. This is also observed in HPV infected cells, where E6 can lead to 
p53 degradation [20, 57, 58]. Furthermore, HTLV-1 infection has been linked to 
AKT (protein kinase B) activation, which is part of the PI3K (phosphotidylinositol-
3 kinase)/AKT/mTOR (mechanistic target of rapamycin) pathway. Aberrant AKT 
activation could deregulate some of the same pathway targets as in HPV infection 
as PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
alpha), which is involved in the PI3K/AKT/mTOR pathway, is frequently amplified 
in both HPV(+) and HPV(-) tumours [36, 66-71, 252, 276-278, 280]. The presence 
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of other viral pathways in this data can also be explained by a study, which 
demonstrated that upon infection of any of four DNA viruses (HPV, EBV, 
adenovirus and polyomavirus), common pathways and proteins become 
deregulated, such as the NOTCH pathway [281]. In addition to viral pathways, the 
viral carcinogenesis pathway was also overrepresented in all four HNSCC cell lines 
in the EC pathway enrichment analysis. The viral carcinogenesis pathway describes 
the mechanism of carcinogenesis of HPV and other viruses (hepatitis B, hepatitis 
C, EBV, HTLV-I and Karposi’s sarcoma-associated herpesvirus). As described 
before, the initial mechanisms of carcinogenesis may differ between the viruses, 
but the same downstream oncogenes may be involved, leading to 
overrepresentation of this pathway [281]. 
Pathway enrichment analysis based on DHS and EC data highlighted signalling 
pathways already linked to HNSCC or of potential importance (Hippo pathway), 
which were not found in analysis based on RNA-seq data. Instead, the latter 
highlighted the involvement of protein/RNA processes (over-representation of 
pathways such as translation factors, cytoplasmic ribosomal proteins, ribosome, 
protein processing in endoplasmic reticulum and RNA transport), as well as 
significant involvement of micro RNA (miRNA)-targeted processes in UDSCC2(+) 
cells. MiRNAs repress mRNA by blocking their translation or targeting the mRNA 
for degradation [134]. It has been reported by a number of studies that miRNA 
levels can be altered in the presence of HPV, which may explain the presence of 
miRNA pathways in the data here [134, 282-284].  
The importance of ECs has previously been demonstrated by their association with 
cell identity [173, 175]. Reflecting this, our data revealed a very small number of 
genes (n=33) to be associated with ECs in all cell lines, clearly delineating the cells’ 
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origin in HNSCC and highlighting the ECs’ role in HNSCC development. As 
mentioned earlier, ECs have previously been associated with HNSCC cells, for 
example the KLF5 EC [179]. In addition, our data highlighted the EGFR and TP63 
as ECs and the main pathways which appear to be regulated by EC genes in all cell 
lines, are associated with cell adhesion (focal adhesion and 64 integrin) and the 
viral carcinogenesis pathway. Interestingly, it was observed that many TFs, 
including those highlighted by TF motif analysis were regulated by ECs, including 
p63, p73, AP-1, KLF and RUNX. In addition, LHX/DLX ECs were revealed to be 
UDSCC2(+)-specific, reflecting the cell line specificity of UDSCC2(+) TF motifs. 
Therefore, EC analysis supports our data and agrees with previously published data. 
ECs may prove useful in pointing towards mechanisms of HNSCC. 
Analysis of the regulatory network did not reveal clear differences between HPV(+) 
and HPV(-) cell lines. This may be due to the fact that UDSCC2(+) cells exhibit 
large differences compared to the remaining HNSCC cell lines. However, it must 
also be considered that only two cell lines from each subgroup were analysed and 
a larger sample size may reveal distinctions between HPV(+) and HPV(-) cells. 
Therefore, although the initial trigger for HNSCC development may differ (HPV 
oncoproteins in HPV(+) cells and mutations in both HPV(+) and HPV(-) cells), 
downstream cis-regulation and pathway signalling appears to be similar. 
In conclusion, a combination of genome-wide analyses have been used to elucidate 
the regulatory and the transcriptome of HNSCC cells. The data have highlighted 
the majority of stable DHS peaks to overlap between the four HNSCC cell lines 
investigated, indicating a common core regulatory network shared by the cell lines. 
This was confirmed by TF motif analysis and pathway enrichment analysis, where 
many of the same TF motifs and pathways were identified in all four cell lines. 
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However, the UDSCC2(+) cells exhibited a subset of unique pathways and TF 
motifs which could be explained by their hypopharyngeal origin. DNase I-
hypersensitivity assay identified HNSCC-related pathways and TF motifs, while 
RNA-seq revealed the involvement of miRNAs. In addition, our data has identified 
pathways known to be deregulated in HNSCC (EGFR, MAPK, WNT, TGF-), as 
well as TFs associated with the development of HNSCC (AP-1, p63, KLF and 
RUNX). The Hippo pathway and its transcription effector, TEAD, has also been 
highlighted to be of importance in HNSCC cells.  
Limitations of these results include the method of assigning the nearest gene to each 
DHS in order to conduct pathway enrichment analyses. While this method has been 
used previously to elucidate which processes distal regulatory elements are 
involved with [285, 286], the advent of chromatin conformation capture has 
highlighted the oversimplification of this method [287]. Chromatin conformation 
capture allows the spatial identification of long-range chromatin interactions 
between distal regulatory elements and promoters. For example, other groups by 
using chromatin conformation capture have found that 27% of distal elements can 
interact with its nearest gene, while 47% of distal elements can interact with the 
nearest active gene [142]. Therefore, by using chromatin conformation capture to 
investigate distal element-promoter interactions and conduct subsequent pathway 
analysis, identification of the biological processes involved in the cells could be 
improved. 
A second limitation of the findings of this chapter is the small sample size of four 
cell lines. Investigations of this sample size was further limited by the use of a 
pharyngeal cell line (UDSCC2(+)), which exhibited distinct differences in its 
regulatory landscape, as discussed earlier. This limitation possibly hindered the 
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identification of differences between the cis-regulatory network of HPV(+) and 
HPV(-) cell lines. To overcome this limitation, the DNase I-hypersensitivity assay 
could be conducted in a larger sample size of oral SCC cell lines. 
Finally, the results described in this chapter are incomplete without including data 
from normal, untransformed cells of similar origin; this has been approached in the 
next chapter (Chapter 4). Data in Chapters 3 and 4 also laid a foundation for follow-
up analyses to investigate interactions between different regulatory networks 
identified (Chapter 5) and the Hippo and EGFR pathways (Chapter 6). 
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CHAPTER 4: CHARACTERISATION OF THE 
NON-TUMOURIGENIC ORAL 
KERATINOCYTE REGULATORY NETWORK 
4.1 Introduction 
In the previous chapter, cis-regulatory elements were identified by conducting 
genome-wide DNase I hypersensitive assay. TF motifs which were distal-specific 
and common to all HNSCC (head and neck squamous cell carcinoma) cell lines 
were identified and were indicative of TFs involved in the functioning of regulatory 
elements. These included AP-1, TEAD (TEA domain transcription factor), 
p53/p63/p73, RUNX (runt-related transcription factor) and CTCF (CCCTC-
binding factor)/BORIS. In addition, pathway enrichment analysis revealed the 
EGFR (epidermal growth factor receptor) and Hippo pathways be involved in 
HNSCC. 
4.2 Aims 
In terms of selecting potential therapeutic targets, an understanding of how the 
HNSCC network differs from that of non-tumourigenic oral keratinocytes is 
required. One possibility of how the networks may differ is that certain TFs and 
signalling pathways are only activated in either cancer or in non-tumour cells. 
Alternatively, the same pathways could be recognized in both cell types but with 
different activities of their repressive and activating components. Based on the 
observations from Chapter 1, combined with published data, the latter option would 
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be more likely. Furthermore, cancer-related changes within a pathway could be due 
to replacement of specific TFs within a family, their overexpression due to genetic 
and non-genetic causes and/or enhancement of signalling pathway activation 
downstream of TF binding.  
To test this hypothesis, the DNase I hypersensitivity assay was attempted in two 
non-tumour cell types: primary OTKs (oral tonsil keratinocytes) and OKF6 
(hTERT immortalised oral keratinocytes). Several attempts were undertaken to 
achieve this goal, however, due to slow population doubling times of both cell 
types, a small-scale version of the DNase I assay was used where five million nuclei 
per DNase I preparation were used, rather than 20 million. The assay was carried 
out as described in Chapter 3 and tested initially using VU40T(-) cells. 
Unfortunately, this approach was not successful in the non-tumour cells. Therefore, 
an alternative method was explored called, ATAC (Assay for Transposase-
Accessible Chromatin), followed by next-generation sequencing (ATAC-seq). 
ATAC-seq was performed in OTK, OKF6 and at this point a third primary non-
tumour cell type was obtained, HOK (human oral keratinocyte) cells. ATAC-seq 
was unsuccessful in OKF6 and HOK cells, as will be discussed next. Therefore, in 
this chapter the small-scale DNase I-seq assay in VU40T(-), OKF6 and OTK cells 
is described, as well as, ATAC-seq data for OTK cells. In addition, RNA-seq data 
for HOK cells is shown, as it was unsuccessful in OTK and OKF6 cells. 
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4.3 Small-scale DNase I hypersensitivity assay test in 
VU40T(-) cells 
The VU40T(-) cells were treated with 50U of DNase I based on the results described 
in Chapter 3, Section 3.4. An untreated sample served as the negative control and 
the samples were visualised on an agarose gel (Figure 4.1). 
 
 
Figure 4.1. Agarose gel electrophoresis of DNase I digested chromatin.  
Five million nuclei from VU40T(-) cells were isolated and treated with 50U of DNase I 
enzyme for 3 mins at 37oC. The sample was visualised on a 2% agarose gel. A ‘No DNase 
I’ negative control was used to assess for endogenous chromatin digestion. The absence of 
a DNA smear in the negative control indicates intact chromatin. 
 
The release of small DNA fragments was observed from the upper DNA band of 
high molecular weight DNA which confirmed digestion. To enrich for the desired 
sized fragments of 100-200bp, the DNA fragments were separated by size using 
ultra-centrifugation; 13 fractions were collected and visualised by gel 
electrophoresis (Figure 4.2A). Upon visualisation, it was not clear whether 
fractionation was unsuccessful or whether fractionated fragments could not be 
Ladder 
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detected due to low DNA concentration. Therefore, to increase DNA concentration, 
fractions 1-3, 4-9 and 10-13 were combined based on DNA fragment sizes obtained 
in the large-scale assay. Combined fractions were visualised on an agarose gel 
(Figure 4.2B). A strong band was observed in fractions 10-13 of 10kb; bands of 
the same size were also observed in fractions 1-3 and 4-9, though these were much 
weaker. A smear could also be observed between 50-200bp in each set of fractions, 
which may be the accumulation of smaller DNA fragments. Therefore, qPCR 
(quantitative polymerase chain reaction) was conducted to test for DHS (DNase I 
hypersensitive site) enrichment. The KRT (keratin)-6A DHS primers were used as 
a positive control and the ‘no DHS’ primers as the negative control (Figure 4.2C). 
The fold-enrichments of fractions 1-4, 5-9 and 10-13 were 41.6-, 61.3- and 267.8-
fold, respectively. This suggested that DHSs are enriched using the small-scale 
assay in VU40T(-) cells (Figure 4.2C). 
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Figure 4.2. Fractionation and enrichment of VU40T(-) DNase I fragments.  
(A) Generated DNA fragments were separated by centrifugation on a sucrose gradient and 
13 fractions were collected and visualised on an agarose gel to check for fractionation. (B) 
Combined fractions 1-3, 4-9 and 10-13 were merged and visualised by agarose 
electrophoresis. (C) QPCR was conducted at the ‘KRT6A DHS’ region. The signal was 
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4.4 Small-scale DNase I hypersensitivity assay in oral 
keratinocyte cells 
Nuclei isolation was conducted in OTK, OKF6 and HOK cells. Due to the difficulty 
in obtaining a sufficient number of cells to isolate nuclei, only two NP-40 
concentrations were tested, 0.01% and 0.02%. These two concentrations were 
chosen based on the lower range of NP-40 concentrations tested in HNSCC cells. 
It was found that the 0.02% NP-40 concentration yielded nuclei within the optimum 
range, as described in Chapter 3, Section 3.4.  
A sufficient number of nuclei could not be isolated from the three cell types to 
optimise DNase I digestion. However, based on frequent observations of chromatin 
degradation in negative control samples of non-tumour cells (not shown), it was 
thought that non-tumour cells may display higher sensitivity to DNase I digestion. 
Therefore, based on the DNase I amount used in HNSCC cells, 30U and 40U were 
used in the non-tumour cells (Figures 4.3A and B). DNase I digestion was not 
successful in HOK cells, as the nuclei preparation remained viscous, indicating 
intact DNA and so was not taken forward. In the OKF6 samples, the release of high 
molecular weight fragments in preparations digested with 30U or 40U of DNase I 
were observed, however no observable difference between the two digestions was 
detected (Figure 4.3A). A very faint smear could be observed in the ‘no DNase I’ 
negative control, indicating some degradation of the chromatin (Figure 4.3A). The 
OTK nuclei preparation treated with 40U of DNase I yielded the release of more 
DNA fragments compared to the 30U preparation. However, the 30U preparation 
appeared similar to the negative control sample, in which a faint smear could be 
observed, indicating chromatin degradation (Figure 4.3B). In order to assess for 
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any DHS enrichment, the 40U OKF6 and OTK samples were taken forward for 
qPCR. 
In order to confirm the enrichment of DHSs, qPCR was conducted on each fraction 
set using the KRT6A DHS primers and its signal was normalised to the signal 
obtained from amplification of the ‘no DHS’ region. In OKF6 cells, fold change 
over the negative control signal for 40U DNase I preparation was 0.4-fold for 
fractions 1-3 and 4-9, and 0.7-fold for fractions 10-13 (Figure 4.4A). In OTK cells, 
the 40U nuclei preparation displayed fold change of 1.6-, 2.5- and 0.7-fold (Figure 
4.4B). Therefore, in OKF6 cells, there was no DHS enrichment over background 
and in OTK cells, an enrichment of maximum 2.5-fold was observed. This result 





Figure 4.3. Visualisation of DNase I digested chromatin by agarose gel 
electrophoresis.  
Nuclei were isolated from (A) OKF6 cells and (B) OTK cells and treated with 30U or 40U 
of DNase I enzyme for 3 mins at 37C. Samples were visualised on a 2% agarose gel. A 
‘no DNase I’ negative control was used to assess for endogenous chromatin digestion.
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Figure 4.4. Enrichment of DHSs in non-tumour keratinocytes assessed by qPCR.  
Fractions between 1-3, 4-9 or 10-13 were merged and collected from (A) OKF6 and (B) 
OTK cells. QPCR was conducted at the KRT6A DHS region. The signal was normalised to 
a negative control ‘no DHS’ region. The bars represent the range between technical 
duplicates. 
 
4.5 ATAC-seq sample preparation 
The ATAC (Assay for Transposase Accessible Chromatin)-seq method allows for 
genome-wide mapping of accessible chromatin regions with the advantage of 
requiring fewer cells (25,000-50,000) compared to DNase I-seq [181]. This 
technique involves a digestion with a transposase enzyme, which is flanked by 
adapter sequences. When the enzyme cuts at open regions of the genome, adapters 
are also inserted, thereby combining the chromatin digestion and library preparation 
steps. ATAC-seq was used to identify open chromatin regions in OTK cells and 
HOK cells. Only the data for OTK cells is shown here, as sequencing of HOK and 
OKF6 cells was unsuccessful.  
The transposition reaction was conducted in OTK cells, followed by PCR 
(polymerase chain reaction) to amplify the library. After five cycles of PCR, qPCR 
was carried out to quantify the library and calculate additional PCR cycles needed, 
as recommended by Buenrostro et al. [181]. To calculate the number of additional 
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PCR cycles required, the SYBR fluorescence values were plotted against cycle 
number (Figure 4.5). The number of cycles corresponding to 25% of the maximum 
fluorescence signal indicated the number of additional cycles required. The OTK 
library required eight additional PCR cycles, which was within the range of 6-11 
cycles recommended for maintaining library complexity [181] (Figure 4.5). The 
size of the final OTK library was assessed using the Bioanalyzer system. DNA 
fragments were observed between 100bp to 1kb; the desirable fragment size for 
sequencing is less than 1kb and so the library was of sufficient quality to be 




Figure 4.5. Enrichment of ATAC library by PCR assessed by qPCR.  
QPCR was carried out using primers specific to the library adapter sequences. The SYBR 
fluorescence signal values were plotted against cycle number. To calculate the number of 
additional PCR cycles required: the baseline fluorescence value was taken away from the 
fluorescence saturation value; 25% of this value was calculated and the baseline value was 
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Figure 4.6. Electropherogram of OTK ATAC library using the Agilent Bioanalyzer 
system.  
The DNA marker can be observed on the electropherogram as two peaks; a lower marker 
at 35bp and an upper marker at 10,380bp. To determine the average library size, gates were 
set surrounding the library peak. The ATAC-library size was between 100bp and 1kb.  
 
 
4.6 Mapping of ATAC-seq peaks 
The ATAC library was sequenced as described in Materials and Methods, Section 
2.12. A total number of 37,953,387 reads were obtained and 47.3% of reads were 
aligned. The HOMER (Hypergeometric Optimization of Motif EnRichment) 
software was used to identify OTK ATAC-seq peaks by using the ‘findpeaks’ 
command and the ‘variable peak’ setting. The following parameters were applied: 
fragment length of 350bp, minimum distance of 400bp and FDR (false discovery 
rate) of 0.01%. A total of 60,329 peaks were called. An example of the sequenced 
ATAC-seq data at the TP63 gene can be seen in Figure 4.7.  
The called ATAC peaks were annotated by genomic feature using the HOMER 
‘AnnotatePeaks’ function. The peaks were annotated into the following categories, 
intergenic, intron, promoter, exon, TTS and UTR (untranslated region) (Figure 
4.8). ATAC regions were distributed similarly between intergenic and intronic 
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regions (36.7% and 39% of regions, respectively) while 16.5% of regions 
overlapped with promoters, agreeing with the distribution of DHSs in HNSCC cells 
(Figure 4.8 and Figure 3.11). This pattern of distribution agrees with published 
literature [288, 289].  
 
 
Figure 4.7. UCSC screenshot of ATAC-seq peaks at the TP63 gene.  
The ATAC-seq reads were aligned to the hg19 genome and the Bigwig file was uploaded 
to the UCSC (University of California Santa Cruz) genome browser, along with the four 
HNSCC DHS files. The ATAC-seq coverage track is displayed in green. OTK ATAC-seq 
peaks were called using HOMER and a total of 60,329 peaks were called (called peaks are 
depicted by black bars below the coverage track). The ‘layered H3K27Ac’ track displays 
previously published data; the active histone mark, H3K27Ac in a panel of 125 ENCODE 
(ENCyclopaedia Of DNA Elements) cell lines. The pink peaks in the H3K27Ac track 
represent the NHEK (normal human epidermal keratinocyte) cell line, indicating that some 
of these DHSs are epithelial specific. The ‘DNase Clusters’ track displays previously 





Figure 4.8. Genomic distribution of OTK ATAC-seq peaks.  
A total of 60,329 OTK ATAC-seq peaks were annotated using the ‘AnnotatePeaks’ 
function in HOMER to the following regions: intergenic regions, introns, promoters, exons, 
transcription termination sites (TTS) and untranslated regions (UTR). 
 
4.7 Peak location overlap of OTK and HNSCC cell line 
peaks 
The locations of called peaks were used to investigate the overlap between open 
regions in non-tumour cells and HNSCC cells. The ‘PCAexplorer’ script within the 
R software was used to construct a heatmap based on peak location (Figure 4.9A). 
All HNSCC DHS peaks and all OTK ATAC peaks (merged HNSCC-OTK dataset) 
were considered. The largest variation between peak location was between the OTK 
and HNSCC cells, while SCC040(-) and VU147(+) cells were the most similar 
(Figure 4.9A). 
Differences in peak locations of HNSCC and non-tumour cells was investigated 
further by principal components analysis (PCA) (Figure 4.9B). PCA analysis 
revealed two main components (PC1 and PC2). PC1 separated UDSCC2(+) peaks 
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from the HNSCC cell lines and OTK cells, while PC2 separated the HNSCC DHS 
peaks and OTK ATAC peaks (Figure 4.9B). Therefore, peak location variability is 
observed between the non-tumour and HNSCC cells. 
 
 
Figure 4.9. Differences in peak locations of ATAC-seq and DNase I-seq.  
The ‘PCAexplorer’ script in the R software was used to analyse variability between ATAC 
peak and HNSCC DHS peak locations. (A) A variation heatmap based on OTK and 
HNSCC cell line peak location was constructed. Clusters were assigned a score between 
0.1 and 1 based on variability (a score of 1 indicates no variability). (B) Principal 
components plot based on peak location revealed two principal components; PC1 which 




4.8 Transcription factor motif analysis in OTK ATAC 
open regions 
HOMER was used to conduct known TF motif analysis in order to determine which 
transcription factors (TFs) may be involved in the OTK cells. A total of 185 known 
TF motifs were identified and the top 20 motifs are shown in Figure 4.10A. Five 
groups of motifs were identified for the following TFs: AP-1, CTCF/BORIS, p53, 
KLF (Krüppel-like factor)/SP1 (specificity protein 1) and ETS (E twenty-six 
transcription factor) (Figure 4.10A). The motif which appeared the most frequently 
in the list of top 20 motifs (11/20) was the AP-1 TF motif. In addition, the 
percentage of ‘target sequences with motif’ was investigated and it was found that 
between 3% and 36% of sequences harboured the AP-1 motif in OTK cells (Figure 
4.10A). The motifs for CTCF and its paralogue BORIS were found in, 8.2% and 
12% of target sequences, respectively (Figure 4.10A). Members of the p53 family 
which includes p63 and p73 were also enriched in OTK cells. The p63 and p53 
motifs were present in 4.9% and 12.8% of target sequences with motif, respectively 
(Figure 4.10A). Motifs for the KLF/SP1 TFs were also enriched. Motifs for KLF-
4 and -5 were found in 38.7% and 14.1% of target sequences, respectively, while 
the SP-1 motif was enriched in 15% of sequences (Figure 4.10A). The FLI1 (friend 
leukemia integration 1) and ELK1 (ETS domain-containing protein 1) TFs which 
are members of the ETS TF family were found in 28.7% and 18% of target 
sequences, respectively (Figure 4.10A).  
The OTK top 20 TF list and the HNSCC-merged motif list were compared (Figure 
4.10B). It was found that the majority of motifs were shared between the two 
datasets (16/20; 80%) and were enriched in OTK cells and at least one HNSCC cell 
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line. Only four TFs were specific to OTK cells, which included SP1, KLF4, FLI1 
and ELK (Figure 4.10B). 
In addition to ‘known motif’ analysis, de novo motif analysis was conducted to 
predict similar motifs. The analysis was conducted in OTK cells and compared to 
the four HNSCC cell lines; a total of 32 motifs were predicted in OTK ATAC 
regions and the top 10 TF motifs were analysed (AP-1, ETS, KLF/SP-1, TEAD, 
p53/p63, NFY, RUNX, CTCF, CEBP (CCAAT/enhancer-binding protein) (Figure 
4.11A). Agreeing with known motif analysis, the AP-1 TF motif displayed the 
highest enrichment in target sequences in OTK, SCC040(-) and VU147(+) cells, in 
addition, AP-1 was the most statistically significant motif in these cell lines (Figure 
4.11A).  
The overlap of de novo motifs was compared between OTK and HNSCC cells to 
highlight HNSCC-specific, OTK-specific and motifs shared between non-tumour 
and HNSCC cells (Figure 4.11B). One OTK-specific TF was identified, EKLF 
(erythroid kruppel-like factor or KLF1), while enrichment of the CEBP 
(CCAAT/enhancer-binding protein) motif was shared between OTK and one other 
HNSCC cell line (UDSCC2(+)) (Figure 4.11B). Six motifs were shared between 
all cell types which included AP-1, ETS, KLF/SP1, p53/p63 and NFY (Figure 
4.11B). The TEAD and RUNX motifs were shared between all cell types except 
UDSCC2(+) cells, while CTCF was enriched in OTK, SCC040(-) and VU147(+) 
cells (Figure 4.11B). Eight TF motifs were HNSCC-specific and included FOX 
(Forkhead)-(x), AC-acceptor, GFY (golgi associated olfactory signaling regulator), 
IRX (Iroquois Homeobox Protein)/GRHL (grainyhead-like protein), NRF (nuclear 
respiratory factor)-1, LHX (LIM homeobox), NF (nuclear factor)-1 and CRE 




Figure 4.10. The top 20 TF motifs predicted in OTK ATAC-seq peaks.  
(A) HOMER known motif prediction was used to predict motifs in the OTK ATAC-peaks. 
A total of 185 motifs were predicted; the top 20 are shown in the table. (B) The top 20 OTK 
motifs were compared with those identified in the HNSCC-merged DHS dataset. In (B) 
green boxes indicate motifs predicted in both OTK and HNSCC peaks and white boxes 
indicate motifs predicted only in OTK peaks. 








Sequences  with 
Motif
Fold-change Motif  logo
F O S L 1 -1.65E+04 33.00 6.29 19.06
A T F 3 -1.61E+04 35.30 7.54 21.36
B A T F -1.55E+04 34.40 7.40 21.51
A P 1 -1.45E+04 36.17 8.79 24.30
F O S L 2 -1.32E+04 24.18 3.95 16.34
J U N -1.14E+04 19.40 2.84 14.64
B A C H 2 -5.56E+03 12.54 2.47 19.70
C T C F -2.38E+03 8.22 2.33 28.35
P 6 3 -2.30E+03 12.76 5.02 39.34
P 5 3 -1.93E+03 4.94 1.07 21.66
B O R I S -1.89E+03 12.02 5.07 42.18
N F - E 2 -1.71E+03 3.69 0.67 18.16
M A F K -1.67E+03 8.05 2.87 35.65
B A C H 1 -1.65E+03 3.37 0.57 16.91
S P 1 -1.45E+03 15.15 7.99 52.74
N R F 2 -1.42E+03 3.00 0.53 17.67
K L F 5 -1.27E+03 38.67 28.35 73.31
K L F 4 -1.25E+03 14.07 7.60 54.02
F L I 1 -1.18E+03 28.74 19.77 68.79
E L K 1 -9.94E+02 18.00 11.31 62.83


























Figure 4.11. Top 10 de novo motifs in OTK cells and HNSCC cell lines.  
(A) HOMER was used to predict de novo motifs using OTK ATAC peaks and HNSCC 
DHS peaks. A total of 32, 21, 23, 22 and 24 motifs were predicted for OTK, VU40T(-), 
SCC040(-), VU147(+) and UDSCC2(+) cells, respectively. For each motif, the percentage 
of motifs in target sequences is displayed and the size of the circles represent p-value. (B) 
The overlap of TF motifs between OTK and HNSCC was investigated. A total of 19 motifs 
were divided into three categories: shared (10/19; 53%), OTK-specific (1/19; 5%) and 
HNSCC-specific (8/19; 42%).  
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4.9 Pathway enrichment analysis of OTK ATAC open 
regions 
HOMER was used to conduct pathway enrichment analysis by assigning each open 
chromatin region to the nearest gene TSS. A total of 277 pathways were identified 
and the top 20 pathways were investigated (Appendix: Table 9). The top 20 
pathways were combined with those top 20 identified in the four HNSCC cell lines 
(Figure 3.16) which yielded 55 different pathways (Figure 4.12). As before, the 






Figure 4.12. Pathway enrichment analysis of genes assigned to HNSCC DHSs and 
ATAC peaks in OTK cells.  
Analysis revealed 55 enriched pathways in OTK cells compared with four HNSCC cell 
lines. The pathways were ranked by log p-value; green represents the least statistically 
significant pathways, red represents most significant and blank boxes indicate no 
enrichment. The pathways were grouped into five groups by cell line representation: (1) 
over-represented in all (22/55; 40%), (2) under-represented in UDSCC2(+) (4/55; 7%), (3) 
over-represented in OTK (17/55; 31%), (3a) under-represented in UDSCC2(+) (15/55; 
27%), (3b) over-represented in UDSCC2(+) (2/55; 4%), (4) over-represented in 
UDSCC2(+) (4/55; 7%), (5) over-represented in HNSCC only (7/55; 13%).  
Pathways Function OTK SCC040(-) VU40T(-) VU147(+) UDSCC2(+) log -
value
Pathways in cancer Cancer-related
(1)
EGFR1 Signaling Pathway HNSCC-related
TGF-beta Signaling Pathway HNSCC-related
ErbB signaling pathway HNSCC-related
Focal adhesion Cell adhesion
Integrated Pancreatic Cancer Pathway Cancer-related
Endocytosis Cytoskeletal
Alpha6-Beta4 Integrin Signaling Pathway Cell adhesion/migration
FoxO signaling pathway Cell proliferation
Chronic myeloid leukemia Cancer-related
Cell cycle Cell proliferation
Small cell lung cancer Cancer-related
p53 signaling pathway HNSCC-related
Renal cell carcinoma Cancer-related
Regulation of actin cytoskeleton Cytoskeletal
Prostate Cancer Cancer-related
Insulin Signaling Metabolism
Integrated Breast Cancer Pathway Cancer-related
Adherens junction Cell adhesion
MAPK Signaling Pathway HNSCC-related
Leptin signaling pathway Metabolism
Signaling of Hepatocyte Growth Factor Receptor Cell growth/proliferation
DNA damage response (only ATM dependent) DNA regulation
(2)
Senescence and Autophagy Senescence
Prolactin Signaling Pathway Metabolism/immune function/development
AMPK signaling pathway Metabolism
Hippo signaling pathway Cell adhesion/migration/proliferation
(3a)
(3)
Fc gamma R-mediated phagocytosis Immune function
Rap1 signaling pathway Cell migration
Phosphatidylinositol signaling system Cell signalling
Inositol phosphate metabolism Metabolism
Inflammatory mediator regulation of TRP channels CNS/Immune function
Wnt Signaling Pathway HNSCC-related
Proteoglycans in cancer Cell adhesion/migration/proliferation
Huntington's disease CNS
Non-alcoholic fatty liver disease (NAFLD) Metabolism
Interferon type I Immune function
Circadian rhythm CNS
Axon guidance CNS
Ubiquitin mediated proteolysis Protein/RNA processing
Dopaminergic synapse CNS
Protein processing in endoplasmic reticulum Protein/RNA processing
(3b)
Thyroid signalling hormone pathway Development/cell growth
TNF-alpha/NF-kB Signaling Pathway Immune function
(4)
RB in Cancer HNSCC-related
Androgen receptor signaling pathway Cell growth/proliferation



















When grouped by cell type representation, five groups of pathways were identified. 
Group (1) contained pathways over-represented equally in OTK and HNSCC cells 
and contained the most pathways (22/55) (Figure 4.12). Many of the pathways 
were HNSCC-related (5/22; EGFR, ERBB, TGF (transforming growth factor)-, 
p53 and MAPK signalling pathways), cancer-related (7/22) or cell adhesion 
pathways (3/22). Among the most statistically significant pathways in this group 
were the EGFR, ERBB and ‘pathways in cancer’ (Figure 4.12). Group (2) 
contained four pathways all of which were under-represented in UDSCC2(+) cells 
and were largely over-represented in the remaining cell types. The majority of 
pathways in this group (3/4) were involved in metabolism (Figure 4.12). Group (3) 
contained 17 pathways under-represented in HNSCC cells, while being strongly 
over-represented in OTK cells. This group could be divided into two subsets: 3a 
and 3b. Subset 3a included 15 pathways which were strongly under-represented in 
UDSCC2(+) cells, while subset 3b included two pathways which were over-
represented in UDSCC2(+) (protein processing in endoplasmic reticulum and 
thyroid signalling hormone pathways) (Figure 4.12). Pathways in subset 3a 
included the five pathways related to CNS: inflammatory mediator regulation of 
TRP (transient receptor potential) channels, Huntington’s disease, circadian 
rhythm, axon guidance and dopaminergic synapse. In addition, some of the most 
over-represented pathways in OTK cells was the Hippo pathway, RAP1 (Rap1 
GTPase) and phosphatidylinositol signalling pathways. Interestingly, the HNSCC-
related pathway WNT (wingless) was also over-represented in OTK cells (Figure 
4.12). Group (4) consisted of five pathways which were under-represented in OTK 
cells and over-represented in UDSCC2(+) cells and in at least one other HNSCC 
cell line. Pathways in this group included the pRB (retinoblastoma protein) in 
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cancer, androgen receptor signalling and mRNA processing pathways (Figure 
4.12). Group (5) consisted of seven pathways which were not represented in OTK 
cells at all and strongly over-represented in HNSCC cells. Three pathways in this 
group were associated with viral infection (viral carcinogenesis, Epstein-Barr virus 
infection, HTLV (Human T-cell leukemia virus)-I pathways) (Figure 4.12). There 
were no pathways which were strictly OTK-specific and absent in HNSCC cells.  
In summary, the majority of HNSCC-related, cancer-related and cell adhesion 
pathways appear to be involved in OTK cell function to the same extent as in 
HNSCC cells. Having said this, a number of pathways were clearly more involved 
in OTK cells than in HNSCC cell lines as shown in Group (3a), which included 
pathways such as Hippo, CNS (central nervous system)-related pathways, 
phosphatidylinositol signalling system and WNT pathways (Figure 4.12). 
4.10 Enhancer cluster analysis of OTK ATAC open 
regions 
To further investigate ATAC open regions in OTK cells, the HOMER software was 
used to conduct enhancer cluster (EC) analysis, which revealed 592 ECs in OTK 
ATAC peaks. Pathway enrichment analysis was conducted on the ATAC EC-
associated genes and to highlight differences, the top 20 pathways were combined 
with the top 20 HNSCC EC (enhancer cluster) pathways to give 59 pathways 
(Appendix: Tables 5-8 and 10, Figure 4.13). Pathways were grouped by cell 
representation which revealed six groups. Group (1) consisted of three pathways 
(focal adhesion, 64 integrin and Fc gamma R-mediated phagocytosis pathways) 
which were strongly over-represented in all cell types (Figure 4.13). Group (2) 
 192 
 
consisted of six pathways which were over-represented more significantly in OTK 
cells than in HNSCC. This group included the phosphatidylinositol signalling 
system, inositol phosphate, dopaminergic synapse and two pathways related to 
protein/RNA processing (protein processing in endoplasmic reticulum and 
ubiquitin mediated proteolysis) (Figure 4.13). Group (3) consisted of 13 pathways 
which were largely under-represented in UDSCC2(+) cells and over-represented in 
the remaining HNSCC cell lines and OTK cells (Figure 4.13). Nearly one third of 
the pathways are associated with cell adhesion. Notably, the pathways in cancer and 
Hippo signalling pathways were significantly over-represented in OTK cells and 
the EGFR pathway was significantly over-represented in the OTK, SCC040(-) and 
VU147(+) cells (Figure 4.13). Group (4) consisted of 16 pathways which were 
consistently over-represented in OTK cells and over-represented in at least one 
HNSCC cell line, though largely under-represented in SCC040(-) cells (Figure 
4.13). Group (4) pathways can be summarised as HNSCC-related (RAS, WNT, 
ERBB and MAPK signalling pathways), CNS associated (Huntington’s, signalling 
pathways in glioblastoma and inflammatory mediator regulation of TRP channels) 
and immune function-related (IL (interleukin)-3, IL-6 and RANKL/RANK (tumour 
necrosis factor receptor superfamily member 11a) signalling) (Figure 4.13). Group 
(5) consisted of seven pathways which were consistently under-represented in OTK 
cells and were largely under-represented in HNSCC cells. This group included two 
pathways associated with DNA regulation (DNA replication and mismatch repair) 
and the TGF- pathway (Figure 4.13). Group (6) consisted of 14 pathways which 
were HNSCC-specific. This group contained pathways associated with DNA 
regulation (nucleotide excision repair, DNA polymerase /primase complex and 
RPA (replication protein A) complex) and immune function (NF-B signalling, 
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systemic lupus erythematosus and leukocyte transendothelial migration) (Figure 
4.13). In addition, the transcriptional misregulation pathway, and two viral 





Figure 4.13. Pathway enrichment analysis of genes assigned to enhancer clusters in 
OTK cells and HNSCC cell lines.  
Analysis revealed 59 different pathways across the OTK and four HNSCC cell lines. The 
pathways were ranked by log p-value; green represents the least statistically significant 
pathways, red represents most significant and blank boxes indicate no enrichment. The 
pathways were grouped into 6 groups by cell representation: (1) over-represented in all 
(3/59; 5%), (2) more over-represented in OTK (6/59; 10%), (3) under-represented in 
UDSCC2(+) (13/59; 22%), (4) consistently over-represented in OTK (16/59; 12%), (5) 
more over-represented in HNSCC (7/59; 12%), (6) exclusively over-represented in 
HNSCC (14/59; 24%). 
Pathway Function OTK SCC040(-) VU40T(-) VU147(+) UDSCC2(+)
log p-value
Focal adhesion Cell adhesion
(1)Fc gamma R-mediated phagocytosis Immune function
Alpha6-Beta4 Integrin Signaling Pathway Cell adhesion/migration
Thyroid signaling hormone pathway Development/cell growth
(2)
Phosphatidylinositol signaling system Cell signalling
Protein processing in endoplasmic reticulum Protein/RNA processing
Dopaminergic synapse CNS
Inositol phosphate metabolism Metabolism
Ubiquitin mediated proteolysis Protein/RNA processing
Proteoglycans in cancer Cell adhesion/migration/proliferation
(3)
Apoptosis Cell death
Pathways in cancer Cancer-related
Hippo signaling pathway Cell adhesion/migration/proliferation
EGFR1 Signaling Pathway HNSCC-related
Adherens junction Cell adhesion
Pancreatic cancer Cancer-related
Androgen receptor signaling pathway Cell growth/proliferation
Integrated Pancreatic Cancer Pathway Cancer-related
Integrin-mediated cell adhesion Cell adhesion
Integrated Breast Cancer Pathway Cancer-related
Regulation of actin cytoskeleton Cytoskeletal
Rap1 signaling pathway Cell migration
Huntington's disease CNS
(4)
Ras signaling pathway HNSCC-related
Small cell lung cancer Cancer-related
Wnt signaling pathway HNSCC-related
Cell cycle Cell proliferation
ErbB signaling pathway HNSCC-related
IL-3 Signaling Pathway Immune function
Endocytosis Cytoskeletal
MAPK signaling pathway HNSCC-related
FAS pathway and Stress induction of HSP regulation Cell death
Hypertrophy Model Protein processing
IL-6 Signaling Pathway Immune function
Inflammatory mediator regulation of TRP channels CNS/Immune function
RANKL/RANK Signaling Pathway Immune function
Signaling of Hepatocyte Growth Factor Receptor Cell growth/proliferation
Signaling Pathways in Glioblastoma CNS
TGF-beta signaling pathway HNSCC-related
(5)
DNA replication DNA regulation
IL-1 Signaling Pathway Immune function
Arrhythmogenic right ventricular cardiomyopathy (ARVC) Cell adhesion
Pathogenic Escherichia coli infection Bacterial
Mismatch repair DNA regulation
Estrogen signaling pathway Cell growth/proliferation
Viral carcinogenesis Viral
(6)
Epithelial cell signaling in Helicobacter pylori infection Bacterial
NF-kappa B signaling pathway Immune function
Bacterial invasion of epithelial cells Bacterial
Leukocyte transendothelial migration Immune function/cell migration
Nucleotide excision repair DNA regulation
DNA polymerase alpha / primase complex DNA regulation
Systemic lupus erythematosus Immune function
RPA complex DNA regulation
Alcoholism Metabolism
Endometrial cancer Cancer-related
Tight junction Cell adhesion












To investigate similarities between EC-related genes in OTK and HNSCC cells, the 
overlap between the two datasets was analysed (Figure 4.14). A total of 592 OTK 
EC genes were annotated and 72% of these genes were OTK-specific (427/592), 
while 28% (165/592) of genes were shared with HNSCC cells (Figure 4.14).  
The ConsensusPath database was used to conduct pathway enrichment analysis on 
each set of genes: OTK-specific, HNSCC-specific and shared between OTK and 
HNSCC (shared), which revealed 16, 80 and 43 pathways, respectively. All 16 
pathways for OTK-specific genes and the top 20 pathways for the remaining two 
gene datasets were taken for further analysis, which gave a total of 47 different 
pathways (Figure 4.15). The pathways were ranked by p-value and grouped by cell 
representation, which formed six groups and were categorised into 19 broad 
functions: bacterial, bone development, cancer-related, cell adhesion, death, 
differentiation, growth, proliferation, migration, signalling, cytoskeletal, HNSCC-
related, immune function, kidney degeneration, metabolism, micro RNA (miRNA), 





Figure 4.14. Percentage overlap of EC genes between OTK and HNSCC cells. 
HOMER was used to assign 592 genes to each OTK EC. The EC genes were compared 
with those assigned to HNSCC ECs. The percentage of OTK-specific EC genes and those 









Figure 4.15. Pathway enrichment analysis of enhancer cluster genes. 
HOMER was used to assign genes to enhancer clusters. The overlap of EC genes between 
HNSCC and OTK was investigated: 427 genes were OTK-specific, 1,044 genes were 
HNSCC-specific and 165 genes were shared between OTK and HNSCC cells. Pathway 
enrichment analysis was conducted using the ConsensusPath tool on each gene set. The 
pathways were ranked by log p-value; green represents the least statistically significant 
pathways, red represents most significant and blank boxes indicate no enrichment. The 
pathways were grouped in six groups: (1) over-represented in all (3/47; 6%), (2) over-
represented in OTK- and HNSCC-specific genes (6/47; 13%), (3) HNSCC-specific and 
shared (8/47; 17%), (4) OTK-specific (7/47; 15%), (5) HNSCC-specific (11/47; 23%), (6) 
shared (12/47; 26%), (6a) highly over-represented in shared (5/47; 11%), (6b) over-
represented in shared (7/47; 15%). 
Pathway Function OTK-specific HNSCC-specific OTK/HNSCC
log p-value
VEGFA-VEGFR2 Signaling Pathway Cell growth
(1)
EMT transition in Colorectal Cancer Cancer-related
Focal Adhesion Cell adhesion
Bacterial invasion of epithelial cells Bacterial
(2)
EGF-EGFR Signaling Pathway Cell growth
Androgen receptor signaling pathway Cell growth
Alpha 6 Beta 4 signaling pathway Cell adhesion
Rap1 signaling pathway Cell adhesion/migration
Insulin Signaling Metabolism
Nuclear Receptors Meta-Pathway Transcription
(3)
Primary Focal Segmental Glomerulosclerosis FSGS Kidney degeneration
Small cell lung cancer Cancer-related
TGF-beta Signaling Pathway HNSCC-related
miR-targeted genes in epithelium miRNA
miR-targeted genes in muscle cell miRNA
Regulation of actin cytoskeleton Cytoskeletal
JAK-STAT Cell proliferation/differentiation/migration/death
EPO Receptor Signaling Cell growth/proliferation
(4)
Notch Signaling Pathway HNSCC-related
RORA activates gene expression Transcription
Kit receptor signaling pathway Cell growth/proliferation
NR1D1 (REV-ERBA) represses gene expression Transcription
Vitamin D Receptor Pathway Transcription
HIF1A and PPARG regulation of glycolysis Metabolism
Cellular senescence Sencescence
(5)
Fc gamma R-mediated phagocytosis Immune function
Hair Follicle Development Cell growth
Hippo signaling pathway Cell adhesion/migration/proliferation
Leukocyte transendothelial migration Cell migration
miR-targeted genes in lymphocytes miRNA
Osteoclast differentiation Bone development
Pathways in cancer Cancer-related
Proteoglycans in cancer Cell adhesion
RANKL-RANK (Receptor activator of NFKB (ligand)) Signaling Pathway Immune function
Viral carcinogenesis Viral
Adherens junction Cell adhesion
(6a)
(6)
Arrhythmogenic Right Ventricular Cardiomyopathy Cell adhesion
Cellular response to heat stress Cell growth/death
Glucocorticoid Receptor Pathway Cell signalling





Hfe effect on hepcidin production Metabolism
IL-7 Signaling Pathway Immune function
miRNA Regulation of DNA Damage Response miRNA
Regulation of Apoptosis by Parathyroid Hormone-related Protein Cell death
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Group (1) consisted of three pathways which were over-represented in all three 
datasets (VEGF (vascular endothelial growth factor) signalling pathway, EMT 
(epithelial to mesenchymal) transition in colorectal cancer and focal adhesion 
pathways) (Figure 4.15). Group (2) consisted of six pathways which were over-
represented in OTK-specific and HNSCC-specific genes. These pathways included 
two cell growth associated pathways (EGFR and androgen receptor signalling), 
which were over-represented more significantly in HNSCC-specific genes. A 
pathway involved in bacterial infection (bacterial invasion of epithelial cells 
pathway) was significantly over-represented in both the datasets (Figure 4.15). The 
remaining three pathways (46, RAP1 and insulin signalling) were also over-
represented in both gene sets. Group (3) consisted of eight pathways, which were 
over-represented in HNSCC-specific and shared gene sets: the HNSCC- and 
cancer-related pathways (TGF- and small cell lung cancer, respectively) were 
more highly over-represented in HNSCC-specific pathways, as were the miRNA-
related pathways (miR-targeted genes in epithelium and muscle cell) (Figure 4.15). 
Group (4) consisted of seven OTK gene-specific pathways, which were largely 
related to cell growth/proliferation and transcription. The transcription-associated 
pathways included the ‘RORA (retinoic acid related orphan receptor A) activates 
gene expression’ pathway, the ‘NR1D1 (REV-ERBA) represses gene expression’ 
(NR1D1-nuclear receptor subfamily 1 group D member 1) pathway and the vitamin 
D receptor pathway (Figure 4.15). The cell growth/proliferation pathways included 
the EPO (erythropoietin) receptor signalling pathway and the kit receptor signalling 
pathway. Notably, this group also included the NOTCH (neurogenic locus notch 
homolog) pathway as being over-represented specifically in OTK cells (Figure 
4.15). Group (5) consisted of 11 pathways which were strongly HNSCC-specific 
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(Figure 4.15). Distinctly from OTK-specific pathways, group (5) included 
pathways related to immune function (FC gamma R-mediated phagocytosis 
pathway), senescence (cellular senescence pathway), cell 
adhesion/migration/proliferation (Hippo pathway), cell migration (leukocyte 
transendothelial migration pathway) and the viral carcinogenesis pathway (Figure 
4.15). Group (6) consisted of 12 pathways which were over-represented in the 
‘shared’ gene set. Based on statistical significance, this group could be divided into 
two subsets: 6a and 6b (Figure 4.15). Subset 6a included five pathways which 
displayed higher statistical significance than those in subset 6b and included three 
pathways involved in cell adhesion (adherens junction, arrhythmogenic right 
ventricular cardiomyopathy and integrin-mediated cell adhesion pathways) (Figure 
4.15). The remaining pathways in subset 6a included the cellular response to heat 
stress and glucocorticoid receptor pathways. Subset 6b included two pathways 
related to metabolism: ‘HFE effect on hepcidin production pathway’ (HFE-
homeostatic iron regulator), which is involved in iron metabolism and the 
adipogenesis pathway (Figure 4.15). Interestingly, no HNSCC-related pathways 
were over-represented in this group, but the cancer-related endometrial and gastric 
pathways were over-represented in subset 6b (Figure 4.15).  
The EC genes were further analysed to investigate genes encoding for TFs in OTK 
cells and compare with the TF genes annotated in HNSCC cells. A total of 25 genes 
were identified that could be divided into nine families: p53, AP-1, ETS, SP1, KLF, 
RUNX, GRHL, LHX and DLX (distal-less homeobox) (Table 4.1). The p53 gene 
family includes TP53, TP63 and TP73. While TP53 was not annotated as an EC 
gene, TP63 was HNSCC-specific and TP73 was annotated in UDSCC2(+) and 
OTK cells (Table 4.1). Other HNSCC-specific EC genes included the AP-1 genes 
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(FOSL1 (FOS like 1, AP-1 transcription factor subunit) and ATF3), ETS genes 
(ELF3, ETV-3 (ETS variant 3), -5, -6 and EHF (ETS homologous factor), SP1, KLF 
genes (KLF-7, -13), RUNX1, GRHL2, LHX-2, -3 and DLX-3, -6 (Table 4.1). OTK-
specific EC genes included ETS1 and KLF9 (Table 4.1). EC genes shared between 
OTK and HNSCC cells included, FOS, FOSB, ETS2 and KLF-6, -10. 








4.11 Genome-wide gene expression analysis (RNA-seq) in 
non-tumour keratinocyte cells 
Genome-wide RNA-seq was conducted to elucidate differences between HNSCC 
gene expression and non-tumourigenic primary cells to put the ATAC-seq data into 
context. RNA-seq was unsuccessful in OTK cells, however data was obtained for 
another primary non-tumour oral cell type- HOK (human oral keratinocyte). HOK 
RNA-seq analysis was conducted as described for HNSCC cell lines (Chapter 3, 
Section 3.12). The Galaxy platform was used to analyse the data as described in 
Materials and Methods, Section 2.13.5. Within Galaxy, the Hisat2 tool was used to 
align reads to the hg19 genome. A total of 26,281,754 reads were sequenced and 
92.3% of reads were aligned to the genome. Only genes with an FPKM (fragments 
per kilobase exon per million mapped reads) value above 1 were considered for 
downstream analysis; a total of 12,228 genes were analysed. 
The ‘PCAexplorer’ script in the R software was used to investigate differences in 
HNSCC gene expression compared to that in HOK cells. Gene FPKM values were 
used to conduct the PCA analysis (Figure 4.16). Four principal components were 
identified (PC1-4); over 40% of variability could be accounted for by PC1 (Figure 
4.16A). It was found that PC1 accounted for differences in HNSCC gene expression 
compared to the HOK cells (Figure 4.16B). In addition, hierarchical clustering of 
FPKM values for the five cell types further highlighted gene expression differences 





Figure 4.16. Principal components (PCA) and clustering analyses of gene expression 
data.  
(A) Four principal components (PCs) were identified upon clustering of gene FPKM 
values: PC1 (42.76%), PC2 (32.5%), PC3 (13.2%) and PC4 (11.5%). (B) PC1 accounted 
for 42.76% of variability due to differences between HNSCC gene expression and HOK 
expression. PC2 accounted for 32.5% of variability due to differences between 
UDSCC2(+) gene expression compared to the remaining HNSCC cell lines and HOK cells. 
(PCA plots for PC3 and PC4 are shown in Appendix: Figure 2). (C) Clustering analysis of 
FPKM values revealed greatest variability to be between HOK gene expression and 




To further investigate differences in gene expression, pathway enrichment analysis 
was conducted on the top 2,000 genes ranked by FPKM values for the HOK cells 
and four HNSCC cell lines. The analysis was conducted using the ConsensusPath 
database and data for KEGG (Kyoto Encyclopedia of Genes and Genomes) and 
Wikipathways were extracted. As before, the pathways were ranked by p-value and 
grouped by cell representation, which resulted in two main groups (Figure 4.17). 
Group (1) consisted of 26 pathways which were significantly over-represented in 
HOK cells. This group could be further divided into three subsets: 1a, 1b and 1c 
(Figure 4.17). Subset 1a contained four pathways which were significantly over-
represented in HOK and nearly all HNSCC cells (Figure 4.17). Pathways in this 
subset exclusively contained pathways related to protein/RNA processing, 
including mRNA processing, translation factors, cytoplasmic ribosomal proteins 
and ribosome pathways (Figure 4.17). Subset 1b contained 19 pathways which 
were more significantly over-represented in HOK cells compared to HNSCC cells 
and were largely associated with miRNA (miR-targeted genes in leukocytes, 
muscle cell, lymphocytes and epithelium pathways), protein/RNA processing 
(RNA transport, protein processing in endoplasmic reticulum and spliceosome 
pathways) and CNS (Parkinson’s, Huntington’s and Alzheimer disease). Subset 1c 
consisted of four HOK-specific pathways which included pathways associated with 
miRNA in squamous cells and proteasome degradation and two pathways were 
associated with metabolism (non-alcoholic fatty liver disease and thermogenesis 
pathways) (Figure 4.17). Group (2) contained 14 pathways which were less 
represented in the five cell types. This group could be divided into two subsets: 2a 
and 2b. Subset 2a consisted of five pathways which showed comparable statistical 
significance in HOK cells and in at least one HNSCC cell line (Figure 4.17). 
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Pathways in this subset were associated with cell proliferation (cell cycle and 
androgen receptor signalling pathway) and adhesion (adherens and proteoglycans 
in cancer). In addition, the HNSCC-related pathway TGF- was present in this 
group, however, the pathway was not enriched in VU40T(-) cells (Figure 4.17). 
Subset 2b consisted of nine pathways which were more over-represented in HNSCC 
than in HOK cells. This subset contained cell adhesion related pathways (tight 
junction, ARVC (arrhythmogenic right ventricular cardiomyopathy), dilated 
cardiomyopathy), pRB in cancer pathway, pathways in cancer and three pathways 
related to development (thyroid signalling hormone, oocyte meiosis and 





Figure 4.17. Gene expression analysis of HOK and HNSCC cells by RNA-seq.  
Genome-wide RNA-seq was conducted in non-tumourigenic primary HOK cells and in 
four HNSCC cell lines. The genes were ranked by FPKM (fragments per kilobase exon per 
million mapped reads) value and the top 2000 genes were taken for pathway enrichment 
analysis by using the Consensus DB tool. The pathways were ranked by log p-value; green 
represents the least statistically significant pathways, red represents most significant and 
blank boxes indicate no enrichment. The pathways were grouped by cell representation into 
two groups and five subgroups: (1) significantly over-represented in HOK (27/41; 66%), 
(1a) over-represented in all (4/41; 10%), (1b) over-represented in HOK (19/41; 12%), (2) 
under-represented in all (14/41; 34%) (2a) over-represented in all (5/41; 12%), (2b) over-
represented in HNSCC (9/41; 22%).  
Pathway Function HOK SCC040(-) VU40T(-) VU147(+) UDSCC2(+)
log -value
mRNA Processing Protein/RNA processing
(1a)
(1)
Translation Factors Protein/RNA processing
Cytoplasmic Ribosomal Proteins Protein/RNA processing
Ribosome Protein/RNA processing
RNA transport Protein/RNA processing
(1b)
Protein processing in endoplasmic reticulum Protein/RNA processing
miR-targeted genes in epithelium miRNA
Focal adhesion Cell adhesion
Regulation of actin cytoskeleton Cytoskeletal
Estrogen signaling pathway Cell growth/proliferation
Spliceosome Protein/RNA processing
VEGFA-VEGFR2 Signaling Pathway Cell growth/proliferation
Epstein-Barr virus infection Viral
Electron Transport Chain Metabolism
Pathogenic Escherichia coli infection Bacterial
Primary Focal Segmental Glomerulosclerosis FSGS Renal degeneration
Parkinson's disease CNS
miR-targeted genes in leukocytes miRNA
miR-targeted genes in muscle cell miRNA




Non-alcoholic fatty liver disease (NAFLD) Metabolism
(1c)
Thermogenesis Metabolism
miR-targeted genes in squamous cell miRNA
Proteasome Degradation Protein/RNA processing
Cell cycle Cell proliferation
(2a)
(2)
Androgen receptor signaling pathway Cell growth/proliferation
Adherens junction Cell adhesion
Proteoglycans in cancer Cell adhesion
TGF-beta Signaling Pathway HNSCC-related
Thyroid signaling hormone pathway Development/cell growth
(2b)
Tight junction Cell adhesion
ATF6-alpha activates chaperone genes Protein/RNA processing
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Cell adhesion
Dilated cardiomyopathy Cell adhesion
Oocyte meiosis Development
Retinoblastoma (RB) in Cancer HNSCC-related
Pathways in cancer Cancer-related










To investigate regulatory elements in non-tumourigenic oral keratinocytes, ATAC 
(Assay for Transposase-Accessible Chromatin)-seq was conducted as an alternative 
to the DNase I-hypersensitivity assay. The genomic distribution of ATAC-seq 
peaks displays high similarity to HNSCC (head and neck squamous cell carcinoma) 
DHS (DNase I hypersensitive site) peaks, suggesting that locations of open regions 
in both techniques are comparable as has been suggested previously [161, 188, 238, 
239]. 
The transcription factor (TF) motif analyses of ATAC peaks revealed the EKLF 
(erythroid Krüppel-like factor) (KLF1) and KLF4 motifs to be OTK (oral tonsil 
keratinocyte)-specific. In addition, the OTK-specific EC-regulated TF genes 
included KLF9. The 17-member KLF TF family are involved in many different 
processes. For example, erythropoiesis (KLF-1, -2, -3 and -11), adipogenesis (KLF-
2, -3 and -7), cardiac homeostasis (KLF-5, -6, -10, -13, -15 and -16) and epithelial 
homeostasis (KLF-4, -5, -9 and -13) [290].  
KLF4 is known to be a negative cell cycle regulator and in line with this, a decrease 
in KLF4 protein expression in oral SCC samples has been reported [260, 291]. 
KLF4 normally binds the cyclin-dependent kinase inhibitor gene (CDKN1) and the 
cyclin B1 gene (CCNB1) to regulate the cell cycle [13, 16, 292]. In addition, upon 
DNA damage KLF4 can block the CCNE1 gene which encodes cyclin E, thereby 
activating cell cycle checkpoints and preventing cell cycle progression [293]. 
Downregulation of KLF9 has been observed in oesophageal SCC compared to the 
surrounding normal tissue and KLF9 plays a role in the inhibition of growth, 
migration and metastasis of oesophageal SCC cells [294].  
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Therefore, the absence of the KLF4 and KLF9 motifs from the top 20 HNSCC 
motifs and their presence in the OTK cells may indicate suppression of KLF4- and 
KLF9-mediated cell cycle processes in these HNSCC cell lines. This decrease was 
also reflected by our RNA-seq data when comparing KLF4 and KLF9 expression 
in HOK (human oral keratinocyte) cells and HNSCC cells (data not shown).  
KLF1 is central to erythropoiesis and plays a role in gene regulation, haem 
biosynthesis and cell cycle regulation [295]. Despite the role of KLF1 being largely 
restricted to erythroid tissues, recently, increased KLF1 levels in cervical cancer 
cells have been reported and has been linked to cell proliferation, metastasis and 
invasion via interaction with the PI3K (phosphotidylinositol-3 kinase)/AKT 
(protein kinase B) pathway [296, 297]. This evidence indicates KLF1 as having a 
pro-tumourigenic role in epithelial cells. Our RNA-seq data however demonstrates 
higher KLF1 expression in HOK cells compared to HNSCC cells. However, in our 
HNSCC cell lines, the KLF1 motif and transcript levels are not detected and so it 
may be that KLF1 overexpression does not contribute to HNSCC in these cells. This 
difference could be attributed to the fact that HOK cells are of foetal origin. Having 
said this, even during development, KLF1 expression remains restricted to 
erythrocytes [85]. 
Pathway overrepresentation analysis revealed pathways previously linked to 
HNSCC to be shared between OTK and HNSCC cells, for example, the TGF 
(transforming growth factor)- and EGFR pathways. EGFR is frequently reported 
as being overexpressed in HNSCC cells, but it is also essential for non-tumour 
keratinocyte function in processes such as, proliferation, migration, adhesion and 
survival [26, 81]. Indeed, blocking of EGFR in non-tumour keratinocyte cells can 
result in cell death [298]. TGF- is a cytokine, which in non-tumour cells can inhibit 
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proliferation and induce cell differentiation, while in cancer cells, including in 
HNSCC, TGF- can be pro-tumourigenic [118, 299]. Therefore, the presence of 
similar pathways in both OTK and HNSCC cells could be explained by the fact that 
these pathways are needed for the normal maintenance of cells. Moreover, as in the 
case of TGF-, some genes and their proteins can exert tumour suppressor affects 
in some environments and tumourigenic in others.  
Other pathways in our data common to both non-tumour and HNSCC cells were 
associated with micro RNAs (miRNAs). MiRNAs are small RNA molecules which 
block mRNA translation or target mRNA for degradation [134]. It has been reported 
by a number of studies that miRNA levels can be altered in the presence of HPV 
(human papillomavirus) [134, 282-284, 300]. On the other hand, in non-
tumourigenic oral cells, miRNAs are required for normal cell function [301].  
Analysis of EC (enhancer cluster) genes revealed annotated Hippo pathway genes 
to be HNSCC-specific. In addition, analysis of OTK ATAC peaks revealed the 
Hippo pathway to be highly enriched. The Hippo pathway is important in regulating 
cell growth through cell adhesion molecule and cell-cell signalling [92, 302, 303]. 
However, in cancer, loss of cell-cell signalling leads to aberrant cell growth [304, 
305]. Therefore, it may be that signal inputs to the Hippo pathway such as 
mechanical cell stress function in non-tumour cells, while in cancer cells this may 
be lost. Further investigation of EC annotated genes of the Hippo pathway revealed 
SMAD3 (mothers against decapentaplegic homolog 3) and the TGF- receptor 1 
gene (TGFBR1). SMAD3 is part of the SMAD TF family and is activated by the 
TGF- receptor [88]. Cross-talk between the Hippo and TGF- pathways and their 
role in EMT (epithelial to mesenchymal transition) has previously been reported. It 
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has been shown that one of the Hippo transcriptional regulators, TAZ (tafazzin) can 
form a heteromeric complex with SMAD2/3/4 and upon TGF- activation the 
complex can activate TGF- target genes including those involved in EMT [88, 
306]. Therefore, it may be that in non-tumour cells upstream components of the 
Hippo pathway are active, which function to restrict cell growth, while in cancer 
cells, downstream transcriptional regulators are active resulting in aberrant cell 
growth. 
EC pathways specific to HNSCC cells included the viral carcinogenesis pathway. 
Annotated genes in this pathway included genes which have previously been 
reported to be deregulated in HNSCC (PIK3CA (phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha) and JUN) [36, 66-70, 72, 117, 252, 
255]. The overlap in pathways affected in both HPV(-) and HPV(+) cell lines is 
evident in this data, as described in Chapter 1 (Table 1.1 and Figure 1.8). However, 
further investigations may uncover novel genes and pathways which are 
deregulated in both HPV(-) and HPV(+) cells, providing an opportunity for the 
development of new therapies. 
The NOTCH pathway was found to be over-represented in the OTK-specific EC 
dataset. This is in line with published data where NOTCH1 inactivating mutations 
are frequently observed in HNSCC [36, 66-71]. Another study has reported that 
Notch1 overexpression leads to cell cycle arrest and differentiation by induction of 
p21 expression [22]. Therefore, this data indicates that NOTCH1 silencing may 
have a role in these HNSCC cell lines as a tumour suppressor gene.  
Limitations of this chapter include the use of ATAC-seq, as the method yields fewer 
mapped peaks compared to DNase I-seq. The inclusion of mitochondrial DNA 
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contributes to this limitation despite the method being improved in recent years, as 
discussed in Section 1.11.3. Additionally, it may be due to the inclusion of feeder 
layer cells, which are mouse embryonic fibroblast cells required for the growth of 
human keratinocytes. While mitochondrial DNA and mouse DNA can be 
computationally filtered out after sequencing, during sequencing, such DNA can 
deplete the number of reads from the nuclear DNA [195]. This may be one of the 
reasons OKF6 and HOK ATAC-seq did not work, as upon sequencing OKF6 and 
HOK ATAC samples displayed very high background and so peaks could not be 
called.  
A third limitation of this chapter is that the RNA-seq data for non-tumourigenic 
cells was derived from HOK cells, while the ATAC-seq data was derived from OTK 
cells; the RNA-seq experiment was unsuccessful for the OTK and OKF6 RNA 
samples. The reason for this is likely to be a technical issue, as the quality of RNA 
indicated by the RNA integrity number was sufficient. Due to time constrictions 
and limited amount of RNA, it was not possible to repeat the sequencing.  
Making comparisons between HOK RNA with OTK ATAC open regions must be 
conducted with caution, as the HOK cells are of foetal origin, while OTK cells are 
derived from an adult. Data derived from the same cell type would overcome this 
limitation. However, while the origin of HOK and OTK cells differ, encouragingly, 
the pathways identified in pathway enrichment analysis showed some overlap with 
those in the HNSCC cells, and also overlap with the each other (i.e. HOK RNA-seq 
pathways and OTK ATAC-seq pathways). Therefore, useful data can be derived 
from the HOK cells, but it must be interpreted with caution. A further limitation is 
that the RNA-seq and ATAC-seq data was derived from one cell type each. 
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Therefore, to strengthen this data, the sample size of non-tumour cells can be 
increased, and the sequencing assays can be conducted in the same cell types. 
In summary, comparison of the HNSCC cell lines’ regulatory network and that of 
non-tumourigenic oral cells has revealed some differences, for example, the 
presence of the NOTCH pathway in non-tumour cells and the viral carcinogenesis 
pathway in HNSCC cells. However, overall, large overlap is also evident between 
the cell types involving the EGFR and Hippo pathways, as well as the KLF and AP-





CHAPTER 5: INVESTIGATION OF p63, 
TEAD4 AND AP-1 TRANSCRIPTION FACTOR 
BINDING IN HNSCC CELL LINES 
5.1 Introduction 
The previous two results chapters aimed to map open chromatin regions in four 
HNSCC (head and neck squamous cell carcinoma) cell lines and in non-
tumourigenic primary oral keratinocytes. The open chromatin regions were 
interrogated using known and de novo transcription factor (TF) motif analyses in 
order to investigate which TFs may be involved in these HNSCC cells. Analysis of 
known motifs in HNSCC indicated the involvement of five TF families: AP-1, 
p53/p63, KLF (Krüppel-like factor), RUNX (runt-related transcription factor) and 
TEAD (TEA domain transcription factor). This finding was supported by de novo 
motif analysis in both HNSCC and non-tumour cells. Furthermore, the motifs 
appeared to be unique to distal DNase I hypersensitive sites (DHSs), apart from the 
AP-1 motif which was also found in promoter DHSs, though stronger association 
at distal regions was observed (Figure 3.15). Therefore, these TF families were 
investigated further. 
The AP-1 motif was one of the most enriched TF motifs in the merged-HNSCC 
dataset and in the OTK (oral tonsil keratinocyte) cells. The AP-1 TF is a dimer 
consisting of two main families: JUN (JUN, JUNB, JUND) and FOS (FOS, FOSL1 
(FOS like 1, AP-1 transcription factor subunit) and FOSL2). Homodimers can form 
of JUN proteins, while JUN and FOS proteins can form heterodimers [307]. 
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Members of the JUN and FOS families have been associated with many cancers, 
including HNSCC [253, 255, 308].  
The p63 motif was also enriched in our HNSCC and OTK cells and was uniquely 
present in distal HNSCC cell line DHSs. The p63 protein is a key epithelial 
regulator and is essential in epithelial organisation [12]. However, in HNSCC cells, 
TP63 is often over-amplified and has pro-survival effects [257, 309]. Indeed, in our 
data we observed the presence of an EC (enhancer cluster) at the TP63 gene, 
specific to HNSCC cell lines, which aligned with a higher level of TP63 expression 
observed in the RNA-seq data. The TP63 gene is rarely deleted unlike its family 
member p53, which often undergoes inactivating mutations in cancer [36, 66-71]. 
Furthermore, a study in which p63 ChIP was conducted in non-tumourigenic human 
foreskin keratinocyte (HFK) cells revealed that p63 binding was associated with 
processes such as senescence, while in laryngeal cells, p63 was associated with 
positive growth factor signalling [138]. Therefore, p63 could serve as an alternative 
therapeutic target to p53.  
The RUNX1-3 TF family motif was enriched in the HNSCC cells, OTK cells and 
uniquely at distal HNSCC DHSs. In addition, the RUNX1 and RUNX2 genes were 
annotated in the HNSCC DHSs. Both RUNX1 and RUNX3 have been implicated 
in HNSCC [255, 261, 264, 310] and RUNX2 has been reported to display abnormal 
methylation patterns in HNSCC [262, 263].  
The motif for the KLF TF family is enriched in our HNSCC cell lines. The KLF 
family has previously been implicated in cancer; KLF4 has been associated with 
poor patient prognosis in HNSCC, while in oral SCC cell lines, KLF5 
overexpression has been observed through a decrease in a suppressive micro RNA 
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(miRNA) which regulates KLF5 expression [310, 311]. In addition, whole-genome 
sequencing data derived from HNSCC tumours have revealed recurrent focal 
amplifications of enhancer clusters (ECs) near the KLF5 gene, which can lead to 
KLF5 protein overexpression [179].  
The TEAD motif was enriched in all four HNSCC cell lines investigated here. 
TEADs are a family of four TFs and are the downstream TF effectors of the Hippo 
pathway, as discussed next [312]. 
5.2 Hippo pathway 
The potential involvement of the Hippo pathway in HNSCC was a novel finding at 
the time of the project’s development. The Hippo pathway was over-represented in 
pathway enrichment analysis of HNSCC and OTK cells. The pathway is involved 
in organ growth and regulation of cell-cell contact inhibition by influencing 
transcription of genes involved in cell proliferation and growth [88, 92] (Figure 
5.1). The pathway involves a cascade of kinase proteins: MST (macrophage 
stimulating)-1 and -2 and LATS (Large Tumour Suppressor kinase)-1 and -2 [88, 
92]. When active, MST1/2 form a complex and phosphorylate a scaffold protein, 
SAV1 (Salvador homolog 1). MST1/2 then phosphorylate LATS1/2 and its scaffold 
protein MOB1A/1B (Figure 5.1). LATS1/2 in turn phosphorylate and promote 
cytoplasmic stabilisation of the downstream transcriptional effectors, TAZ 
(tafazzin) and YAP (yes-associated protein) [88, 92]. Upon receiving signals such 
as mechanical stress, in their phosphorylated state YAP/TAZ are restricted to the 
cytoplasm, have no transcriptional effect and are eventually targeted for 
degradation (Figure 5.1). In environments of low cell density, YAP/TAZ are 
unphosphorylated and free to translocate to the nucleus [88] (Figure 5.1). To induce 
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transcription, YAP and TAZ must bind to a TF such as TEAD which are a family 
of four highly homologous proteins (TEAD1-4) and share a highly conserved DNA 
binding domain [312]. The TEAD TF family are the main mediators of YAP/TAZ; 
studies designed to disrupt YAP/TAZ/TEAD interactions have revealed a decreased 
response to EMT (epithelial to mesenchymal transition) and anchorage-
independent growth [313]. In addition to TEAD, the KLF4, RUNX-1, -3 and AP-1 
(JUN) TFs can also serve as binding partners for the Hippo transcriptional 
regulators, YAP/TAZ [272]. 
 
 
Figure 5.1. The Hippo signalling pathway. 
(A) Upon activation of the Hippo pathway, the MST1/2 kinase proteins form a complex 
with the scaffold protein SAV1 and phosphorylate it. The MST1/2 kinases then 
phosphorylate the LATS1/2 kinases and its scaffold proteins MOB1A/1B. LATS1/2 then 
phosphorylate YAP/TAZ, stabilising them in the cytoplasm and inhibiting transcription. 
(B) In environments of low cell density, the Hippo pathway is switched off leading to 
dephosphorylation of the core kinases (MST1/2 and LATS1/2), the scaffold proteins 
(SAV1 and MOB1A/1B) and of YAP/TAZ. YAP/TAZ are then free to translocate to the 
nucleus and activate gene transcription of Hippo target genes such as CTGF, which is 
involved in processes such as cell proliferation and growth. 
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5.3 The role of the Hippo pathway in HNSCC 
As briefly addressed in the main introduction (Section 1.5), the role of the Hippo 
pathway in recent years has become more prominent in HNSCC, particularly the 
role of YAP (recently reviewed by Segrelles et al., 2018) [314]. For example, a 
study in which a total of 221 HNSCC tumours from the TCGA and University 
Hospital of A Coruña cohorts were interrogated, found PIK3CA gene 
overexpression to correlate with YAP protein inactivation and expression of Hippo-
target genes [315]. Furthermore, the gene for the cadherin protein FAT1, which is 
involved in cell-cell signalling via the Hippo pathway, has been found to undergo 
frequent inactivation mutations and deletions (Table 1.1) [36, 66, 68, 70, 71, 316]. 
The loss of FAT1 has been found to result in inactivation of YAP, correlating with 
disease progression [93]. In addition, a study conducted in 35 HNSCC tumours 
found positive correlation between YAP expression and tumour metastasis, 
moreover, YAP expression co-localised at the tumours’ invasive margin [87]. 
Therefore, the role of the Hippo pathway in HNSCC has previously been 
established, however its role at the chromatin level is lacking and will be addressed 
in this chapter. 
5.4 Aims 
In this chapter, the aim was to investigate the role of the AP-1, p53/p63, KLF, 
RUNX and TEAD TFs and the EGFR (epidermal growth factor receptor) and Hippo 
pathways by conducting in silico analysis of a panel of primary HNSCC tumours 
obtained from The Cancer Genome Atlas (TCGA) database [36]. This was followed 
by gene expression analysis by qPCR (quantitative polymerase chain reaction) in 
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our cell lines. Based on this analysis, the role of p63-AP1-TEAD in the HNSCC 
transcriptional network was further investigated by conducting ChIP-seq 
(chromatin immunoprecipitation-sequencing) to investigate their genome-wide 
binding patterns and possible interactions.  
5.5 In silico analysis of a panel of 496 HNSCC tumours 
obtained from The Cancer Genome Atlas (TCGA) 
database 
Before investigating the TF network in the HNSCC cell lines, analysis of a panel 
of 496 HNSCC tumours was conducted to establish whether the same TF network 
could be of importance in primary HNSCC tumours. The tumour panel was 
obtained from The Cancer Genome Atlas (TCGA) and data analysis was conducted 
using the cBioPortal tool [36, 317]. The analysis involved information on HPV 
(human papillomavirus) status, gene alterations and RNA expression. The genes 
considered were of the Hippo signalling pathway (YAP1, WWTR1 (WW domain 
containing transcription regulator 1) (encodes TAZ) and the TEAD TF family), the 
AP-1 TF (FOS, FOSL1, FOSL2, JUN, JUNB and JUND), KLF4/5, RUNX1-3, TP63 
and EGFR. It was observed that the majority of gene alterations were amplifications 
and upregulation of RNA transcript levels (Figure 5.2). Of the TF genes, the TP63 
gene was the most frequently altered in the HNSCC tumour panel (36%), followed 
by FOSL1 (12%) and TEAD4 (10%) (Figure 5.2). Both KLF-4 and -5 were altered 
in 8% of tumours, while RUNX1-3 were altered in 7%, 5% and 4% of tumours, 
respectively. Of pathway genes, the EGFR gene was altered in 21% of tumours, 
YAP1 and WWTR1 was altered in 17% and 22% of tumours, respectively (Figure 
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5.2). Therefore, alterations in the genes for p63, AP-1, EGFR and the Hippo 
pathways appear to be associated with HNSCC tumours and predominantly involve 
gene amplification and RNA upregulation, suggesting that the investigated TFs are 




Figure 5.2. Gene alterations in the TCGA provisional HNSCC tumour cohort of 496 tumours.  
The cBioPortal tool was used to visually represent the percentage of tumours with one or more gene alteration in any given gene. Rows represent 





The incidence of co-occurrence and mutual exclusivity between gene alterations in 
the same tumour was investigated. Statistically significant co-occurrence between 
TP63/WWTR1, FOS/FOSB, YAP1/JUND, TP63/KLF4 were identified (Table 5.1). 
No genes investigated displayed statistically significant mutual exclusivity (Table 
5.1). Therefore, an association appears to be present in the TCGA tumour panel 
between genes for Hippo and AP-1, as well as TP63 and KLF4.  
Table 5.1. In silico analysis of co-occurrent gene alterations performed using the 
TCGA, ‘provisional HNSCC’ tumour cohort of 496 tumours. 






TP63 WWTR1 290 96 29 81 2.133 <0.001 
FOS FOSB 453 23 9 11 >3 <0.001 
YAP1 JUND 407 72 7 10 2.089 0.013 
TP63 KLF4 306 152 13 25 1.354 0.016 
The cBioPortal tool was used for analysis. Log odds ratio (OR) was calculated for gene A 
and gene B to reveal the likelihood of alterations in the two genes being mutually exclusive 
or co-occurent. OR = (A∗D)/(B∗C); where A = number of cases altered in both genes; B = 
number of cases altered in Gene 1 but not Gene 2; C = number of cases altered in Gene 2 
but not Gene 1; and D = number of cases altered in either gene. Alterations in each gene 
pair is then assigned to a category; mutually exclusive, tendency to co-occur or no 
association [318]. 
 
Using the MEXPRESS tool, which allows visualisation of TCGA clinical data, 
correlation between HPV status and gene expression of the AP-1, TEAD, KLF, 
RUNX gene families, as well as TP63, YAP1 and EGFR was investigated [319]. An 
example plot for the TEAD4 gene is shown in Figure 5.3. TEAD4 expression 
displayed statistically significant negative correlation with HPV status (P=0.009) 
(Figure 5.3). Analysis of other genes revealed a statistically significant positive 
correlation between HPV status and expression of JUND, TEAD2 and RUNX3 
(Table 5.2). Negative correlation was found between expression of TEAD1, 
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TEAD4, FOSL1, FOSL2, RUNX2, TP63, EGFR, YAP1, WWTR1 and HPV status 
(Table 5.2). No statistically significant correlation was observed between HPV 
status and FOS, FOSB, JUN, JUNB, KLF4, KLF5, RUNX and TEAD3 (Table 5.2). 
Therefore, this data strengthens the association of the genes for AP-1, p63, EGFR 
and Hippo with HNSCC and their affects could be dependent on HPV status. 
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Table 5.2. Correlation between gene expression and HPV presence using the TCGA 
HNSCC data. 
Gene P-value 
Correlation between gene 
expression and HPV 
presence 
JUND 1.54E-02 Positive 
TEAD2 1.52E-02 Positive 
RUNX3 1.45E-02 Positive 
TEAD1 1.41E-02 Negative 
EGFR 3.41E-06 Negative 
FOSL1 7.42E-08 Negative 
RUNX2 4.4E-03 Negative 
TEAD4 9.03E-03 Negative 
TP63 1.73E-04 Negative 
YAP1 1.94E-09 Negative 
FOSL2 2.98E-04 Negative 
WWTR1 2.44E-06 Negative 
FOS 0.469 None (not significant) 
FOSB 0.747 None (not significant) 
JUN 0.494 Negative (not significant) 
JUNB 0.768 Positive (not significant) 
KLF4 0.812 Positive (not significant) 
KLF5 0.405 Negative (not significant) 
RUNX1 0.141 Positive (not significant) 






Figure 5.3. Visualisation of clinical data using the TCGA cohort of HNSCC tumours and its correlation with TEAD4 gene expression. 
The ‘MEXPRESS’ tool was used to visualise data for the TEAD4 gene. The samples were ordered by TEAD4 expression which displays the statistical 
significance of the relationship between gene expression and eight other parameters: lymphocyte infiltration, age at diagnosis, clinical stage, pack years smoked, 
tobacco smoking history, HPV status p16 testing, pathologic stage, gender, sample type. However, only the correlation between ‘HPV status p16 testing’ and 
gene expression were analysed here. HPV status was determined by the presence of p16 by immunohistochemistry. Samples showing a positive signal for p16 
are indicated by the dark grey bars in the ‘hpv status p16 testing’ track. Though the MEXPRESS tool only displays p16 staining for the tumours, the TCGA 




5.6 QPCR analysis of transcription factor genes 
To investigate the role of the genes highlighted above, qPCR was conducted to 
determine gene expression in our four HNSCC cell lines (SCC040(-), VU40T(-), 
VU147(+) and UDSCC2(+)). Gene expression in the normal, immortalised OKF6 
cell line was also assessed as a control. Gene expression levels were normalised to 
the GAPDH housekeeping gene. 
Expression levels of members of the AP-1 TF family (FOS, FOSB, FOSL1, FOSL2, 
JUN, JUNB and JUND) were investigated (Figure 5.4A-G). The FOS gene was 
expressed at very low levels in OKF6, VU40T(-), VU147(+) and UDSCC2(+) cells, 
while high expression was observed only in SCC040(-) cells (Figure 5.4A). On the 
other hand, FOSB was expressed at very low levels in SCC040(-), however FOSB 
was expressed at consistent levels in OKF6, VU40T(-) and UDSCC2(+) cells, while 
in VU147(+) cells FOSB was highly expressed (Figure 5.4B). Expression of 
FOSL2, JUN, JUNB, JUND was highest in SCC040(-) cells, while FOSL1 was 
highly expressed in VU40T(-) and VU147(+) (Figure 5.4C-G). OKF6 cells display 
uniform expression across the AP-1 genes apart from high expression of JUND and 
no expression of FOS (Figure 5.4A-G).  
The expression levels of ATF3, a member of the ATF (activating transcription 
factor) family, which can dimerise with the JUN family, and expression levels of 
BACH (BTB domain and CNC homolog)-1, a TF harbouring the AP-1 motif were 
investigated [320]. The SCC040(-) cells expressed ATF3 most highly, while lowest 





Figure 5.4 TF gene expression levels in HNSCC and OKF6 cell lines were assessed by 
qPCR. 
QPCR was conducted to determine the expression levels in OKF6 (green bars) and HNSCC 
(blue bars: HPV(-) cells, red bars: HPV(+) cells) cells of the (A) FOS, (B) FOSB, (C) 
FOSL1, (D) FOSL2, (E) JUN, (F) JUNB, (G) JUND, (H) ATF3, (I) BACH1, (J) TEAD1, 
(K) TEAD2, (L) TEAD3, (M) TEAD4, (N) TP63, (O) KLF4, (P) KLF5, (Q) RUNX1 and 
(R) RUNX2. Expression levels were normalised to GAPDH. The error bars represent SEM 




Expression levels of the TEAD TF gene family were investigated (Figure 5.4J-M). 
TEAD1 expression was highest in OKF6 cells and lowest in VU147(+) and 
UDSCC2(+) cell lines (Figure 5.4J). TEAD2 expression was relatively consistent 
between all five cell lines, while TEAD3 expression was lowest in SCC040(-), 
VU147(+) and UDSCC2(+) cells (Figure 5.4K and L). TEAD4 was expressed 
highest in the HNSCC cell lines (Figure 5.4M).  
Expression levels of TP63 was also investigated and levels were consistent in four 
cell lines apart from UDSCC2(+) cells where levels showed a small decrease 
(Figure 5.4N). 
Due to the large gene family of the KLF TFs, only genes most well studied in 
HNSCC were selected for investigation, which included KLF4 and KLF5 [179, 310, 
311] (Figure 5.4O and P). Expression levels of KLF4 was highest in OKF6 and 
SCC040(-) cells, while KLF5 expression was lowest in both VU147(+) and 
UDSCC2(+) cells. 
Gene expression of the RUNX family members, RUNX1 and RUNX2 were 
investigated (Figure 5.4Q and R). RUNX1 expression was highest in VU40T(-) 
and VU147(+) cells, while RUNX2 expression was highest in SCC040(-) cells and 
lowest in VU147(+) and UDSCC2(+) cells. 
In summary, in silico TCGA analysis revealed the p63, AP-1, EGFR and the Hippo 
pathways to have strong association with HNSCC. Of these genes, the TP63 gene 
was the most altered gene in the TCGA HNSCC tumour cohort and its expression 
negatively correlated with the HPV status of the tumours. In our data, TP63 was 
expressed in all four HNSCC cell lines investigated. Of the AP-1 genes, FOSL1 
was the most altered AP-1 gene in the TCGA data and negatively correlated with 
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tumour HPV status. Furthermore, in our cell lines, FOSL1 was one of the most 
highly expressed genes. The TCGA HNSCC tumours displayed JUND alterations 
least frequently, however JUND alterations were significantly co-occurrent with 
YAP1 alterations and displayed significant positive correlation with HPV status. In 
addition, the JUND gene was one of the most highly expressed AP-1 genes in our 
HNSCC cell lines. Of the TEAD genes, TEAD4 was the most highly expressed in 
the TCGA data analysis and was most highly expressed in all four HNSCC cell 
lines compared to OKF6 cells. Therefore, for the next step of the investigation, 
genome-wide TF binding of FOSL1, JUND, p63 and TEAD4 were investigated by 
ChIP-seq. 
5.7 ChIP-seq of TEAD4, p63, FOSL1 and JUND 
ChIP-seq was conducted in VU40T(-) and VU147(+) cell lines, as they displayed 
high gene expression for all four TFs. ChIP was performed in three independent 
biological replicates, as described in Chapter 2, Section 2.8. Before the ChIP 
samples were sequenced, successful immunoprecipitation and enrichment for 
binding sites were tested. 
5.7.1 ChIP quality control 
QPCR was conducted to determine successful ChIP using primers designed at 
putative TF binding sites. These sites were selected based on ChIP-seq data 
obtained from the Cistrome database [217]. ChIP-seq data for the four HNSCC cell 
lines used here were not available, therefore data from similar cell types were used 
to find TF binding sites and design qPCR primers. The following datasets were 
used: p63 ChIP-seq data from an oesophageal SCC cell line (KYSE-70) [79], 
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TEAD4 ChIP-seq data from a lung carcinoma cell line (A549) [321] and ChIP-seq 
data for JUND and FOSL1 from a cervical cancer cell line (HeLa-S3) [322]. Using 
a list of top putative binding sites, a binding site was selected and verified as a DHS 
site in our data for the VU40T(-) and VU147(+) cell lines, indicating possible TF 
binding. Binding sites near the PC (pyruvate carboxylase), ANXA2 (annexin 2), 
LNMA (lamin A/C), and S100A10 (S100 calcium binding protein A10) genes were 
selected as sites to assess FOSL1 and JUND ChIP enrichment (Figure 5.5 and 
Appendix: Figures 3-5), two sites for p63 (site 1 near to the TP73 and site 2 near 
to the JMJD7 (jumonji domain containing 7) gene) (Appendix: Figure 6 and 
Figure 5.6) and two sites for TEAD4 ChIPs (sites 1 and 2) were also selected 






Figure 5.5. UCSC (University of California Santa Cruz) browser screenshot for 
FOSL1 and JUND ChIPs at the PC gene.  
QPCR primers were selected near the PC gene to test for potential FOSL1 and JUND 
binding. The qPCR product (mapped on to the coverage tracks) overlaps with subsequent 
FOSL1 and JUND TF ChIP peaks in the VU40T(-) and VU147(+) cell lines (green and 
blue tracks, respectively); the data were obtained from the Cistrome database and is shown 
as a black track. The site also overlaps with a DHS in both VU40T(-) (blue track) and 







Figure 5.6. UCSC browser screenshot for p63 ChIP at the JMJD7 gene (site 2).  
QPCR primers were selected near the JMJD7 gene to test for potential p63 binding. The 
qPCR product (mapped on to the coverage tracks) overlaps with subsequent p63 TF ChIP 
peaks in the VU40T(-) and VU147(+) cell lines (orange tracks); the data were obtained 
from the Cistrome database and are shown as a black track. The site also overlaps with a 







Figure 5.7. UCSC browser screenshot for TEAD4 ChIP (site 2).  
QPCR primers were selected ~2.2kb upstream of the KRT (keratin)-80 TSS to test for 
potential TEAD4 binding. The qPCR product (mapped on to the coverage tracks) overlaps 
with subsequent TEAD4 TF ChIP peaks in the VU40T(-) and VU147(+) cell lines (purple 
tracks); the data were obtained from the Cistrome database and are shown as a black track. 
The site also overlaps with a DHS in both VU40T(-) (blue track) and VU147(+) (pink track) 
cell lines. The remaining tracks show the outcome of subsequent ChIP-seq experiments in 
VU40T(-) and VU147(+) cells indicating binding at TEAD4 (purple tracks).  
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Each AP-1 primer set was first tested in one biological replicate of VU40T(-) 
FOSL1 and JUND ChIPs (Figure 5.8A). To assess the ChIP enrichment at the 
putative regions the ‘no DHS’ primer was used as a negative control. The data were 
normalized against the signal from an input sample and shown as ‘% of input’. The 
signal was compared to the ‘no antibody’ control sample (Figure 5.8A). ChIP 
enrichment was observed at all locations when compared to the ‘no antibody’ signal 
and as expected, enrichment was much lower at the ‘no DHS’ region. For the 
FOSL1 ChIP the observed fold change for the positive control primers above the 
‘no antibody’ sample was between 10- and 60-fold and between 3- and 7-fold in 
the ‘no DHS’ region. For the JUND ChIP the observed fold change over the ‘no 
antibody’ sample was between 8- and 50-fold and between 6- and 10-fold over the 
‘no DHS’ region for JUND ChIP. (Figure 5.8A). As enrichment was the highest 
for the PC region, this primer set was used to assess the ChIP efficiency in three 







Figure 5.8. VU40T(-) AP-1 ChIP assessed by qPCR. 
(A) Four AP-1 positive control qPCR primers were tested in VU40T(-) FOSL1 and JUND 
ChIPs. A negative control primer designed to a ‘no DHS’ region was also used. The 
positive and negative qPCR signals were assessed in the ‘no antibody’ sample to control 
for background and in the input sample to calculate the ChIP percentage input. The PC 
primer was used to assess the three biological replicates in (B) VU40T(-) and (C) 
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For each biological replicate of FOSL1 ChIP in VU40T(-) cells, binding displayed 
24.0-, 29.8- and 45.0-fold change at the PC site over the ‘no antibody’ signal and 
15.5-, 14.2-, 17.2-fold change over the ‘no DHS’ region (Figure 5.8B). For each 
replicate of JUND binding at the PC site over the ‘no antibody’ sample, the signal 
showed 11.3-, 12.3- and 15.5-fold change and 4.4-, 4.5- and 3.7-fold change over 
the ‘no DHS’ region (Figure 5.8B). In VU147(+) cells, FOSL1 enrichment over 
the ‘no antibody’ sample was 24.5-, 20.7- and 60.0-fold and 28.6-, 25.8- and 0.5-
fold over the ‘no DHS’ region in the three replicates (Figure 5.8B). JUND binding 
fold enrichment over the ‘no antibody’ sample was 13.5-, 14.0- and 50-fold and 39-
, 140- and 10-fold change over the ‘no DHS’ signal for each replicate (Figure 
5.8C). Based on data obtained from sequenced samples which displayed high 
background (not shown), a fold change of at least three over the ‘no antibody’ signal 
was set as the qPCR signal cut-off. Therefore, all three VU40T(-) ChIP biological 
replicates for FOSL1 or JUND were pooled and sequenced. For VU147(+) cells, 
only biological replicates one and two were pooled and taken for sequencing, as the 
ChIPs for replicate three did not appear to work. 
Primers were also tested for p63 and TEAD4 ChIPs. Primers for p63 sites 1 and 2 
were designed near to the TP73 and JMJD7 genes, respectively (Appendix: Figure 
6 and Figure 5.6). Primers for TEAD4 sites 1 and 2 were designed ~35kb 
downstream of the PCED1B (PC-esterase domain containing 1B) TSS and ~2.2kb 
upstream of the KRT80 TSS, respectively (Appendix: Figure 7 and 5.7). 
Each p63 primer set was tested in one biological replicate of p63 or TEAD4 ChIP 
from VU40T(-) cells. p63 ChIP fold change over ‘no antibody’ was 1.6- and 14.8-
fold for sites 1 and site 2, respectively, while fold change over the ‘no DHS’ region 
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was 2.9- and 4.8-fold, respectively (Figure 5.9A). Therefore, the p63 site 2 primer 
set was selected to assess enrichment of other p63 ChIP samples. 
VU40T(-) TEAD4 ChIP biological replicate 1 was also tested using the TEAD4 
primer sets (Figure 5.9B). TEAD4 ChIP fold change over ‘no antibody’ was 1.2- 
and 5.9-fold for TEAD4 sites 1 and 2, respectively, while fold change over the ‘no 
DHS’ region was 0.5- and 2.7-fold, respectively (Figure 5.9B). Therefore, the 
TEAD4 site 2 primer set was selected to assess enrichment of other TEAD4 ChIP 
samples. 
The remaining two p63 ChIP biological replicates for VU40T(-) cells were assessed 
by using the p63 site 2 primer set (Figure 5.9C). p63 ChIP fold change over the ‘no 
antibody’ samples was 23.0- and 6.8-fold for p63 ChIP replicates 2 and 3, 
respectively, while over ‘no DHS’ enrichment was 7.0- and 2.8-fold, respectively 
(Figure 5.9C).  
TEAD4 ChIP enrichment of VU40T(-) biological replicates two and three was 
assessed using the TEAD4 site 2 primer set (Figure 5.9D). TEAD4 fold change 
over ‘no antibody’ was 8.7- and 2.8-fold, while enrichment over the ‘no DHS’ 





Figure 5.9. QPCR was conducted to assess p63 and TEAD4 ChIP enrichment in 
VU40T(-) and VU147(+) cells. 
Two primer sets were designed to two putative binding sites in (A) p63 (p63 site 1 
and site 2) and (B) TEAD4 (TEAD4 site 1 and site 2). The ‘no DHS’ primer was 
used as a negative control. A ‘no antibody’ sample was also included to control for 
background. ChIP was conducted in three biological replicates in VU40T(-) cells 
for (C) p63 and (D) TEAD4 and three biological replicates in VU147(+) cells for 









1 2 3 1 2 3

















1 2 3 1 2 3

















1 2 3 1 2 3

















1 2 3 1 2 3


















































Therefore, for sequencing of VU40T(-) p63 ChIPs, all three biological replicates 
were quantified and combined in equal concentrations. For VU40T(-) TEAD4 ChIP 
samples, only biological replicate one showed enrichment over the negative control 
region, therefore this experiment was taken for sequencing.  
In VU147(+) cells, p63 ChIP samples were assessed by qPCR using the p63 site 2 
primer set (Figure 5.9E). p63 fold change over ‘no antibody’ was 4.4-, 48 and 8.0-
fold, respectively, while fold change over ‘no DHS’ was 8.0-, 16.0-, and 8.0-fold 
for replicates 1-3, respectively (Figure 5.9E). VU147(+) TEAD4 ChIP was 
assessed using the TEAD4 site 2 primer. TEAD4 ChIP fold change over ‘no 
antibody was 2.0-, 16.0- and 16.0-fold for replicates 1-3, respectively. TEAD4 ChIP 
fold change over ‘no DHS’ was 0.5-, 3.5- and 5.4-fold for replicates 1-3, 
respectively (Figure 5.9F). Therefore, all three VU147(+) p63 ChIP biological 
replicates were pooled and taken for sequencing, while TEAD4 replicates 2 and 3 
were pooled and sequenced. 
5.7.2 Mapping of ChIP-seq data 
The sequencing libraries were synthesised for the p63, TEAD4, FOSL1 and JUND 
ChIP samples described above and sequencing was conducted as described in 
Methods and Materials, Sections 2.9.3 and 2.12. In VU40T(-) cells, between 10,137 
and 75,970 peaks were found across the four TF ChIPs and between 7,704 and 
49,309 peaks in VU147(+) cells (Table 5.3 and Figure 5.10). p63 shows the 
highest number of binding sites in both cell lines, which could be either due to the 
widespread transcriptional regulation (as expected from cells originating from 








ChIP VU40T(-) VU147(+) 
p63 75,970 49,309 
TEAD4 10,137 11,927 
FOSL1 39,824 7,446 






Figure 5.10. UCSC screenshot of VU40T(-) and VU147(+) p63, TEAD4, FOSL1 and 
JUND ChIP-seq peaks at the TP63 gene. 
The ChIP-seq reads for p63, TEAD4, FOSL1 and JUND ChIPs conducted in VU40T(-) 
cells and VU147(+) cells were aligned to the hg19 genome and the Bigwig files were 
uploaded to the UCSC genome browser, along with the files for VU40T(-) DHS (light blue 
track) and VU147(+) (red track). The ChIP-seq peaks were called using HOMER for p63 




5.7.3 ChIP-seq pathway enrichment analysis 
HOMER (Hypergeometric Optimization of Motif EnRichment) was used to 
conduct pathway enrichment analysis for each TF ChIP-seq experiment in VU40T(-
) and VU147(+) cells, in which the closest gene was assigned to each peak, as before 
(Chapter 1, Section 3.10 and Chapter 2, Section 4.9). The top 20 pathways for each 
TF ChIP were taken for further analysis.  
In VU40T(-) cells a total of 35 pathways were over-represented and could be 
grouped into nine clusters based on TF enrichment (Figure 5.11). The largest of 
which was group (1) and consisted of 11 pathways over-represented in all four TFs. 
Six of these pathways were associated with cell adhesion and migration, including 
proteoglycans in cancer, Hippo, leukocyte transendothelial migration, adherens 
junction, RAP1 (Rap1 GTPase) signalling, myometrial relaxation and contraction 
pathways. The EGFR pathway was also highly over-represented in this group 
(Figure 5.11). Interestingly, the Hippo pathway appears highly over-represented in 
all four TFs, although the highest association is observed in the TEAD4 ChIP 
dataset. Group (2) consisted of four pathways under-represented in TEAD4 and 
included the HNSCC-related pathways WNT (wingless) and RAS (resistance to 
audiogenic seizures) signalling (Figure 5.11). Group (3) consisted of four pathways 
under-represented in p63 including the PI3K (phosphotidylinositol-3 kinase)-AKT 
(protein kinase B) signalling, 64 integrin signalling and tight junction pathways. 
Other HNSCC-related pathways were over-represented in groups (4), (5) and (7), 
which display pathways over-represented in p63/JUND, TEAD4/JUND and p63, 
respectively (Figure 5.11). These pathways included ERBB signalling, TGF 
(transforming growth factor)- and MAPK. Cancer-related pathways were also 
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over-represented in group (5) which included renal cell carcinoma and small cell 
lung cancer pathways (Figure 5.11). 
 
 
Figure 5.11. Pathway enrichment analysis of p63, TEAD4, FOSL1 and JUND ChIP-
seq in VU40T(-) cells.  
Pathway enrichment analysis was conducted, and the top 20 pathways were taken from 
each ChIP-seq experiment. The analysis revealed a total of 35 different pathways. The 
pathways were ranked by log p-value; green represents the least statistically significant 
pathways, red represents most significant and blank boxes indicate no enrichment. The 
pathways were grouped into 9 groups by TF: (1) over-represented in all (11/35; 31%), (2) 
under-represented in TEAD4 (4/35; 11%), (3) under-represented in p63 (4/35; 11%), (4) 
under-represented in TEAD4/FOSL1 (6/35; 6%), (5) under-represented in p63/FOSL1 
(3/35; 7%), (6) under-represented in FOSL1 (1/35; 3%), (7) over-represented in p63 (3/35; 
9%), (8) over-represented in FOSL1 (1/35; 3%), (9) under-represented in all (2/35; 6%).
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In VU147(+) cells, a total of 36 pathways were over-represented and could be 
grouped into seven clusters (Figure 5.12). One of the largest groups was group (1), 
which included pathways over-represented in all ChIP datasets (Figure 5.12). 
Several pathways in group (1) overlapped with those in VU40T(-) group (1) 
(pathways in cancer, proteoglycans in cancer, Hippo, EGFR, endocytosis, adherens 
junction and RAP1 signalling) (Figure 5.12). Group (2) included four pathways 
under-represented in p63, three of which were associated with cell adhesion (focal 
adhesion, ECM (extracellular matrix)-receptor interaction and ARVC pathways). 
Group (3) included six pathways under-represented in TEAD4. Interestingly, cell 
adhesion-related pathways were not present in this group. Group (4) was the second 
largest group and included nine pathways over-represented in p63/JUND, relating 
largely to immune function. Groups (5) and (6) included pathways less represented 
in the ChIP datasets, while group (7) included pathways under-represented in 





Figure 5.12. Pathway enrichment analysis of p63, TEAD4, FOSL1 and JUND ChIP-
seq in VU147(+) cells.  
Pathway enrichment analysis was conducted, and the top 20 pathways were taken from 
each ChIP-seq experiment. The analysis revealed a total of 36 different pathways. The 
pathways were ranked by log p-value; green represents the least statistically significant 
pathways, red represents most significant and blank boxes indicate no enrichment. The 
pathways were grouped into 7 groups by TF: (1) over-represented in all (11/36; 31%), (2) 
under-represented in p63 (4/36; 11%), (3) under-represented in TEAD4 (6/36; 17%), (4) 
under-represented in TEAD4/FOSL1 (9/36; 25%), (5) over-represented in FOSL1 (1/36; 




ChIP-seq pathway enrichment analysis for the four TFs revealed that over half of 
the VU40T(-) pathways (51%; 18/35) overlapped with 47% (17/36) of VU147(+) 
pathways (Figure 5.11 and 5.12). In both cell lines, all four TFs are strongly 
involved in cancer-related pathways (pathways in cancer and proteoglycans in 
cancer), cell adhesion, migration or proliferation-related pathways (Hippo, 
adherens junction and RAP1) and the EGFR pathway. In addition, in both cell lines 
the p63 TF was most involved in cell adhesion/migration/proliferation-related 
pathways (RAP1, adherens and regulation of actin cytoskeleton), as well as in 
HNSCC-related pathways RAS/MAPK and ERBB. On the other hand, p63 was less 
involved in other HNSCC-related pathways, namely PI3K/AKT. In both cell lines, 
p63 was also less involved in some of the cell-adhesion related pathways, though 
these were distinct in the two cell lines; tight junction and 64 integrin signalling 
pathways in VU40T(-) cells and focal adhesion and ECM-receptor interaction 
pathways in VU147(+) cells (Figure 5.11 and 5.12).  
Regarding TEAD4 ChIP pathway enrichment, in both cell lines the TEAD4 TF was 
largely involved in pathways associated with cell adhesion, migration and 
proliferation, which included the Hippo, focal adhesion and adherens junction 
pathways (Figure 5.11 and 5.12). TEAD4 was less involved in WNT, RAS/MAPK 
and regulation of actin cytoskeleton in both cell lines. In addition, TEAD4 was less 
involved in pathways associated with metabolism such as, insulin signalling, 
glycerolipid metabolism, vitamin A and carotenoid metabolism in VU40T(-) cells 
and insulin signalling and prolactin signalling in VU147(+) cells (Figure 5.11 and 
5.12). 
The AP-1 factors were associated in both cell lines, largely with cell adhesion 
pathways (Hippo, adherens junction, RAP1, 64 integrin signalling pathways), as 
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well as the EGFR/PI3K/AKT pathway. Furthermore, the AP-1 factors were less 
involved in MAPK in both cell lines, while FOSL1 was less involved in ERBB, 
TGF- in both cell lines and WNT in VU147(+) cells. Interestingly, in both cell 
lines JUND is more associated than FOSL1 with the Hippo and EGFR signalling 
pathways (Figure 5.11 and 5.12). 
Furthermore, many of the same pathways overlapped with the DHS HNSCC 
pathways. In VU40T(-) cells, 49% of ChIP pathways overlapped with DHS 
pathways (Figure 5.11 and 3.16). In VU147(+) cells, 43% of pathways overlapped 




5.7.4 Transcription factor motif analysis of p63, TEAD4 and AP-1 
ChIP-seq data 
De novo motif analysis was carried out using VU40T(-) ChIP-seq datasets for p63, 
TEAD4, FOSL1 and JUND for which between 22 and 23 de novo motifs were 
predicted. The top five TF motifs are shown for each dataset (Figure 5.13). In the 
p63 ChIP-seq dataset, the most highly enriched motifs were p63 and AP-1, 
HMBOX (homeobox)-HES, TEAD and RUNX (Figure 5.13). In the FOSL1 and 
JUND ChIP-seq datasets the most enriched motif was AP-1; other motifs in the 
FOSL1 dataset were CEBP (CCAAT Enhancer Binding Protein)/HLF (hepatic 
leukemic factor), ETS (E twenty-six transcription factor), RUNX and TEAD, while 
in JUND ChIP data the motifs were ETS, GRHL (grainyhead-like protein), TEAD 
and RUNX (Figure 5.13). In the TEAD4 ChIP-seq motif dataset, the AP-1 motif 
was the most enriched, followed by TEAD, p53/p63, EGR (early growth response) 
and RUNX (Figure 5.13). 
Over half (56.9%) of the p63 ChIP-seq peaks were found to be p63-specific and did 
not show overlap with AP-1 or TEAD4 peaks. De novo motif analysis was 
conducted on the p63-specific peaks to reveal the p63 motif to be the most enriched, 
followed by TEAD, ERG (ETS related gene), AP-1 and KLF5 (Figure 5.13). 
In summary, the ChIPs for the four TFs indicate high enrichments for respective TF 
motifs as well as common enrichment for AP-1, TEAD and RUNX motifs. 
However, they also show specificity: HMBOX/HES (hairy and enhancer of split) 
for p63, CEBP/HLF for FOSL1, GRHL for JUND and EGR for TEAD4 (Figure 
5.13). In addition, AP-1 TFs associate more with the ETS family motif, while 
p53/p63 is not present in the top five motifs. The presence of the TEAD motif in 
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the p63-specific peaks, but lack of peak overlap may be due to the poorer quality of 
TEAD4 immunoprecipitation.  
 
 
Figure 5.13. TF motif analysis of VU40T(-) ChIP-seq peaks. 
ChIP-seq was conducted in p63, FOSL1 and JUND to obtain three sets of peaks 
representing TF binding events. A fourth dataset was formed by analysing p63 peaks (p63 
only) which did not overlap with any of the remaining ChIP-seq datasets for FOSL1, JUND 
and TEAD4. De novo motif analysis was conducted in each dataset using the 
‘findMotifsGenome’ script within HOMER. A total of 22, 22, 22, 23 and 24 motifs were 
predicted for p63, FOSL1, JUND, TEAD4 and p63 only ChIP-seq peaks, respectively. The 
top 5 motifs were ranked by percentage of target sequences that contained them. The size 
of the circles represents p-value. 
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5.7.5 Analysis of transcription factor binding overlap 
To determine whether the TF motif co-occurrence reflects physical co-binding 
between the TFs, overlap between ChIP peaks was investigated in both cell lines. 
This was achieved by using HOMER to create a merged-ChIP peaks dataset which, 
similarly to the merged-DHS dataset, indicates regions of overlap. In VU40T(-) and 
VU147(+) cells it was found that the majority of JUND peaks overlap with p63 
peaks (58% and 62%, respectively), while only 21% and 10% of p63 peaks overlap 
with JUND, respectively (Figure 5.14A and B). This pattern was also observed in 
the FOSL1/p63 overlap data where in VU40T(-) cells 53% of FOSL1 peaks 
overlapped with 28% of p63 peaks, while in VU147(+) cells, 56% of FOSL1 peaks 
overlapped with 9% of p63 peaks (Figure 5.14A and B). Between both of the AP-
1 factors, in VU40T(-) cells, 36% of FOSL1 peaks overlapped with 51% of JUND 
peaks and in VU147(+) cells, 50% of FOSL1 peaks overlapped with 49% of JUND 
peaks (Figure 5.14A and B). Next, the overlap between TEAD4 and p63 was 
investigated. In VU40T(-) cells, 2% of p63 peaks overlapped with 18% of TEAD4 
peaks, while in VU147(+) cells 68% of TEAD4 peaks overlapped with 17% of p63 
peaks (Figure 5.14A and B). Finally, the overlap between TEAD4 and AP-1 was 
investigated in VU40T(-) cells and it was found that 8% of TEAD4 peaks overlap 
with 2% of FOSL1 peaks, while 7% of TEAD4 peaks overlap with 3% of JUND 





Figure 5.14. Overlap between p63, JUND, FOSL1 and TEAD4 ChIP-seq peaks in 
VU40T(-) and VU147(+) cells. 
P63 and JUND peak location was investigated to find percentage overlap between TF binding in (A) 
VU40T(-) cells: 75,970 p63 ChIP-seq peaks and 27,537 JUND peaks were mapped; 21% of p63 
peaks overlapped with 58% of JUND peaks and in (B) VU147(+) cells: 43,309 p63 peaks and 7,704 
JUND peaks were mapped; 10% of p63 peaks overlapped with 62% of JUND peaks. p63 and FOSL1 
peak location was investigated in (C) VU40T(-) cells: 75,970 p63 peaks and 39,824 FOSL1 peaks 
were mapped; 28% of p63 peaks overlapped with 53% of FOSL1 peaks and in (D) VU147(+) cells: 
43,309 p63 peaks and 7,446 FOSL1 peaks were mapped; 9% of p63 peaks overlapped with 56% of 
FOSL1 peaks. JUND and FOSL1 peak location was investigated in (E) VU40T(-) cells: 27,537 
JUND peaks and 39,824 FOSL1 peaks were mapped; 51% of JUND peaks overlapped with 36% of 
FOSL1 peaks and in (F) VU147(+) cells: 7,704 JUND peaks and 7,446 FOSL1 peaks were mapped; 
49% of JUND peaks overlapped with 50% of FOSL1 peaks. TEAD4 and p63 peak location was 
investigated in (G) VU40T(-) cells: 75,970 p63 peaks and 10,137 TEAD4 peaks were mapped; 2% 
of p63 peaks overlapped with 18% of TEAD4 peaks and in (H) VU147(+) cells: 49,309 p63 peaks 
and 11,927 TEAD4 peaks were mapped; 17% of p63 peaks overlapped with 68% of TEAD4 peaks. 
In VU40T(-) cells, (I) FOSL1 peak overlap with TEAD4 peaks was investigated: 39,824 FOSL1 
and 10,137 TEAD4 peaks were mapped; 2% of FOSL1 peaks overlapped with 8% of TEAD4 peaks 
and (J) 27,537 JUND peaks and 10,137 TEAD4 peaks were mapped: 3% of JUND peaks overlapped 
with 7% of TEAD4 peaks.  
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The distribution of ChIP peaks across the four TFs was analysed in VU40T(-) cells 
to investigate the frequency of binding events (Figure 5.15). Due to similar 
involvement of the FOSL1 and JUND TFs, the peaks for FOSL1 and JUND were 
combined and called AP-1. Analysis of peak distribution revealed that nearly half 
(47.6%) of peaks were bound by p63 only (Figure 5.15). AP-1 only bound peaks 
were 15.1%, while 26.2% of peaks were bound by p63 and AP-1. It was also 
observed that a small percentage of peaks bound either only TEAD4, TEAD4/AP-
1 or TEAD4/p63 (1.0%, 0.3% and 0.7%, respectively). However, when all four 
factors are bound, the percentage of peaks increases to 9.1% (Figure 5.15). 
Interestingly, the frequency of TEAD4 binding increases the most in the presence 
of both p63 and both AP-1 factors. Therefore, the localisation of TEAD4 binding 
with FOSL1, JUND and p63 was investigated in VU40T(-) cells by analysing peak 
location proximity; p63, FOSL1 and JUND binding was investigated 3kb upstream 
and downstream of each TEAD4 peak. The analysis revealed that indeed the 









Figure 5.15. ChIP peak distribution of p63, TEAD4 and AP-1 peaks in VU40T(-) cells. 
The ‘mergepeaks’ function in HOMER was used to investigate peak location to analyse 
the distribution of ChIP peaks in p63, TEAD4 and AP-1 (JUND, FOSL1). A merged-ChIP 
peaks dataset was created to count distinct binding events, as well as co-binding. A total of 
90,902 peaks were identified for p63 (43,236 peaks), TEAD4 (901 peaks) and AP-1 




















Figure 5.16. Visual representation of co-localisation of TEAD4 binding in VU40T(-) 
peaks with p63, FOSL1 and JUND peaks. 
By using the ‘AnnotatePeaks’ tool in HOMER, TEAD4 peaks (centre of peaks visualized 
by red vertical line) were annotated 3kb upstream and downstream with (A) p63, (B), 
FOSL1 and (C) JUND reads (indicated by yellow). The resulting matrix file was clustered 
using the GeneCluster 3.0 program and the following settings: ‘log transform data’, ‘center 
genes’, ‘Cluster’, ‘Correlation (centered)’ and ‘Centroid linkage’. Heatmap images were 





In silico analysis of genetic alterations in the TCGA (The Cancer Genome Atlas) 
panel of HNSCC (head and neck squamous cell carcinoma) tumours revealed the 
TP63 gene to be one of the most frequently altered genes, agreeing with previously 
published data [66-70, 72]. Further to this, our data revealed that nearly 50% of the 
HNSCC cell line regulatory network identified by chromatin immunoprecipitation-
sequencing (ChIP-seq) is regulated by p63. Amplification of the p63 gene has been 
linked to HNSCC tumours by several studies [12, 13, 16, 257, 258]. p63 
overexpression can lead to inhibition of epithelial differentiation and uncontrolled 
self-renewal of keratinocyte cells, which could lead to cancers such as HNSCC 
[16]. Therefore, deregulation of p63 may be one of the mechanisms by which the 
HNSCC cell lines investigated here function. 
Upon the analysis of the p63, FOSL1 and JUN VU40T(-) and VU147(+) ChIP-seq 
datasets, more peaks were called in the VU40T(-) ChIP samples compared to the 
VU147(+) samples. A reason for this could simply be that the TFs bind more 
frequently in VU40T(-) cells than in VU147(+) cells. This could suggest differential 
expression; however, our gene expression data indicates that these TFs are 
expressed at similar levels. In addition, the number of DNase I-hypersensitive sites 
were similar in both cell lines, indicating that the same number of open sites are 
available for TF binding to occur. Technical differences may be a more likely 
explanation for the discrepancy in the number of ChIP-seq peaks. For example, 
inefficiency of the formaldehyde cross-linking step can lead to fewer protein-DNA 
complexes being preserved. As a result, these regions are sequenced less frequently 
within the cell population, leading to fewer peaks being called. To overcome this, 
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the sequencing depth could be increased to improve the mapping of such sites. A 
further reason may be higher background in the VU147(+) input sample compared 
to the VU40T(-) input, which could lead to the identification of fewer peaks in the 
ChIP samples upon normalisation to input. It could be argued that perhaps 
VU147(+) cells exhibit greater genomic instability compared to VU40T(-) cells, 
leading to the discrepancy in ChIP-seq peak numbers. However, all ChIP samples 
are normalised against a corresponding input sample to control for genome 
amplifications and deletions. In addition, a false discovery rate is applied to allow 
control over false positive peak predictions. Therefore, without conducting further 
experiments, this method of analysis may not be suitable for comparison of specific 
TF binding sites between different ChIP samples and cell lines. However, in order 
to investigate genome-wide processes by, for example, pathway enrichment 
analysis, this method has been useful in highlighting processes relevant to HNSCC, 
as similar pathways were identified in both cell types, as discussed next. 
Our initial hypothesis of AP-1 and TEADs being involved in HNSCC cell line gene 
regulation was also confirmed by our ChIP-seq data. Gene expression analysis by 
qPCR revealed expression levels of FOSL1 and JUND to be among the highest. In 
addition, FOSL1 was the most amplified AP-1 gene in the TCGA cohort. In 
HNSCC cell lines, FOSL1 and the JUN family of proteins have previously been 
found to promote expression of the IL (interleukin)-8 protein, which can promote 
tumour growth, invasion and metastasis [255, 323]. To support these findings, our 
AP-1 ChIP-seq data reveal the involvement of pathways associated with cell 
growth, migration and invasion (Hippo, adherens junction, RAP1 signalling and 
64 integrin signalling pathways). Mechanisms by which AP-1 may induce pro-
tumourigenic effects such as invasion and cell growth have been reported 
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previously. In mouse models it has been shown that a reduction in Jun and Fosl1 
protein expression through knockdown of the histone demethylase enzyme Kdm4a 
can inhibit cell invasion and tumour growth [252]. In addition, JUNB knockout in 
HNSCC cell lines has been shown to reduce cell invasion and migration [253]. 
Further to this, published studies have reported FOSL1 protein overexpression in 
HNSCC cells to be associated with processes such as cell adhesion, proliferation 
and migration through activation of the PI3K (phosphotidylinositol-3 kinase)/AKT 
pathway [254, 256]. Our data supports this finding, as AP-1 ChIP-seq revealed 
strong over-representation of the PI3K/AKT pathway.  
In summary, our AP-1 ChIP-seq and gene expression data in HNSCC cell lines, as 
well as analysis of genetic alterations in the TCGA HNSCC tumours, agree on the 
involvement of AP-1 in HNSCC. This is also supported by previously published 
data which demonstrates the role of AP-1 in tumour growth, invasion, migration 
and metastasis. 
One of the mechanisms by which the Hippo pathway has been recognized in 
HNSCC is by associations between YAP (yes-associated protein) expression and 
HNSCC tumours [87, 324, 325]. For example, YAP protein expression has been 
shown to correlate well with HNSCC tumour grade and metastasis [87]. 
Furthermore, overexpression of the YAP1 gene has been reported to positively 
correlate with poor prognosis in HNSCC patients [324]. The analysis of the TCGA 
cohort showed that the YAP1 gene was altered in 17% of tumours and even more 
frequent upregulation was observed for WWTR1 (22%), which encodes the TAZ 
(tafazzin) protein. The functions of YAP and TAZ have been investigated in kidney 
epithelial cells. Read outs such as transcription of Hippo target genes, cell size and 
migration were measured and it was found that YAP is largely able to compensate 
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for the loss of TAZ [326]. Interestingly, in HNSCC, the alterations in YAP and 
TAZ appear to be largely mutually exclusive, and at least 39% of HNSCC tumours 
are characterized by an alteration in one of the genes. Therefore, it may be that YAP 
could be a more effective therapeutic target than TAZ. In addition to genetic 
alterations of YAP1 and WWTR1, the TEAD4 gene was altered in 10% of the TCGA 
cohort and upregulation of the TEAD4 transcript was observed in our HNSCC cell 
lines compared to the non-tumourigenic OKF6 cells. This agrees with published 
data in which upregulation of both TEAD4 RNA and protein levels have been 
observed in HNSCC cell lines compared to primary human normal oral keratinocyte 
(HNOK) cells [316]. Furthermore, in the same study, TEAD4 protein 
overexpression was also observed in HNSCC tissues compared to surrounding 
normal tissue [316]. Therefore, genetic amplifications occur to a large degree in the 
Hippo pathway, deregulating expression of Hippo target genes and affect 
transcriptional regulators (YAP and TAZ) more than TFs themselves (TEADs). 
As well as investigations into YAP and TEAD separately, their association with 
each other has also been established by previous studies. For example, using TCGA 
data, it has been shown that both TEAD4 RNA levels and YAP protein, correlate 
well with HNSCC tumour onset and levels increase with higher tumour grade and 
stage [327]. Furthermore, in HNSCC cell lines it was shown that TEAD knockdown 
can block activation of YAP target genes, thereby slowing cell growth [316, 328]. 
Another study reported YAP/TAZ target genes to be involved in HNSCC tumour 
progression, among which were, TEAD1, TEAD4, ETS1 and JUN [327]. Therefore, 
in recent years, the involvement of the Hippo pathway at the transcriptional level 
in HNSCC has been demonstrated, agreeing with the observations in our data. 
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To support the role of YAP and TEAD in tumour progression, our TEAD4 ChIP-
seq pathway enrichment analysis revealed that TEAD4 forms a regulatory network 
involved in the Hippo, focal adhesion and adherens junction pathways. Disruption 
of cell-cell and cell-ECM (extracellular matrix) junctions have been demonstrated 
to be a hallmark of cell invasion, metastasis and tumour progression [329]. 
Therefore, overall, our ChIP-seq data strongly support the involvement of p63, AP-
1 and TEAD in HNSCC and in enhancing HNSCC-related signalling pathways. 
The analysis also shows large degree of overlap and therefore potential co-
regulation within p63/AP-1/TEAD regulatory network. 
Our ChIP-seq data have demonstrated significant AP-1 and p63 co-binding, in 
addition, the data reveals the AP-1 motif to be enriched in p63 ChIP-seq motif 
analysis. This has also been observed by Saladi et al., 2017, where p63 ChIP-seq 
data conducted in a laryngeal SCC cell line revealed the FOSL1 motif to be amongst 
the top enriched motifs [138]. This finding is supported by Si et al., 2016, in a 
different laryngeal SCC cell line, TF motif analysis of p63 ChIP-seq data revealed 
high enrichment of the AP-1 motif [330]. Moreover, Saladi et al., 2017 
demonstrated by luciferase reporter assays the induction of the AP-1 response 
element by ΔNp63α and upregulation of the FOSL1 gene by microarrays [330]. 
Furthermore, this study also used three publicly available microarray datasets of a 
total 125 HNSCC tumour samples and conducted in silico analysis. A statistically 
significant correlation was found between TP63 and JUNB/FOSL1 gene expression 
[330]. 
ChIP-seq data also revealed a particularly strong overlap of TEAD4 peaks with p63 
peaks and revealed enrichment of TEAD and p63 motifs in both datasets, indicating 
association between the TFs. Published data investigating the role of TEAD and 
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p63 is lacking, however it has been demonstrated that TEAD can bind to the Np63 
promoter to induce its repression [331]. Associations between p63 and YAP have 
also been reported in HNSCC. For example, the Np63 protein can directly bind 
the YAP1 promoter to inhibit its expression [138, 139]. Furthermore, a study 
conducted in a laryngeal SCC cell line reports that p63 knockdown can reduce 
YAP-dependent oncosphere formation [138]. While on the other hand, it has been 
demonstrated that YAP can promote the degradation of p63 in HNSCC cells [87, 
332, 333]. In addition, YAP/TEAD interactions have been commonly associated 
with EMT (epithelial to mesenchymal transition), cell transformation and cell 
growth, which are processes highlighted by our pathway enrichment analyses [272, 
334, 335]. Therefore, published data demonstrates that p63, YAP and TEAD can 
influence each other’s expression, moreover the proteins can work together to 
promote HNSCC tumour progression. It may be that these effects are induced by 
YAP/TEAD interactions, however it must be considered that TEAD is not the only 
transcription partner for YAP, as KLF (Krüppel-like factor)-4, RUNX (runt-related 
transcription factor) and p73 can also interact with YAP [272].  
Furthermore, our data revealed overlap between TEAD4 and AP-1 binding, in 
addition, motif analysis of AP-1 and TEAD ChIP-seq data, showed enrichment of 
both AP-1 and TEAD motifs in both ChIP experiments. This finding is supported 
by investigations conducted by other groups. Lui et al., 2016 conducted motif 
analysis of JUND and FOSL1 ChIP-seq peaks in cell lines derived from four 
different cancers: lung adenocarcinoma, colorectal carcinoma, endometrial 
adenocarcinoma and neuroblastoma. The analysis revealed the TEAD motif to be 
among the top most enriched motifs in the JUND and FOSL1 peaks [274]. Further 
to this, co-regulation between YAP and JUND has previously been assessed using 
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reporter assays. It was found in a colorectal carcinoma cell line that YAP/TAZ 
knockdown, but not JUND knockdown resulted in decreased TEAD4 expression, 
while expression levels of Hippo target genes ANKRD1 (Ankyrin repeat domain 
containing) and DOCK9 (dedicator of cytokinesis 9) significantly decreased after 
TEAD and JUND inhibition [274]. Another study demonstrated by reporter assays, 
the association of TEAD and AP-1 with the transcriptional regulation of the YAP 
target genes, CTGF and ANKRD1 [272]. This confirmed co-regulation between 
TEAD and AP-1. There is also evidence highlighting a central role for TEAD in 
YAP/TEAD/AP-1-mediated gene regulation. For example, using breast cancer 
cells, transfection of YAP and JUN/FOS dimers together can increase 
mammosphere size, while AP-1 alone has no effect. This phenotype was dependent 
on TEAD, as mutated TEAD yielded no change in phenotype [272]. Therefore, 
TEAD seems to be central to transcriptional and phenotypic change mediated by 
YAP/TEAD/AP-1. Altogether our data and published evidence indicates co-
regulation between AP-1 and TEAD4 in HNSCC cell lines and other cancers. 
In addition to evidence of co-regulation between TEAD and AP-1, TEAD/AP-1 co-
binding at regulatory elements has been observed. A study showed that in a lung 
adenocarcinoma cell line nearly 90% of TEAD4/AP-1 (FOSL1 and FOSL2) peaks 
overlapped with active enhancer marks (H3K4me1 and H3K27ac) [274]. This 
finding supports our data which demonstrated TEAD4 and AP-1 motif enrichment 
in distal DHSs (DNase I hypersensitive sites) of the HNSCC cell lines. Further 
strengthening this finding, co-regulation between TEAD and AP-1 TFs has also 
been reported in breast carcinoma cells at active enhancers [272]. JUN ChIP-seq 
experiments revealed that the vast majority of JUN peaks overlapped with 
YAP/TAZ/TEAD4 peaks and most were found at active enhancers associated with 
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the regulation of cell proliferation [272]. Altogether, the data suggests co-regulation 
and perhaps interaction between TEAD and AP-1 at regulatory elements to drive 
transcription of Hippo target genes. In line with this, our pathway enrichment 
analysis revealed a subset of pathways involving the TEAD4, FOSL1 and JUND 
TFs, which were largely related to cell adhesion pathways, including the Hippo 
pathway [88, 272, 274].  
In summary, our data and that of others have highlighted AP-1, p63 and TEAD as 
being important epithelial transcriptional regulators, and in the context of HNSCC 
are involved in processes such as tumour growth, invasion, migration and 
metastasis. However, published evidence report associations between two of the 
three factors investigated and data reporting associations between all three TFs is 
lacking. In the case of TEAD4, our data indicates a stronger association between 
the three TFs, than between one or two, as TEAD4 binding events increase by nine-
fold when all three TFs bind together compared to one or two TFs binding in the 
case of TEAD4 (Figure 5.17).  
Although the three TF groups appear to be key for HNSCC tumour and/or cell line 
regulation, there are possibly other factors contributing to this network. Analysis of 
p63-specific ChIP-seq peaks demonstrated enrichment of the KLF5 motif. 
Associations between p63 and KLF5 have previously been identified and found to 
induce tumour-promoting effects. For example, KLF5 overexpression has been 
reported by EC (enhancer cluster) activation in HNSCC cell lines, leading to 
activation of cancer-related genes, including TP63 [179]. Agreeing with this, our 
RNA-seq data reveals that KLF5 was the most highly expressed KLF gene in all 
four HNSCC cell lines, on the other hand, KLF5 was overexpressed more in the 
RNA-seq data for the non-tumour HOK (human oral keratinocyte) cells (data not 
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shown). However, in mice studies of epidermal keratinocyte cells, Klf5 
overexpression studies have shown to decrease levels of TAp63 and Np63 leading 
to abnormal epithelial stratification and hypoproliferation of keratinocytes [336]. 
This contradiction in findings may be due to the study being conducted during early 
development, during which Klf5 levels are restricted and cell maintenance can be 
taken over by other members of the Klf family [337].  
It appears that TEAD4 is an important part of the described regulatory network, as 
evidenced by visual representation of p63, FOSL1 and JUND co-localisation with 
TEAD4 (Figure 5.16), as well as TCGA data highlighting that nearly 70% of 
HNSCC tumours contain an alteration in the gene of a Hippo transcriptional 
regulator (YAP, WWTR1, TEAD1-4) (Figure 5.2). Therefore, the Hippo pathway 
may present a therapeutic target in HNSCC, which is explored in the next chapter. 
A limitation of this chapter is the ChIP-seq analysis of one oral SCC cell line 
(VU40T(-)), namely the TF motif analysis and the investigation of the AP1-p63-
TEAD4 network. Further work could include the analysis of the VU147(+) ChIP-
seq datasets for p63, FOSL1, JUND and TEAD4 ChIPs. In addition, the use of 
HNSCC tumour samples or, as mentioned before, increasing the number of oral 
SCC cell lines investigated would strengthen the data. Furthermore, determining 
the samples’ HPV status could allow for the identification of differences in the AP1-





Figure 5.17. Summary of p63, TEAD4 and AP-1 (FOSL1/JUND) binding events. 
In environments of low cell density, the Hippo pathway is switched off, leading to 
dephosphorylation of the core kinases (MST1/2 and LATS1/2), the scaffold proteins 
(SAV1 and MOB1A/1B) and YAP/TAZ [88, 92]. YAP/TAZ are then free to translocate to 
the nucleus and activate gene transcription of Hippo target genes such as CTGF, which is 
involved in processes such as cell proliferation and growth [88, 92]. Our data reveals that 
the total number of ChIP-seq binding events involving TEAD4/FOSL1/JUND (AP-1) were 
305, p63/TEAD4 were 657, TEAD4 only were 901 and p63/TEAD4/AP-1 were 8,274. Our 
ChIP-seq data indicates a stronger association between three TFs, than between one or two, 
as evidenced by the increase of TEAD4 binding events by nine-fold in the presence of AP-
1 and p63. Therefore, it may be that p63, TEAD4, FOSL1 and JUND can regulate Hippo 




CHAPTER 6: INVESTIGATION OF THE 
HIPPO PATHWAY AS A POTENTIAL 
THERAPEUTIC TARGET IN HNSCC 
6.1 Introduction 
The previous chapters have highlighted the p63, AP (activator protein)-1 and TEAD 
(TEA domain transcription factor)-4 transcription factors (TFs) to be important in 
the function of our HNSCC (head and neck squamous cell carcinoma) cell lines. In 
addition, the TEAD4 TF has been observed to be important to the HNSCC 
regulatory network. Furthermore, the discussions of the previous two results 
chapters have described published data on the role of the Hippo pathway in cell 
growth and proliferation in HNSCC cells [88, 92]. In line with this, a potential 
therapy for HNSCC may be the pharmacological disruption of the Hippo pathway, 
as discussed next. 
6.1.1 Therapeutic targets of the Hippo pathway 
In cancer cells, several compounds have previously been identified to activate the 
Hippo pathway, promoting phosphorylation of its components and inhibiting 
transcription of Hippo target genes. This resulted in decreased cell growth and 
proliferation [92, 302, 303]. The compounds can be categorised into three main 
groups based on where in the pathway they cause their effect: (1) activators of 
Hippo kinases (MST (macrophage stimulating)-1/2 and LATS (large tumour 
suppressor protein kinase)-1/2), (2) activators of transcription mediator proteins 
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Figure 6.1. Druggable targets of the Hippo pathway. 
Activators of the Hippo pathway can be classed into four main groups: (i) MST1/2 activators 
promote MST1/2 phosphorylation: QLT0267 inhibits ILK1 and statins inhibit Rho GTPases, (ii) 
LATS1/2 activators promote LATS1/2 phosphorylation: statins inhibit Rho GTPases, Y27632 
inhibits ROCK and latrunculin inhibits F-actin and, (iii) YAP/TAZ activators promote YAP/TAZ 
phosphorylation: dasatinib inhibits the YES kinase protein, auranofin and XAV939 promote 




Figure 6.2. Druggable targets of the Hippo pathway and their mechanisms. 
Activation of GPCRs (G-protein coupled receptors) leads to activation of Rho GTPases and in turn ROCK. ROCK has a role in F-actin assembly and F-actin monomers can 
inhibit LATS1/2 phosphorylation allowing YAP/TAZ nuclear localisation. Binding of growth factors to receptor tyrosine kinases can activate the PI3K/ILK/AKT (protein 
kinase B) pathway. PI3K can phosphorylate ILK, which then phosphorylates AKT. AKT then phosphorylates a site on MST1/2 which can block its kinase activity. Energy 
stress activates the AMPK kinase, which phosphorylates AMOTL, which in turn phosphorylates YAP/TAZ. AMOT proteins can bind to and sequester phosphorylated 
YAP/TAZ at tight junctions. The YES protein kinase phosphorylates YAP/TAZ promoting nuclear localisation to initiate gene transcription. On the other hand, CDK1 
phosphorylates YAP/TAZ to promote its cytoplasmic retention. 
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Many of the compounds are able to disrupt the Hippo pathway through interference 
of the cytoskeletal network. For example, an activator of MST1/2 called QLT2067, 
functions by inhibiting ILK1 (integrin-linked kinase 1) [303] (Figure 6.1). ILK1 is 
part of the PI3K (phosphotidylinositol-3 kinase)/ILK/AKT axis where PI3K can 
phosphorylate ILK1, which in turn phosphorylates AKT leading to phosphorylation 
of a MST1/2 site, inhibiting its kinase activity [338-340] (Figure 6.2). A second 
type of MST1/2 inhibitor exploits mechanical ECM (extracellular matrix) stress as 
being a trigger of the Hippo pathway. Rho (rhodopsin) GTPases and ROCK (Rho-
associated coiled-coil containing protein kinase) are required for assembly and 
disassembly of actin filaments during ECM stress [341] (Figure 6.2). To achieve 
this, Rho GTPase and ROCK can inactivate LATS1/2 and MST1/2 stimulated by 
an upstream cholesterol synthesis pathway [342]. Drugs such as statins can disrupt 
this process by inhibiting Rho GTPases leading to activation of MST1/2 and 
LATS1/2, while a compound called Y27632 can inhibit ROCK, which promotes 
LATS1/2 phosphorylation [92, 302, 303] (Figure 6.1 and 6.2). A third drug called 
latrunculin can bind and inhibit polymerisation of F-actin monomers which 
normally inactivate LATS1/2 [92, 302, 303] (Figure 6.1 and 6.2).  
Compounds which target YAP/TAZ exert their effect by promoting YAP/TAZ 
phosphorylation and cytoplasmic retention. Therapeutic activators of YAP include 
dasatinib which can inhibit the YES kinase protein (Figure 6.1 and 6.2). YES 
phosphorylates a YAP tyrosine site, which promotes YAP nuclear localisation [302, 
303, 342, 343]. A second mechanism by which YAP/TAZ can be inhibited is by 
stabilisation of a family of tight junction scaffold proteins called AMOT 
(angiomotin) (AMOT, AMOTL1 and AMOTL2). AMOT proteins can sequester 
YAP/TAZ to tight junctions and prevent YAP/TAZ nuclear localisation and 
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activate LATS1/2 phosphorylation [303] (Figure 6.2). Two compounds (Auranofin 
and XAV939) can promote the stabilisation of AMOT proteins thereby preventing 
translocation of YAP/TAZ to the nucleus [303, 344] (Figure 6.1). Metformin 
treatment can result in energy stress, leading to activation of AMP kinase (AMPK) 
which in turn phosphorylates AMOTL, promoting YAP/TAZ cytoplasmic retention 
[303] (Figure 6.1 and 6.2). Taxol can activate cyclin dependent kinase 1 (CDK1), 
which phosphorylates YAP, promoting its cytoplasmic retention, while 
phosphorylation of TAZ promotes its degradation [303, 345] (Figure 6.1 and 6.2).  
The third group of compounds function to disrupt YAP/TAZ/TEAD interactions. 
Verteporfin (VP) is an FDA (food and drug administration) approved 
photosensitizer used in the treatment of macular degeneration, but it has also been 
found that VP can disrupt the binding of YAP to TEAD [346-350]. VP has been 
shown to reduce nuclear YAP levels and increase levels of 14-3-3, which sequesters 
YAP/TAZ to adherens junctions and targets it for degradation [303, 342, 343, 351] 
(Figure 6.1 and 6.2). In addition, it has been shown that VP can directly bind to 
YAP to disrupt its interaction with TEAD [348, 349, 352]. Cyclic peptides have 
also been designed to specifically inhibit YAP/TEAD interaction. Zhou et al. report 
a YAP-like peptide, which binds to TEAD blocking YAP/TEAD interaction [353] 
(Figure 6.1 and 6.2). 
6.1.2 Cross-talk between the Hippo and EGFR pathways 
In HNSCC, EGFR (epidermal growth factor receptor) overexpression is observed 
in up to 90% of HNSCC tumours [36, 70, 91]. However, despite EGFR 
overexpression being observed in the majority of HNSCC tumours, only 10-20% 
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of patients respond to treatment with cetuximab, a monoclonal antibody, which 
binds and inhibits the EGFR ligand-binding domain [109, 354].  
Investigations of our cell lines and in silico analysis of TCGA (The Cancer Genome 
Atlas) primary HNSCC tumours have highlighted both the Hippo pathway and 
EGFR to be significantly overexpressed. Furthermore, as the previous chapters 
have demonstrated, the TEAD4 TF is closely involved in other elements of the 
regulatory network, including those regulating EGFR response. Therefore, it was 
hypothesised that investigations into Hippo/EGFR pathway cross-talk may offer an 
approach to attenuate cetuximab-resistance. To support this hypothesis, a study has 
described a feedback loop between the EGFR and Hippo pathways in cervical SCC 
[355]. The study reported that constitutively active or overexpressed YAP led to 
overexpression of the EGFR ligands, AREG (amphiregulin), EGFR and TGF 
(transforming growth factor)- (tumour growth factor ) and treatment with TGF-
 or AREG resulted in activation of EGFR/PI3K/MAPK and inactivation of the 
Hippo pathway through EGFR phosphorylation and YAP dephosphorylation, 
respectively [355]. This resulted in increased migration and proliferation of cervical 
cancer cells, suggesting a positive feedback loop between the EGFR and Hippo 
pathways [355]. Additionally, co-treatment of cervical SCC cells with AG1478 
(EGFR tyrosine kinase inhibitor) and VP resulted in inhibition of colony formation 
and reduction in levels of AREG [355]. Subsequent to the initiation of this PhD 
project, cross-talk between the Hippo and EGFR pathways has also been observed 




Our data and published data suggest an interaction between the Hippo and EGFR 
pathways. As HNSCC patients often display considerable cetuximab resistance, the 
primary aim of this chapter was to investigate the effect of Hippo inhibition in 
HNSCC cells. The secondary aim was to observe whether disruption of both the 
Hippo and EGFR pathways could attenuate cetuximab resistance.  
6.2 The effect of Verteporfin (VP) on VU40T(-) and 
VU147(+) HNSCC cell lines 
The first experiment was designed to examine whether disruption of the Hippo 
pathway can affect HNSCC cell line viability. For these experiments, verteporfin 
(VP) was used, as it offers the advantage of disrupting the Hippo pathway at the 
transcription level. 
6.2.1 The effect of VP treatment on HNSCC cell line viability 
A cell viability assay was conducted in VU40T(-) cells to find the most effective 
VP treatment conditions. The cells were treated with vehicle and a serial dilution of 
eight concentrations of VP between 0.72µM and 0.00563µM (Figure 6.3). The 
absorbance levels, which are proportional to the metabolic activity of the cells, were 
measured after 24, 48, 72 or 96hrs of VP treatment and the values were normalized 





Figure 6.3. VP treatment reduces VU40T(-) cell viability in a dose-dependent manner. 
VU40T(-) cells were treated with vehicle (DMSO), 0.72, 0.36, 0.18, 0.1, 0.05, 0.023, 0.011 
or 0.00563µM of VP. Absorbance levels were measured every 24hrs for 96hrs. A 
significant reduction in cell viability was observed at 72hrs and 96hrs post-treatment. The 
error bars represent SEM of biological triplicates. Statistical significance was calculated 
using an unpaired t-test (*P<0.05, **P<0.005, ***P<0.0005). 
 
 
After 24 and 48hrs of VP treatment there was little observable effect on cell viability 
even at the highest concentration. It could be that the drug was exerting a cytostatic 
effect, however, this cannot be tested using the cell viability assay alone. A 
significant reduction in viability was observed after 72hrs and 96hrs for the three 
highest VP concentrations (0.72μM and 0.36μM) (Figure 6.3). As the largest 
observable decrease in cell viability was after 96hrs, in all further experiments the 
cells were treated with VP for 96hrs. 
In order to find the 20% inhibitory concentration (EC20) of VP in VU40T(-) and 
VU147(+) cells, they were treated for 96hrs with the six highest VP concentrations 
described in Figure 6.2. A dose-response curve was plotted to establish the EC20 








































Methods, Section 2.16 (Figure 6.4A and 6.4B). The EC20 was established at 
0.38µM and 0.08µM in VU40T(-) and VU147(+) cells, respectively. The EC50 was 
established at 0.81µM and 0.15µM, respectively. Therefore, VU147(+) cells 





Figure 6.4. Cell viability dose-response curves for cell viability after VP treatment. 
SigmaPlot was used to plot sigmoidal dose-response curves based on cell viability in cells 
treated for 96hrs with vehicle (DMSO), 0.72, 0.36, 0.18, 0.1, 0.05 or 0.023µM VP in (A) 
VU40T(-) cells and (B) VU147(+) cells. EC50 and EC20 were calculated by determining 
the concentrations which reduce viable cells by 50% or 20%, respectively. The EC20 was 
established at 0.38μM and 0.08μM, the EC50 was established at 0.81µM and 0.15µM for 




6.2.2 The effect of VP treatment on apoptosis and cell cycle 
distribution in VU40T(-) cells 
To establish the effect of VP treatment on apoptosis and the cell cycle profile of 
VU40T(-) cells, two sets of FACS (fluorescence-activated cell sorting) analyses 
were conducted. VU40T(-) cells were treated with EC20 VP for 96hrs. The 
proportion of VU40T(-) cells in each cell cycle phase was determined by propidium 
iodide staining (Figure 6.5A). No change in the percentage of cells in S phase was 
found after VP treatment (15.6% vs. 14.9% in control and treated, respectively). 
However, there was a small but significant decrease in cells in G2/M phase after 
VP treatment; from 20% to 18%, while cells in G1 phase increased after VP 
treatment from 59.9% to 63.6% (Figure 6.5A). Therefore, it could be that VP 
treatment in VU40T(-) cells can alter the cell cycle distribution. However, the 
observed change was very small and further experiments to support this data would 
need to be conducted. 
In the second FACS experiment the effect of VP treatment on apoptosis was tested. 
VU40T(-) cells were stained with propidium iodide and FITC (fluorescein)-
conjugated annexin V (Figure 6.6A and B). A reduction in viable cells after VP 
treatment was observed, from 87.1% to 77.6%, however this reduction was not 
statistically significant (Figure 6.6C). The percentage of cells in early apoptosis 
before and after treatment was similar (0.5% and 0.3%, respectively) (Figure 
6.6C). There was a statistically significant increase in the percentage of cells in late 
apoptosis after VP treatment from 8.8% to 12.7% (Figure 6.6C). An increase in 
necrotic cells was also observed after VP treatment from 3.6% to 9.3% (Figure 
6.6C). Therefore, the data suggests that VP may be able to promote apoptosis in 
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VU40T(-) cells. However, the observed changes are small and further experiments 




Figure 6.5. VP treatment alters the cell cycle distribution of VU40T(-) cells.  
VU40T(-) cells were treated with EC20 VP (0.38M) or vehicle for 96hrs. Cell cycle was 
assessed by propidium iodide staining after (A) vehicle or (B) VP treatment. The proportion 
of cells in G1, S or G2/M phase was measured. (C) A significant increase in the proportion 
of cells in G1 phase and decrease in the proportion of cells in G2/M was observed after VP 
treatment. The error bars represent SEM of 7 biological replicates. P-value was determined 
























































Figure 6.6. VP treatment promotes apoptosis in VU40T(-) cells.  
VU40T(-) cells were treated with EC20 VP (0.38M) or vehicle for 96hrs. Cells were 
double stained with annexin-FITC V and propidium iodide to measure the proportion of 
viable, early apoptotic, late apoptotic or necrotic cells after (A) vehicle or (B) VP treated 
cells. (C) A significant increase in cells in late apoptosis was observed. The error bars 
represent SEM of biological triplicates. P-value was determined by conducting an unpaired 
t-test (*P<0.05, ‘n.s’ denotes ‘not significant’). 
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6.2.3 The effect of VP treatment on TEAD4 chromatin binding in 
the VU40T(-) cell line 
To determine whether VP treatment can disrupt TEAD binding, TEAD4 ChIP 
(chromatin immunoprecipitation)-qPCR (quantitative polymerase chain reaction) 
was conducted in VU40T(-) cells after VP treatment (Figure 6.7). VU40T(-) cells 
were treated for 96hrs with either EC20 VP or vehicle. For each condition three 
biological replicates of chromatin were collected and in addition to conducting the 
TEAD4 ChIP, an input sample was collected and a ‘no antibody’ ChIP control were 
included. QPCR was carried out on each sample to observe changes in TEAD4 
binding after VP treatment. To do this, three TEAD4 binding sites were selected 
based on three criteria. The first criterion was to use TEAD4 chromatin 
immunoprecipitation-sequencing (ChIP-seq) peak scores (which are indicative of 
protein binding) from VU40T(-) ChIP-seq data from the previous chapter. A cut-
off score was set to identify a subset of genes where TEAD4 is known to bind. The 
second criterion was RNA-seq data obtained from VU40T(-) vehicle and VP treated 
cells (discussed in Section 6.3). Output for differential gene expression analysis was 
used to obtain the values for log2 fold change between vehicle and VP treated cells. 
The third criterion was the base mean value (mean number of counts for each gene), 
which was taken into account to ensure the gene had robust basal expression levels. 
The YWHA (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein)-E, KCTD (potassium channel tetramerization domain containing)-2 and 
ADAM (eukaryotic translation initiation factor 3 subunit J)-9 genes were selected 
as putative TEAD4 binding sites and qPCR was conducted at these regions (Figure 
6.7). The samples were normalised to either VP input or vehicle input and to ‘no 
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antibody’ samples. Though not significant, a decrease in TEAD4 binding was 





Figure 6.7. TEAD4 ChIP-qPCR analysis in VU40T(-) cells. 
VU40T(-) cells were treated with either EC20 VP or vehicle DMSO for 96hrs. TEAD4 
ChIP was conducted followed by qPCR at three putative TEAD4 binding sites at the 
YWHAE, KCTD2 and ADAM9 genes. ChIP signal was normalised to input to obtain 
percentage input and this value was normalised to the ‘no antibody’ signal. The error bars 
represent SEM of biological triplicates. Statistical significance was calculated using an 
unpaired t-test (n.s denotes ‘not significant’). 
 
6.2.4 The effect of VP treatment on AP-1 and p63 transcription 
factor gene expression in VU40T(-) and VU147(+) cell lines 
To investigate any changes to the p63/AP-1/TEAD regulatory network as a result 
of disruption of TEAD4 binding, gene expression levels of the aforementioned TFs 
were investigated by qPCR after VP treatment. Expression levels of the AP-1 genes 
were first investigated. In VU40T(-) cells, expression levels of FOSB (FosB proto-










































transcription factor subunit) and JUND (JUND proto-oncogene, AP-1 transcription 
factor subunit) remained stable, while levels of FOSL1 (FOS like 1, AP-1 
transcription factor subunit) and JUN increased and a small decrease in JUNB levels 
were observed (Figure 6.8A). FOS (FOS proto-oncogene, AP-1 transcription factor 
subunit) was expressed at very low levels in VU40T(-) cells. In VU147(+) cells, 
JUNB expression decreased 2.4-fold (Figure 6.8A).  
Expression levels of TP63 were investigated in VU40T(-) cells and an increase of 
2.5-fold was observed, while no change in VU147(+) cells was observed (Figure 






Figure 6.8. QPCR gene expression analysis of genes of the AP-1 and p63 TF genes in 
VU40T(-) and VU147(+) cells after VP treatment.  
VU40T(-) and VU147(+) cells were treated with EC20 VP. Gene expression changes were 
investigated in (A) AP-1 TF genes (FOS, FOSL1, FOSL2, JUN, JUNB, JUND) and (B) 
TP63. The error bars represent the SEM between biological triplicates. Statistical 
significance was calculated using an unpaired t-test. Gene expression changes were not 
significant between untreated and VP treated samples. 
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6.3 RNA-seq analysis of VP treated VU40T(-) cells 
To explore genome-wide changes in gene expression after VP treatment, RNA-seq 
was conducted in VU40T(-) cells. RNA was extracted from three biological 
replicate samples of EC20 VP (0.38μM) treated VU40T(-) cells and of vehicle 
treated samples. RNA-seq data was analysed as described in Materials and 
Methods, Section 2.13.5. A total of 7,713 genes were identified in the vehicle 
sample and 8,038 genes in the VP treated sample. Within the Galaxy platform, the 
Stringtie file was input into the DESeq2 tool to conduct differential gene expression 
analysis. Genes whose log2 fold change was >1 or <-1 were taken for pathway 
enrichment analysis. Pathway enrichment analysis was conducted using the 
ConsensusPath database and a total of 64 pathways were annotated with the 
upregulated genes and 83 pathways were annotated with the downregulated genes.  
The top 20 pathways for each dataset are presented here (Figure 6.9). Among the 
upregulated pathways was the apoptosis pathway, indicating promotion of anti-
tumourigenic effects (Figure 6.9A). However, the most prominent pathways were 
cell adhesion pathways (focal adhesion, integrin mediated cell adhesion, focal 
adhesion-PI3K/AKT/mTOR (mechanistic target of rapamycin) signalling and 
NOTCH (neurogenic locus notch homolog) pathways). Downregulated pathways 
included RNA and protein processing pathways such as, mRNA processing, 
spliceosome, RNA transport and RNA degradation (Figure 6.9B). In addition, 
HNSCC-related pathways were downregulated such as pRB (retinoblastoma 
protein) in cancer, EGF-EGFR, MAPK and TGF- pathways (Figure 6.9B). 





Figure 6.9. Pathway enrichment analysis of RNA-seq data from VP treated VU40T(-
) cells 
VU40T(-) cells were treated with EC20 VP or vehicle for 96hrs and RNA-seq analysis was 
conducted. Genes with an FPKM (fragments per kilobase exon per million mapped reads) 
above 1 were taken forward for pathway enrichment analysis (7,713 genes in the vehicle 
sample were identified and 8,038 genes in the VP sample were identified). Using the 
Deseq2 tool, differentially expressed genes were identified: 1,324 genes were upregulated 
after VP treatment and 1,259 genes were downregulated. Pathway enrichment analysis was 
conducted using the ConsensusPath database. (A) A total of 64 pathways were annotated 
with the upregulated genes and (B) 83 pathways were annotated with the downregulated 
genes. The top 20 pathways for each dataset are presented here. 
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6.4 Establishing a VP response in non-tumourigenic 
primary keratinocyte cells 
6.4.1 The effect of VP treatment on non-tumourigenic cell viability 
The TEAD4 ChIP-qPCR data demonstrated that VP treatment may disrupt TEAD4 
binding, while RNA-seq data revealed that this could result in the downregulation 
of HNSCC-related processes. Therefore, the next aim was to investigate what effect 
disruption of TEAD4 binding would have in non-tumour oral cells.  
The effect of VP was tested in primary non-tumour cells (human oral keratinocytes 
(HOKs)) to allow for comparison of VP response between non-tumour cells with 
HNSCC cells. The same range of VP concentrations previously tested in the 
HNSCC cells were also used in the HOK cells. The effect on HOK cells was 
comparable to that of VU147; the EC50 was 0.1μM compared to 0.08μM, 
respectively (Figure 6.10). VP had the least effect on the viability of the VU40T(-
) cells. Therefore, HOK cells are similarly sensitive to VP compared to VU147(+) 



























Figure 6.10. VP dose-response curve in HNSCC and non-tumour cells. 
VU40T(-), VU147(+) and HOK cells were treated with 0.72, 0.36, 0.18, 0.1, 0.05, 0.023, 
0.011 or 0.00563µM of VP. Absorbance levels were measured every 24hrs for 96hrs and 
normalised to vehicle. SigmaPlot was used to plot sigmoidal dose-response curves. The 




6.5 Investigation of cross-talk between the EGFR and 
Hippo pathways 
6.5.1 Basal EGFR protein levels in HNSCC and non-tumour cells 
Due to previously published evidence of Hippo/EGFR pathway cross-talk, the next 
aim was to observe changes in genes associated with the EGFR pathway after VP 
treatment [355-358]. First, basal levels of the EGFR protein were examined in the 
VU40T(-), VU147(+) and in non-tumour HOK cells, and EGFR levels were 
normalised to lamin A/C housekeeping protein. Levels of EGFR were higher in 
both the HNSCC cell lines, compared to the HOK cells, agreeing with previously 
published data [36, 70, 91] (Figure 6.11A and B). Therefore, HNSCC cells express 
higher EGFR protein levels than do non-tumour cells, indicating activation of the 
EGFR signalling pathway. 
As discussed earlier, a feedback loop between YAP, EGFR and EGFR-like ligands 
(AREG and EREG) has previously been reported [355]. In order to determine 
whether a decrease in TEAD4 binding after VP treatment could induce changes in 
AREG, EREG and EGFR transcript levels in HNSCC cell lines, VU40T(-) and 
VU147(+) cells were treated with VP and transcript levels were investigated 
(Figure 6.12). In both VU40T(-) and VU147(+) cell lines, after VP treatment, a 
small decrease in transcript levels of all three ligands was observed (Figure 6.12). 
However, this change was not statistically significant and further experiments 
would be required to conclude the observed reduction in transcript levels of EGF-







Figure 6.11. EGFR protein expression by western blot in HNSCC cell lines and non-
tumour primary cells. 
Western blot to show EGFR protein expression in HOK, VU40T(-) and VU147(+) cells. 
Lamin A/C was used as a loading control. (B) HOK, VU40T(-) and VU147(+) EGFR 
expression levels were normalised to levels of lamin A/C. The error bars represent SEM of 
biological triplicates. Statistical significance was calculated using an unpaired t-test; n.s 






























































Figure 6.12. QPCR gene expression analysis of genes of the EGFR and EGF-like 
ligands in VU40T(-) and VU147(+) cells after VP treatment.  
VU40T(-) and VU147(+) cells were treated with EC20 VP (0.38µM). Gene expression 
changes were investigated in AREG, EREG and EGFR. The error bars represent SEM of 
biological triplicates. Statistical significance was calculated using an unpaired t-test. Gene 






































6.5.2 The effect of EGFR inhibition on HNSCC cells 
The next aim was to disrupt the EGFR pathway with the aim of reducing viability 
of HNSCC cells. To achieve this, two known EGFR inhibitors were used, a 
monoclonal antibody, cetuximab, and tyrphostin (AG1478), which is a tyrosine 
kinase inhibitor that blocks the EGFR receptor at its intracellular domain [354, 
359]. 
The first experiment was to treat the VU40T(-) and VU147(+) cells with cetuximab 
and investigate the effect on cell viability. Previously published studies conducted 
on HNSCC cell lines have used between 5-240nM of cetuximab [360-362]. 
Therefore, to elicit a response, the cells were treated with 10pM to 10μM for 96hrs 
at increments of one order of magnitude. Despite the high concentrations of 
cetuximab used, no effect on cell viability was observed in either cell line (Figure 
6.13A and B).  
Due to previous evidence of interaction between the EGFR and Hippo pathways, it 
was hypothesised that cetuximab may have an effect when used as a co-treatment 
with VP [355]. Therefore, VU40T(-) and VU147(+) cells were treated with the 
same range of cetuximab concentrations as before (Figure 6.13) and co-treated with 
EC20 or EC50 VP, as determined by the dose-response curve (Figure 6.4). As 
expected, in both HNSCC cell lines treatment with EC20 or EC50 VP resulted in a 
20% and 50-60% reduction in cell viability, respectively (Figure 6.14A and B). 
However, in both cell lines after co-treatment with cetuximab, cell viability 
remained at the same level as with VP only treatment (Figure 6.14). Therefore, in 






Figure 6.13. Cell viability assay in HNSCC cells after cetuximab treatment. 
(A) VU40T(-) and (B) VU147(+) cells were treated with seven concentrations of cetuximab 
between 10pM-100M at increments of one order of magnitude for 96hrs. The error bars 






Figure 6.14. Cell viability assay in HNSCC cells with cetuximab and VP co-treatment. 
(A) VU40T(-) and (B) VU147(+) cells were treated for 96hrs with EC20 VP only (0.38M 
and 0.08M, respectively) or co-treated with 0.0001, 0.001, 0.01, 0.1, 1, 10 or 100M of 
cetuximab. The error bars represent SEM of biological triplicates. 
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Since cetuximab did not influence cell viability in the HNSCC cell lines, the 
VU40T(-) cells were treated with an alternative EGFR inhibitor, AG1478. A time-
course for a cell viability assay was conducted to determine the most effective 
timepoint. Cells were treated for 24, 48, 72 or 96hrs with AG1478; a range of seven 
concentrations from 0.0625µM to 4µM at 2-fold increments were used. A dose-
dependent response was observed at each timepoint, however as there was no 
significant difference between 72 and 96hrs of treatment, 96hrs of treatment was 
used for further experiments (Figure 6.15A). A dose-response curve was plotted to 
find the EC20 of the cells after 96hrs of treatment, which was 0.58µM (Figure 
6.15B). 
To investigate the effect of AG1478 and VP co-treatment in VU40T(-) cells, the 
cells were treated with either EC20 VP (0.38µM), EC20 AG1478 (0.58µM) or both 
(Figure 6.16). A 20% reduction in cell viability was observed after EC20 VP only 
treatment and a 10% reduction with EC20 AG1478. A 30% reduction in cell 
viability was observed after co-treatment (Figure 6.16). Therefore, upon single 
treatments, the expected reduction in cell viability was observed. However, upon 
co-treatment of VP and AG1478, while a larger decrease in cell viability was 







Figure 6.15. Cell viability assay in VU40T(-) cells treated with AG1478. 
(A) To find the AG1478 EC20 and the most effective timepoint, VU40T(-) cells were 
treated with vehicle (ethanol) or 0.0625, 0.125, 0.25, 0.5, 1, 2 or 0.4M of AG1478 for 24, 
48, 72 or 96hrs. Absorbance levels were measured every 24hrs for 96hrs and normalised to 
vehicle. (B) A 96hrs sigmoidal dose-response curve was plotted using SigmaPlot to find 
the EC20 (0.58µM) and EC50 (1.39µM), which were calculated by determining the 
concentrations which reduce viable cells by 20% or 50%, respectively. The error bars 
represent SEM of biological triplicates. Statistical significance was calculated using an 






Figure 6.16. Co-treatment of VU40T(-) cells with EC20 VP and AG1478. 
VU40T(-) cells were treated for 96hrs with vehicle, EC20 VP, EC20 AG1478 or both. Cell 
viability was measured by normalising to vehicle. The error bars represent SEM of 
biological triplicates. Statistical significance was calculated using an unpaired t-test (n.s. 


































The data described in the previous results chapters have highlighted the Hippo 
pathway as being one of the key pathways in the cis-regulation of the HNSCC (head 
and neck squamous cell carcinoma) cell lines. Despite the Hippo pathway being 
extensively investigated by many groups, in HNSCC, the focus has largely been on 
YAP (yes-associated protein) and its correlation with tumour grade and cell 
proliferation [87, 93, 314, 363]. However, based on our evidence, it was 
hypothesised that the investigation of the Hippo downstream transcription effector, 
TEAD4 could hold value as a therapeutic target. Published investigations of the 
TEAD transcription factors (TFs), while not extensive in HNSCC, have been 
reported to correlate with tumour grade and progression [316]. Therefore, due to 
the association of Hippo with HNSCC tumour progression, verteporfin (VP) was 
used to disrupt YAP/TEAD interaction with the aim of disrupting the Hippo 
pathway and its downstream targets. 
Our data demonstrated that VP treatment can reduce cell viability of both VU40T(-
) and VU147(+) cells. This effect was accompanied by a small increase in cells in 
G1 phase, a small decrease in cells in G2/M phase and a small increase in cells 
appearing to undergo apoptosis. Due to the small changes, taken together, these data 
indicate either slowing of cell proliferation, cell cycle arrest, senescence or cell 
death. Therefore, it cannot be determined with these experiments alone, the 
mechanism of VP in reducing cell viability. The reason for the small changes could 
be due to the concentration of VP used (EC20) where only 20% of cells are affected 
by this dose. Therefore, a higher concentration such as EC50 could be used to exert 
a larger measurable effect. In addition, supporting data would be useful such as 
 292 
 
trypan blue staining and counting the cells before and after VP treatment. This 
would provide data on whether the cells are viable and whether they are in fact 
undergoing proliferation. However, to support the above findings, our RNA-seq 
pathway enrichment analysis of VP treated VU40T(-) cells revealed that genes 
involved in the apoptosis pathway and cell cycle pathway are upregulated and 
downregulated, respectively. These findings while not previously investigated in 
HNSCC, are in line with published data derived from other cancers. For example, 
VP treatment can promote cell cycle arrest in pancreatic, endometrial and 
retinoblastoma cancer cells [349, 364, 365], reduce viability of ovarian cancer cells, 
reduce cell growth in bladder cancer cell lines and increase apoptosis in pancreatic 
cancer cells [364, 366, 367]. Therefore, it can be concluded that VP results in 
reduced cell viability in the HNSCC cells here. In addition, our preliminary data 
and published data of others suggest that this effect could be through the induction 
of apoptosis and alteration of cell cycle distribution. However, in the cell lines 
investigated here, further experiments to support this are required. 
TEAD4 ChIP-qPCR was conducted at three of the most differentially expressed 
genes after VP treatment. A reduction in TEAD4 chromatin binding was observed, 
however, this result was not statistically significant. A reason for this could be 
biological variation between ChIP experiments, introduced by the dynamic nature 
of TF binding. For example, there is evidence that TFs can bind for durations of 
between 0.5-12 seconds [247]. This could, therefore, introduce variability between 
cell populations. In addition, TEAD4 ChIP-seq variability can be augmented by 
Hippo pathway stimuli, such as cell growth and density, therefore TEAD chromatin 
binding may vary depending on the degree of cell-cell contact. To reduce 
variability, cell density could be controlled more strictly by conducting cell counts 
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to ensure similar final cell densities before carrying out ChIP. To further strengthen 
this data and investigate whether the effect of VP is specific to the TEAD TF, 
negative control regions could be tested by qPCR, i.e. genes where TEAD4 binds 
but gene expression does not change after VP treatment. Therefore, the data for the 
effect of VP on TEAD4 chromatin binding, while not statistically significant, which 
could be attributed to biological variation, a trend towards reduced TEAD4 binding 
after VP treatment can be observed. To support this, while previously TEAD 
binding after VP treatment has not directly been investigated, it has been shown in 
breast cancer cells by luciferase reporter assays that VP can reduce TEAD activity 
[368].  
The three genes selected to investigate differential binding were YWHAE (tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein E), KCTD 
(potassium channel tetramerization domain containing)-2 and ADAM9 (eukaryotic 
translation initiation factor 3 subunit J 9). The YWHAE gene encodes 14-3-3, 
which is one of seven members of the 14-3-3 protein family [351, 369]. One of the 
functions of the 14-3-3 proteins is sequestering YAP/TAZ (tafazzin) to adherens 
junctions when the Hippo pathway is active and downstream transcription is 
inactive (Figure 6.1). VP treatment has been seen to increase levels of 14-3-3 
(encoded by YWHAZ) and reduce nuclear YAP levels [351]. Furthermore, 
published evidence reports that VP can directly bind YAP [346-350]. However, our 
RNA-seq data, revealed a decrease in YWHAE transcript level after VP treatment, 
as well as of other members of the 14-3-3 gene family (YWHAB, YWHAH and 
YWHAZ). Published findings suggest that VP may bind to YAP in the cytoplasm, 
preventing its transit to the nucleus and resulting in a decrease in nuclear YAP 
levels, while also increasing 14-3-3 activity. To investigate whether VP influences 
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YAP localisation, immunofluorescence for the YAP protein could be conducted. 
Alternatively, in the cell lines here, it may be that VP can also induce YAP 
degradation or reduce YAP1 gene transcription by other mechanisms, leading to a 
reduction in 14-3-3 transcription. To determine this, investigation of YAP protein 
localisation and 14-3-3 protein levels would be required. To support this hypothesis, 
an alternative YAP-independent mechanism for VP has been reported by Dasari et 
al. in an endometrial cancer cell line. The cells were transfected with siRNA for 
YAP1 and VP treatment still resulted in a cytotoxic effect. On the other hand, in an 
endometrial cancer organoid model, nuclear YAP levels were downregulated after 
exposure to VP resulting in cytotoxicity, which has also been observed in other cell 
types, as discussed earlier [303, 342, 343, 351]. Therefore, it may be that VP can 
influence the activity of the Hippo pathway independently of YAP, and so 14-3-3 
activity is not required to maintain low YAP levels. 
The protein encoded by the second differentially expressed gene, KCTD2 is an 
adaptor protein for the cullin3 E3 ubiquitin ligase complex, which targets pRB 
(retinoblastoma protein) for degradation [20, 370]. The pRB protein is often 
disrupted in HNSCC, leading to aberrant cell cycle progression [56, 62]. 
Interestingly, RNA-seq analysis revealed that after VP treatment KCTD2 levels 
decrease. On the other hand, RNA-seq pathway enrichment analysis revealed the 
pRB pathway to be downregulated by VP treatment. A reason for this discrepancy 
may be that some genes annotated in the pRB pathway can be overexpressed and 
contribute to tumour progression. For example, the gene which encodes the E2F3 
(E2 factor 3) protein, a TF for the pRB pathway, was annotated in our data. E2F3 
has been shown to be overexpressed in renal cell carcinoma and involved in 
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inducing transcription of genes associated with cell proliferation [371]. Therefore, 
it may be that VP can, to some extent, restore cell cycle control. 
The ADAM9 (metalloproteinase disintegrin cysteine-rich protein 9) gene has 
previously been observed to be overexpressed in many cancers including in oral 
SCC cell lines. It has been demonstrated that ADAM9 can induce anti-apoptotic 
effects mediated by the EGFR (epidermal derived growth factor)/AKT (protein 
kinase B) pathway [372]. Encouragingly, our RNA-seq data revealed that VP 
reduces ADAM9 transcript levels [372]. 
The primary non-tumour HOK (human oral keratinocyte) cells displayed reduced 
viability with a similar EC50 value to VU147(+) cells, but more sensitivity than 
VU40T(-) cells. To investigate these differences, VP treatment of VU147(+) and 
HOK cells followed by RNA-seq and ChIP-qPCR experiments could be conducted 
to compare with the data derived from the VU40T(-) cells to determine differences 
in the mechanism of action of VP.  
One of the mechanisms by which VP could induce a reduction in cell viability could 
be by inhibition of TEAD-mediated transcription. For example, Takeuchi et al. 
have shown that knockdown of TEAD4 in oral SCC cell lines can promote cell 
cycle arrest, which agrees with observations of our data [316]. Furthermore, it has 
been shown in epithelial breast cancer cells, that disruption of TAZ/TEAD activity 
can abolish cell proliferation [373]. Therefore, based on our and published 
evidence, it may be that disruption of TEAD binding can reduce cell viability 
through transcription inhibition of TEAD target genes. However, as mentioned 
earlier further experiments must be conducted to conclude that VP results in 
disruption of TEAD4 binding in VU40T(-) cells. 
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RNA-seq data may also offer insights into mechanisms by which VP can exert its 
affects. Upon receiving signals of energy and mechanical stress, the main function 
of the Hippo pathway is regulation of cell growth and proliferation by mediating 
the cytoskeletal network and cell adhesion molecules [313, 314, 374] (Figure 6.1). 
Cell adhesion molecules can be tumour suppressive as they can restrict aberrant cell 
growth and cell invasion [304, 329]. In cancer however, normal Hippo signalling is 
lost, leading to aberrant cell-cell signalling, proliferation and growth [304, 305]. 
Our RNA-seq data after VP treatment revealed upregulation of predominantly cell 
adhesion related pathways including the NOTCH pathway, which has been 
demonstrated to be tumour suppressive [21, 22] and frequently inactivated in 
HNSCC [36, 66-71]. While the Hippo pathway was not annotated in the top 20 
pathways of either dataset (upregulated or downregulated genes), the pathway was 
annotated at the 28th position in the upregulated dataset, suggesting that it is active, 
and its downstream effects are inhibited. Therefore, one mechanism of action of VP 
may be to restore signalling between the Hippo pathway and cell adhesion 
molecules.  
Pathways downregulated as a result of VP treatment revealed many to be related to 
RNA and protein processing. Aberrant splicing and upregulation of RNA/protein 
processing has been reported previously in HNSCC cells and in other cancer types, 
leading to activation of genes associated with cell survival, such as EGFR [375-
377]. Our data revealed HNSCC-related pathways such as, EGFR, MAPK and 
TGF- signalling to be downregulated after VP treatment, indicating that VP could 
reduce HNSCC cell viability by diminishing the effect of pathways involved in 
HNSCC cell survival [56, 66, 74, 77, 78, 275]. 
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In the previous chapter, it was highlighted that TEAD binding overlaps with other 
TFs and could contribute to cross-talk between signalling pathways. Here we 
investigated whether disrupting TEAD binding affects gene expression of the AP-
1 and p63 TFs. The observed changes in AP-1 and TP63 gene expression after VP 
treatment were not statistically significant. As mentioned earlier, the non-
significant result could be due to treatment with the EC20 dose and it could be that 
EC50 treatment may yield a significant change. In VU40T(-) cells, levels of TP63 
increased, while in VU147(+) cells levels decreased. There is published evidence 
that TEAD can bind to the Np63 promoter to induce its repression and so it could 
be that VP is able abolish this effect by disrupting TEAD binding [331]. On the 
other hand, in HNSCC cells, YAP has a role in p63 degradation, while VP can 
promote YAP degradation [87, 303, 332, 333, 342, 343, 351]. Therefore, the 
contrasting effect of VP treatment in VU40T(-) and VU147(+) cells on TP63 
expression may be due to the complex associations between YAP/TEAD/p63. 
However, further investigations would be required to elucidate the mechanisms 
underlying this, including repeating the experiment with EC50 VP doses to 
investigate changes in gene expression and the effect on TEAD4 binding. In 
addition, interrogation of p63 and YAP protein levels could strengthen this data. 
Next, it was investigated whether VP treatment would affect transcription of AP-1 
genes, which would indicate alterations in AP-1 activity. Although not statistically 
significant, in VU40T(-) cells, FOSL1 expression levels increased after VP 
treatment, while JUNB levels in VU147(+) cells decreased. JUNB knockdown has 
been reported to reduce metastasis and invasion in HNSCC cell lines [253]. It has 
also been reported that knockdown of FOSL1 can result in slowed HNSCC cell line 
proliferation, migration and invasion [256]. However, the function of AP-1 dimers 
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can be complicated as their function can differ depending on their binding partner 
[307, 378]. Therefore, these reported effects may be dependent on dimer 
composition. While VP treatment results in changes in AP-1 gene expression, 
which could be in part due to disruption of TEAD, AP-1 and p63, binding would 
have to be assessed by ChIP-seq to determine whether AP-1 binding has in fact 
been altered at genes involved in tumour promotion. In addition, as mentioned 
before, further experiments are required to determine whether VP and TEAD4 
activity has influence on AP-1 and p63 gene expression.  
To explore the EGFR pathway, EGFR protein expression was investigated in 
VU40T(-) and VU147(+) cells and compared with expression in normal HOK cells. 
Although both HNSCC cell lines showed higher EGFR protein expression over 
normal oral cells, the result was not conclusive. Therefore, this experiment would 
have to be repeated. Further investigation of the EGFR pathway was conducted by 
treating the VU40T(-) and VU147(+) cells with cetuximab. No detectable change 
in cell viability was observed. To test whether cetuximab does have an effect, a cell 
line which is sensitive to cetuximab could be used as a positive control. On the other 
hand, treatment with the tyrosine kinase inhibitor, AG1478 resulted in a reduction 
in cell viability in a dose-dependent manner, which has also been reported by other 
groups [379-381]. A reason for a reduction in cell viability with AG1478 and not 
with cetuximab may be that in HNSCC cell lines, cetuximab-resistance has been 
attributed to changes in levels of specific ERBB proteins, including ERBB-2 and -
3, which treatment with tyrosine kinase inhibitors can overcome [113, 382]. For 
example, AG1478 has been reported to target and block ERBB2 activity [382]. 
Therefore, it may be that AG1478 can target components of the EGFR/PI3K 
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(phosphotidylinositol-3 kinase) pathway which contribute to cetuximab-resistance, 
rendering cetuximab ineffective. 
Gene expression levels of the EGF-like ligands, AREG, EREG and of EGFR 
showed a small decrease after VP treatment. This is in agreement with a previous 
study in which overexpression of YAP resulted in increased transcript and protein 
levels of AREG and EGFR [355]. In addition, the same study demonstrated that 
treatment with AREG resulted in dephosphorylation of the core kinases of the 
Hippo pathway (MST (macrophage stimulating)-1/2 and LATS (large tumour 
suppressor protein kinase)-1/2) and of YAP, resulting in increased EGFR and 
AREG expression [355]. Therefore, it may be that this feedback loop is also active 
in HNSCC cell lines. However, changes in gene expression of EGF-like ligands 
was not statistically significant, which may be due to the use of a low concentration 
of VP. To strengthen this finding, cells could be treated with a higher concentration 
of VP, alternatively protein levels of the EGF-like ligands after EC20 VP treatment 
could be assessed. In addition, treatment with protein EGF-like ligands before and 
after VP treatment, followed by investigation of the Hippo kinases and YAP could 
be assessed. 
One of the aims of this project was to investigate whether EGFR and Hippo pathway 
inhibition, by VP and cetuximab co-treatment, would have a synergistic effect on 
HNSCC cell viability. However, such an effect was not observed, moreover the 
reduction in cell viability was not statistically significant. However, the expected 
20% reduction in cell viability was observed, as the cells were treated with EC20 
doses of both drugs. The reason for not observing a synergistic effect may be that 
receptor tyrosine kinases and the Hippo pathway contribute to HNSCC cell viability 
but do so independently. Alternatively, it may be that the PI3K/AKT pathway is 
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activated independently of receptor tyrosine kinases where AG1478 exerts its effect 
[383]. 
In conclusion, we observe that VP treatment can reduce cell viability of HNSCC 
cell lines in a dose-dependent manner. VP may exert this effect by altering the cell 
cycle distribution of these cells and inducing apoptosis, as described in published 
literature [349, 364-367]. However, the observed effects are too small to determine 
this result conclusively. Having said this, the potential effect of VP on the cell cycle 
and induction of apoptosis is encouraging, as it supported by RNA-seq data where 
upregulation of pathways such as apoptosis and NOTCH and downregulation of 
pathways such as the cell cycle is observed. In addition, VP appears to upregulate 
cell adhesion pathways, which may have anti-tumourigenic effects in HNSCC cells, 
while downregulating HNSCC-related signalling pathways (EGFR, MAPK, TGF-
). Although VP appears to exert tumour suppressive effects in both HNSCC cell 
lines, ultimately leading to a decrease in cell viability, non-tumourigenic oral 
keratinocytes appear to be similarly affected, thereby limiting the clinical potential 
of VP.  
Limitations of the findings in this chapter include the lack of statistically significant 
results with the use of VP, which may have been obtained with use of a higher VP 
dose, as supported by published data [349, 364-367]. Therefore, while the work in 
this chapter is preliminary and is thus far encouraging, further experiments are 





CHAPTER 7: GENERAL DISCUSSION AND 
FUTURE WORK 
The aim of this study was to investigate the HNSCC (head and neck squamous cell 
carcinoma) cell line cis-regulatory network and compare the findings with non-
tumourigenic cells to reveal how the network may differ. The investigation was 
conducted with the ultimate aim of using the regulatory networks to identify 
therapeutic targets. 
To address the first aim of elucidating the HNSCC cell line cis-regulatory network, 
investigations of open chromatin regions led to the identification of over 70,000 
regulatory elements, primarily driven by the p63-AP1-TEAD transcription factor 
(TF) network. The network appears to be highly overlapping, suggesting cross-talk 
of signalling pathways on a transcriptional level. This addresses a gap in the 
literature concerning p63 and its association with TEAD (TEA domain transcription 
factor) and AP-1. ChIP (chromatin immunoprecipitation)-seq data in this study 
have demonstrated close overlap of TEAD4 binding with p63 and AP-1. Moreover, 
our data demonstrated that binding of all three TFs occur more frequently than 
binding of TEAD4 alone. This indicates that there could be co-regulation between 
the three factors. Cell transfection experiments using short interfering RNAs 
(siRNA) or short hairpin loop RNAs (shRNA) could be conducted to investigate 
whether TF binding is dependent on another TF within the network. There is 
evidence from colorectal carcinoma cells that while AP-1 and TEAD4 can co-
regulate transcription, physical interaction may occur and is mediated by the SRC 
(proto-oncogene, non-receptor tyrosine kinase) family of transcription co-factors 
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[274]. To determine this in HNSCC cells, co-immunoprecipitation assays could be 
conducted to examine whether any combination of p63, AP-1 and TEAD4 TFs 
physically interact.  
Apart from the p63-AP1-TEAD network, other potentially contributing TFs have 
been identified which are worth further investigation, such as the KLF (Krüppel-
like factor) TF family. In particular, KLF5 which has been associated with an EC 
in HNSCC cell lines and tumours and has been associated with activation of genes 
involved in SCC cell identity [179]. Furthermore, the transcriptional network in the 
HNSCC cell lines and non-tumour cells appears to be largely similar, with some 
notable exceptions such as KLF4 and KLF9. Both these TFs may be more active in 
the regulatory network of non-tumour cells and are known to play anti-proliferative 
and pro-apoptotic roles [293, 294].  
The TEAD and p63 motifs were found to be specific to distal sites, while the AP-1 
motif was more prominent in distal sites as compared to promoter elements. To 
support this, binding of TEAD4, JUND and FOSL1 (FOS-like 1, AP-1 transcription 
factor subunit) has previously been shown to largely overlap with active enhancer 
regions [274]. To verify the binding of the TFs at enhancer elements, H3K27ac and 
H3K4me1 chromatin immunoprecipitation (ChIP-seq) experiments could be 
conducted as these histone modifications form part of the signature for active 
enhancers [129, 162, 170]. The resulting data can be mapped to the genome to 
investigate the overlap of active enhancer histone marks with the TF ChIP-seq data. 
This can be followed by enhancer/promoter reporter assays to establish whether the 
promoter can in fact be driven by the identified putative enhancer. The latter would 
be particularly important as the identified network is based mostly on distal 
regulatory elements and current analyses of enhancer-gene assignments are 
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oversimplified, as discussed in Chapter 3. An alternative method such as chromatin 
conformation capture could identify more accurately distal element-promoter 
interactions and improve the identification of the biological processes involved. 
Interestingly, the investigation of open chromatin regions in HNSCC cells lines and 
non-tumour cells revealed that they were dominated by the AP-1 motif. 
Experiments to explore the role of AP-1 could include knockdown or knockout of 
AP-1 subunits. However, due to the varied composition of AP-1 (consisting of a 
member of the FOS family (FOS, FOSB, FOSL1 and FOSL2) and a member of the 
JUN family (JUN, JUNB, JUND)), the TF can be heterogeneous in its function. For 
example, JUNB knockdown has been reported to reduce HNSCC cell line 
metastasis and invasion, but not cell proliferation [253]. On the other hand, 
knockdown of FOSL1 resulted in slowed HNSCC cell line proliferation, migration 
and invasion [256]. Another study conducted in epidermal SCC has shown that JUN 
can promote transformation of keratinocytes, while JUNB inhibits transformation 
and cell growth [384]. Moreover, it has been reported that the AP-1 dimer 
composition can alter based on HNSCC tumour progression [385]. This was 
reflected in the data here where the cell lines are derived from various tumour stages 
and AP-1 subunit transcript levels differed not only between cell lines, but also 
between subunits. In addition, our FOSL1 and JUND ChIP-seq pathway analysis 
revealed distinct categories of pathways, which were more over-represented either 
in FOSL1 or JUND ChIP. Therefore, despite AP-1 forming a main part of the 
HNSCC cell line regulatory network, interrogation of the role of AP-1 could be 
difficult due to its highly heterogenic function. 
The interrogation of the HNSCC cell line cis-regulatory network further highlighted 
enhancer clusters (ECs) regulatory regions, which have been reported to control 
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genes of particular importance in maintaining cell identity [173, 175]. By 
comparing HNSCC cell line and OTK (oral tonsil keratinocyte) pathway 
enrichment analyses of ECs, it was found that the EGFR (epidermal growth factor 
receptor), TGF (transforming growth factor)-, MAPK and WNT (wingless) 
pathways appear in both datasets. This indicates that these pathways are required 
for oral epithelial cell identity, but also have the potential to become deregulated in 
cancer, which has been reported previously [29, 36, 66, 102, 103, 275, 386]. Our 
data also revealed that over-represented pathways in HNSCC and non-tumour cell 
EC datasets, as well as in AP-1, p63 and TEAD4 TF ChIP-seq data, included not 
only HNSCC-associated pathways (EGFR and WNT), but also the Hippo pathway, 
as well as pathways associated with cell-cell and cell-ECM (extracellular matrix) 
regulation (adherens junction, focal adhesion and regulation of actin cytoskeleton). 
The finding of differential ECs between HNSCC and non-tumour cells was evident 
upon identification of HNSCC-specific and OTK-specific EC genes. For example, 
Hippo pathway was HNSCC-specific, while the NOTCH (neurogenic locus notch 
homolog) pathway was OTK-specific. As already discussed, Hippo signalling and 
TEAD activity appear to be important in the regulation of HNSCC cells, while 
NOTCH is tumour suppressive in HNSCC [23]. A reason for the differential EC 
identification between non-tumour and HNSCC cells could be gene overexpression. 
For example, mutations in a KLF5 EC have been reported to not only lead to KLF5 
protein overexpression, but also TP63 activation in HNSCC cell lines [179]. p63 
overexpression can lead to inhibition of epithelial differentiation and uncontrolled 
self-renewal of keratinocyte cells [16]. Therefore, mutations within regulatory 
elements for HNSCC-promoting genes could be one of the mechanisms for the 
presence of ECs. A strategy to determine whether this is the case would be to 
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compare the DHS and ChIP-seq data with copy number alterations and mutational 
analyses of the cell lines. Analysis of ECs reveals them to be important in both 
HNSCC and non-tumour oral cells forming the basis of epithelial regulation but can 
be deregulated in cancer. In addition, based on TF motif and ChIP-seq analysis, the 
regulation of these elements is likely to be conducted, at least in part, by the p63, 
TEAD4 and AP-1 TFs, expression of which could be driven by genetic mutations 
and amplifications. 
One of the aims of this project was to use the HNSCC cell line regulatory network 
to identify therapeutic targets. Verteporfin (VP) had previously been shown to 
disrupt YAP (yes-associated protein)/TEAD binding, however, TEAD-DNA 
binding had not previously been investigated [346-350]. Data in this project has 
demonstrated that VP treatment can result in decreased cell viability in the VU40T(-
) and VU147(+) cell lines, agreeing with published data [349, 364-367]. While it is 
not conclusive from the data here, VP may exert its effect through induction of 
apoptosis and altering the cell cycle distribution. These findings however, are 
preliminary and further studies will be required to draw conclusions as to the 
mechanism of action of VP and its effect on TEAD4 binding. Furthermore, there 
are some limitations of VP which may hinder its use in a clinical setting. Firstly, 
the sensitivity of HOK (human oral keratinocyte) cells to VP is similar to that of 
VU147(+) cells and more sensitive than VU40T(-) cells. Before VP can be used 
clinically to target the Hippo pathway, the mechanism underlying the difference in 
sensitivity especially between HOK and HNSCC cells needs to be elucidated. A 
second limitation is that VP has been reported to be poorly soluble in plasma, as 
well as having a low plasma half-life leading to low blood concentrations [387]. 
Thirdly, VP is photosensitive and there is evidence that exposure to ambient light 
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while in cell culture can lead to the formation of protein aggregates, which may 
interfere with cell growth [388]. Therefore, an alternative therapy could be cyclic 
peptides which, similarly to VP, directly inhibit TEAD activity but are not light 
sensitive and are more selective in their targets [353, 389]. Alternatively, shRNA 
could be used to inhibit the YAP binding domain of TEAD, or its DNA-binding 
domain, as has been proposed previously [390, 391]. 
Another aim of this project was to investigate differences underlying the cis-
regulation of the HPV (human papillomavirus)-(+) and HPV(-) cell lines. However, 
no clear difference in cis-regulation was observed, possibly due to the small number 
of cell lines. To address this, the number of HPV(+) and HPV(-) models would need 
to be increased to investigate this further.  
In conclusion, our data confirms published findings in HNSCC cells, but also 
contributes novel findings such as the relationship between AP-1, TEAD4 and p63. 
The cis-regulatory network underlying both HNSCC cell lines and non-
tumourigenic oral keratinocyte cells involves AP-1, TEAD4 and p63, which 
influence key pathways involved in normal epithelial function, such as EGFR, 
WNT, and Hippo. These pathways in turn influence key processes including cell-
cell adhesion and cell-ECM signalling. However, these pathways can become 
deregulated and promote HNSCC.  
The effect of VP on the Hippo pathway, particularly TEAD activity cannot be 
concluded by the results described in this thesis alone. Further experiments must be 
conducted to strengthen the mechanism of action of VP in these cells. However, 
preliminary data indicate that VP can influence processes involved in reducing cell 
viability and can alter gene expression of genes involved in apoptosis, as well as 
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affecting other HNSCC-related pathways. Therefore, the Hippo pathway has been 
demonstrated as being a potential therapeutic target and VP may be a useful tool in 
investigations of the pathway, but further experiments must be conducted to 




Table 1. Top 20 statistically significant transcription factor motifs in SCC040(-) cells. 
Motif analysis was conducted using the ‘findMotifsGenome’ script within HOMER. A 




Table 2. Top 20 statistically significant transcription factor motifs in VU40T(-) cells.  
Motif analysis was conducted using the ‘findMotifsGenome’ script within HOMER. A 





Table 3. Top 20 statistically significant transcription factor motifs in VU147(+) cells.  
Motif analysis was conducted using the ‘findMotifsGenome’ script within HOMER. A 





Table 4. Top 20 statistically significant transcription factor motifs in UDSCC2(+) 
cells.  
Motif analysis was conducted using the ‘findMotifsGenome’ script within HOMER. A 









Figure 1. Genome-wide distribution of enhancer cluster (EC) peaks.  
The locations of the ECs were mapped to intergenic, intronic, promoter, untranslated 
regions (UTR), transcription termination site (TTS), exon. This was conducted by 

























































Table 5. Top 20 Enhancer cluster pathways found in SCC040 cells.  
A total of 459 ECs were found and by using the ‘AnnotatePeaks’ script within HOMER 
pathway, overrepresentation analysis was conducted to identify 352 pathways.  
 
 
S C C 0 4 0 ( - )  E n h a n c e r  C l u s t e r s :  P a t h w a y  o v e r r e p r e s e n t a t i o n
Te r m E n r i c h m e n t l o g P
#  o f  
g e n e s  i n  
t e r m
#  t a r g e t  
g e n e s  i n  
t e r m
%  o f  
t a r g e t s  i n  
t e r m
G e n e  s y m b o l s D a t a b a s e
EG F R 1  S i g n a l i n g
Pa t h w ay
4.85E-05 -9.934 177 15 8.47
CAV2, CTNND1, EGFR, ELF3, ERRFI1, 
MAP3K14, PLCG2, PLEC, PTK2B, RAC1, 
SMAD3, SOCS3, SP1, TGIF1, VAV2
WP
A d h e re n s j u n c t i o n 8.73E-05 -9.346 73 8 10.96
ACTN4, BAIAP2, CDH1, CTNND1, EGFR, 
IQGAP1, RAC1, SMAD3
KEGG
P ro t e o g l yc a n s  i n  
c a n c e r
1.33E-04 -8.925 225 14 6.22
ANK3, CAV2, CD44, COL21A1, CTTN, 
EGFR, IQGAP1, MIR21, PLAU, PLCG2, 
RAC1, SDC1, VAV2, WNT7A
KEGG
Wn t  S i g n a l i n g  
Pa t h w ay  N e t Pa t h
1.82E-04 -8.612 115 11 9.57
BTRC, CDH1, CTNNBIP1, DKK1, DLG1, JUP, 
LRP5, RAC1, SMAD3, TFAP2A, WNT7A
WP
A l p h a 6 - B e t a 4  
I n t e g r i n  S i g n a l i n g  
Pa t h w ay
3.91E-04 -7.848 69 8 11.59
DST, EGFR, ITGA6, LAMA3, PLEC, RAC1, 
SFN, SMAD3
WP
L e u ko c y t e  
t ra n s e n d o t h e l i a l  
m i g ra t i o n
5.16E-04 -7.57 118 9 7.63
ACTN4, CLDN1, CTNND1, F11R, PLCG2, 
PTK2B, RAC1, RAPGEF4, VAV2
KEGG
A r r hy t h m o g e n i c  
r i g h t  v e n t r i c u l a r  
c a rd i o myo p a t hy  
( A RVC )
6.09E-04 -7.404 74 7 9.46
ACTN4, CDH2, DSG2, ITGA6, ITGB6, JUP, 
LMNA
KEGG
V i ra l  c a rc i n o g e n e s i s 7.40E-04 -7.209 206 12 5.83
ACTN4, CDK6, DLG1, EGR2, GTF2A1, 
HDAC11, HIST1H2BM, HIST1H2BO, 
HIST1H4E, PKM, RAC1, TBPL2
KEGG
Re g u l a t i o n  o f  a c t i n  
c y t o s ke l e t o n
1.03E-03 -6.874 214 12 5.61
ACTN4, BAIAP2, BDKRB2, EGFR, IQGAP1, 
ITGA6, ITGB6, MYH9, MYLK, RAC1, SSH3, 
VAV2
KEGG
H i p p o  s i g n a l i n g  
p a t h w ay
3.21E-03 -5.741 153 9 5.88
BTRC, CDH1, DLG1, FRMD6, ID1, SMAD3, 
SMAD7, WNT7A, WWTR1
KEGG
H T LV- I  i n fe c t i o n 5.07E-03 -5.284 259 12 4.63
BCL2L1, DLG1, EGR2, FOSL1, MAP3K14, 
NRP1, POLD4, SLC2A1, SMAD3, TBPL2, 
TNFRSF1A, WNT7A
KEGG
Pa t h w ay s  i n  c a n c e r 5.09E-03 -5.281 327 14 4.28
BCL2L1, CDH1, CDK6, EGFR, FADD, GSTP1, 
ITGA6, JUP, LAMA3, PLCG2, RAC1, 
SLC2A1, SMAD3, WNT7A
KEGG
Wn t  s i g n a l i n g  
p a t h w ay
6.15E-03 -5.092 139 8 5.76
BTRC, CTNNBIP1, DKK1, FOSL1, LRP5, 
RAC1, SMAD3, WNT7A
KEGG
I n t e g ra t e d  B re a s t  
C a n c e r  Pa t h w ay
6.18E-03 -5.087 152 10 6.58
ANXA1, CDH1, EGFR, FADD, GADD45A, 
NCOA3, RAC1, SMAD7, SP1, ZMYND8
WP
A p o p t o s i s 6.94E-03 -4.971 86 6 6.98
BCL2L1, CAPN2, FADD, IRAK2, MAP3K14, 
TNFRSF1A
KEGG
Fo c a l  a d h e s i o n 7.77E-03 -4.858 207 10 4.83
ACTN4, CAPN2, CAV2, EGFR, ITGA6, 
ITGB6, LAMA3, MYLK, RAC1, VAV2
KEGG
N F - ka p p a  B  s i g n a l i n g
p a t h w ay
9.08E-03 -4.701 91 6 6.59
BCL10, BCL2L1, MAP3K14, PLAU, PLCG2, 
TNFRSF1A
KEGG
Pa n c re a t i c  c a n c e r 9.61E-03 -4.645 66 5 7.58 BCL2L1, CDK6, EGFR, RAC1, SMAD3 KEGG
E p i t h e l i a l  c e l l  
s i g n a l i n g  i n  
H e l i c o b a c te r  p y l o r i  
i n fe c t i o n
1.09E-02 -4.522 68 5 7.35 EGFR, F11R, MAP3K14, PLCG2, RAC1 KEGG
TG F  B e t a  S i g n a l i n g
Pa t h w ay
1.40E-02 -4.268 55 5 9.09 FST, ITGB6, SMAD3, SMAD7, TGIF1 WP
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Table 6. Top 20 Enhancer cluster pathways found in VU40T(-) cells.  
A total of 477 ECs were found and by using the ‘AnnotatePeaks’ script within HOMER 
pathway, overrepresentation analysis was conducted to identify 346 pathways. 
 
 
V U 4 0 T ( - )  E n h a n c e r  C l u s t e r s :  P a t h w a y  o v e r r e p r e s e n t a t i o n
Te r m E n r i c h m e n t l o g P
#  o f  
g e n e s  i n  
t e r m
#  t a r g e t  
g e n e s  i n  
t e r m
%  o f  
t a r g e t s  i n  
t e r m
G e n e  s y m b o l s D a t a b a s e
L e u ko c y te  
t ra n s e n d o t h e l i a l
m i g ra t i o n
7.28E-07 -14.13 118 13 11.02
ACTN4, ARHGAP35, CLDN1, CLDN16, 
CTNNB1, CTNND1, PTK2, PTK2B, 
RAC1, RAPGEF3, RAPGEF4, RASSF5, 
VAV2
KEGG
A d h e re n s j u n c t i o n 1.60E-05 -11.04 73 9 12.33
ACTN4, CDH1, CTNNB1, CTNND1, 
EGFR, PTPN1, PVRL1, RAC1, TJP1
KEGG
A l p h a 6 - B e t a 4  
I n t e g r i n  S i g n a l i n g  
Pa t h w ay
8.04E-05 -9.429 69 9 13.04
DST, EGFR, ITGB4, PLEC, PTK2, RAC1, 
SFN, YWHAQ, YWHAZ
WP
R a p 1  s i g n a l i n g  
p a t h w ay
9.98E-05 -9.212 211 14 6.64
CDH1, CTNNB1, CTNND1, EGFR, 
EPHA2, ID1, LPAR3, PARD6B, RAC1, 
RAPGEF3, RAPGEF4, RASSF5, TIAM1, 
VAV2
KEGG
A r r hy t h m o g e n i c  
r i g h t  v e n t r i c u l a r  
c a rd i o myo p a t hy  
( A RVC )
1.25E-04 -8.989 74 8 10.81
ACTN4, CDH2, CTNNB1, ITGA2, 
ITGA3, ITGB4, ITGB6, JUP
KEGG
H i p p o  s i g n a l i n g  
p a t h w ay
2.87E-04 -8.158 153 11 7.19
BTRC, CDH1, CTNNB1, DLG1, 
FRMD6, ID1, PARD6B, STK3, 
WWTR1, YWHAQ, YWHAZ
KEGG
Fo c a l  a d h e s i o n 3.07E-04 -8.087 207 13 6.28
ACTN4, ARHGAP35, CAPN2, CAV1, 
CTNNB1, EGFR, ITGA2, ITGA3, 
ITGB4, ITGB6, PTK2, RAC1, VAV2
KEGG
A n d ro g e n  re c e p t o r  
s i g n a l i n g p a t h w ay
5.27E-04 -7.548 88 9 10.23
CAV1, CTNNB1, EGFR, ETV5, FHL2, 
NCOA3, PTK2, RAC1, SP1
WP
R A N K L / R A N K  
S i g n a l i n g  Pa t h w ay
5.35E-04 -7.533 54 7 12.96
FHL2, IKBKB, LYN, PTK2, RAC1, 
TNFRSF11B, TRAF6
WP
M A P K  s i g n a l i n g
p a t h w ay
7.34E-04 -7.217 256 14 5.47
DUSP5, DUSP6, DUSP7, EGFR, 
HSPA1A, HSPB1, IKBKB, IL1A, 
MAP3K13, MECOM, RAC1, RPS6KA5, 
STK3, TRAF6
KEGG
A r r hy t h m o g e n i c  
r i g h t  v e n t r i c u l a r  
c a rd i o myo p a t hy
7.47E-04 -7.199 74 8 10.81
ACTN4, CDH2, CTNNB1, ITGA2, 
ITGA3, ITGB4, ITGB6, JUP
WP
I n t e g r i n - m e d i a te d  
c e l l  a d h e s i o n
1.25E-03 -6.688 99 9 9.09
CAPN2, CAV1, ITGA2, ITGA3, ITGB4, 
ITGB6, PTK2, RAC1, VAV2
WP
M A P K  s i g n a l i n g
p a t h w ay
1.31E-03 -6.64 163 12 7.36
DUSP5, DUSP6, DUSP7, EGFR, 
HSPA1A, HSPB1, IKBKB, IL1A, 
MAP3K13, RAC1, STK3, TRAF6
WP
EG F R 1  S i g n a l i n g
Pa t h w ay
2.64E-03 -5.937 177 12 6.78
CAV1, CTNND1, EGFR, ELF3, EPS8, 
ERRFI1, PLEC, PTK2B, RAC1, 
RPS6KA5, SP1, VAV2
WP





I L - 1  S i g n a l i n g  
Pa t h w ay
3.51E-03 -5.652 12 3 25.00 IL1A, IL1RAP, TRAF6 WP
Re g u l a t i o n  o f  a c t i n  
c y t o s ke l e t o n
4.41E-03 -5.424 214 11 5.14
ACTN4, ARHGAP35, EGFR, ITGA2, 
ITGA3, ITGB4, ITGB6, PTK2, RAC1, 
TIAM1, VAV2
KEGG
B a c te r i a l  i nva s i o n  o f  
e p i t h e l i a l  c e l l s
4.54E-03 -5.395 76 6 7.89
CAV1, CDH1, CTNNB1, PTK2, RAC1, 
SEPT9
KEGG
Pa t h o g e n i c  
E s c h e r i c h i a  c o l i  
i n fe c t i o n
5.20E-03 -5.259 55 5 9.09
CDH1, CLDN1, CTNNB1, YWHAQ , 
YWHAZ
KEGG
T i g h t  j u n c t i o n 6.16E-03 -5.09 134 8 5.97
ACTN4, AMOTL1, CLDN1, CLDN16, 




Table 7. Top 20 Enhancer cluster pathways found in VU147(+) cells.  
A total of 380 ECs were found and by using the ‘AnnotatePeaks’ script within HOMER 
pathway overrepresentation analysis was conducted to identify 396 pathways. 
 
 
V U 1 4 7 ( + ) E n h a n c e r  C l u s t e r s :  P a t h w a y  o v e r r e p r e s e n t a t i o n
Te r m E n r i c h m e n t l o g P
#  o f  
g e n e s  i n  
t e r m
#  t a r g e t  
g e n e s  i n  
t e r m
%  o f  
t a r g e t s  i n  
t e r m
G e n e  s y m b o l s D a t a b a s e
EG F R 1  S i g n a l i n g
Pa t h w ay
7.32E-06 -11.82 177 19 10.73446
CAV2, CBLC, CTNND1, EGFR, ELF3, 
ERRFI1, MAP2K3, MAP3K14, MAPK7, 
MTA2, MYC, PLD1, PLEC, PTK2B, RAC1, 
RALGDS, SP1, TGIF1, VAV2
WP
R a p 1  s i g n a l i n g
p a t h w ay
5.57E-05 -9.796 211 17 8.056872
ACTB, CDH1, CTNND1, EFNA5, EGFR, 
EPHA2, GNAI2, ID1, MAP2K3, MET, 
PARD6B, RAC1, RALGDS, RAPGEF1, 
SIPA1L3, VAV2, VEGFB
KEGG
Fo c a l  a d h e s i o n 1.51E-04 -8.796 207 16 7.729469
ACTB, ACTN4, CAPN2, CAV2, EGFR, FLNA, 
ITGA2, ITGB6, LAMA5, LAMB3, MET, 
PTK2, RAC1, RAPGEF1, VAV2, VEGFB
KEGG
E n d o c y t o s i s 3.98E-04 -7.829 203 15 7.389163
AP2S1, ARF6, ARRB2, CAV2, CBLC, CLTB, 
EGFR, EPN3, HSPA1A, MET, NEDD4, 
PARD6B, PIP5KL1, PLD1, SMURF1
KEGG
I n t e g r i n - m e d i a te d  
c e l l  a d h e s i o n
5.08E-04 -7.585 99 11 11.11111
CAPN2, CAPNS1, CAV2, ITGA2, ITGB6, 
MAP2K3, MAPK7, PTK2, RAC1, RAPGEF1, 
VAV2
WP
A l p h a 6 - B e t a 4  
I n t e g r i n  S i g n a l i n g
Pa t h w ay
5.10E-04 -7.581 69 9 13.04348
DST, EGFR, LAMA5, LAMB3, MET, PLEC, 
PTK2, RAC1, SFN
WP
S m a l l  c e l l  l u n g  
c a n c e r
5.13E-04 -7.575 86 9 10.46512
BCL2L1, CDKN1B, CDKN2B, ITGA2, 
LAMA5, LAMB3, MYC, PTK2, RXRA
KEGG
Pa t h w ay s  i n  c a n c e r 5.44E-04 -7.516 327 20 6.116208
BCL2L1, CBLC, CDH1, CDKN1B, CDKN2B, 
EGFR, FADD, ITGA2, JUP, LAMA5, LAMB3, 
MET, MYC, PLD1, PTK2, RAC1, RALGDS, 
RASSF1, RXRA, VEGFB
KEGG
A d h e re n s  j u n c t i o n 7.72E-04 -7.167 73 8 10.9589
ACTB, ACTN4, CDH1, CTNND1, EGFR, 
MET, RAC1, TJP1
KEGG
B a c t e r i a l  i nva s i o n  o f  
e p i t h e l i a l  c e l l s
1.01E-03 -6.898 76 8 10.52632
ACTB, CAV2, CBLC, CDH1, CLTB, MET, 
PTK2, RAC1
KEGG
Tra n s c r i p t i o n a l  
m i s re g u l a t i o n  i n  
c a n c e r
1.14E-03 -6.775 179 13 7.26257
BCL2L1, CDKN1B, CDKN2C, DOT1L, 
HIST1H3H, JUP, MET, MYC, PLAU, PTK2, 
RXRA, SP1, SPINT1
KEGG
L e u ko c y te  
t ra n s e n d o t h e l i a l  
m i g ra t i o n
1.35E-03 -6.611 118 10 8.474576
ACTB, ACTN4, CLDN16, CLDN9, CTNND1, 
GNAI2, PTK2, PTK2B, RAC1, VAV2
KEGG
Fo c a l  A d h e s i o n 1.44E-03 -6.542 184 15 8.152174
ACTB, CAV2, EGFR, FLNA, ITGA2, ITGB6, 
LAMA5, LAMB3, MAP2K3, MAPK7, MET, 
PTK2, RAC1, RAPGEF1, VEGFB
WP
M A P K  s i g n a l i n g  
p a t h w ay
1.58E-03 -6.45 256 16 6.25
ARRB2, EGFR, FLNA, GADD45B, HSPA1A, 
HSPB1, IL1A, MAP2K3, MAP3K11, 
MAP3K14, MAP3K8, MAPK7, MKNK2, 
MYC, RAC1, TNFRSF1A
KEGG
I n t e g ra t e d  
Pa n c re a t i c  C a n c e r  
Pa t h w ay
2.44E-03 -6.015 194 15 7.731959
ANXA1, BBC3, CDKN1B, CDKN2B, EGFR, 
FADD, FTL, GPRC5A, MAPK7, MYC, 
NOXA1, RAC1, RXRA, SP1, TNFRSF1A
WP
P ro t e o g l yc a n s  i n  
c a n c e r
3.21E-03 -5.74 225 14 6.222222
ACTB, CAV2, CBLC, EGFR, FLNA, ITGA2, 
MET, MIR21, MYC, PLAU, PLAUR, PTK2, 
RAC1, VAV2
KEGG
M A P K  s i g n a l i n g  
p a t h w ay
3.63E-03 -5.62 163 13 7.97546
ARRB2, EGFR, FLNA, HSPA1A, HSPA5, 
HSPB1, IL1A, MAP3K11, MAP3K14, 
MAP3K8, MAPK7, MYC, RAC1
WP
A r r hy t h m o g e n i c  
r i g h t  v e n t r i c u l a r  
c a rd i o myo p a t hy  
( A RVC )
3.84E-03 -5.563 74 7 9.459459
ACTB, ACTN4, ITGA2, ITGB6, JUP, LMNA, 
SGCA
KEGG
S i g n a l i n g Pa t h w ay s  
i n  G l i o b l a s t o m a
5.74E-03 -5.161 80 8 10
CDKN1B, CDKN2B, CDKN2C, EGFR, 
ERRFI1, MAP2K3, MDM4, MET
WP
R a s  s i g n a l i n g
p a t h w ay
8.55E-03 -4.762 226 13 5.752212
ARF6, BCL2L1, EFNA5, EGFR, EPHA2, 





Table 8. Top 20 Enhancer cluster (EC) pathways found in UDSCC2(+) cells.  
A total of 558 ECs were found and by using the ‘AnnotatePeaks’ script within HOMER 
pathway overrepresentation analysis was conducted to identify 209 pathways. 
 
 
U D S C C 2 ( + )  E n h a n c e r  C l u s t e r s :  P a t h w a y  o v e r r e p r e s e n t a t i o n
Te r m E n r i c h m e n t l o g P
#  o f  
g e n e s  i n  
g e r m
#  t a r g e t  
g e n e s  i n  
t e r m
%  o f  
t a r g e t s  i n  
t e r m
G e n e  s y m b o l s D a t a b a s e
Sy s t e m i c  l u p u s  
e r y t h e m a t o s u s








D N A  re p l i c a t i o n 6.91E-04 -7.277 36 3 8.33 RPA4,PCNA,PRIM2 KEGG
E n d o c y t o s i s 2.86E-03 -5.857 203 5 2.46 PSD3,AP2M1,HSPA1A,CAV2,EGFR KEGG
Fo c a l  a d h e s i o n 3.11E-03 -5.773 207 5 2.42 GSK3B,RAPGEF1,MYLPF,CAV2,EGFR KEGG
I L - 3  S i g n a l i n g
Pa t h w ay
3.73E-03 -5.592 104 4 3.85 GSK3B,ID1,RAPGEF1,HSPB1 WP
M i s m a tc h  re p a i r 5.55E-03 -5.193 23 2 8.70 RPA4,PCNA KEGG
H y p e r t ro p hy  M o d e l 6.75E-03 -4.998 20 2 10.00 ATF3,IFRD1 WP
H T LV- I  i n fe c t i o n 8.04E-03 -4.824 259 5 1.93 GSK3B,ATF3,PCNA,CDC27,FOS KEGG
E s t ro g e n  s i g n a l i n g  
p a t h w ay
1.26E-02 -4.37 100 3 3.00 FOS,HSPA1A,EGFR KEGG




M A P K  s i g n a l i n g
p a t h w ay
1.78E-02 -4.028 163 4 2.45 FOS,HSPB1,HSPA1A,EGFR WP
S i g n a l i n g o f  
H e p a t o c y t e  G ro w t h  
Fa c t o r  Re c e p t o r
1.78E-02 -4.027 33 2 6.06 RAPGEF1,FOS WP
R PA  c o m p l ex 1.95E-02 -3.937 4 1 25.00 RPA4 KEGG
D N A  p o l y m e ra s e  
a l p h a  /  p r i m a s e  
c o m p l ex
1.95E-02 -3.937 4 1 25.00 PRIM2 KEGG
N u c l e o t i d e  exc i s i o n  
re p a i r
2.21E-02 -3.814 47 2 4.26 RPA4,PCNA KEGG
C e l l  c yc l e 2.24E-02 -3.799 124 3 2.42 GSK3B,PCNA,CDC27 KEGG
FA S  p a t h w ay  a n d  
S t re s s  i n d u c t i o n  o f  
H S P  re g u l a t i o n
2.33E-02 -3.76 38 2 5.26 HSPB1,LMNA WP
I L - 6  S i g n a l i n g
Pa t h w ay
2.33E-02 -3.758 99 3 3.03 GSK3B,FOS,HSPB1 WP
Fo c a l  A d h e s i o n 2.65E-02 -3.629 184 4 2.17 GSK3B,RAPGEF1,CAV2,EGFR WP
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Table 9. Top 20 statistically significant transcription factor motifs in OTK cells.  
A total of 185 motifs were identified. Pathway enrichment analysis was conducted in 






Table 10. Top 20 Enhancer cluster (EC) pathways found in OTK cells.  
A total of 592 ECs were found and by using the ‘AnnotatePeaks’ script within HOMER 








Figure 2. Principal components analysis (PCA) of OTK and HNSCC cells. 
Analysis was conducted using the ‘PCAexplorer’ script within the R software. (A) Four 
principal components (PCs) were identified upon clustering of gene FPKM values: PC1 
(42.76%), PC2 (32.51%), PC3 (13.2%) and PC4 (11.53%). (B) PC1 accounted for 42.76% 
of variability due to differences in HNSCC gene expression compared to HOK cells. PC2 
accounted for 32.5% of variability due to differences in UDSCC2(+) gene expression 
compared to the remaining HNSCC cell lines and HOK cells. (C) PC3 accounted for 13.2% 
of variability due to differences in VU147(+) cells compared to the remaining HNSCC cells 
and HOK cells. (D) PC4 accounted for 11.53% of variability due to differences in 








Figure 3. UCSC browser screenshot for FOSL1 and JUND ChIPs at the ANXA2 gene.  
qPCR primers were selected near the ANXA2 gene to test for potential FOSL1 and JUND 
binding. The qPCR product (mapped on to the coverage tracks) overlaps with FOSL1 and 
JUND TF ChIP peaks in the VU40T(-) and VU147(+) cell lines; the data were obtained 
from the Cistrome database and are shown as a black track. The site also overlaps with a 
DHS in both VU40T(-) (blue track) and VU147(+) (red track) cell lines. The ‘Txn Factor 





Figure 4. UCSC browser screenshot for FOSL1 and JUND ChIPs at the LMNA gene.  
QPCR primers were selected near the LMNA gene to test for potential FOSL1 and JUND 
binding. The qPCR product (mapped on to the coverage tracks) overlaps with FOSL1 and 
JUND TF ChIP peaks in the VU40T(-) and VU147(+) cell lines; the data were obtained 
from the Cistrome database and are shown as a black track. The site also overlaps with a 
DHS in both VU40T(-) (blue track) and VU147(+) (pink track) cell lines. The ‘Txn Factor 





Figure 5. UCSC browser screenshot for FOSL1 and JUND ChIPs at the S100A10 
gene.  
QPCR primers were selected near the S100A10 gene to test for potential FOSL1 and JUND 
binding. The qPCR product (mapped on to the coverage tracks) overlaps with FOSL1 and 
JUND TF ChIP peaks in the VU40T(-) and VU147(+) cell lines; the data were obtained 
from the Cistrome database and are shown as a black track. The site also overlaps with a 
DHS in both VU40T(-) (blue track) and VU147(+) (pink track) cell lines. The ‘Txn Factor 





Figure 6. UCSC browser screenshot for p63 ChIP at the TP73 gene (site 1).  
QPCR primers were selected near the TP73 gene to test for potential p63 binding. The 
qPCR product (mapped on to the coverage tracks) overlaps with p63 TF ChIP peaks in the 
VU40T(-) and VU147(+) cell lines; the data were obtained from the Cistrome database and 
are shown as a black track. The site also overlaps with a DHS in both VU40T(-) (blue track) 





Figure 7. UCSC browser screenshot for TEAD4 ChIP (site 1).  
QPCR primers were selected ~35kb downstream of the PCED1B TSS to test for potential 
TEAD4 binding. The qPCR product (mapped on to the coverage tracks) overlaps with 
TEAD4 TF ChIP peaks in the VU40T(-) and VU147(+) cell lines; the data were obtained 
from the Cistrome database and are shown as a black track. The site also overlaps with a 
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